<!DOCTYPE html>
<html lang="en">
  <head>
    <title>WO2019051257A2 - Methods for treating hepatitis b infections 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/WO2019051257A2/en">
    <meta name="description" content="
     Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient&#39;s genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Methods for treating hepatitis b infections 
       ">
    <meta name="DC.date" content="2018-09-07" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient&#39;s genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations. 
   
   ">
    <meta name="citation_patent_application_number" content="PC:T/US2018/049998">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/e5/3c/fc/88c74e172346ad/WO2019051257A2.pdf">
    <meta name="citation_patent_publication_number" content="WO:2019051257:A2">
    <meta name="DC.date" content="2019-03-14">
    <meta name="DC.contributor" content="Patricia MENDEZ" scheme="inventor">
    <meta name="DC.contributor" content="William T. SYMONDS III" scheme="inventor">
    <meta name="DC.contributor" content="Douglas Dieterich" scheme="inventor">
    <meta name="DC.contributor" content="Arbutus Biopharma Corp" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">WO2019051257A2 - Methods for treating hepatitis b infections 
        - Google Patents</h1>
  <span itemprop="title">Methods for treating hepatitis b infections 
       </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/e5/3c/fc/88c74e172346ad/WO2019051257A2.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">WO2019051257A2</dd>
    <meta itemprop="numberWithoutCodes" content="2019051257">
    <meta itemprop="kindCode" content="A2">
    <meta itemprop="publicationDescription" content="International application publshed with declaration under Article 17 (2) (a)">
    <span>WO2019051257A2</span>
    <span>PCT/US2018/049998</span>
    <span>US2018049998W</span>
    <span>WO2019051257A2</span>
    <span>WO 2019051257 A2</span>
    <span>WO2019051257 A2</span>
    <span>WO 2019051257A2</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 2018049998 W</span>
    <span>US2018049998 W</span>
    <span>US 2018049998W</span>
    <span>WO 2019051257 A2</span>
    <span>WO2019051257 A2</span>
    <span>WO 2019051257A2</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">WO</dd>
    <dd itemprop="countryName">WIPO (PCT)</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>mol</dd>
    <dd itemprop="priorArtKeywords" repeat>lipid</dd>
    <dd itemprop="priorArtKeywords" repeat>hbv</dd>
    <dd itemprop="priorArtKeywords" repeat>sirna</dd>
    <dd itemprop="priorArtKeywords" repeat>patient</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2017-09-11">2017-09-11</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Ceased</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">PCT/US2018/049998</dd>

  <dt>Other languages</dt>
  <dd itemprop="otherLanguages" itemscope repeat>
    <a href="/patent/WO2019051257A2/fr">
      <span itemprop="name">French</span> (<span itemprop="code">fr</span>)
    </a>
  </dd>

  <dt>Other versions</dt>
  <dd itemprop="directAssociations" itemscope repeat>
    <a href="/patent/WO2019051257A3/en">
      <span itemprop="publicationNumber">WO2019051257A3</span>
      (<span itemprop="primaryLanguage">en</span>
    </a>
  </dd>

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>Patricia MENDEZ</dd>
  <dd itemprop="inventor" repeat>William T. SYMONDS III</dd>
  <dd itemprop="inventor" repeat>Douglas Dieterich</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    Arbutus Biopharma Corp
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>Arbutus Biopharma Corp</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2017-09-11">2017-09-11</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2018-09-07">2018-09-07</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2019-03-14">2019-03-14</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-09-07">2018-09-07</time>
    <span itemprop="title">Application filed by Arbutus Biopharma Corp</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">Arbutus Biopharma Corp</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-03-14">2019-03-14</time>
    <span itemprop="title">Publication of WO2019051257A2</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/WO2019051257A2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-03-11">2020-03-11</time>
    <span itemprop="title">Anticipated expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-03-26">2020-03-26</time>
    <span itemprop="title">Publication of WO2019051257A3</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/WO2019051257A3/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Ceased</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&amp;NR=2019051257A2&amp;KC=A2&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/WIPO/PCTUS2018049998/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="patentscopeLink">
        <a href="https://patentscope.wipo.int/search/en/WO2019051257" itemprop="url" target="_blank"><span itemprop="text">PatentScope</span></a>
      </li>

      
      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/WO2019051257A2" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">**C(C(CNC(C(F)(F)F)=O)[C@]1O)O[C@](CO)[C@@]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">**C(C(CNC(C(F)(F)F)=O)[C@]1O)O[C@](CO)[C@@]1O</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">36</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SCKQPFVBRJQINF-RKDXNWHRSA-N</span>
      <span itemprop="name">CC(C)(C)OC(N(C[C@@H](CC1)O)[C@H]1C(OC)=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)OC(N(C[C@@H](CC1)O)[C@H]1C(OC)=O)=O</span>
      <span itemprop="inchi_key">SCKQPFVBRJQINF-RKDXNWHRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ADYGKTWSELPLSQ-OZRWLHRGSA-N</span>
      <span itemprop="name">CC(C)(CCO)OC([C@@H]([C@H]1O)NC(C)=O)O[C@H](CO)[C@@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(CCO)OC([C@@H]([C@H]1O)NC(C)=O)O[C@H](CO)[C@@H]1O</span>
      <span itemprop="inchi_key">ADYGKTWSELPLSQ-OZRWLHRGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UDZIZGYKZYFCBJ-SECBINFHSA-N</span>
      <span itemprop="name">CC(CCC[C@H](C(C)=O)NC)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(CCC[C@H](C(C)=O)NC)=O</span>
      <span itemprop="inchi_key">UDZIZGYKZYFCBJ-SECBINFHSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LKEGKBBCBWKBQP-QMMMGPOBSA-N</span>
      <span itemprop="name">CC(CC[C@@H](C(C)=O)NC)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(CC[C@@H](C(C)=O)NC)=O</span>
      <span itemprop="inchi_key">LKEGKBBCBWKBQP-QMMMGPOBSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DURWGZLSXWZYOD-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(c(ccc(CNC)c1)c1C(C)=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(c(ccc(CNC)c1)c1C(C)=O)=O</span>
      <span itemprop="inchi_key">DURWGZLSXWZYOD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VVJUVSIWPDZFJA-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(c1cc(NC)cc(C(C)=O)c1)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(c1cc(NC)cc(C(C)=O)c1)=O</span>
      <span itemprop="inchi_key">VVJUVSIWPDZFJA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WPAUZBHKXZRUGA-JMAFDKGASA-N</span>
      <span itemprop="name">CS(N)(=O)=[O]O[C@H](CCO[C@@H]1CO)[C@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CS(N)(=O)=[O]O[C@H](CCO[C@@H]1CO)[C@H]1O</span>
      <span itemprop="inchi_key">WPAUZBHKXZRUGA-JMAFDKGASA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JUYSISNCVQMIAP-IWSPIJDZSA-N</span>
      <span itemprop="name">N/C(/C1CC1)=[O]\O[C@H](CCO[C@@H]1CO)[C@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">N/C(/C1CC1)=[O]\O[C@H](CCO[C@@H]1CO)[C@H]1O</span>
      <span itemprop="inchi_key">JUYSISNCVQMIAP-IWSPIJDZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QFLUGZCBHVGCMT-BPDFOOOXSA-N</span>
      <span itemprop="name">OC[C@H]([C@@H]1O)OCC(CNS(C(F)(F)F)(=O)=O)[C@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">OC[C@H]([C@@H]1O)OCC(CNS(C(F)(F)F)(=O)=O)[C@H]1O</span>
      <span itemprop="inchi_key">QFLUGZCBHVGCMT-BPDFOOOXSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
  </ul>

  

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q</span>&mdash;<span itemprop="Description">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/00</span>&mdash;<span itemprop="Description">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/68</span>&mdash;<span itemprop="Description">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/6876</span>&mdash;<span itemprop="Description">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/6883</span>&mdash;<span itemprop="Description">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/713</span>&mdash;<span itemprop="Description">Double-stranded nucleic acids or oligonucleotides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/51</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/54</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/549</span>&mdash;<span itemprop="Description">Sugars, nucleosides, nucleotides or nucleic acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/51</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/54</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/554</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/11</span>&mdash;<span itemprop="Description">DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/113</span>&mdash;<span itemprop="Description">Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/1131</span>&mdash;<span itemprop="Description">Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K45/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K45/06</span>&mdash;<span itemprop="Description">Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/10</span>&mdash;<span itemprop="Description">Type of nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/14</span>&mdash;<span itemprop="Description">Type of nucleic acid interfering nucleic acids [NA]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/30</span>&mdash;<span itemprop="Description">Chemical structure</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/33</span>&mdash;<span itemprop="Description">Chemical structure of the base</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/00</span>&mdash;<span itemprop="Description">Applications; Uses</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/30</span>&mdash;<span itemprop="Description">Special therapeutic applications</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/31</span>&mdash;<span itemprop="Description">Combination therapy</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/00</span>&mdash;<span itemprop="Description">Applications; Uses</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/30</span>&mdash;<span itemprop="Description">Special therapeutic applications</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2320/34</span>&mdash;<span itemprop="Description">Allele or polymorphism specific uses</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q</span>&mdash;<span itemprop="Description">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/00</span>&mdash;<span itemprop="Description">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/70</span>&mdash;<span itemprop="Description">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/701</span>&mdash;<span itemprop="Description">Specific hybridization probes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q1/706</span>&mdash;<span itemprop="Description">Specific hybridization probes for hepatitis</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q</span>&mdash;<span itemprop="Description">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q2600/00</span>&mdash;<span itemprop="Description">Oligonucleotides characterized by their use</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q2600/106</span>&mdash;<span itemprop="Description">Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q</span>&mdash;<span itemprop="Description">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q2600/00</span>&mdash;<span itemprop="Description">Oligonucleotides characterized by their use</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Q2600/156</span>&mdash;<span itemprop="Description">Polymorphic or mutational markers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hepatitis B virus</span>
        <span itemprop="definition">(abbreviated as &#34;HBV&#34;) is a member of the Hepadnavirus family.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the virus particle</span>
        <span itemprop="definition">(sometimes referred to as a virion) includes an outer lipid envelope and an icosahedral nucleocapsid core composed of protein.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleocapsid</span>
        <span itemprop="definition">encloses the viral DNA and a DNA polymerase that has reverse transcriptase activity.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the outer envelope</span>
        <span itemprop="definition">contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells, typically liver hepatocytes.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">filamentous and spherical bodies lacking a core</span>
        <span itemprop="definition">can be found in the serum of infected individuals. These particles are not infectious and are composed of the lipid and protein that forms part of the surface of the virion, which is called the surface antigen (HBsAg), and is produced in excess during the life cycle of the virus.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBsAg</span>
        <span itemprop="definition">surface antigen</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the genome of HBV</span>
        <span itemprop="definition">is made of circular DNA, but it is unusual because the DNA is not fully double-stranded.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One end of the full length strand</span>
        <span itemprop="definition">is linked to the viral DNA polymerase.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the genome</span>
        <span itemprop="definition">is 3020-3320 nucleotides long (for the full-length strand) and 1700-2800 nucleotides long (for the shorter strand).</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the negative-sense (non-coding)</span>
        <span itemprop="definition">is complementary to the viral mRNA.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the viral DNA</span>
        <span itemprop="definition">is found in the nucleus soon after infection of the cell.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">There are four known genes encoded by the genome</span>
        <span itemprop="definition">called C, X, P, and S.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the core protein</span>
        <span itemprop="definition">is coded for by gene C (HBcAg), and its start codon is preceded by an upstream in-frame AUG start codon from which the pre-core protein is produced.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBeAg</span>
        <span itemprop="definition">is produced by proteolytic processing of the pre-core protein.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the DNA polymerase</span>
        <span itemprop="definition">is encoded by gene P.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Gene S</span>
        <span itemprop="definition">is the gene that codes for the surface antigen (HBsAg).</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBsAg gene</span>
        <span itemprop="definition">is one long open reading frame but contains three in frame &#34;start&#34; (ATG) codons that divide the gene into three sections, pre-S l, pre-S2, and S. Because of the multiple start codons, polypeptides of three different sizes called large, middle, and small are produced.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ATG</span>
        <span itemprop="definition">start codons</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">is a complex process. Although replication takes place in the liver, the virus spreads to the blood where viral proteins and antibodies against them are found in infected people. The structure, replication and biology of HBV is reviewed in D. Glebe and C.M.Bremer, Seminars in Liver Disease, Vol. 33, No. 2, pages 103-112 (2013).</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Infection of humans with HBV</span>
        <span itemprop="definition">can cause an infectious inflammatory illness of the liver. Infected individuals may not exhibit symptoms for many years. It is estimated that about a third of the world population has been infected at one point in their lives, including 350 million who are chronic carriers. The virus is transmitted by exposure to infectious blood or body fluids. Perinatal infection can also be a major route of infection. The acute illness causes liver inflammation, vomiting, jaundice, and possibly death. Chronic hepatitis B may eventually cause cirrhosis and liver cancer.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, wherein a C/C genotype at rs 12079860 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having a different genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0021">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV infected patient</span>
        <span itemprop="definition">comprising:</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24).</span>
        <meta itemprop="num_attr" content="0028">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV infected patient</span>
        <span itemprop="definition">comprising:</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV inhibitor</span>
        <span itemprop="definition">comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24).</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient, comprising administering to the patient an effective amount of an HBV antigen inhibitor, wherein the patient had been determined to have a C/C genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide an HBV antigen inhibitor for the prophylactic or therapeutic treatment of a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide the use of an HBV antigen inhibitor to prepare a medicament for treating a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0035">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 1</span>
        <span itemprop="definition">Illustrates an intermediate compound of formula Ie, wherein a targeting ligand/linker is bound to a solid phase support, and wherein Pg 1 is the protecting group DMTr.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2</span>
        <span itemprop="definition">Illustrates a representative compound of formula Id wherein a targeting ligand is bound to a solid phase support, with a nucleic acid covalently bound.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3</span>
        <span itemprop="definition">Illustrates a representative compound of formula Id, wherein a targeting ligand-nucleic acid conjugate has been cleaved from a solid phase support and deprotected to provide the compound of formula I.</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNPs</span>
        <span itemprop="definition">single nucleotide polymorphisms</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL-28B</span>
        <span itemprop="definition">inter leukin 28B</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL-28A</span>
        <span itemprop="definition">inter leukin 28 A</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL28B</span>
        <span itemprop="definition">encodes  â - â 3, which induces antiviral activity by itself and through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) complex, which induces IFN-stimulated genes (ISGs).</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">JK-STAT</span>
        <span itemprop="definition">Janus kinase-signal transducer and activator of transcription</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL28A</span>
        <span itemprop="definition">encodes IFN-X2.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNPs</span>
        <span itemprop="definition">associated with these genes and with increased IFN- 2 and/or IFN- 3 expression.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the table shown below</span>
        <span itemprop="definition">includes a non-limiting list of these IL28A/B SNPs, which may be used in methods of the invention described herein.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rsl2979860CT/rs8099917TG</span>
        <span itemprop="definition">indicates that these SNPs have been reported to be in high linkage disequilibrium with rsl2979860.</span>
        <meta itemprop="num_attr" content="0049">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">â  rs368234815</span>
        <span itemprop="definition">is located upstream of IFNL3/IL28B; a frameshift variant gives rise to IFNL4. See, e.g., Tanaka et al, Nat Genet 2009, 41 : 1 105-1 109; Fischer et al., Hepatol. 2012,</span>
        <meta itemprop="num_attr" content="0049">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at any one or a combination of the SNPs listed in the table above, wherein a patient having the relevant genotype or combination of genotypes has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least one SNP from the above table</span>
        <span itemprop="definition">is detected.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a combination of at least 2 SNPs from the above table</span>
        <span itemprop="definition">are detected.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a combination of at least 3 SNPs from the above table</span>
        <span itemprop="definition">are detected.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a combination of at least 4 SNPs from the above table</span>
        <span itemprop="definition">are detected.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a combination of at least 5 SNPs from the above table</span>
        <span itemprop="definition">are detected.</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a patient&#39; s genotype at the rsl2979860 SNP</span>
        <span itemprop="definition">is detected.</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the rsl2979860 SNP</span>
        <span itemprop="definition">is located approximately 3 kb upstream of the IL-28B gene  â see, e.g., Ge et al, Nature 2009, 461 :399-401).</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">individuals having a C/C genotype at rsl2979860</span>
        <span itemprop="definition">have a higher likelihood of positively responding to an HBV antigen inhibitor treatment than individuals having another genotype at this location.</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">patients having a combination of a CT genotype at rsl2979860 and a TG or TT genotype at rs8099917</span>
        <span itemprop="definition">may also have a higher likelihood of positively responding to an HBV antigen inhibitor treatment.</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a patient&#39; s genotype at the rs8099917 SNP</span>
        <span itemprop="definition">is detected.</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the rs8099917 SNP</span>
        <span itemprop="definition">is located in an intergenic region between IL28A and IL28B,  â 8kb downstream from IL28B and  â 16kb upstream from IL28A  â see, e.g., Suppiah et al., Nat Genet 2009, 41 : 1 100-1 104; Tanaka et al., Nat Genet 2009, 41 : 1 105-1109).</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a T/T genotype at rs8099917</span>
        <span itemprop="definition">is indicative of a HBV infected patient that has a higher likelihood of responding to an HBV antigen inhibitor, as compared to an HBV infected patient having a different genotype at this location. Additionally, in certain embodiments, a patient having combination of a T/G genotype at rs8099917 and C/T genotype at rsl2979860 may also have a higher likelihood of positively responding to an HBV antigen inhibitor treatment.</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a patient&#39;s genotype at the rsl2980275 SNP</span>
        <span itemprop="definition">is detected.</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rsl2980275</span>
        <span itemprop="definition">is also located near the IL28B gene  â see, e.g., Tanaka et al., Nat Genet</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an A/A genotype at rsl2980275</span>
        <span itemprop="definition">is indicative of a HBV infected patient that has a higher likelihood of responding to an HBV antigen inhibitor, as compared to an HBV infected patient having a different genotype at this location.</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, rs8099917 and/or rsl2980275, wherein a C/X genotype at rsl2079860, a T/Z genotype at rs8099917 and/or an A/A genotype at rsl2980275 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at rsl2079860, rs8099917 and/or rsl2980275, wherein X is C or T; and Z is T or G.</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is C. In certain embodiments, Z is T. In certain embodiments, X is T and Z is G. In certain embodiments, X is T and Z is T. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860 is detected. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rs8099917 is detected. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2980275 is detected.</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, wherein a C/C genotype at rsl2079860 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having a different genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method described herein</span>
        <span itemprop="definition">further comprises obtaining a biological sample from the hepatitis B virus (HBV) infected patient.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising:</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method described herein</span>
        <span itemprop="definition">further comprises administering an effective amount of an HBV antigen inhibitor to the HBV infected patient having a C/C genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an effective amount of an HBV antigen inhibitor for a patient having a C/C genotype at rsl2079860</span>
        <span itemprop="definition">is less than an effective amount of an HBV antigen inhibitor for a patient having a different genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV infected patient having a C/C genotype at rsl2079860</span>
        <span itemprop="definition">is administered a different HBV antigen inhibitor treatment regimen than an HBV infected patient having a different genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV infected patient having a C/C genotype at rsl2079860</span>
        <span itemprop="definition">is administered a lower dosage of the HBV antigen inhibitor and/or is administered the HBV antigen inhibitor for a shorter period of time as compared to an HBV infected patient having a different genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV infected patient</span>
        <span itemprop="definition">comprising:</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860;</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24).</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient comprising:</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860;</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24).</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">provide a method of treating a hepatitis B virus (HBV) infected patient, comprising administering to the patient an effective amount of an HBV antigen inhibitor, wherein the patient had been determined to have a C/C genotype at rsl2079860.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV</span>
        <span itemprop="definition">hepatitis B virus</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitors</span>
        <span itemprop="definition">are described in detail below. Thus, in certain embodiments, the</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">is an agent described herein.</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a core antigen inhibitor.</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a surface antigen inhibitor.</span>
        <meta itemprop="num_attr" content="0095">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is selected from an oligonucleotide, a small molecule or a polypeptide.</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a small molecule.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an oligonucleotide.</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is a siRNA molecule.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an siRNA molecule selected from the siRNA molecules described in Tables A and B.</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">comprises a combination of two or more siRNA molecules selected from the siRNA molecules described in Tables A and B or the Examples.</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">comprises a combination of three or more siRNA molecules selected from the siRNA molecules described in Tables A and B or the Examples.</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24).</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">(e.g., siRNA) is comprised in a lipid nanoparticle formulation, wherein the lipid nanoparticle formulation comprises a cationic lipid and a non-cationic lipid.</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is selected from the group consisting of 1,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane ( â - DLenDMA; Compound (515)) , 3-((6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19- yloxy)-N,N-dimethylpropan-l -amine (DLin-MP-DMA; Compound (508)), (6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is cholesterol or a derivative thereof. In certain embodiments, the non-cationic lipid is a phospholipid.</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a mixture of a phospholipid and cholesterol or a derivative thereof.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is selected from the group consisting of dipalmitoyl phosphatidylcholine (DPPC), distearoylphosphatidyl choline (DSPC), and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPC</span>
        <span itemprop="definition">dipalmitoyl phosphatidylcholine</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">distearoylphosphatidyl choline</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid formulation</span>
        <span itemprop="definition">further comprises a conjugated lipid that inhibits aggregation of particles.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid that inhibits aggregation of particles</span>
        <span itemprop="definition">is a polyethyleneglycol (PEG)-lipid conjugate.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from the group consisting of a PEG-diacylglycerol (PEG- DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, a PEG- dimyristyloxypropyl (PEG-DMA) conjugate and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is a PEG-CDMA conjugate.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 48 mol % to about 62 mol % of the total lipid present in each particle within the formulation.</span>
        <meta itemprop="num_attr" content="0111">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">comprises a phospholipid and cholesterol or cholesterol derivative, wherein the phospholipid comprises from about 7 mol % to about 17 mol % of the total lipid present in each particle within the formulation and the cholesterol or derivative thereof comprises from about 25 mol % to about 40 mol % of the total lipid present in each particle within the formulation.</span>
        <meta itemprop="num_attr" content="0111">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid that inhibits aggregation of particles</span>
        <span itemprop="definition">comprises from about 0.5 mol % to about 3 mol % of the total lipid present in each particle within the formulation.</span>
        <meta itemprop="num_attr" content="0111">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is conjugated to a targeting moiety.</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an oligonucleotide, such as an siRNA, and the oligonucleotide is conjugated to a targeting moiety.</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">e.g., siRNA</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is com rised within a compound of formula I</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R a</span>
        <span itemprop="definition">is targeting ligand</span>
        <meta itemprop="num_attr" content="0115">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is an oligonucleotide; the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl;</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R A</span>
        <span itemprop="definition">is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR B , Ci-io alkyl C2-io alkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy;</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R B</span>
        <span itemprop="definition">is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support;</span>
        <meta itemprop="num_attr" content="0120">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methods of the invention</span>
        <span itemprop="definition">further comprise administering at least one additional therapeutic agent.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the at least one additional therapeutic agent</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV infected patient</span>
        <span itemprop="definition">is further infected with hepatitis D virus (HDV).</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HDV</span>
        <span itemprop="definition">hepatitis D virus</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitor</span>
        <span itemprop="definition">refers to a compound that can inhibit the expression and/or function of an HBV antigen  â i.e., core or surface antigen), either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">may be of natural or synthetic origin.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV antigen inhibitors</span>
        <span itemprop="definition">include but are not limited to, e.g., oligonucleotides, small molecules and polypeptides.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">small molecule</span>
        <span itemprop="definition">includes organic molecules having a molecular weight of less than about, e.g., 1000 amu. In one embodiment a small molecule can have a molecular weight of less than about 800 amu. In another embodiment a small molecule can have a molecular weight of less than about 500 amu.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV inhibitor</span>
        <span itemprop="definition">does not comprise interferon (TFN).</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a core antigen inhibitor.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">core antigen inhibitor</span>
        <span itemprop="definition">refers to a compound that can inhibit the expression and/or function of an HBV core antigen.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV core antigen inhibitor</span>
        <span itemprop="definition">is a capsid inhibitor.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a capsid inhibitor</span>
        <span itemprop="definition">may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Capsid inhibitors</span>
        <span itemprop="definition">also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like).</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, at least 90%, at least 95% or at least 99%.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitor</span>
        <span itemprop="definition">includes compounds described in International Patent Applications Publication Numbers WO2013006394, WO2014106019, and WO2014089296, including the following compounds:</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitor</span>
        <span itemprop="definition">also includes the compounds Bay-41-4109 (see International Patent Application Publication Number WO/2013/144129), AT-61 (see International Patent Application Publication Number WO/1998/33501 ; and King, RW, et al., Antimicrob Agents Chemother., 1998, 42, 12, 3179-3186), DVR-01 and DVR-23 (see International Patent Application Publication Number WO 2013/006394; and Campagna, MR, et al., J. of Virology, 2013, 87, 12, 6931, and pharmaceutically acceptable salts thereof:</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitor</span>
        <span itemprop="definition">also includes the compounds Compound 3, GLS-4, and NVR</span>
        <meta itemprop="num_attr" content="0137">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a surface antigen inhibitor (sAg inhibitor).</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">surface antigen inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting the expression and/or function of a surface antigen either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the surface antigen inhibitor</span>
        <span itemprop="definition">is a sAg secretion inhibitor.</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sAg secretion inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting, either directly or indirectly, the secretion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells.</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">detectably inhibits the secretion of sAg as measured, e.g., using assays known in the art or described herein, e.g., ELISA assay or by Western Blot.</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">inhibits the secretion of sAg by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. In certain embodiments, the inhibitor reduces serum levels of sAg in a patient by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sAg secretion inhibitor</span>
        <span itemprop="definition">includes compounds described in United States Patent Number 8,921,381, as well as compounds described in United States Patent Application Publication Numbers 2015/0087659 and 2013/0303552.</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term</span>
        <span itemprop="definition">includes the compounds PBHBV-001 and PBHBV-2-15, and pharmaceutically acceptable salts thereof:</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an anti-HBsAg antibody, e.g., mAbs.</span>
        <meta itemprop="num_attr" content="0143">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBIG</span>
        <span itemprop="definition">hepatitis B immune globulin</span>
        <meta itemprop="num_attr" content="0143">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an oligonucleotide.</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Oligomeric nucleotides</span>
        <span itemprop="definition">can be designed to target one or more genes and/or transcripts of the HBV genome, thereby inhibiting HBV antigen either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term &#34;oligonucleotideâ or âoligomeric nucleotideâ</span>
        <span itemprop="definition">refers to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally- or non-naturally occurring bases, sugars and intersugar (backbone) linkages.</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is an antisense molecule.</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is a small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA) or microRNA (miRNA).</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is a siRNA molecule.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">small- interfering RNA</span>
        <span itemprop="definition">or &#34;siRNAâ as used herein refers to double stranded RNA (i.e., duplex RNA) that is capable of reducing or inhibiting the expression of a target gene or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the siRNA sequence) when the siRNA is in the same cell as the target gene or sequence.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif).</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNAs</span>
        <span itemprop="definition">may be about 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21- 23 (duplex) nucleotides in length.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA duplexes</span>
        <span itemprop="definition">may comprise 3 &#39; overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5&#39; phosphate termini.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of siRNA</span>
        <span itemprop="definition">include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand.</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">are chemically synthesized.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coli RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al, Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al, Proc. Natl. Acad. Sci.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dsRNA</span>
        <span itemprop="definition">are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dsRNA</span>
        <span itemprop="definition">may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the dsRNA</span>
        <span itemprop="definition">can encode for an entire gene transcript or a partial gene transcript.</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">may be encoded by a plasmid  â e.g. , transcribed as sequences that automatically fold into duplexes with hairpin loops).</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may comprise one or more modified ribonucleotides and/or one or more backbone modifications (e.g., one or more ribonucleotides with a 2 -0- methyl modification, one or more UNA moieties, one or more 2&#39;-Fluoro nucleotides, and/or one or more phosphorothioate linkers).</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more ribonucleotides with a 2 -0- methyl modification</span>
        <span itemprop="definition">e.g., one or more ribonucleotides with a 2 -0- methyl modification, one or more UNA moieties, one or more 2&#39;-Fluoro nucleotides, and/or one or more phosphorothioate linkers.</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5&#39; and/or 3&#39; overhang on one or both strands of the siRNA</span>
        <span itemprop="definition">comprises 1-4  â e.g., 1, 2, 3, or 4) modified and/or unmodified deoxythymidine (t or dT) nucleotides, 1-4  â e.g., 1, 2, 3, or 4) modified  â e.g., 2&#39;OMe) and/or unmodified uridine (U) ribonucleotides, and/or 1-4  â e.g., 1, 2, 3, or 4) modified  â e.g., 2&#39;OMe) and/or unmodified ribonucleotides or deoxyribonucleotides having complementarity to the target sequence (e.g., 3&#39;overhang in the antisense strand) or the complementary strand thereof (e.g., 3&#39; overhang in the sense strand).</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">t or dT</span>
        <span itemprop="definition">deoxythymidine</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is an isolated, double stranded, siRNA molecule, that includes a sense strand and an antisense strand that is hybridized to the sense strand.</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">target one or more genes and/or transcripts of the HBV genome.</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV inhibitor</span>
        <span itemprop="definition">may be a composition comprising a combination  â e.g., a cocktail, pool, or mixture) of siRNAs that target different regions of the HBV genome, and thereby inhibit HBV antigen.</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is an siRNA molecule selected from the siRNA molecules described in Tables A and B.</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sense and antisense strands</span>
        <span itemprop="definition">are useful, for example, for making siRNA molecules that are useful to reduce the expression of one or more HBV genes in vivo or in vitro.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These sense and antisense strands</span>
        <span itemprop="definition">are also useful, for example, as hybridization probes for identifying and measuring the amount of HBV genome in a biological material, such as a tissue or blood sample from a human being infected with HBV or HBV/HDV.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an oligonucleotide</span>
        <span itemprop="definition">(such as the sense and antisense RNA strands set forth in Tables A and B) of the invention specifically hybridizes to or is</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotide</span>
        <span itemprop="definition">need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an oligonucleotide</span>
        <span itemprop="definition">is specifically hybridizable when binding of the oligonucleotide to the target sequence interferes with the normal function of the target sequence to cause a loss of utility or expression therefrom, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or, in the case of in vitro assays, under conditions in which the assays are conducted.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">may include 1, 2, 3, or more base substitutions as compared to the region of a gene or mRNA sequence that it is targeting or to which it specifically hybridizes.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">comprises a combination of two or more different siRNA molecules (e.g., a cocktail) selected from the siRNA molecules described in Tables A and B. In certain embodiments, the HBV antigen inhibitor comprises a combination of three or more different siRNA molecules selected from the siRNA molecules described in Tables A and B.</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides compositions  â e.g., pharmaceutical compositions) that include one of the two way or three way combinations of the siRNAs set forth in Tables A and B (see, e.g., Examples 26 and 27). In one aspect, the present invention provides combinations of two or three siRNA molecules, such as the combinations disclosed in the Examples, and compositions comprising such combinations, and uses of such combinations.</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the HBV antigen inhibitor</span>
        <span itemprop="definition">is a pharmaceutical composition comprising one or more  â e.g., a cocktail) of the siRNAs described herein and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Table A</span>
        <span itemprop="definition">the HBV antigen inhibitor is a pharmaceutical composition comprising one or more  â e.g., a cocktail) of the siRNAs described herein and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SEQ ID NO:225</span>
        <span itemprop="definition">ususuaCuAgUGCcaUuuguuca</span>
        <meta itemprop="num_attr" content="0199">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SEQ ID NO:226</span>
        <span itemprop="definition">us GsAaCaAauGgcaCuAgUaAas csuUU</span>
        <meta itemprop="num_attr" content="0199">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is Arrowhead-ARC-520 (see United States Patent Number 8,809,293; and Wooddell CI, et al., Molecular Therapy, 2013, 21, 5, 973-985).</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotide</span>
        <span itemprop="definition">includes siRNA molecules that target GalNAc 5 and REP 2139, REP-2165 (see, e.g., WO 2016/077321, Al-Mathtab et al., PLoS ONE</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV antigen inhibitor</span>
        <span itemprop="definition">e.g., an oligonucleotide, such as an siRNA</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid nanoparticle formulation</span>
        <span itemprop="definition">is comprised within a lipid nanoparticle formulation.</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV antigen inhibitor</span>
        <span itemprop="definition">e.g., an oligonucleotide, such as an HBV antigen inhibitor</span>
        <meta itemprop="num_attr" content="0210">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">is conjugated to a targeting moiety.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV antigen inhibitor</span>
        <span itemprop="definition">e.g., an oligonucleotide, such as an siRNA</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula (I) or compound of formula (XX)</span>
        <span itemprop="definition">is comprised within a compound of formula (I) or compound of formula (XX).</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methods of the invention</span>
        <span itemprop="definition">further comprise administering at least one additional therapeutic agent.</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the at least one additional therapeutic agent</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additional therapeutic agent</span>
        <span itemprop="definition">may be an HBV antigen inhibitor described herein.</span>
        <meta itemprop="num_attr" content="0218">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Category I treatments</span>
        <span itemprop="definition">are directed to the use of agents that control, e.g., inhibit, viral replication.</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reverse transcriptase inhibitor</span>
        <span itemprop="definition">is a nucleoside analog.</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reverse transcriptase inhibitor</span>
        <span itemprop="definition">is a nucleoside analog reverse-transcriptase inhibitor (NARTI or NRTI).</span>
        <meta itemprop="num_attr" content="0222">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reverse transcriptase inhibitor</span>
        <span itemprop="definition">is a nucleotide analog reverse- transcriptase inhibitor (NtARTI or NtRTI).</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reverse transcriptase inhibitor</span>
        <span itemprop="definition">includes, but is not limited to: entecavir, clevudine, telbivudine, lamivudine, adefovir, and tenofovir, tenofovir disoproxil, tenofovir alafenamide, tenofovir disoproxil fumarate, adefovir dipivoxil, (lR,2R,3R,5R)-3-(6-amino-9H- 9-purinyl)-2-fluoro-5-(hydroxymethyl)-4-methylenecyclopentan-l-ol (described in U. S. Patent No.</span>
        <meta itemprop="num_attr" content="0224">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reverse transcriptase inhibitor</span>
        <span itemprop="definition">includes, but is not limited to, entecavir, lamivudine, and (lR,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5-(hydroxymethyl)-4- methylenecyclopentan- 1 -ol .</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reverse transcriptase inhibitor</span>
        <span itemprop="definition">includes, but is not limited to a covalently bound phosphoramidate or phosphonamidate moiety of the above-mentioned reverse transcriptase inhibitors, or as described in, for example, U.S. Patent No. 8,816,074, US 2011/0245484 Al, and US 2008/0286230A1.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reverse transcriptase inhibitor</span>
        <span itemprop="definition">includes, but is not limited to, nucleotide analogs that comprise a phosphoramidate moiety, such as, methyl ((((lR,3R,4R,5R)-3-(6-amino-9H- purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl (((lR,2R,3R,4R)-3-fluoro-2-hydroxy-5-methylene-4-(6-oxo-l,6- dihydro-9H-purin-9-yl)cyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotide analogs</span>
        <span itemprop="definition">that comprise a phosphoramidate moiety, such as, methyl ((((lR,3R,4R,5R)-3-(6-amino-9H- purin-9-yl</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the individual diastereomers thereof</span>
        <span itemprop="definition">which includes, for example, methyl ((R)- ((( 1 R, 3R,4R, 5R)-3 -(6-amino-9H-purin-9-yl)-4-fluoro-5 -hydroxy-2- methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl ((S)- ((( 1 R, 3R,4R, 5R)-3 -(6-amino-9H-purin-9-yl)-4-fluoro-5 -hydroxy-2- methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reverse transcriptase inhibitor</span>
        <span itemprop="definition">includes, but is not limited to a phosphonamidate moiety, such as, tenofovir alafenamide, as well as those described in US 2008/0286230 Al .</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phosphonamidate moiety</span>
        <span itemprop="definition">such as, tenofovir alafenamide, as well as those described in US 2008/0286230 Al .</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods for preparing stereoselective phosphoramidate or phosphonamidate containing actives</span>
        <span itemprop="definition">are described in, for example, U.S. Patent No. 8,816,074, as well as US 201 1/0245484 Al and US 2008/0286230 Al .</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsid inhibitors</span>
        <span itemprop="definition">which may be used in methods of the invention are described above.</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cccDNA</span>
        <span itemprop="definition">Covalently closed circular DNA</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cccDNA formation inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting the formation and/or stability of cccDNA either directly or indirectly.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cccDNA formation inhibitor</span>
        <span itemprop="definition">may include, but is not limited to, any compound that inhibits capsid disassembly, rcDNA entry into the nucleus, and/or the conversion of rcDNA into cccDNA.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">detectably inhibits the formation and/or stability of the cccDNA as measured, e.g., using an assay described herein.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitor</span>
        <span itemprop="definition">inhibits the formation and/or stability of cccDNA by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cccDNA formation inhibitor</span>
        <span itemprop="definition">includes compounds described in International Patent Application Publicati the following compound:</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cccDNA formation inhibitor</span>
        <span itemprop="definition">includes, but is not limited to those generally and specifically described in United States Patent Application Publication Number US</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cccDNA formation inhibitor</span>
        <span itemprop="definition">includes, but is not limited to, 1- (phenylsulfonyl)-N-(pyridin-4-ylmethyl)-lH-indole-2-carboxamide; 1-Benzenesulfonyl- pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide; 2-(2-chloro-N-(2-chloro-5- (trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4- ylmethyl)acetamide; 2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N- (pyridin-4-ylmethyl)acetamide; 2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4- (trifluoromethyl)phenyl</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain embodiments of the invention</span>
        <span itemprop="definition">are directed to the use of agents that are HBV entry inhibitors.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Entry inhibitors</span>
        <span itemprop="definition">include Myrcludex-B, NTCP inhibitor small molecules, and FXR agonist EYP001 (see, e.g., Gripon, P., Cannie, I. and Urban, S. Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hepatitis B virus</span>
        <span itemprop="definition">uses its surface lipopeptide pre-Sl for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NTCP</span>
        <span itemprop="definition">sodium/bile acid cotransporter</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Myrcludex B</span>
        <span itemprop="definition">is a synthetic N-acylated pre-S l that can also dock to NTCP, blocking the virus&#39;s entry mechanism.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Category II treatments</span>
        <span itemprop="definition">are directed to the use of agents that reduce viral antigens.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligomeric nucleotides</span>
        <span itemprop="definition">that may be used in methods of the invention are described above (e.g., an HBV antigen inhibitor described herein).</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sAg secretion inhibitor</span>
        <span itemprop="definition">includes compounds that are capable of inhibiting, either directly or indirectly, the secretion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells. Examples of sAg secretion inhibitors that may be used in methods of the invention are described above (e.g., an HBV antigen inhibitor described herein).</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-HBsAg agents</span>
        <span itemprop="definition">include anti-HBsAg antibodies, e.g., mAbs. This term also includes hepatitis B immune globulin (HBIG).</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBIG</span>
        <span itemprop="definition">hepatitis B immune globulin</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Agents that Improve Immune Response Category III treatments</span>
        <span itemprop="definition">are directed to the use of agents that improve the immune response against viral infection.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least one &#39;immune enhancer&#39; agent</span>
        <span itemprop="definition">is used in combination with at least one &#39;immune stimulant agent&#39; .</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such a combination</span>
        <span itemprop="definition">can be used in further combination with at least one agent that controls viral replication and/or at least one agent that reduces the viral antigens.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Certain aspects of the invention</span>
        <span itemprop="definition">are directed to the use of agents that act to improve an immune response by reducing or eliminating immune exhaustion, e.g. , by using checkpoint inhibitors, thereby enhancing the immune response.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an immune enhancer</span>
        <span itemprop="definition">is a PD-L1 inhibitor.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PD-L1 inhibitors</span>
        <span itemprop="definition">are a group of agents that act to inhibit the association of the programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein 1 (PD-1).</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Immune enhancers</span>
        <span itemprop="definition">include the following:</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-PD-1 mAbs</span>
        <span itemprop="definition">e.g., Nivolumab, Pembrolizumab;</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-PD-Ll mAbs</span>
        <span itemprop="definition">e.g., Atezolizumab, Avelumab</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-CTLA4 mAbs</span>
        <span itemprop="definition">e.g., Ipilimumab</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-VISTA mAbs</span>
        <span itemprop="definition">e.g., JNJ-61610588</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-LAG3 mAbs</span>
        <span itemprop="definition">e.g., BMS-986016</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-TEVB mAbs</span>
        <span itemprop="definition">e.g., TSR-022</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">peptidomimetics</span>
        <span itemprop="definition">e.g., AU P-12</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">immune stimulant</span>
        <span itemprop="definition">includes compounds that are capable of modulating an immune response (e.g., stimulating an innate and/or adaptive immune response (e.g., an adjuvant)).</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">immune stimulant</span>
        <span itemprop="definition">includes polyinosinic:polycytidylic acid (poly I:C) and interferons.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">immune stimulant</span>
        <span itemprop="definition">includes agonists of stimulator of IFN genes (STING) and interleukins.</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term</span>
        <span itemprop="definition">also includes HBsAg release inhibitors, TLR-7 agonists (GS-9620, RG- 7795), T-cell and/or B-cell stimulators (GS-4774, OX-40 agonists (BMS 986178), anti-GITR agonists (BMS-986156)), RIG-1 inhibitors (SB-9200), and SMAC-mimetics (Birinapant).</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term</span>
        <span itemprop="definition">also includes the following:</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-HBV vaccines</span>
        <span itemprop="definition">Engerix-B, RECOMBIVAX HB, GS-4744, Heplisav-B</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">interferons</span>
        <span itemprop="definition">Pegylated IFN-a2a, Peglyated IFN-a2b, IFN-a, IFN- â</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IFN- â</span>
        <span itemprop="definition">interferons</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">STING agonists</span>
        <span itemprop="definition">cGAMP, cGAMP bisphosphorot ioate, ADU S I 00, and other small molecule compounds</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TLR9 agonists</span>
        <span itemprop="definition">(CYT-009, CpG dinucleotides);</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TLR3 agonists</span>
        <span itemprop="definition">(Ampligen/poly I:C12U);</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IL-2</span>
        <span itemprop="definition">aldesleukin</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hepatitis B virus</span>
        <span itemprop="definition">refers to a virus species of the genus</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Orthohepadnavirus</span>
        <span itemprop="definition">which is a part of the Hepadnaviridae family of viruses, and that is capable of causing liver inflammation in humans.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hepatitis D virus</span>
        <span itemprop="definition">refers to a virus species of the genus Deltaviridae, which is capable of causing liver inflammation in humans.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HDV</span>
        <span itemprop="definition">is a small circular enveloped RNA virus that can propagate only in the presence HBV.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HDV</span>
        <span itemprop="definition">requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hepatitis D</span>
        <span itemprop="definition">has the highest mortality rate of all the hepatitis infections.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the routes of transmission of HDV</span>
        <span itemprop="definition">are similar to those for HBV.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term âgeneâ</span>
        <span itemprop="definition">is used broadly to refer to any segment of nucleic acid associated with a biological function. Genes include coding sequences and/or the regulatory sequences required for their expression. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gene</span>
        <span itemprop="definition">refers to a nucleic acid fragment that expresses mRNA, functional RNA, or specific protein, including regulatory sequences.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Fusion RNA</span>
        <span itemprop="definition">refers to sense RNA, antisense RNA, ribozyme RNA, siRNA, or other RNA that may not be translated but yet has an effect on at least one cellular process.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Genes</span>
        <span itemprop="definition">also include nonexpressed DNA segments that, for example, form recognition sequences for other proteins.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Genes</span>
        <span itemprop="definition">can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">endogenous gene</span>
        <span itemprop="definition">refers to a native gene in its natural location in the genome of an organism.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNP</span>
        <span itemprop="definition">single nucleotide polymorphism</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">various methods for detecting polymorphisms</span>
        <span itemprop="definition">include, but are not limited to, sequencing, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230: 1242 (1985); Cotton et al., PNAS 85 :4397 (1988); and Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules (Orita et al, PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285 : 125-144 (1993); and Hayashi et al., Genet.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Sequence variations at specific locations</span>
        <span itemprop="definition">can also be assessed by nuclease protection assays such as RNase and 51 protection or chemical cleavage methods.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sequence variations</span>
        <span itemprop="definition">may be detected using a real-time PCR assay (e.g., employing a fluorescent probe).</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SNP genotyping</span>
        <span itemprop="definition">can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent).</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a biological sample</span>
        <span itemprop="definition">from a human subject</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">e.g., genomic DNA, mRNA or both</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">detecting</span>
        <span itemprop="definition">is used in the broadest sense to include both qualitative and quantitative measurements of a specific molecule, for example, measurements of a specific molecule such as a chromosome, a DNA sequence, individual nucleic acids, etc.</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">obtaining a biological sample from a hepatitis B patient</span>
        <span itemprop="definition">is used to refer to obtaining the sample directly from the patient, as well as obtaining the sample indirectly from an intermediary individual (e.g., obtaining the sample from a courier who obtained the sample from a nurse who obtained the sample from the patient).</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an intermediary individual</span>
        <span itemprop="definition">e.g., obtaining the sample from a courier who obtained the sample from a nurse who obtained the sample from the patient.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">biological sample</span>
        <span itemprop="definition">refers to a body sample from any animal, but preferably is from a mammal, more preferably from a human.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">samples</span>
        <span itemprop="definition">include biological fluids such as serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, whole blood, biopsy material, urine, cerebro-spinal fluid, saliva, sputum, tears, perspiration, and mucus.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tissue extracts</span>
        <span itemprop="definition">such as homogenized tissue and cellular extracts, and cellular samples (e.g., oral epithelial cells).</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a higher likelihood of responding to an HBV antigen inhibitor</span>
        <span itemprop="definition">refers to the likelihood of a patient having a favorable response to the HBV antigen inhibitor.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Favorable responses</span>
        <span itemprop="definition">include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a favorable response</span>
        <span itemprop="definition">is a reduction in HBV DNA or RNA (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more; or e.g., is undetectable after e.g., 1, 2, 3, 4, 5, 6 months, etc.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a favorable response</span>
        <span itemprop="definition">is sustained virological response (SVR).</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a favorable response</span>
        <span itemprop="definition">is a reduction in HBV core protein (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more).</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a favorable response</span>
        <span itemprop="definition">is a reduction in surface antigen (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more).</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a favorable response</span>
        <span itemprop="definition">is seroconversion (e.g., HBsAg seroconversion).</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">patients that have a C/C genotype at rsl2079860</span>
        <span itemprop="definition">may have a faster rate of surface antigen decline in response to the administration of an HBV antigen inhibitor as compared to a patient having a different genotype.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">patients that have a C/C genotype at rsl2079860</span>
        <span itemprop="definition">may have greater decline in surface antigen in response to the administration of an HBV antigen inhibitor as compared to a patient having a different genotype. In certain embodiments, patients that have a C/C genotype at rsl2079860 may have a higher likelihood of seroconverting in response to an HBV inhibitor as compared to a patient having a different genotype.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods of measuring a response to an HBV antigen inhibitor</span>
        <span itemprop="definition">are known in the art, for example, an assay described in Example 27 may be used.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">treatment</span>
        <span itemprop="definition">refers to clinical intervention in an attempt to alter the typical disease course of the individual being treated. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, treatments described herein are used to delay development of a disease or to slow the progression of a disease.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">patient</span>
        <span itemprop="definition">refers to any animal including mammals such as humans, higher non-human primates, rodents domestic and farm animals such as cow, horses, dogs and cats.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the patient</span>
        <span itemprop="definition">is a human patient.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phrases &#34;effective amountâ</span>
        <span itemprop="definition">means an amount of a compound described herein that (i) treats or prevents a hepatitis B virus infection, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a hepatitis B virus infection, or (iii) prevents or delays the onset of one or more symptoms of a hepatitis B virus infection.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a target gene</span>
        <span itemprop="definition">refers to the ability of a siRNA described herein to silence, reduce, or inhibit expression of a target gene (e.g., a gene within the HBV genome).</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a test sample</span>
        <span itemprop="definition">e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a siRNA</span>
        <span itemprop="definition">that silences, reduces, or inhibits expression of the target gene.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Expression of the target gene in the test sample</span>
        <span itemprop="definition">is compared to expression of the target gene in a control sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) that is not contacted with the siRNA.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Control samples</span>
        <span itemprop="definition">e.g. , samples expressing the target gene</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">silencing, inhibition, or reduction of expression of a target gene</span>
        <span itemprop="definition">is achieved when the value of the test sample relative to the control sample (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.) is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable assays</span>
        <span itemprop="definition">include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA,</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an &#34;effective amountâ or âtherapeutically effective amountâ of a therapeutic nucleic acid such as a siRNA</span>
        <span itemprop="definition">is an amount sufficient to produce the desired effect, e.g., an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of a siRNA.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">inhibition of expression of a target gene or target sequence</span>
        <span itemprop="definition">is achieved when the value obtained with a siRNA relative to the control  â e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.) is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable assays for measuring the expression of a target gene or target sequence</span>
        <span itemprop="definition">include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">refers to a polymer containing at least two nucleotides (i.e., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form and includes DNA and RNA.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotides</span>
        <span itemprop="definition">contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Bases</span>
        <span itemprop="definition">include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids</span>
        <span itemprop="definition">include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs and/or modified residues include, without limitation,</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">can include one or more UNA moieties.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">includes any oligonucleotide or polynucleotide, with fragments containing up to 60 nucleotides generally termed oligonucleotides, and longer fragments termed polynucleotides.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a deoxyribooligonucleotide</span>
        <span itemprop="definition">consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5&#39; and 3&#39; carbons of this sugar to form an alternating, unbranched polymer.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DNA</span>
        <span itemprop="definition">may be in the form of, e.g., antisense molecules, plasmid DNA, pre- condensed DNA, a PCR product, vectors, expression cassettes, chimeric sequences,</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">may be in the form, for example, of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">small interfering RNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dicer-substrate dsRNA</span>
        <span itemprop="definition">small hairpin RNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aiRNA</span>
        <span itemprop="definition">asymmetrical interfering RNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miRNA</span>
        <span itemprop="definition">microRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">microRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">microRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">mRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tRNA</span>
        <span itemprop="definition">tRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rRNA</span>
        <span itemprop="definition">tRNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">vRNA</span>
        <span itemprop="definition">viral RNA</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polynucleotide and oligonucleotide</span>
        <span itemprop="definition">refer to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally-occurring bases, sugars and intersugar (backbone) linkages.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polynucleotide and oligonucleotide</span>
        <span itemprop="definition">also include polymers or oligomers comprising non -naturally occurring monomers, or portions thereof, which function similarly.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">modified or substituted oligonucleotides</span>
        <span itemprop="definition">are often preferred over native forms because of properties such as, for example, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">degenerate codon substitutions</span>
        <span itemprop="definition">may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)).</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an &#34;isolatedâ or âpurifiedâ DNA molecule or RNA molecule</span>
        <span itemprop="definition">is a DNA molecule or RNA molecule that exists apart from its native environment.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An isolated DNA molecule or RNA molecule</span>
        <span itemprop="definition">may exist in a purified form or may exist in a non- native environment such as, for example, a transgenic host cell.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an &#34;isolatedâ or âpurifiedâ nucleic acid molecule or biologically active portion thereof</span>
        <span itemprop="definition">is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an &#34;isolated&#34; nucleic acid</span>
        <span itemprop="definition">is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5&#39; and 3&#39; ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the isolated nucleic acid molecule</span>
        <span itemprop="definition">can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gene</span>
        <span itemprop="definition">refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Gene product</span>
        <span itemprop="definition">refers to a product of a gene such as an RNA transcript or a polypeptide.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">unlocked nucleobase analogue</span>
        <span itemprop="definition">refers to an acyclic nucleobase in which the C2&#39; and C3&#39; atoms of the ribose ring are not covalently linked.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">unlocked nucleobase analogue</span>
        <span itemprop="definition">includes nucleobase analogues having the following structure identified as Structure A:</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Base</span>
        <span itemprop="definition">is any natural or unnatural base such as, for example, adenine (A), cytosine (C), guanine (G) and thymine (T).</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">UNA useful in the practice of the present invention</span>
        <span itemprop="definition">include the molecules identified as acyclic 2&#39;-3 &#39;-seco-nucleotide monomers in U. S. patent serial number 8,314,227 which is incorporated by reference herein in its entirety.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid</span>
        <span itemprop="definition">refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) âsimple lipids,â which include fats and oils as well as waxes; (2) âcompound lipids,â which include phospholipids and glycolipids; and (3) âderived lipidsâ such as steroids.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particle</span>
        <span itemprop="definition">includes a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., siRNA) to a target site of interest (e.g., cell, tissue, organ, and the like).</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic nucleic acid</span>
        <span itemprop="definition">e.g., siRNA</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle of the invention</span>
        <span itemprop="definition">is typically formed from a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle that includes a nucleic acid molecule</span>
        <span itemprop="definition">e.g. , siRNA molecule</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is fully encapsulated within the lipid particle, thereby protecting the nucleic acid from enzymatic degradation.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles</span>
        <span itemprop="definition">are extremely useful for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (e.g., sites physically separated from the administration site), and they can mediate silencing of target gene expression at these distal sites.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">may be complexed with a condensing agent and encapsulated within a lipid particle as set forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm,</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acid-lipid particles and their method of preparation</span>
        <span itemprop="definition">are disclosed in, e.g., U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid encapsulated</span>
        <span itemprop="definition">can refer to a lipid particle that provides a therapeutic nucleic acid such as a siRNA, with full encapsulation, partial encapsulation, or both.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">e.g., siRNA</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is fully encapsulated in the lipid particle (e.g., to form a nucleic acid-lipid particle).</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid conjugate</span>
        <span itemprop="definition">refers to a conjugated lipid that inhibits aggregation of lipid particles.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid conjugates</span>
        <span itemprop="definition">include, but are not limited to, PEG-lipid conjugates such as, e.g., PEG coupled to dialkyloxypropyls (e.g., PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see, e.g., U. S. Patent No.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic PEG lipids</span>
        <span itemprop="definition">cationic PEG lipids, polyoxazoline (POZ)-lipid conjugates (e.g., POZ-DAA conjugates), polyamide oligomers (e.g., ATTA-lipid conjugates), and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">POZ</span>
        <span itemprop="definition">polyoxazoline</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DAA</span>
        <span itemprop="definition">polyoxazoline conjugates</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polyamide oligomers</span>
        <span itemprop="definition">e.g., ATTA-lipid conjugates</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG or POZ</span>
        <span itemprop="definition">can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Any linker moiety suitable for coupling the PEG or the POZ to a lipid</span>
        <span itemprop="definition">can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-ester containing linker moieties</span>
        <span itemprop="definition">such as amides or carbamates, are used.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amphipathic lipid</span>
        <span itemprop="definition">refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hydrophilic characteristics</span>
        <span itemprop="definition">derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phospholipids</span>
        <span itemprop="definition">include, but are not limited to,</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phosphatidylcholine</span>
        <span itemprop="definition">phosphatidyl ethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine,</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amphipathic lipids</span>
        <span itemprop="definition">can be mixed with other lipids including triglycerides and sterols.</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">neutral lipid</span>
        <span itemprop="definition">refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids</span>
        <span itemprop="definition">include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipid</span>
        <span itemprop="definition">refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anionic lipid</span>
        <span itemprop="definition">refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins,</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diacylphosphatidylserines</span>
        <span itemprop="definition">diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines,</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophobic lipid</span>
        <span itemprop="definition">refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable examples</span>
        <span itemprop="definition">include, but are not limited to, diacylglycerol, dialkylglycerol, N-N- dialkylamino, l,2-diacyloxy-3-aminopropane, and l,2-dialkyl-3-aminopropane.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipid</span>
        <span itemprop="definition">and âamino lipidâ are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group).</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is typically protonated (i.e., positively charged) at a pH below the pK a of the cationic lipid and is substantially neutral at a pH above the pK a .</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids of the invention</span>
        <span itemprop="definition">may also be termed titratable cationic lipids.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">comprise: a protonatable tertiary amine (e.g., pH-titratable) head group; C 18 alkyl chains, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and ether, ester, or ketal linkages between the head group and alkyl chains.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a protonatable tertiary amine</span>
        <span itemprop="definition">e.g., pH-titratable</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 18 alkyl chains</span>
        <span itemprop="definition">wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ether, ester, or ketal linkages between the head group and alkyl chains</span>
        <span itemprop="definition">e.g., 1, 2, or 3</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such cationic lipids</span>
        <span itemprop="definition">include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA,  â -DLenDMA, DLin-K-DMA, DLin-K- C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4- DMA, DLen-C2K-DMA, y-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), and DLin-M-C3 -DMA (also known as MC3).</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">salts</span>
        <span itemprop="definition">includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions.</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anions</span>
        <span itemprop="definition">include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate,</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl</span>
        <span itemprop="definition">includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative saturated straight chain alkyls</span>
        <span itemprop="definition">include, but are not limited to, methyl, ethyl, w-propyl, Â«-butyl, ft-pentyl, w-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, isobutyl, tert-b tyl, isopentyl, and the like.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">saturated cyclic alkyls</span>
        <span itemprop="definition">include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkenyl</span>
        <span itemprop="definition">includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative straight chain and branched alkenyls</span>
        <span itemprop="definition">include, but are not limited to, ethylenyl, propylenyl, 1 -butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-l-butenyl, 2- methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl</span>
        <span itemprop="definition">includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons.</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative straight chain and branched alkynyls</span>
        <span itemprop="definition">include, without limitation, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1- pentynyl, 2-pentynyl, 3 -methyl- 1 butynyl, and the like.</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl</span>
        <span itemprop="definition">includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocycle</span>
        <span itemprop="definition">includes a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocycle</span>
        <span itemprop="definition">may be attached via any heteroatom or carbon atom.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Heterocycles</span>
        <span itemprop="definition">include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituents</span>
        <span itemprop="definition">include, but are not limited to, oxo, halogen, heterocycle, -CN, -OR x ,</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">halogen</span>
        <span itemprop="definition">includes fluoro, chloro, bromo, and iodo.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term &#34;fusogenicâ</span>
        <span itemprop="definition">refers to the ability of a lipid particle to fuse with the membranes of a cell.</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the membranes</span>
        <span itemprop="definition">can be either the plasma membrane or membranes surrounding organelles, e.g., endosome, nucleus, etc.</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aqueous solution</span>
        <span itemprop="definition">refers to a composition comprising in whole, or in part, water.</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">organic lipid solution</span>
        <span itemprop="definition">refers to a composition comprising in whole, or in part, an organic solvent having a lipid.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">electro dense core</span>
        <span itemprop="definition">when used to describe a lipid particle described herein, refers to the dark appearance of the interior portion of a lipid particle when visualized using cryo transmission electron microscopy (&#34;cyroTEM&#34;).</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cryoTEM</span>
        <span itemprop="definition">cryo transmission electron microscopy</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some lipid particles of the present invention</span>
        <span itemprop="definition">have an electron dense core and lack a lipid bilayer structure.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some lipid particles of the present invention</span>
        <span itemprop="definition">have an electron dense core, lack a lipid bilayer structure, and have an inverse Hexagonal or Cubic phase structure.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-bilayer lipid packing</span>
        <span itemprop="definition">provides a 3-dimensional network of lipid cylinders with water and nucleic acid on the inside, i.e., essentially a lipid droplet interpenetrated with aqueous channels containing the nucleic acid.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Distal site</span>
        <span itemprop="definition">refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism.</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âSerum-stableâ in relation to nucleic acid-lipid particles</span>
        <span itemprop="definition">means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or RNA.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable assays</span>
        <span itemprop="definition">include, for example, a standard serum assay, a DNAse assay, or an R Ase assay.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Systemic delivery</span>
        <span itemprop="definition">refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as a siRNA within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Systemic delivery of lipid particles</span>
        <span itemprop="definition">can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âLocal delivery,â as used herein,</span>
        <span itemprop="definition">refers to delivery of an active agent such as a siRNA directly to a target site within an organism.</span>
        <meta itemprop="num_attr" content="0347">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an agent</span>
        <span itemprop="definition">can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the liver, heart, pancreas, kidney, and the like.</span>
        <meta itemprop="num_attr" content="0347">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">virus particle load</span>
        <span itemprop="definition">refers to a measure of the number of virus particles (e.g., HBV and/or HDV) present in a bodily fluid, such as blood.</span>
        <meta itemprop="num_attr" content="0348">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">particle load</span>
        <span itemprop="definition">may be expressed as the number of virus particles per milliliter of, e.g., blood.</span>
        <meta itemprop="num_attr" content="0348">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Particle load testing</span>
        <span itemprop="definition">may be performed using nucleic acid amplification based tests, as well as non-nucleic acid-based tests (see, e.g., Puren et al., The Journal of Infectious Diseases, 201 :S27-36 (2010)).</span>
        <meta itemprop="num_attr" content="0348">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mammal</span>
        <span itemprop="definition">refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can be provided in several forms including, e.g., as one or more isolated small- interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each strand</span>
        <span itemprop="definition">is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR</span>
        <span itemprop="definition">are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25 :263-269 (1983); Sambrook et al, supra; Ausubel et al, supra), as are PCR methods (see, U.S. Patent Nos. 4,683, 195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)).</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Expression libraries</span>
        <span itemprop="definition">are also well known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">are chemically synthesized.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotides that comprise the siRNA molecules of the invention</span>
        <span itemprop="definition">can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al, J. Am. Chem. Soc, 109:7845 (1987); Scaringe et al, Nucl.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotides</span>
        <span itemprop="definition">makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5&#39;-end and phosphoramidites at the 3&#39;-end.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">small scale syntheses</span>
        <span itemprop="definition">can be conducted on an Applied Biosystems synthesizer using a 0.2  â  scale protocol.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">syntheses at the 0.2  â  scale</span>
        <span itemprop="definition">can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, CA).</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Protogene</span>
        <span itemprop="definition">Protogene</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a larger or smaller scale of synthesis</span>
        <span itemprop="definition">is also within the scope of this invention.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification</span>
        <span itemprop="definition">are known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules</span>
        <span itemprop="definition">can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA.</span>
        <meta itemprop="num_attr" content="0353">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each strand</span>
        <span itemprop="definition">can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.</span>
        <meta itemprop="num_attr" content="0353">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles</span>
        <span itemprop="definition">comprising one or more oligonucleotides  â e.g. , one or more siRNA molecules, such as one or more siRNA molecules described in Tables A and B) and one or more of cationic (amino) lipids or salts thereof, may be administered.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles described herein</span>
        <span itemprop="definition">further comprise one or more non-cationic lipids.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">further comprise one or more conjugated lipids capable of reducing or inhibiting particle aggregation.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are useful, for example, for delivering a therapeutically effective amount of siRNA into cells (e.g. , liver cells) of a human body infected with HBV or HBV/HDV, thereby treating the HBV infection and/or HDV infection and/or ameliorating one or more symptoms of HBV infection and/or HDV infection.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the different siRNA molecules</span>
        <span itemprop="definition">may be co-encapsulated in the same lipid particle, or each type of siRNA species present in the cocktail may be encapsulated in its own particle, or some siRNA species may be coencapsulated in the same particle while other siRNA species are encapsulated in different particles within the formulation.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA molecules of the invention</span>
        <span itemprop="definition">are fully encapsulated in the lipid particle.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles described herein</span>
        <span itemprop="definition">preferably comprise one or more siRNA (e.g., siRNA molecules described in Tables A and B), a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA molecule</span>
        <span itemprop="definition">is fully encapsulated within the lipid portion of the lipid particle such that the siRNA molecule in the lipid particle is resistant in aqueous solution to nuclease degradation.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles described herein</span>
        <span itemprop="definition">are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 1 10 nm, or from about 70 to about 90 nm.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">have a median diameter of from about 30 nm to about 150 nm.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">also typically have a lipid:nucleic acid ratio (e.g., a lipid:siRNA ratio) (mass/mass ratio) of from about 1 : 1 to about 100: 1, from about 1 : 1 to about 50: 1, from about 2 : 1 to about 25 : 1, from about 3 : 1 to about 20: 1, from about 5 : 1 to about 15 : 1 , or from about 5 : 1 to about 10: 1.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">are serum-stable nucleic acid-lipid particles which comprise one or more siRNA molecules (e.g., a siRNA molecule as described in Tables A and B), a cationic lipid  â e.g., one or more cationic lipids of Formula ZI-ZIII or salts thereof as set forth herein), a non-cationic lipid (e.g., mixtures of one or more phospholipids and cholesterol), and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates).</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules</span>
        <span itemprop="definition">e.g., a siRNA molecule as described in Tables A and B</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a non-cationic lipid</span>
        <span itemprop="definition">e.g., mixtures of one or more phospholipids and cholesterol</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle</span>
        <span itemprop="definition">may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more siRNA molecules (e.g., siRNA molecules described in Tables A and B) that target one or more of the genes described herein.</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules</span>
        <span itemprop="definition">e.g., siRNA molecules described in Tables A and B</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acid-lipid particles and their method of preparation</span>
        <span itemprop="definition">are described in, e.g., U. S. Patent Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501 ; 6, 110,745; and 6,320,017; and PCT Publication No. WO 96/40964, the disclosures of which are each herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the one or more siRNA molecules</span>
        <span itemprop="definition">may be fully encapsulated within the lipid portion of the particle, thereby protecting the siRNA from nuclease degradation.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA in the nucleic acid-lipid particle</span>
        <span itemprop="definition">is not substantially degraded after exposure of the particle to a nuclease at 37Â°C for at least about 20, 30, 45, or 60 minutes.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA in the nucleic acid-lipid particle</span>
        <span itemprop="definition">is not substantially degraded after incubation of the particle in serum at 37Â°C for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">is complexed with the lipid portion of the particle.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle compositions</span>
        <span itemprop="definition">are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term &#34;fully encapsulatedâ</span>
        <span itemprop="definition">indicates that the siRNA (e.g., a siRNA molecule as described in Tables A and B) in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free DNA or RNA.</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">e.g., a siRNA molecule as described in Tables A and B</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a fully encapsulated system</span>
        <span itemprop="definition">preferably less than about 25% of the siRNA in the particle is degraded in a treatment that would normally degrade 100% of free siRNA, more preferably less than about 10%, and most preferably less than about 5% of the siRNA in the particle is degraded.</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">âFully encapsulatedâ</span>
        <span itemprop="definition">also indicates that the nucleic acid-lipid particles are serum- stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">full encapsulation</span>
        <span itemprop="definition">may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid.</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">fluorescent dye exclusion assay</span>
        <span itemprop="definition">which uses a dye that has enhanced fluorescence when associated with nucleic acid.</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Specific dyes</span>
        <span itemprop="definition">such as OliGreen Â® and</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RiboGreen Â®</span>
        <span itemprop="definition">(Invitrogen Corp.; Carlsbad, CA) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and/or single- or double-stranded ribonucleotides. Encapsulation is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent. Detergent-mediated disruption of the liposomal bilayer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye.</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a nucleic acid-lipid particle composition comprising a plurality of nucleic acid-lipid particles.</span>
        <meta itemprop="num_attr" content="0363">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle composition</span>
        <span itemprop="definition">comprises a siRNA molecule that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle composition</span>
        <span itemprop="definition">comprises siRNA that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or</span>
        <meta itemprop="num_attr" content="0365">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the proportions of the components</span>
        <span itemprop="definition">can be varied and the delivery efficiency of a particular formulation can be measured using, e.g., an endosomal release parameter (ERP) assay.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ERP</span>
        <span itemprop="definition">endosomal release parameter</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles described herein</span>
        <span itemprop="definition">are useful for the prophylactic or therapeutic delivery, into a human infected with HBV or HBV/HDV, of siRNA molecules that silence the expression of one or more HBV genes, thereby ameliorating at least one symptom of HBV infection and/or HDV infection in the human.</span>
        <meta itemprop="num_attr" content="0367">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more of the siRNA molecules described herein</span>
        <span itemprop="definition">are formulated into nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment.</span>
        <meta itemprop="num_attr" content="0367">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutically effective amount of the nucleic acid-lipid particle</span>
        <span itemprop="definition">can be</span>
        <meta itemprop="num_attr" content="0367">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles described herein</span>
        <span itemprop="definition">are particularly useful for targeting liver cells in humans which is the site of most HBV gene expression.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Administration of the nucleic acid-lipid particle</span>
        <span itemprop="definition">can be by any route known in the art, such as, e.g., oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, or intradermal.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">is administered systemically, e.g., via enteral or parenteral routes of administration.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">downregulation of HBV gene expression</span>
        <span itemprop="definition">is determined by detecting HBV RNA or protein levels in a biological sample from a mammal after nucleic acid- lipid particle administration. In other embodiments, downregulation of HBV gene expression is determined by detecting HBV mRNA or protein levels in a biological sample from a mammal after nucleic acid-lipid particle administration. In certain embodiments, downregulation of HBV gene expression is detected by monitoring symptoms associated with HBV infection in a mammal after particle administration.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids or salts thereof</span>
        <span itemprop="definition">may be used in the lipid particles of the present invention either alone or in combination with one or more other cationic lipid species or non-cationic lipid species.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">include the (R) and/or (S) enantiomers thereof.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is a dialkyl lipid.</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dialkyl lipids</span>
        <span itemprop="definition">may include lipids that comprise two saturated or unsaturated alkyl chains, wherein each of the alkyl chains may be substituted or unsubstituted.</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of the two alkyl chains</span>
        <span itemprop="definition">comprise at least, e.g., 8 carbon atoms, 10 carbon atoms, 12 carbon atoms, 14 carbon atoms, 16 carbon atoms, 18 carbon atoms, 20 carbon atoms, 22 carbon atoms or 24 carbon atoms.</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is a trialkyl lipid.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">trialkyl lipids</span>
        <span itemprop="definition">may include lipids that comprise three saturated or unsaturated alkyl chains, wherein each of the alkyl chains may be substituted or unsubstituted.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of the three alkyl chains</span>
        <span itemprop="definition">comprise at least, e.g., 8 carbon atoms, 10 carbon atoms, 12 carbon atoms, 14 carbon atoms, 16 carbon atoms, 18 carbon atoms, 20 carbon atoms, 22 carbon atoms or 24 carbon atoms.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula ZI</span>
        <span itemprop="definition">having the following structure are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently hydrogen (H) or an optionally substituted Ci-Ce alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R 1 and R 2 may j oin to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;</span>
        <meta itemprop="num_attr" content="0377">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C1-C6 alkyl to provide a quaternary amine</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C10-C24 alkyl, C10-C24 alkenyl, C10-C24 alkynyl, or C10-C24 acyl, wherein at least one of R 4 and R 5 comprises at least two sites of unsaturation; and</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, or 4.</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently an optionally substituted C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl. In one preferred embodiment, R 1 and R 2 are both methyl groups. In other preferred embodiments, n is 1 or 2. In other embodiments, R 3 is absent when the pH is above the pK a of the cationic lipid and R 3 is hydrogen when the pH is below the pK a of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R 3 is an optionally substituted C1-C4 alkyl to provide a quaternary amine. In further, R 3 is absent when the pH is above the pK a of the cationic lipid and R 3 is hydrogen when the pH is below the pK a of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R 3 is an optionally substituted C1-C4 alkyl to provide a quaternary amine. In</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are independently an optionally substituted C12-C20 or C14-C22 alkyl, C12-C20 or C14-C22 alkenyl, C12-C20 or C14-C22 alkynyl, or C12-C20 or C14-C22 acyl, wherein at least one of R 4 and R 5 comprises at least two sites of unsaturation.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, an arachidonyl moiety, and a docosahexaenoyl moiety, as well as acyl derivatives thereof (e.g., linoleoyl, linolenoyl,  â -linolenoyl, etc.).</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl derivatives thereof</span>
        <span itemprop="definition">e.g., linoleoyl, linolenoyl,</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one of R 4 and R 5</span>
        <span itemprop="definition">comprises a branched alkyl group (e.g., a phytanyl moiety) or an acyl derivative thereof (e.g., a phytanoyl moiety).</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the octadecadienyl moiety</span>
        <span itemprop="definition">is a linoleyl moiety.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the octadecatrienyl moiety</span>
        <span itemprop="definition">is a linolenyl moiety or a  â -linolenyl moiety.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are both linoleyl moieties, linolenyl moieties, or  â -linolenyl moieties.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZI</span>
        <span itemprop="definition">is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), l,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-dilinoleyloxy- (N,N-dimethyl)-butyl-4-amine (C2-DLinDMA), 1 ,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4- amine (C2-DLinDAP), or mixtures thereof.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DLinDMA</span>
        <span itemprop="definition">l,2-dilinoleyloxy-N,N-dimethylaminopropane</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DLenDMA</span>
        <span itemprop="definition">1,2-dilinoleyloxy- (N,N-dimethyl)-butyl-4-amine</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C2-DLinDAP</span>
        <span itemprop="definition">1,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4-</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZI</span>
        <span itemprop="definition">forms a salt (preferably a crystalline salt) with one or more anions.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZI</span>
        <span itemprop="definition">is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oxalate</span>
        <span itemprop="definition">e.g., hemioxalate</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthesis of cationic lipids such as DLinDMA and DLenDMA, as well as additional cationic lipids,</span>
        <span itemprop="definition">is described in U.S. Patent Publication No. 20060083780, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as C2-DLinDMA and C2-DLinDAP, as well as additional cationic lipids, is described in international patent application number WO2011/000106 the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula ZII</span>
        <span itemprop="definition">having the following structure (or thereof) are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0385">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C12-C24 alkyl, C12-C24 alkenyl, C12-C24 alkynyl, or C12-C24 acyl;</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3 and R 4</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R 3 and R 4 mayjoin to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 5</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C 1-C6 alkyl to provide a quaternary amine;</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m, n, and p</span>
        <span itemprop="definition">are either the same or different and are independently either 0, 1, or 2, with the proviso that m, n, and p are not simultaneously 0;</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">q</span>
        <span itemprop="definition">is 0, 1, 2, 3, or 4;</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y and Z</span>
        <span itemprop="definition">are either the same or</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZII</span>
        <span itemprop="definition">is 2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[l,3]-dioxolane (DLin-K-C2-DMA; &#34;XTC2&#34; or âC2Kâ), 2,2-dilinoleyl-4- (3-dimethylaminopropyl)-[l,3]-dioxolane (DLin-K-C3 -DMA; &#34;C3Kâ), 2,2-dilinoleyl-4-(4- dimethylaminobutyl)-[l,3]-dioxolane (DLin-K-C4-DMA; &#34;C4Kâ), 2,2-dilinoleyl-5- dimethylaminomethyl-[l,3]-dioxane (DLin-K6-DMA), 2,2-dilinoleyl-4-N-methylpepiazino- [l,3]-dioxolane (DLin-K-</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZII</span>
        <span itemprop="definition">is DLin-K-C2-DMA. In some embodiments, the cationic lipid of Formula ZII forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula ZII is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DLin-K-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DLin-K-C2-DMA, DLin-K-C3-DMA, DLin-K-C4-DMA, DLin-K6-DMA, DLin-K-MPZ, DO- K-DMA, DS-K-DMA, DLin-K-MA, DLin-K-TMA.Cl, DLin-K 2 -DMA, and D-Lin-K-N- methylpiperzine, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled &#34;Improved Amino Lipids and Methods for the Delivery of Nucleic Acids,&#34; filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids of Formula ZIII</span>
        <span itemprop="definition">having the following structure are useful in the present invention:</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are either the same or different and are independently an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is either absent or is hydrogen (H) or a C1-C6 alkyl to provide a quaternary amine;</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are either absent or present and when present are either the same or different and are independently an optionally substituted C1-C10 alkyl or C2-C10 alkenyl; and n is 0, 1, 2, 3, or 4.</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently an optionally substituted C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl. In a preferred embodiment, R 1 and R 2 are both methyl groups. In another preferred embodiment, R 4 and R 5 are both butyl groups. In yet another preferred embodiment, n is 1. In other embodiments, R 3 is absent when the pH is above the pK a of the cationic lipid and R 3 is hydrogen when the pH is below the pK a of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R 3 is an optionally substituted C1-C4 alkyl to provide a quaternary amine.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are independently an optionally substituted C2-C6 or C2-C4 alkyl or C2-C6 or C2-C4 alkenyl.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZIII</span>
        <span itemprop="definition">comprises ester linkages between the amino head group and one or both of the alkyl chains.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZIII</span>
        <span itemprop="definition">forms a salt (preferably a crystalline salt) with one or more anions.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZIII</span>
        <span itemprop="definition">is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of the alkyl chains in Formula ZIII</span>
        <span itemprop="definition">contains cis double bonds at positions 6, 9, and 12 (i.e., cis,cis,cis-A 6 ,A 9 , w ), in an alternative embodiment, one, two, or three of these double bonds in one or both alkyl chains may be in the trans configuration.</span>
        <meta itemprop="num_attr" content="0393">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of Formula ZIII</span>
        <span itemprop="definition">has the structur</span>
        <meta itemprop="num_attr" content="0394">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MC3</span>
        <span itemprop="definition">cationic lipids</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">additional cationic lipids</span>
        <span itemprop="definition">e.g., certain analogs of MC3</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">U.S. Provisional Application No. 61/185,800</span>
        <span itemprop="definition">entitled âNovel Lipids and Compositions for the Delivery of Therapeuticsâ</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">U. S. Provisional Application No. 61/287,995</span>
        <span itemprop="definition">entitled âMethods and Compositions for Delivery of Nucleic Acids,â filed December 18, 2009, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as CLinDMA, as well as additional cationic lipids</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in PCT Publication No.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">WO 09/086558</span>
        <span itemprop="definition">the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids</span>
        <span itemprop="definition">such as DO-C-DAP, DMDAP, DOTAP.Cl, DLin-M-C2-DMA, as well as additional cationic lipids, is described in PCT Application No. PCT US2009/060251, entitled âImproved Amino Lipids and Methods for the Delivery of Nucleic Acids,&#34; filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthesis of a number of other cationic lipids and related analogs</span>
        <span itemprop="definition">has been described in U.S. Patent Nos.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LIPOFECTAMINE Â®</span>
        <span itemprop="definition">including DOSPA and DOPE, available from Invitrogen</span>
        <meta itemprop="num_attr" content="0400">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TRANSFECTAM Â®</span>
        <span itemprop="definition">including DOGS, available from Promega Corp.</span>
        <meta itemprop="num_attr" content="0401">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 50 mol % to about 90 mol %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 mol %, or from about 55 mol % to about 70 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of cationic lipid present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by  â  5 mol %.</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target amount of cationic lipid</span>
        <span itemprop="definition">is 57.1 mol %, but the actual amount of cationic lipid may be  â  5 mol %,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle; however, one skilled in the art will understand that the total mol % may deviate slightly from 100% due to rounding, for example, 99.9 mol % or 100.1</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipids used in the lipid particles of the invention</span>
        <span itemprop="definition">can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of non-cationic lipids</span>
        <span itemprop="definition">include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC),</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phospholipids</span>
        <span itemprop="definition">such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DOPG</span>
        <span itemprop="definition">dioleoylphosphatidylglycerol</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPG</span>
        <span itemprop="definition">dipalmitoylphosphatidylglycerol</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dioleoylphosphatidyl ethanolamine</span>
        <span itemprop="definition">DOPE</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">palmitoyloleoyl-phosphatidylcholine</span>
        <span itemprop="definition">POPC</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">palmitoyloleoyl -phosphatidyl ethanolamine</span>
        <span itemprop="definition">POPE</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">palmitoyloleyol-phosphatidylglycerol</span>
        <span itemprop="definition">POPG</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dioleoylphosphatidyl ethanolamine 4-(N-maleimidomethyl)-cyclohexane-l-carboxylate</span>
        <span itemprop="definition">DOPE-mal</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dipalmitoyl-phosphatidylethanolamine</span>
        <span itemprop="definition">DPPE</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dimyristoyl- phosphatidylethanolamine</span>
        <span itemprop="definition">DMPE</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">distearoyl-phosphatidylethanolamine</span>
        <span itemprop="definition">DSPE</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">monomethyl -phosphatidyl ethanolamine</span>
        <span itemprop="definition">dimethyl -phosphatidyl ethanolamine, dielaidoyl- phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DEPE</span>
        <span itemprop="definition">dielaidoyl- phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SOPE</span>
        <span itemprop="definition">stearoyloleoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lysophosphatidylcholine</span>
        <span itemprop="definition">dilinoleoylphosphatidylcholine</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids</span>
        <span itemprop="definition">can also be used.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl groups in these lipids</span>
        <span itemprop="definition">are preferably acyl groups derived from fatty acids having C io- C24 carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids</span>
        <span itemprop="definition">include sterols such as cholesterol and derivatives thereof.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol derivatives</span>
        <span itemprop="definition">include polar analogues such as 5a-cholestanol, 5 -coprostanol, cholesteryl-(2&#39; -hydroxy)-ethyl ether, cholesteryl-(4&#39;- hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5p-cholestanone, and cholesteryl decanoate; and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol derivative</span>
        <span itemprop="definition">is a polar analogue such as cholesteryl-(4&#39;-hydroxy)-butyl ether.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesteryl-(2&#39;-hydroxy)-ethyl ether</span>
        <span itemprop="definition">is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid present in the lipid particles</span>
        <span itemprop="definition">comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the non-cationic lipid present in the lipid particles comprises or consists of one or more phospholipids, e.g., a cholesterol -free lipid particle formulation. In yet other embodiments, the non-cationic lipid present in the lipid particles comprises or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation.</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids suitable for use in the present invention</span>
        <span itemprop="definition">include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nonphosphorous containing lipids</span>
        <span itemprop="definition">such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate,</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 45 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof or range therein</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mixture</span>
        <span itemprop="definition">may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid component in the mixture</span>
        <span itemprop="definition">may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid component in the mixture</span>
        <span itemprop="definition">comprises from about 5 mol % to about 17 mol %, from about 7 mol % to about 17 mol %, from about 7 mol % to about 15 mol %, from about 8 mol % to about 15 mol %, or about 8 mol %, 9 mol %, 10 mol %, 11 mol %, 12 mol %, 13 mol %, 14 mol %, or 15 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle formulation comprising a mixture of phospholipid and cholesterol</span>
        <span itemprop="definition">may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid formulation useful in the practice of the invention</span>
        <span itemprop="definition">has a lipid to drug (e.g., siRNA) ratio of about 10: 1 (e.g., a lipid:drug ratio of from 9.5: 1 to 1 1 : 1, or from 9.9: 1 to 11 : 1, or from 10: 1 to 10.9: 1).</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid to drug</span>
        <span itemprop="definition">e.g., siRNA</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 9.5: 1 to 1 1 : 1, or from 9.9: 1 to 11 : 1, or from 10: 1 to 10.9: 1).</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid formulation useful in the practice of the invention</span>
        <span itemprop="definition">has a lipid to drug (e.g., siRNA) ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5 : 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid to drug</span>
        <span itemprop="definition">e.g., siRNA ratio of about 9: 1</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5 : 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol component in the mixture</span>
        <span itemprop="definition">may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol component in the mixture</span>
        <span itemprop="definition">comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol or derivative thereof</span>
        <span itemprop="definition">may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation</span>
        <span itemprop="definition">may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, or 40 mol % (or any fraction thereof or range therein) of the total mol %,</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle formulation</span>
        <span itemprop="definition">may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle formulation</span>
        <span itemprop="definition">may comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative thereof) (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of non-cationic lipid present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by  â  5 mol %,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %.</span>
        <meta itemprop="num_attr" content="0433">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">may further comprise a lipid conjugate.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid</span>
        <span itemprop="definition">is useful in that it prevents the aggregation of particles.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable conjugated lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer-lipid conjugates (CPLs), and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">is a PEG-lipid.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids suitable for use in the invention</span>
        <span itemprop="definition">include, without limitation, mPEG2000-l,2-di-O-alkyl- â 3-carbomoylglyceride (PEG-C-DOMG).</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-l,2-di-O-alkyl- â 3-carbomoylglyceride</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-l,2-di-O-alkyl- â 3-carbomoylglyceride</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-l,2-di-O-alkyl- â 3-carbomoylglyceride</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-l,2-di-O-alkyl- â 3-carbomoylglyceride</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-C-DOMG</span>
        <span itemprop="definition">mPEG2000-l,2-di-O-alkyl- â 3-carbo</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG</span>
        <span itemprop="definition">is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co. and other companies and include, but are not limited to, the following:</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEGs</span>
        <span itemprop="definition">such as those described in U. S. Patent Nos. 6,774, 180 and 7,053, 150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mPEG (20 KDa) amine</span>
        <span itemprop="definition">e.g., mPEG (20 KDa) amine</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">monomethoxypolyethyleneglycol-acetic acid</span>
        <span itemprop="definition">MePEG-ClHhCOOH</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-DAA conjugates</span>
        <span itemprop="definition">e.g., PEG-DAA conjugates.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG moiety of the PEG-lipid conjugates described herein</span>
        <span itemprop="definition">may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG moiety</span>
        <span itemprop="definition">has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1 ,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc. ). In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Any linker moiety suitable for coupling the PEG to a lipid</span>
        <span itemprop="definition">can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linker moiety</span>
        <span itemprop="definition">is a non-ester containing linker moiety.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-ester containing linker moiety</span>
        <span itemprop="definition">refers to a linker moiety that does not contain a carboxylic ester bond (-OC(O)-).</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable non-ester containing linker moieties</span>
        <span itemprop="definition">include, but are not limited to, amido (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (- HC(O)O-), urea (-</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a carbamate linker</span>
        <span itemprop="definition">is used to couple the PEG to the lipid.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ester containing linker moiety</span>
        <span itemprop="definition">is used to couple the PEG to the lipid.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable ester containing linker moieties</span>
        <span itemprop="definition">include, e.g., carbonate (-OC(O)O-), succinoyl, phosphate esters (-O-(O)POH-O-), sulfonate esters, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation</span>
        <span itemprop="definition">can be conjugated to PEG to form the lipid conjugate.</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such phosphatidylethanolamines</span>
        <span itemprop="definition">are commercially available, or can be isolated or synthesized using conventional techniques known to those of skill in the art.</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidyl-ethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of Cio to C20</span>
        <span itemprop="definition">are preferred.</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids</span>
        <span itemprop="definition">can also be used. Suitable</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phosphatidylethanolamines</span>
        <span itemprop="definition">include, but are not limited to, dimyristoyl- phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMPE</span>
        <span itemprop="definition">dimyristoyl- phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPE</span>
        <span itemprop="definition">dipalmitoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DOPE</span>
        <span itemprop="definition">dioleoylphosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPE</span>
        <span itemprop="definition">distearoyl-phosphatidylethanolamine</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">AZA</span>
        <span itemprop="definition">or &#34;polyamideâ includes, without limitation, compounds described in U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes. These compounds include a compound having the formula: wherein R is a member selected from the group consisting of hydrogen, alkyl and acyl; R 1 is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R 1 and the nitrogen to which they are bound form an azido moiety; R 2 is a member of the group selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and a side chain of an amino acid; R 3 is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and R 4 R 5 , wherein R 4 and R 5 are independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p is 1 to 4;</span>
        <meta itemprop="num_attr" content="0445">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diacylglycerol</span>
        <span itemprop="definition">or âDAGâ includes a compound having 2 fatty acyl chains</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">both of which have independently between 2 and 30 carbons bonded to the 1 - and 2- position of glycerol by ester linkages.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the acyl groups</span>
        <span itemprop="definition">can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C12), myristoyl</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are the same, i.e., R 1 and R 2 are both myristoyl (i.e., dimyristoyl), R 1 and R 2 are both stearoyl</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Diacylglycerols</span>
        <span itemprop="definition">have the following general formula:</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dialkyloxypropyl</span>
        <span itemprop="definition">includes a compound having 2 alkyl chains</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">both of which have independently between 2 and 30 carbons.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl groups</span>
        <span itemprop="definition">can be saturated or have varying degrees of unsaturation.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Di alkyl oxypropyls</span>
        <span itemprop="definition">have the following general formula:</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is a PEG-DAA conjugate having the following formula:</span>
        <meta itemprop="num_attr" content="0452">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyethyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the long-chain alkyl groups</span>
        <span itemprop="definition">can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (do), lauryl (Co), myristyl (CM), palmityl (C1 â 2), stearyl (C 18 ), and icosyl (do).</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 and R 2</span>
        <span itemprop="definition">are the same, i.e., R 1 and R 2 are both myristyl (i.e., dimyristyl), R 1 and R 2 are both stearyl (i.e., distearyl), etc.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons.</span>
        <meta itemprop="num_attr" content="0455">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.</span>
        <meta itemprop="num_attr" content="0455">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L</span>
        <span itemprop="definition">is a non-ester containing linker moiety.</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable non- ester containing linkers</span>
        <span itemprop="definition">include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-ester containing linker moiety</span>
        <span itemprop="definition">is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate).</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-ester containing linker moiety</span>
        <span itemprop="definition">is an amido linker moiety (i.e. , a PEG- 4-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinamidyl linker moiety (i.e., a PEG- â -DAA conjugate).</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from:</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugates</span>
        <span itemprop="definition">are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock,</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate</span>
        <span itemprop="definition">is a PEG-didecyloxypropyl (Cio) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG-dimyristyloxypropyl (CM) conjugate, a PEG- dipalmityloxypropyl (C 16 ) conjugate, or a PEG-distearyloxypropyl (C 18 ) conjugate.</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG</span>
        <span itemprop="definition">preferably has an average molecular weight of about 750 or about 2,000 daltons.</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">comprises</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">comprises PEG750-C- DMA, wherein the &#34;750â denotes the average molecular weight of the PEG, the âCâ denotes a carbamate linker moiety, and the &#34;DMAâ denotes dimyristyloxypropyl.</span>
        <meta itemprop="num_attr" content="0462">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the terminal hydroxyl group of the PEG</span>
        <span itemprop="definition">is substituted with a methyl group.</span>
        <meta itemprop="num_attr" content="0462">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dialkyloxypropyls</span>
        <span itemprop="definition">can be used in the PEG-DAA conjugates of the present invention.</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophilic polymers</span>
        <span itemprop="definition">can be used in place of PEG. Examples of suitable polymers that can be used in place of PEG include, but are not limited to, polyvinylpyrrolidone,</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polymethyloxazoline</span>
        <span itemprop="definition">polyethyloxazoline, polyhydroxypropyl methacrylamide,</span>
        <meta itemprop="num_attr" content="0464">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polymethacrylamide and polydimethylacrylamide</span>
        <span itemprop="definition">polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethyl cellulose or hydroxyethylcellulose.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et al, Bioconj. Chem., 11 :433-437 (2000); U. S. Patent No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes).</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG</span>
        <span itemprop="definition">poly(ethylene glycol)</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable CPLs</span>
        <span itemprop="definition">include compounds of Formula ZVIII:</span>
        <meta itemprop="num_attr" content="0467">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is a lipid moiety such as an amphipathic lipid, a neutral lipid, or a hydrophobic lipid that acts as a lipid anchor.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable lipid examples</span>
        <span itemprop="definition">include, but are not limited to, diacylglycerolyls, dialkylglycerolyls, N-N-dialkylaminos, 1,2-diacyloxy- 3-aminopropanes, and l,2-dialkyl-3-aminopropanes.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a polymer or an oligomer such as a hydrophilic polymer or oligomer.</span>
        <meta itemprop="num_attr" content="0471">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic polymer</span>
        <span itemprop="definition">is a biocompatable polymer that is nonimmunogenic or possesses low inherent immunogenicity.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic polymer</span>
        <span itemprop="definition">can be weakly antigenic if used with appropriate adjuvants.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable nonimmunogenic polymers</span>
        <span itemprop="definition">include, but are not limited to, PEG, polyamides, polylactic acid, polyglycolic acid, polylactic</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polymer</span>
        <span itemprop="definition">has a molecular weight of from about 250 to about 7,000 daltons.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is a polycationic moiety.</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polycationic moiety</span>
        <span itemprop="definition">refers to a compound, derivative, or functional group having a positive charge, preferably at least 2 positive charges at a selected pH, preferably physiological pH.</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable polycationic moieties</span>
        <span itemprop="definition">include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine, and histidine;</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polycationic moieties</span>
        <span itemprop="definition">can be linear, such as linear tetralysine, branched or dendrimeric in structure.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polycationic moieties</span>
        <span itemprop="definition">have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between about 2 to about 8 positive charges at selected pH values. The selection of which polycationic moiety to employ may be determined by the type of particle application which is desired.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the charges on the polycationic moieties</span>
        <span itemprop="definition">can be either distributed around the entire particle moiety, or alternatively, they can be a discrete concentration of charge density in one particular area of the particle moiety e.g., a charge spike. If the charge density is distributed on the particle, the charge density can be equally distributed or unequally distributed. All variations of charge distribution of the polycationic moiety are encompassed by the present invention.</span>
        <meta itemprop="num_attr" content="0476">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid &#34;Aâ and the nonimmunogenic polymer âWâ</span>
        <span itemprop="definition">can be attached by various methods and preferably by covalent attachment. Methods known to those of skill in the art can be used for the covalent attachment of &#34;Aâ and âW.â Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester, and hydrazone linkages. It will be apparent to those skilled in the art that &#34;Aâ and âWâ must have complementary functional groups to effectuate the linkage. The reaction of these two groups, one on the lipid and the other on the polymer, will provide the desired linkage.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid</span>
        <span itemprop="definition">is a diacyl glycerol and the terminal hydroxyl is activated, for instance with NHS and DCC, to form an active ester, and is then reacted with a polymer which contains an amino group, such as with a polyamide (see, e.g., U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes), an amide bond will form between the two groups.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polyamide</span>
        <span itemprop="definition">see, e.g., U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polycationic moiety</span>
        <span itemprop="definition">can have a ligand attached, such as a targeting ligand or a chelating moiety for complexing calcium.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a ligand attached</span>
        <span itemprop="definition">such as a targeting ligand or a chelating moiety for complexing calcium.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic moiety</span>
        <span itemprop="definition">maintains a positive charge.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ligand that is attached</span>
        <span itemprop="definition">has a positive charge.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable ligands</span>
        <span itemprop="definition">include, but are not limited to, a compound or device with a reactive functional group and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, micelles, immunoglobulins, functional groups, other targeting moieties, or toxins.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 0.1 mol % to about 3 mol %, from about 0.5 mol % to about 3 mol %, or about 0.6 mol %, 0.7 mol %, 0.8 mol %, 0.9 mol %, 1.0 mol %, 1.1 mol %, 1.2 mol %, 1.3 mol %, 1.4 mol %, 1.5 mol %, 1.6 mol %, 1.7 mol %, 1.8 mol %, 1.9 mol %, 2.0 mol %, 2.1 mol%, 2.2 mol%, 2.3 mol %, 2.4 mol %, 2.5 mol %, 2.6 mol %, 2.7 mol %, 2.8 mol %, 2.9 mol % or 3 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid</span>
        <span itemprop="definition">comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">(e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid</span>
        <span itemprop="definition">comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol %</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the percentage of lipid conjugate present in the lipid particles of the invention</span>
        <span itemprop="definition">is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by  â  5 mol %,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %.</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">concentration of the lipid conjugate</span>
        <span itemprop="definition">can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic.</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the rate at which the lipid conjugate exchanges out of the lipid particle and, in turn, the rate at which the lipid particle becomes fusogenic</span>
        <span itemprop="definition">can be varied, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0485">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">other variables</span>
        <span itemprop="definition">including, for example, pH, temperature, ionic strength, etc. can be used to vary and/or control the rate at which the lipid particle becomes fusogenic. Other methods which can be used to control the rate at which the lipid particle becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure.</span>
        <meta itemprop="num_attr" content="0485">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the composition and concentration of the lipid conjugate</span>
        <span itemprop="definition">one can control the lipid particle size.</span>
        <meta itemprop="num_attr" content="0485">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of additional lipid-based carrier systems suitable for use in the present invention</span>
        <span itemprop="definition">include lipoplexes (see, e.g., U.S. Patent Publication No. 20030203865; and Zhang et al., J. Control Release, 100: 165-180 (2004)), pH-sensitive lipoplexes (see, e.g., U. S. Patent Publication No. 20020192275), reversibly masked lipoplexes (see, e.g., U.S. Patent Publication No. 20030180950), cationic lipid-based compositions (see, e.g., U.S. Patent No. 6,756,054; and U. S. Patent Publication No.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic liposomes</span>
        <span itemprop="definition">see, e.g., U. S. Patent Publication Nos. 20030229040, 20020160038, and 20020012998; U. S. Patent No. 5,908,635; and PCT Publication No. WO 01/72283</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anionic liposomes</span>
        <span itemprop="definition">see, e.g., U. S. Patent Publication No. 20030026831</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pH-sensitive liposomes</span>
        <span itemprop="definition">see, e.g., U. S. Patent Publication No. 20020192274; and AU 2003210303</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antibody-coated liposomes</span>
        <span itemprop="definition">see, e.g., U.S. Patent Publication No. 20030108597; and PCT Publication No.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">WO 00/50008</span>
        <span itemprop="definition">cell-type specific liposomes (see, e.g., U.S. Patent Publication No. 20030198664), liposomes containing nucleic acid and peptides (see, e.g., U.S. Patent No. 6,207,456), liposomes containing lipids derivatized with releasable hydrophilic polymers (see, e.g., U.S. Patent Publication No. 20030031704), lipid-entrapped nucleic acid (see, e.g., PCT Publication Nos. WO 03/057190 and WO</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">liposomal compositions</span>
        <span itemprop="definition">see, e.g., U. S. Patent Publication Nos. 20030035829 and 20030072794; and U.S. Patent No. 6,200,599), stabilized mixtures of liposomes and emulsions (see, e.g., EP1304160), emulsion compositions (see, e.g., U.S. Patent No. 6,747,014), and nucleic acid micro-emulsions (see, e.g., U.S. Patent Publication No. 20050037086).</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid</span>
        <span itemprop="definition">e.g., a siRNA molecule, such as an siRNA molecule described in Tables A and B</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic polymer</span>
        <span itemprop="definition">having a linear, branched, star, or dendritic polymeric structure that condenses the nucleic acid into positively charged particles capable of interacting with anionic proteoglycans at the cell surface and entering cells by endocytosis.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polyplex</span>
        <span itemprop="definition">comprises nucleic acid (e.g., a siRNA molecule, such as an siRNA molecule described in Tables A and B) complexed with a cationic polymer such as polyethylenimine (PEI) (see, e.g., U.S. Patent No. 6,013,240; commercially available from Qbiogene, Inc.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">e.g., a siRNA molecule, such as an siRNA molecule described in Tables A and B</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEI</span>
        <span itemprop="definition">polyethylenimine</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">porphyrin</span>
        <span itemprop="definition">see, e.g., U. S. Patent No. 6,620,805</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polyvinyl ether</span>
        <span itemprop="definition">see, e.g., U.S. Patent Publication No. 20040156909</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polycyclic amidinium</span>
        <span itemprop="definition">see, e.g., U. S. Patent Publication No. 20030220289</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">other polymers</span>
        <span itemprop="definition">comprising primary amine, imine, guanidine, and/or imidazole groups (see, e.g., U.S. Patent No. 6,013,240; PCT Publication No. WO/9602655; PCT Publication No. W095/21931 ; Zhang et al, J.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polyplex</span>
        <span itemprop="definition">comprises cationic polymer-nucleic acid complexes as described in U. S. Patent Publication Nos. 2006021 1643, 20050222064,</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may be complexed with cyclodextrin or a polymer thereof.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cyclodextrin-based carrier systems</span>
        <span itemprop="definition">include the cyclodextrin- modified polymer-nucleic acid complexes described in U.S. Patent Publication No.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">may be complexed with a peptide or polypeptide.</span>
        <meta itemprop="num_attr" content="0494">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a protein-based carrier system</span>
        <span itemprop="definition">includes, but is not limited to, the cationic oligopeptide-nucleic acid complex described in PCT Publication No. W095/21931.</span>
        <meta itemprop="num_attr" content="0494">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles</span>
        <span itemprop="definition">in which a nucleic acid (e.g., a siRNA as described in</span>
        <meta itemprop="num_attr" content="0496">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Tables A and B)</span>
        <span itemprop="definition">is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a continuous mixing method, a direct dilution process, and an in-line dilution process.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids</span>
        <span itemprop="definition">may comprise lipids of Formula ZI-III or salts thereof, alone or in combination with other cationic lipids.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non- cationic lipids</span>
        <span itemprop="definition">are egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidyl choline (DOPC), l -palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC), monomethyl-phosphatidylethanolamine, dimethyl- phosphatidylethanolamine, 14:0 PE (1,2-dimyristoyl-phosphatidylethanolamine (DMPE)), 16:0 PE (1,2-dipalmitoyl -phosphatidylethanolamine (DPPE)), 18:0 PE (1,2-distearoyl- phosphatidylethanolamine (DSPE)), 18: 1 PE (1,2-dioleoyl-phosphatidylethanolamine (DOPE)), 18: 1 trans PE (1,2-dielaidoyl -phosphat</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles produced via a continuous mixing method, e.g., a process that includes providing an aqueous solution comprising a siRNA in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (e.g., liposome) encapsulating the siRNA within the lipid vesicle.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a continuous mixing method</span>
        <span itemprop="definition">e.g., a process that includes providing an aqueous solution comprising a siRNA in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g.,</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the organic lipid solution</span>
        <span itemprop="definition">undergoes a continuous stepwise dilution in the presence of the buffer solution (i.e., aqueous solution) to produce a nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0499">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the buffer solution</span>
        <span itemprop="definition">i.e., aqueous solution</span>
        <meta itemprop="num_attr" content="0499">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles formed using the continuous mixing method</span>
        <span itemprop="definition">typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 1 10 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 1 10 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles produced via a direct dilution process that includes forming a lipid vesicle (e.g., liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer.</span>
        <meta itemprop="num_attr" content="0501">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the collection vessel</span>
        <span itemprop="definition">includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution.</span>
        <meta itemprop="num_attr" content="0501">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of dilution buffer present in the collection vessel</span>
        <span itemprop="definition">is substantially equal to the volume of lipid vesicle solution introduced thereto.</span>
        <meta itemprop="num_attr" content="0501">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer</span>
        <span itemprop="definition">will advantageously yield smaller particles.</span>
        <meta itemprop="num_attr" content="0501">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides nucleic acid-lipid particles produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid vesicle (e.g., liposome) solution formed in a first mixing region</span>
        <span itemprop="definition">is immediately and directly mixed with dilution buffer in the second mixing region.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the second mixing region</span>
        <span itemprop="definition">includes a T- connector arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 180Â° flows; however, connectors providing shallower angles can be used, e.g., from about 27Â° to about 180Â° (e.g., about 90Â°).</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pump mechanism</span>
        <span itemprop="definition">delivers a controllable flow of buffer to the second mixing region.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the flow rate of dilution buffer provided to the second mixing region</span>
        <span itemprop="definition">is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This embodiment</span>
        <span itemprop="definition">advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also the concentration of lipid vesicle solution in buffer throughout the second mixing process.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes</span>
        <span itemprop="definition">typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 1 10 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80</span>
        <meta itemprop="num_attr" content="0504">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be sized by any of the methods available for sizing liposomes.</span>
        <meta itemprop="num_attr" content="0505">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sizing</span>
        <span itemprop="definition">may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes.</span>
        <meta itemprop="num_attr" content="0505">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Extrusion of the particles through a small-pore polycarbonate membrane or an asymmetric ceramic membrane</span>
        <span itemprop="definition">is also an effective method for reducing particle sizes to a relatively well-defined size distribution.</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the suspension</span>
        <span itemprop="definition">is cycled through the membrane one or more times until the desired particle size distribution is achieved.</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size.</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids present in the particles</span>
        <span itemprop="definition">e.g., the siRNA molecules</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods</span>
        <span itemprop="definition">may further comprise adding non-lipid polycations which are useful to effect the lipofection of cells using the present compositions.</span>
        <meta itemprop="num_attr" content="0508">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable non-lipid polycations</span>
        <span itemprop="definition">include, hexadimethrine bromide (sold under the brand name POLYBRENE Â® , from Aldrich Chemical Co., Milwaukee, Wisconsin, USA) or other salts of hexadimethrine.</span>
        <meta itemprop="num_attr" content="0508">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable polycations</span>
        <span itemprop="definition">include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. Addition of these salts is preferably after the particles have been formed.</span>
        <meta itemprop="num_attr" content="0508">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid (e.g., siRNA) to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle</span>
        <span itemprop="definition">will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1, from about 0.03 to about 0.1, or from about 0.01 to about 0.08.</span>
        <meta itemprop="num_attr" content="0509">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ratio of the starting materials (input)</span>
        <span itemprop="definition">also falls within this range.</span>
        <meta itemprop="num_attr" content="0509">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle preparation</span>
        <span itemprop="definition">uses about 400  â g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50  â g of nucleic acid.</span>
        <meta itemprop="num_attr" content="0509">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle</span>
        <span itemprop="definition">has a nucleic acid ipid mass ratio of about 0.08.</span>
        <meta itemprop="num_attr" content="0509">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid to nucleic acid (e.g., siRNA) ratios (mass/mass ratios) in a formed nucleic acid-lipid particle</span>
        <span itemprop="definition">will range from about 1 (1:1) to about 100 (100: 1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), from about 4 (4:1) to about 50 (50:1), from about 5 (5: 1) to about 50 (50:1), from about 1 (1:1) to about 25 (25: 1), from about 2 (2: 1) to about 25 (25:1), from about3 (3:l)to about 25 (25:1), from about 4 (4:1) to about 25 (25:1), from about 5 (5:1) to about 25 (25:1), from about 5 (5:1) to about 20 (20:1), from about 5 (5:1) to about 15 (15:1), from about 5 (5:1) to about 10 (10:1), or</span>
        <meta itemprop="num_attr" content="0510">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid</span>
        <span itemprop="definition">may further include a CPL.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CPL-containing lipid particles</span>
        <span itemprop="definition">A variety of general methods for making lipid particle-CPLs (CPL-containing lipid particles) are discussed herein. Two general techniques include the &#34;post-insertionâ technique, that is, insertion of a CPL into, for example, a pre-formed lipid particle, and the &#34;standardâ technique, wherein the CPL is included in the lipid mixture during, for example, the lipid particle formation steps.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the post-insertion technique</span>
        <span itemprop="definition">results in lipid particles having CPLs mainly in the external face of the lipid particle bilayer membrane, whereas standard techniques provide lipid particles having CPLs on both internal and external faces.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAAs and PEG-DAGs).</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipids</span>
        <span itemprop="definition">such as PEG-DAAs and PEG-DAGs.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods of making lipid particle-CPLs</span>
        <span itemprop="definition">are taught, for example, in U.S. Patent Nos. 5,705,385; 6,586,410; 5,981,501 ; 6,534,484; and 6,852,334; U.S. Patent Publication No. 20020072121 ; and PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV inhibitor</span>
        <span itemprop="definition">may be an HBV inhibitor</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may be comprised within a lipid nanoparticle formulation.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These nucleic acid-lipid particles</span>
        <span itemprop="definition">may comprise one or more (e.g., a cocktail) of the double-stranded siRNA molecules described herein (e.g., as described in Tables A and B), a cationic lipid, and a non-cationic lipid.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">further comprise a conjugated lipid that inhibits aggregation of particles.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">comprise one or more (e.g., a cocktail) of the double-stranded siRNA molecules described herein, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises two different double stranded siRNA molecules.</span>
        <meta itemprop="num_attr" content="0515">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises three different double stranded siRNA molecules.</span>
        <meta itemprop="num_attr" content="0516">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNAs</span>
        <span itemprop="definition">are fully encapsulated in the nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the different types of siRNA species present in the cocktail</span>
        <span itemprop="definition">e.g., siRNA compounds with different sequences</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each type of siRNA species present in the cocktail</span>
        <span itemprop="definition">may be encapsulated in a separate particle.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA cocktail</span>
        <span itemprop="definition">may be formulated in the particles described herein using a mixture of two, three or more individual siRNAs (each having a unique sequence) at identical, similar, or different concentrations or molar ratios.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail of siRNAs</span>
        <span itemprop="definition">(corresponding to a plurality of siRNAs with different sequences) is formulated using identical, similar, or different concentrations or molar ratios of each siRNA species, and the different types of siRNAs are co-encapsulated in the same particle.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each type of siRNA species present in the cocktail</span>
        <span itemprop="definition">is encapsulated in different particles at identical, similar, or different siRNA concentrations or molar ratios, and the particles thus formed (each containing a different siRNA payload) are administered separately (e.g., at different times in accordance with a therapeutic regimen), or are combined and administered together as a single unit dose (e.g., with a pharmaceutically acceptable carrier).</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles described herein</span>
        <span itemprop="definition">are serum-stable, are resistant to nuclease degradation, and are substantially non-toxic to mammals such as humans.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid in the nucleic acid-lipid particles of the invention</span>
        <span itemprop="definition">may comprise, e.g., one or more cationic lipids of Formula ZI-III described herein or any other cationic lipid species.</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipid</span>
        <span itemprop="definition">is a dialkyl lipid.</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is a trialkyl lipid.</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is selected from the group consisting of l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-  â , â -dimethylaminopropane (DLenDMA), l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA; Compound (515)), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[l,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[l,3]-dioxolane (DLin-K-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is selected from the group consisting of l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane ( â -DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane ( â -DLinDMA), 1 ,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane ( â -</span>
        <meta itemprop="num_attr" content="0520">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises from about 48 mol % to about 62 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0523">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid in the nucleic acid-lipid particles</span>
        <span itemprop="definition">may comprise, e.g., one or more anionic lipids and/or neutral lipids.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises one of the following neutral lipid components: (1) a mixture of a phospholipid and cholesterol or a derivative thereof; (2) cholesterol or a derivative thereof; or (3) a phospholipid.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPC</span>
        <span itemprop="definition">dipalmitoylphosphatidylcholine</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">distearoylphosphatidylcholine</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">is a mixture of DPPC and cholesterol.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non- cationic lipid</span>
        <span itemprop="definition">is a mixture of DSPC and cholesterol.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid</span>
        <span itemprop="definition">comprises a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from about 7 mol % to about 17 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from about 25 mol % to about 40 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0525">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate in the nucleic acid-lipid particles</span>
        <span itemprop="definition">inhibits aggregation of particles and may comprise, e.g., one or more of the lipid conjugates described herein.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">comprises a PEG-lipid conjugate.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugates</span>
        <span itemprop="definition">include, but are not limited to, PEG-DAG conjugates, PEG-DAA conjugates, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid conjugate</span>
        <span itemprop="definition">is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG- DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">is a PEG-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate in the lipid particle</span>
        <span itemprop="definition">may comprise a PEG- didecyloxypropyl (Cio) conjugate, a PEG-dilauryloxypropyl (C 12 ) conjugate, a PEG- dimyristyloxypropyl (C 14 ) conjugate, a PEG-dipalmityloxypropyl (Ci 6 ) conjugate, a PEG- distearyloxypropyl (C 18 ) conjugate, or mixtures thereof.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate</span>
        <span itemprop="definition">is a PEG-dimyristyloxypropyl (C 14 ) conjugate.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-DAA conjugate</span>
        <span itemprop="definition">is a compound (566) (PEG-C-DMA) conjugate.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid conjugate</span>
        <span itemprop="definition">comprises a POZ-lipid conjugate such as a POZ-DAA conjugate.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugated lipid that inhibits aggregation of particles</span>
        <span itemprop="definition">comprises from about 0.5 mol % to about 3 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0527">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15: 1.</span>
        <meta itemprop="num_attr" content="0528">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a median diameter of from about 30 nm to about 150 nm.</span>
        <meta itemprop="num_attr" content="0529">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has an electron dense core.</span>
        <meta itemprop="num_attr" content="0530">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">comprising: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0531">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0531">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more cationic lipids or salts thereof</span>
        <span itemprop="definition">comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0531">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">(c) one or more non-cationic lipids</span>
        <span itemprop="definition">comprising</span>
        <meta itemprop="num_attr" content="0531">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is a four- component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG2000-C-DMA</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">57.1 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DPPC</span>
        <span itemprop="definition">or DSPC</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">34.3 mol % cholesterol</span>
        <span itemprop="definition">or derivative thereof.</span>
        <meta itemprop="num_attr" content="0532">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 31.5 mol % to about 42.5 mol % of the</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is a three-component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C- DMA), about 61.5 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG2000-C- DMA</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">61.5 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0535">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0535">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids or salts thereof</span>
        <span itemprop="definition">comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0535">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids</span>
        <span itemprop="definition">comprising from about 5 mol % to about 90</span>
        <meta itemprop="num_attr" content="0535">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 47</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is a four- component system which comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C- DMA), about 40 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG2000-C- DMA</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">40 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">10 mol % DPPC</span>
        <span itemprop="definition">or DSPC</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">48 mol % cholesterol</span>
        <span itemprop="definition">or derivative thereof.</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0537">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0537">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipids or salts thereof</span>
        <span itemprop="definition">comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0537">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-cationic lipids</span>
        <span itemprop="definition">comprising from about 25 mol % to about 45 mol</span>
        <meta itemprop="num_attr" content="0537">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mixture of a phospholipid and cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 35</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-cationic lipid mixture in the formulation</span>
        <span itemprop="definition">comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % to about 35 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol or a derivative thereof</span>
        <span itemprop="definition">comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is a three-component system which is phospholipid- free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 35 mol % cholesterol (or derivative thereof).</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-lipid conjugate</span>
        <span itemprop="definition">e.g., PEG750-C-DMA</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">58 mol % cationic lipid</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt thereof</span>
        <span itemprop="definition">e.g., DLin-K-C2-DMA</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 48 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises about 7 mol % to about 17 mol % of the total lipid present in the particle, and wherein the cholesterol or derivative thereof comprises about 25 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 0.5 mol % to about 3.0 mol % of the total lipid present in the particle.</span>
        <meta itemprop="num_attr" content="0541">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules described herein</span>
        <span itemprop="definition">e.g., see, Tables A and B</span>
        <meta itemprop="num_attr" content="0541">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid or a salt thereof</span>
        <span itemprop="definition">comprising from about 48 mol %</span>
        <meta itemprop="num_attr" content="0541">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulations A-Z</span>
        <span itemprop="definition">are included below.</span>
        <meta itemprop="num_attr" content="0542">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation A</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.2%), cationic lipid (53.2%), phospholipid (9.3%), cholesterol (36.4%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.2%)</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (53.2%)</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (9.3%)</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 36.4%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation A</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation A</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation A</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">9:1</span>
        <span itemprop="definition">e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation B</span>
        <span itemprop="definition">which includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.8%), cationic lipid</span>
        <meta itemprop="num_attr" content="0544">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids present</span>
        <span itemprop="definition">may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (0.8%)</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (59.7%)</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (14.2%)</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 25.3%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation B</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation B</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation B</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">9:1</span>
        <span itemprop="definition">e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation C</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.9%), cationic lipid</span>
        <meta itemprop="num_attr" content="0546">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids present</span>
        <span itemprop="definition">may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (1.9%)</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA; Compound (515)) (52.5%)</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (14.8%)</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 30.8%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation C</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation C</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation C</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation D</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.7%), cationic lipid (60.3%), phospholipid (8.4%), cholesterol (30.5%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (0.7%)</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 3- ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (DLin-MP-DMA; Compound (508) (60.3%)</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (8.4%)</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 30.5%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation D</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation D</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation D</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of from about 5:1 to about 15:1, orabout5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid: drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation E</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.8%), cationic lipid (52.1%), phospholipid (7.5%), cholesterol (38.5%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0549">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.8%)</span>
        <meta itemprop="num_attr" content="0549">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate)</span>
        <meta itemprop="num_attr" content="0549">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">composition (Compound (507))</span>
        <span itemprop="definition">(52.1%), the phospholipid is DPPC (7.5%), and cholesterol is present at 38.5%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">formulation E</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation E</span>
        <span itemprop="definition">may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation E may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary formulation F</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.9%), cationic lipid (57.1%), phospholipid (8.1%), cholesterol (33.8%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (0.9%)</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1,2-dilinolenyloxy-  â , â -dimethylaminopropane (DLenDMA), l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA; Compound (515)) (57.1%)</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (8.1%)</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 33.8%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation F</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation F</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation F</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1 , 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation G</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.7%), cationic lipid (61.6%), phospholipid (1 1.2%), cholesterol (25.5%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (1.7%)</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1 ,2-di-y-linolenyloxy-N,N- dimethylaminopropane ( â -DLenDMA; Compound (515)) (61.6%)</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (11.2%)</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 25.5%, wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation G</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation G</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation G</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation H</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.1%), cationic lipid (55.0%), phospholipid (1 1.0%), cholesterol (33.0%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.1%)</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (55.0%)</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (1 1.0%)</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 33.0%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â 0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation H</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation H</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation H</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0553">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation I</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.6%), cationic lipid (53.1%), phospholipid (9.4%), cholesterol (35.0%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.6%)</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (53.1%)</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (9.4%)</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 35.0%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â 0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain embodiments of the invention</span>
        <span itemprop="definition">provide a nucleic acid-lipid particle based on formulation I, which comprises one or more siRNA molecules</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation I</span>
        <span itemprop="definition">may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation I may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation J</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.6%), cationic lipid (59.4%), phospholipid (10.2%), cholesterol (29.8%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (0.6%)</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (59.4%)</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (10.2%)</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 29.8%, wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation J</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation J</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation J</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation K</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.5%), cationic lipid (56.7%), phospholipid (13.1%), cholesterol (29.7%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0557">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (0.5%)</span>
        <meta itemprop="num_attr" content="0557">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate)</span>
        <meta itemprop="num_attr" content="0557">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">composition (Compound (507))</span>
        <span itemprop="definition">(56.7%), the phospholipid is DSPC (13.1%), and cholesterol is present at 29.7%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">formulation K</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation K</span>
        <span itemprop="definition">may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation K may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation L</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.2%), cationic lipid (52.0%), phospholipid (9.7%), cholesterol (36.2%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (2.2%)</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-di-y-linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA; Compound (515)) (52.0%)</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (9.7%)</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 36.2%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation L</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation L</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation L</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation M</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.7%), cationic lipid (58.4%), phospholipid (13.1%), cholesterol (25.7%), wherein the actual amounts of the lipids present may vary by by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.7%)</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (58.4%)</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (13.1%)</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 25.7%, wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation M</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation M</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation M</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation N</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (3.0%), cationic lipid (53.3%), phospholipid (12.1%), cholesterol (31.5%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (3.0%)</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (53.3%)</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (12.1%)</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 31.5%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation N</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation N</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation N</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0561">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation O</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.5%), cationic lipid (56.2%), phospholipid (7.8%), cholesterol (34.7%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.5%)</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (56.2%)</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (7.8%)</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 34.7%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation O</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation O</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation O</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1  â e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation P</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.1%), cationic lipid (48.6%), phospholipid (15.5%), cholesterol (33.8%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (2.1%)</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 3- ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31 -tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (DLin-MP-DMA; Compound (508)) (48.6%)</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (15.5%)</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 33.8%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation P</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation P</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation P</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation Q</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.5%), cationic lipid (57.9%), phospholipid (9.2%), cholesterol (30.3%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.5%)</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (57.9%)</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (9.2%)</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 30.3%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation Q</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation Q</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation Q</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation R</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.6%), cationic lipid</span>
        <meta itemprop="num_attr" content="0565">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids present</span>
        <span itemprop="definition">may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.6%)</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 3- ((6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l -tetraen-19-yloxy)-N,N-dimethylpropan-l -amine (Compound (508)) (54.6%)</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (10.9%)</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 32.8%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation R</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation R</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation R</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid: drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0566">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation S</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.9%), cationic lipid (49.6%), phospholipid (16.3%), cholesterol (31.3%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.9%)</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (49.6%)</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (16.3%)</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 31.3%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â 2 mol %,  â  1 mol %,  â  0.75 mol %,  â 0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation S</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation S</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation S</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation T</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.7%), cationic lipid (50.5%), phospholipid (8.9%), cholesterol (40.0%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (0.7%)</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (50.5%)</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (8.9%)</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 40.0%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation T</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation T</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation T</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1  â e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation U</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.0%), cationic lipid (51.4%), phospholipid (15.0%), cholesterol (32.6%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (1.0%)</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (51.4%)</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (15.0%)</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 32.6%, wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation U</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation U</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation U</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation V</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.3%), cationic lipid (60.0%), phospholipid (7.2%), cholesterol (31.5%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (1.3%)</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is l,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA) (60.0%)</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (7.2%)</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 31.5%, wherein the actual amounts of the lipids present may vary by, e.g.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation V</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation V</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation V</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation W</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.8%), cationic lipid (51.6%), phospholipid (8.4%), cholesterol (38.3%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (1.8%)</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (51.6%)</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (8.4%)</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 38.3%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation W</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation W</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation W</span>
        <span itemprop="definition">may comprise three different siRNA molecules,</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation X</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.4%), cationic lipid</span>
        <meta itemprop="num_attr" content="0572">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids present</span>
        <span itemprop="definition">may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.4%)</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is 1,2- di-Y-linolenyloxy-N,N-dimethylaminopropane ( â -DLenDMA; Compound (515)) (48.5%)</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DPPC (10.0%)</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 39.2%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â 0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation X</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation X</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation X</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1).</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation Y</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.6%), cationic lipid</span>
        <meta itemprop="num_attr" content="0574">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids present</span>
        <span itemprop="definition">may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DMA (compound (566)) (2.6%)</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (61.2%)</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">is DSPC (7.1%)</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at 29.2%, wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particle based on formulation Y</span>
        <span itemprop="definition">which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation Y</span>
        <span itemprop="definition">may comprise two different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation Y</span>
        <span itemprop="definition">may comprise three different siRNA molecules.</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid4ipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid:drug ratio</span>
        <span itemprop="definition">of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary lipid formulation Z</span>
        <span itemprop="definition">includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.2%), cationic lipid (49.7%), phospholipid (12.1%), cholesterol (36.0%), wherein the actual amounts of the lipids present may vary by, e.g. ,  â  5 % (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0576">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is PEG-C-DOMG (compound (567)) (2.2%)</span>
        <meta itemprop="num_attr" content="0576">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate)</span>
        <meta itemprop="num_attr" content="0576">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">composition (Compound (507))</span>
        <span itemprop="definition">(49.7%), the phospholipid is DPPC (12.1%), and cholesterol is present at 36.0%), wherein the actual amounts of the lipids present may vary by, e.g.,  â  5 %&gt; (or e.g.,  â  4 mol %,  â  3 mol %,  â  2 mol %,  â  1 mol %,  â  0.75 mol %,  â  0.5 mol %,  â  0.25 mol %, or  â  0.1 mol %).</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-lipid particle</span>
        <span itemprop="definition">based on formulation Z, which comprises one or more siRNA molecules described herein.</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid lipid particle based on formulation Z</span>
        <span itemprop="definition">may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation Z may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1 , 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein.</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particle</span>
        <span itemprop="definition">has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid: drug ratio</span>
        <span itemprop="definition">of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1).</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles</span>
        <span itemprop="definition">wherein the lipids are formulated as described in any one of formulations A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y or Z.</span>
        <meta itemprop="num_attr" content="0578">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">comprising a nucleic acid-lipid particle and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0579">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles described herein</span>
        <span itemprop="definition">are useful, for example, for the therapeutic delivery of siRNAs that silence the expression of one or more HBV genes.</span>
        <meta itemprop="num_attr" content="0580">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cocktail of siRNAs that target different regions (e.g., overlapping and/or non- overlapping sequences) of an HBV gene or transcript</span>
        <span itemprop="definition">is formulated into the same or different nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment.</span>
        <meta itemprop="num_attr" content="0580">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutically effective amount of the nucleic acid-lipid particles</span>
        <span itemprop="definition">can be administered to the mammal, e.g., for treating HBV and/or HDV infection in a human.</span>
        <meta itemprop="num_attr" content="0580">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more siRNA molecules described herein</span>
        <span itemprop="definition">may be introduced into a cell by contacting the cell with a nucleic acid-lipid particle described herein.</span>
        <meta itemprop="num_attr" content="0581">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more siRNA molecules that silence expression of a Hepatitis B virus gene</span>
        <span itemprop="definition">may be introduced into a cell by contacting the cell with a nucleic acid- lipid particle described herein under conditions whereby the siRNA enters the cell and silences the expression of the Hepatitis B virus gene within the cell.</span>
        <meta itemprop="num_attr" content="0582">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is in a mammal, such as a human.</span>
        <meta itemprop="num_attr" content="0582">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the human</span>
        <span itemprop="definition">has been diagnosed with a Hepatitis B virus infection or a Hepatitis B virus Hepatitis D virus infection.</span>
        <meta itemprop="num_attr" content="0582">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">silencing of the Hepatitis B virus gene expression</span>
        <span itemprop="definition">reduces Hepatitis B virus and/or Hepatitis D virus particle load in the mammal by at least about 50% (e.g., about 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100%) relative to Hepatitis B virus and/or Hepatitis D virus particle load in the absence of the nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0582">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the expression of a Hepatitis B virus gene in a cell</span>
        <span itemprop="definition">may be silenced by contacting a cell comprising an expressed Hepatitis B virus gene with a nucleic acid- lipid particle or a composition (e.g., a pharmaceutical composition) described herein under conditions whereby the siRNA enters the cell and silences the expression of the Hepatitis B virus gene within the cell.</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is in a mammal, such as a human.</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the human</span>
        <span itemprop="definition">has been diagnosed with a Hepatitis B virus infection or a Hepatitis B virus/Hepatitis D virus infection.</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the human</span>
        <span itemprop="definition">has been diagnosed with liver disease caused by a Hepatitis B virus infection or a Hepatitis B</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">silencing of the Hepatitis B virus gene expression</span>
        <span itemprop="definition">reduces Hepatitis B virus and/or Hepatitis D virus particle load in the mammal by at least about 50% (e.g., about 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100%) relative to Hepatitis B virus and/or Hepatitis D virus particle load in the absence of the nucleic acid-lipid particle.</span>
        <meta itemprop="num_attr" content="0584">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles or compositions (e.g., a pharmaceutical composition) described herein</span>
        <span itemprop="definition">are administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal.</span>
        <meta itemprop="num_attr" content="0585">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-lipid particles</span>
        <span itemprop="definition">are administered systemically, e.g., via enteral or parenteral routes of administration.</span>
        <meta itemprop="num_attr" content="0585">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV gene expression</span>
        <span itemprop="definition">may be silenced in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., one or more siRNAs shown in Tables A and B).</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mammal</span>
        <span itemprop="definition">e.g., human</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., one or more siRNAs shown in Tables A and B).</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles</span>
        <span itemprop="definition">comprising one or more siRNAs described herein reduces HBV RNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to HBV RNA levels detected in the absence of the siRNA (e.g., buffer control or irrelevant non-HBV targeting siRNA control).</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">e.g., buffer control or irrelevant non-HBV targeting siRNA control</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles comprising one or more HBV- targeting siRNAs</span>
        <span itemprop="definition">reduces HBV RNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control.</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a negative control</span>
        <span itemprop="definition">such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control.</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV gene expression</span>
        <span itemprop="definition">may be silenced in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., siRNAs described in Tables A and B).</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mammal</span>
        <span itemprop="definition">e.g., human</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., siRNAs described in Tables A and B).</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid- lipid particles comprising one or more HBV siRNAs</span>
        <span itemprop="definition">reduces HBV mRNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to HBV mRNA levels detected in the absence of the siRNA (e.g., buffer control or irrelevant non-HBV targeting siRNA control).</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">e.g., buffer control or irrelevant non-HBV targeting siRNA control</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles comprising one or more HBV-targeting siRNAs</span>
        <span itemprop="definition">reduces HBV mRNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control.</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a negative control</span>
        <span itemprop="definition">such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control.</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">such methods</span>
        <span itemprop="definition">comprise administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNA molecules described herein  â e.g., as described in Tables A and B) that target HBV gene expression.</span>
        <meta itemprop="num_attr" content="0588">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">symptoms associated with HBV and/or HDV infection in a human</span>
        <span itemprop="definition">include fever, abdominal pain, dark urine, joint pain, loss of appetite, nausea, vomiting, weakness, fatigue and yellowing of the skin (jaundice).</span>
        <meta itemprop="num_attr" content="0588">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV and/or HDV</span>
        <span itemprop="definition">may be inactivated in a mammal (e.g., human) in need thereof  â e.g., a human suffering from HBV infection or HBV/HDV infection), the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid- lipid particle comprising one or more siRNAs described herein that target HBV gene expression.</span>
        <meta itemprop="num_attr" content="0589">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-lipid particles comprising one or more HBV-targeting siRNAs</span>
        <span itemprop="definition">lowers, reduces, or decreases HBV protein levels  â e.g., HBV surface antigen protein) by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to the HBV protein levels detected in the absence of the siRNA  â e.g., buffer control or irrelevant non-HBV targeting siRNA control).</span>
        <meta itemprop="num_attr" content="0589">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV protein levels</span>
        <span itemprop="definition">e.g., HBV surface antigen protein</span>
        <meta itemprop="num_attr" content="0589">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBV mRNA</span>
        <span itemprop="definition">can be measured using a branched DNA assay (QuantiGeneÂ®; Affymetrix).</span>
        <meta itemprop="num_attr" content="0590">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the branched DNA assay</span>
        <span itemprop="definition">is a sandwich nucleic acid hybridization method that uses bDNA molecules to amplify signal from captured target RNA.</span>
        <meta itemprop="num_attr" content="0590">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA described herein</span>
        <span itemprop="definition">are also useful in research and development applications as well as diagnostic, prophylactic, prognostic, clinical, and other healthcare applications.</span>
        <meta itemprop="num_attr" content="0591">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">can be used in target validation studies directed at testing whether a specific member of the HBV gene family has the potential to be a therapeutic target.</span>
        <meta itemprop="num_attr" content="0591">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are particularly useful for the introduction of a siRNA molecule (e.g., a siRNA molecule as described in Tables A and B) into cells.</span>
        <meta itemprop="num_attr" content="0593">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a siRNA molecule</span>
        <span itemprop="definition">e.g., a siRNA molecule as described in Tables A and B</span>
        <meta itemprop="num_attr" content="0593">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides methods for introducing a siRNA molecule into a cell.</span>
        <meta itemprop="num_attr" content="0593">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA molecule</span>
        <span itemprop="definition">is introduced into an infected cell. The methods may be carried out in vitro or in vivo by first forming the particles as described above and then contacting the particles with the cells for a period of time sufficient for delivery of siRNA to the cells to occur.</span>
        <meta itemprop="num_attr" content="0593">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the siRNA portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid.</span>
        <meta itemprop="num_attr" content="0594">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (e.g., physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice.</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutically acceptable carrier</span>
        <span itemprop="definition">e.g., physiological saline or phosphate buffer</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">physiological saline or phosphate buffer</span>
        <span itemprop="definition">e.g., physiological saline or phosphate buffer</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable carriers</span>
        <span itemprop="definition">include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Additional suitable carriers are described in, e.g.</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carrier</span>
        <span itemprop="definition">includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutically acceptable</span>
        <span itemprop="definition">refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutically acceptable carrier</span>
        <span itemprop="definition">is generally added following lipid particle formation.</span>
        <meta itemprop="num_attr" content="0596">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle</span>
        <span itemprop="definition">can be diluted into</span>
        <meta itemprop="num_attr" content="0596">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">concentration of particles in the pharmaceutical formulations</span>
        <span itemprop="definition">can vary widely, i.e., from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, etc. , in accordance with the particular mode of administration selected. For example, the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension. Alternatively, particles composed of irritating lipids may be diluted to low concentrations to lessen</span>
        <meta itemprop="num_attr" content="0597">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">may be sterilized by conventional, well-known sterilization techniques.</span>
        <meta itemprop="num_attr" content="0599">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Aqueous solutions</span>
        <span itemprop="definition">can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</span>
        <meta itemprop="num_attr" content="0599">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions</span>
        <span itemprop="definition">can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride.</span>
        <meta itemprop="num_attr" content="0599">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particle suspension</span>
        <span itemprop="definition">may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable.</span>
        <meta itemprop="num_attr" content="0599">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are particularly useful in methods for the therapeutic delivery of one or more siRNA molecules  â e.g. , an siRNA molecule as described in Tables A and B).</span>
        <meta itemprop="num_attr" content="0600">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Systemic delivery for in vivo therapy</span>
        <span itemprop="definition">e.g. , delivery of a siRNA molecule described herein, such as an siRNA described in Tables A and B, to a distal target cell via body systems such as the circulation, has been achieved using nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0602">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides fully encapsulated lipid particles that protect the siRNA from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing.</span>
        <meta itemprop="num_attr" content="0602">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the one or more siRNA molecules</span>
        <span itemprop="definition">may be administered alone in the lipid particles of the invention, or in combination (e.g., co-administered) with lipid particles comprising peptides, polypeptides, or small molecules such as conventional drugs.</span>
        <meta itemprop="num_attr" content="0602">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">administration</span>
        <span itemprop="definition">can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g. , intranasal or intratracheal), transdermal application, or rectal administration.</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Administration</span>
        <span itemprop="definition">can be accomplished via single or divided doses.</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly.</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">are administered intravenously or intraperitoneally by a bolus injection (see, e.g. , U.S. Patent No. 5,286,634).</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Intracellular nucleic acid delivery</span>
        <span itemprop="definition">has also been discussed in Straubringer et al. , Methods Enzymol. , 101 :512 (1983); Mannino et al. ,</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles</span>
        <span itemprop="definition">can be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, Mary Ann Liebert, Inc., Publishers, New York. pp.70-71(1994)).</span>
        <meta itemprop="num_attr" content="0604">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Culver</span>
        <span itemprop="definition">HUMAN GENE THERAPY</span>
        <meta itemprop="num_attr" content="0604">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Mary Ann Liebert, Inc.</span>
        <span itemprop="definition">Publishers, New York. pp.70-71(1994)</span>
        <meta itemprop="num_attr" content="0604">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosures of the above-described references</span>
        <span itemprop="definition">are herein incorporated by reference in their entirety for all purposes.</span>
        <meta itemprop="num_attr" content="0604">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">are administered intravenously, at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In other embodiments, more than about 20%, 30%, 40% and as much as about 60%, 70% or 80% of the total injected dose of the lipid particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In certain instances, more than about 10% of a plurality of the particles is present in the plasma of a mammal about 1 hour after administration. In certain other instances, the presence of the lipid particles is detectable at least about 1 hour after administration of the particle.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence of a siRNA molecule</span>
        <span itemprop="definition">is detectable in cells at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">downregulation of expression of a target sequence, such as a viral or host sequence, by a siRNA molecule</span>
        <span itemprop="definition">is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">downregulation of expression of a target sequence, such as a viral or host sequence, by a siRNA molecule</span>
        <span itemprop="definition">occurs preferentially in infected cells and/or cells capable of being infected.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence or effect of a siRNA molecule in cells at a site proximal or distal to the site of administration</span>
        <span itemprop="definition">is detectable at about 12, 24, 48, 72, or 96 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the invention</span>
        <span itemprop="definition">are administered parenterally or intraperitoneally.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">can be made into aerosol formulations (i.e., they can be &#34;nebulized&#34;) to be administered via inhalation (e.g. , intranasally or intratracheally) (see, Brigham et al. , Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles.</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays</span>
        <span itemprop="definition">have been described, e.g., in U.S. Patent Nos. 5,756,353 and 5,804,212.</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">delivery of drugs using intranasal microparticle resins and lysophosphatidyl -glycerol compounds</span>
        <span itemprop="definition">U.S. Patent</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for parenteral administration</span>
        <span itemprop="definition">include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.</span>
        <meta itemprop="num_attr" content="0609">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">are preferably administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally.</span>
        <meta itemprop="num_attr" content="0609">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particle formulations</span>
        <span itemprop="definition">are formulated with a suitable pharmaceutical carrier.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a suitable pharmaceutical carrier</span>
        <span itemprop="definition">may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON&#39;S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a variety of aqueous carriers</span>
        <span itemprop="definition">may be used, for example, water, buffered water, 0.4% saline, 0.3%&gt; glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">can be sterilized by conventional liposomal sterilization techniques, such as filtration.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions</span>
        <span itemprop="definition">may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanol amine oleate, etc.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These compositions</span>
        <span itemprop="definition">can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the resulting aqueous solutions</span>
        <span itemprop="definition">may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.</span>
        <meta itemprop="num_attr" content="0610">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles disclosed herein</span>
        <span itemprop="definition">may be delivered via oral administration to the individual.</span>
        <meta itemprop="num_attr" content="0611">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like  â see, e.g., U.S. Patent Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes).</span>
        <meta itemprop="num_attr" content="0611">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These oral dosage forms</span>
        <span itemprop="definition">may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents.</span>
        <meta itemprop="num_attr" content="0611">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the unit dosage form</span>
        <span itemprop="definition">When the unit dosage form is a capsule, it may contain, in addition to the materials described above, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed.</span>
        <meta itemprop="num_attr" content="0611">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">these oral formulations</span>
        <span itemprop="definition">may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may</span>
        <meta itemprop="num_attr" content="0612">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each therapeutically useful composition</span>
        <span itemprop="definition">may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.</span>
        <meta itemprop="num_attr" content="0613">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Factors</span>
        <span itemprop="definition">such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.</span>
        <meta itemprop="num_attr" content="0613">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for oral administration</span>
        <span itemprop="definition">can consist of: (a) liquid solutions, such as an effective amount of a packaged siRNA molecule  â e.g., a siRNA molecule described in Tables A and B) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a siRNA molecule, as liquids, solids, granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">liquid solutions</span>
        <span itemprop="definition">such as an effective amount of a packaged siRNA molecule  â e.g., a siRNA molecule described in Tables A and B) suspended in diluents such as water, saline, or PEG 400</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">capsules, sachets, or tablets</span>
        <span itemprop="definition">each containing a predetermined amount of a siRNA molecule, as liquids, solids, granules, or gelatin</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suspensions in an appropriate liquid</span>
        <span itemprop="definition">and</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Tablet forms</span>
        <span itemprop="definition">can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lozenge forms</span>
        <span itemprop="definition">can comprise a siRNA molecule in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the siRNA molecule, carriers known in the art.</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a flavor</span>
        <span itemprop="definition">e.g., sucrose</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pastilles</span>
        <span itemprop="definition">comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the siRNA molecule, carriers known in the art.</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles</span>
        <span itemprop="definition">can be incorporated into a broad range of topical dosage forms.</span>
        <meta itemprop="num_attr" content="0615">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a suspension containing nucleic acid-lipid particles</span>
        <span itemprop="definition">can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.</span>
        <meta itemprop="num_attr" content="0615">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid particles of the invention</span>
        <span itemprop="definition">When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferable to use quantities of the particles which have been purified to reduce or eliminate empty particles or particles with therapeutic agents such as siRNA associated with the external surface.</span>
        <meta itemprop="num_attr" content="0616">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hosts</span>
        <span itemprop="definition">include mammalian species, such as primates (e.g. , humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine.</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">primates</span>
        <span itemprop="definition">e.g. , humans and chimpanzees as well as other nonhuman primates</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">canines</span>
        <span itemprop="definition">felines, equines, bovines, ovines, caprines</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rodents</span>
        <span itemprop="definition">e.g., rats and mice</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lagomorphs</span>
        <span itemprop="definition">e.g., swine.</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of particles administered</span>
        <span itemprop="definition">will depend upon the ratio of siRNA molecules to lipid, the particular siRNA used, the strain of HBV being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about 10 8 -10 10 particles per administration (e.g., injection).</span>
        <meta itemprop="num_attr" content="0618">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the delivery of siRNA molecules</span>
        <span itemprop="definition">can be to any cell grown in culture.</span>
        <meta itemprop="num_attr" content="0620">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cells</span>
        <span itemprop="definition">are animal cells, more preferably mammalian cells, and most preferably human cells.</span>
        <meta itemprop="num_attr" content="0620">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration of particles</span>
        <span itemprop="definition">varies widely depending on the particular application, but is generally between about 1  â  and about 10 mmol.</span>
        <meta itemprop="num_attr" content="0621">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Treatment of the cells with the lipid particles</span>
        <span itemprop="definition">is generally carried out at physiological temperatures (about 37Â°C) for periods of time of from about 1 to 48 hours, preferably of from about 2 to 4 hours.</span>
        <meta itemprop="num_attr" content="0621">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid particle suspension</span>
        <span itemprop="definition">is added to 60-80% confluent plated cells having a cell density of from about 10 3 to about 10 5 cells/ml, more preferably about 2 x 10 4 cells/ml.</span>
        <meta itemprop="num_attr" content="0622">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the concentration of the suspension added to the cells</span>
        <span itemprop="definition">is preferably of from about 0.01 to 0.2  â g/ml, more preferably about 0.1  â g/ml.</span>
        <meta itemprop="num_attr" content="0622">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tissue culture of cells</span>
        <span itemprop="definition">may be required, it is well-known in the art.</span>
        <meta itemprop="num_attr" content="0623">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Freshney</span>
        <span itemprop="definition">Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley - Liss, New York (1994), Kuchler et al, Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and the references cited therein provide a general guide to the culture of cells.</span>
        <meta itemprop="num_attr" content="0623">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cultured cell systems</span>
        <span itemprop="definition">often will be in the form of monolayers of cells, although cell suspensions are also used.</span>
        <meta itemprop="num_attr" content="0623">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ERP</span>
        <span itemprop="definition">Endosomal Release Parameter</span>
        <meta itemprop="num_attr" content="0624">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ERP assay</span>
        <span itemprop="definition">is to distinguish the effect of various cationic lipids and helper lipid components of the lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the endosomal membrane. This assay allows one to determine quantitatively how each component of the lipid particle affects delivery efficiency, thereby optimizing the lipid particle.</span>
        <meta itemprop="num_attr" content="0625">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ERP assay</span>
        <span itemprop="definition">measures expression of a reporter protein  â e.g., luciferase,  â - galactosidase, green fluorescent protein (GFP), etc.), and in some instances, a lipid particle formulation optimized for an expression plasmid will also be appropriate for encapsulating a siRNA.</span>
        <meta itemprop="num_attr" content="0625">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an ERP assay</span>
        <span itemprop="definition">can be adapted to measure downregulation of transcription or translation of a target sequence in the presence or absence of a siRNA. By comparing the ERPs for each of the various lipid particles, one can readily determine the optimized system, e.g., the lipid particle that has the greatest uptake in the cell.</span>
        <meta itemprop="num_attr" content="0625">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid particles of the present invention</span>
        <span itemprop="definition">are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles.</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the presence of the particles</span>
        <span itemprop="definition">can be detected in the cells, tissues, or other biological samples from the subject. The particles may be detected, e.g.</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">detection of a siRNA sequence</span>
        <span itemprop="definition">by direct detection of the particles, detection of a siRNA sequence, detection of the target sequence of interest (i.e., by detecting expression or reduced expression of the sequence of interest), detection of a compound modulated by an EBOV protein (e.g., interferon), detection of viral load in the subject, or a combination thereof.</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">detection of a siRNA sequence</span>
        <span itemprop="definition">i.e., by detecting expression or reduced expression of the sequence of interest</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">detection of a compound modulated by an EBOV protein</span>
        <span itemprop="definition">e.g., interferon</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid particles of the invention</span>
        <span itemprop="definition">can be detected using any method known in the art.</span>
        <meta itemprop="num_attr" content="0629">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a label</span>
        <span itemprop="definition">can be coupled directly or indirectly to a component of the lipid particle using methods well-known in the art.</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a wide variety of labels</span>
        <span itemprop="definition">can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions.</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable labels</span>
        <span itemprop="definition">include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon GreenTM; rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyesTM, and the like; radiolabels such as 3 H, 125 1, 35 S, 14 C, 32 P, 33 P, etc.; enzymes such as horse radish peroxidase, alkaline phosphatase, etc.; spectral colorimetnc labels such as colloidal gold or colored glass or plastic beads such as polystyrene,</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">fluorescent dyes</span>
        <span itemprop="definition">e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon GreenTM</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rhodamine and derivatives</span>
        <span itemprop="definition"></span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the label</span>
        <span itemprop="definition">can be detected using any means known in the art.</span>
        <meta itemprop="num_attr" content="0631">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids</span>
        <span itemprop="definition">e.g., siRNA molecules</span>
        <meta itemprop="num_attr" content="0633">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the detection of nucleic acids</span>
        <span itemprop="definition">may proceed by well-known methods such as Southern analysis, Northern analysis, gel</span>
        <meta itemprop="num_attr" content="0633">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">electrophoresis</span>
        <span itemprop="definition">capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed.</span>
        <meta itemprop="num_attr" content="0636">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HPLC</span>
        <span itemprop="definition">high performance liquid chromatography</span>
        <meta itemprop="num_attr" content="0636">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TLC</span>
        <span itemprop="definition">thin layer chromatography</span>
        <meta itemprop="num_attr" content="0636">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hyperdiffusion chromatography</span>
        <span itemprop="definition">may also be employed.</span>
        <meta itemprop="num_attr" content="0636">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid hybridization format</span>
        <span itemprop="definition">is not critical.</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a variety of nucleic acid hybridization formats</span>
        <span itemprop="definition">are known to those skilled in the art.</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">common formats</span>
        <span itemprop="definition">include sandwich assays and competition or displacement assays.</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hybridization techniques</span>
        <span itemprop="definition">are generally described in, e.g., &#34;Nucleic Acid Hybridization, A Practical Approach,â Eds. Hames and Higgins, IRL Press (1985).</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sensitivity of the hybridization assays</span>
        <span itemprop="definition">may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected.</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid amplification system</span>
        <span itemprop="definition">which multiplies the target nucleic acid being detected.</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning</span>
        <span itemprop="definition">are known.</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA polymerase mediated techniques</span>
        <span itemprop="definition">e.g., NASBATM</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PCR</span>
        <span itemprop="definition">polymerase chain reaction</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LCR</span>
        <span itemprop="definition">ligase chain reaction</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">QP-replicase amplification</span>
        <span itemprop="definition">e.g., QP-replicase mediated techniques</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NASBATM</span>
        <span itemprop="definition">RNA polymerase mediated techniques</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the select sequences</span>
        <span itemprop="definition">can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.</span>
        <meta itemprop="num_attr" content="0639">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids for use as probes</span>
        <span itemprop="definition">e.g., in in vitro amplification methods, for use as gene probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage et al, Tetrahedron Letts., 22: 1859 1862 (1981), e.g., using an automated synthesizer, as described in Needham</span>
        <meta itemprop="num_attr" content="0640">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">In situ hybridization assays</span>
        <span itemprop="definition">are well-known and are generally described in Angerer et al , Methods Enzymol., 152:649 (1987).</span>
        <meta itemprop="num_attr" content="0642">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">in situ hybridization assay</span>
        <span itemprop="definition">cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled.</span>
        <meta itemprop="num_attr" content="0642">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the probes</span>
        <span itemprop="definition">are preferably labeled with radioisotopes or fluorescent reporters.</span>
        <meta itemprop="num_attr" content="0642">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an HBV antigen inhibitor</span>
        <span itemprop="definition">may be an oligonucleotide, such as an siRNA molecule.</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotide</span>
        <span itemprop="definition">such as an siRNA molecule.</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such molecules</span>
        <span itemprop="definition">may be conjugated to a targeting moiety.</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">e.g., siRNA molecule</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">may be comprised within a compound of formula I or XX.</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an oligonucleotide</span>
        <span itemprop="definition">is comprised within a compound of formula I:</span>
        <meta itemprop="num_attr" content="0645">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 a</span>
        <span itemprop="definition">is targeting ligand</span>
        <meta itemprop="num_attr" content="0648">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0649">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0650">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is an oligonucleotide</span>
        <meta itemprop="num_attr" content="0651">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ring A</span>
        <span itemprop="definition">is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl;</span>
        <meta itemprop="num_attr" content="0652">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R A</span>
        <span itemprop="definition">is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR B , Ci-io alkyl C2-io lkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy;</span>
        <meta itemprop="num_attr" content="0653">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R B</span>
        <span itemprop="definition">is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support;</span>
        <meta itemprop="num_attr" content="0654">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</span>
        <meta itemprop="num_attr" content="0655">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 a</span>
        <span itemprop="definition">is targeting ligand</span>
        <meta itemprop="num_attr" content="0657">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0658">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is absent or a linking group</span>
        <meta itemprop="num_attr" content="0659">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is an oligonucleotide; the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl;</span>
        <meta itemprop="num_attr" content="0660">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R A</span>
        <span itemprop="definition">is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR B and Ci-s alkyl that is optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy;</span>
        <meta itemprop="num_attr" content="0661">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R B</span>
        <span itemprop="definition">is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support;</span>
        <meta itemprop="num_attr" content="0662">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.</span>
        <meta itemprop="num_attr" content="0663">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is -C(H)(3- P )(L -saccharide) p , wherein each L 3 is independently a linking group; p is 1, 2, or 3; and saccharide is a monosaccharide or disaccharide.</span>
        <meta itemprop="num_attr" content="0664">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is hydrogen or (Ci-C4)alkyl</span>
        <meta itemprop="num_attr" content="0669">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 , R 5 , R 6 , R 7 , R 8 and R 9</span>
        <span itemprop="definition">are each independently selected from the group consisting of hydrogen, (Ci-Cs)alkyl, (Ci-Cg)haloalkyl, (Ci-C8)alkoxy and (C3-C6)cycloalkyl that is optionally substituted with one or more groups independently selected from the group consisting of halo, (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, (Ci-C 4 )alkoxy and (Ci-C 4 )haloalkoxy;</span>
        <meta itemprop="num_attr" content="0670">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10</span>
        <span itemprop="definition">is -OH, - R 8 R 9 or - F.</span>
        <meta itemprop="num_attr" content="0671">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 11</span>
        <span itemprop="definition">is -OH, -NR 8 R 9 , -F or 5 membered heterocycle that is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxyl, carboxyl, amino, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)alkoxy and (Ci-C 4 )haloalkoxy;</span>
        <meta itemprop="num_attr" content="0672">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is:</span>
        <meta itemprop="num_attr" content="0684">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">G</span>
        <span itemprop="definition">is -NH- or -0-</span>
        <meta itemprop="num_attr" content="0687">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R c</span>
        <span itemprop="definition">is hydrogen, (Ci-C 8 )alkyl, (Ci-C 8 )haloalkyl, (Ci-C 8 )alkoxy, (Ci-C 6 )alkanoyl, (C 3 - C2o)cycloalkyl, (C -C2o)heterocycle, aryl, heteroaryl, monosaccharide, disaccharide or trisacchande; and wherein the cycloalkyl, heterocyle, ary, heteroaryl and saccharide are optionally substituted with one or more groups independently selected from the group consisting of halo, carboxyl, hydroxyl, amino, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)alkoxy and (Ci- C4)haloalkoxy;</span>
        <meta itemprop="num_attr" content="0688">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of hydrogen, (Ci- C 6 )alkyl, (C 9 -C 2 o)alkylsilyl, (R w ) 3 Si-, (C 2 -C 6 )alkenyl, tetrahydropyranyl, (Ci-C 6 )alkanoyl, benzoyl, aryl(Ci-C 3 )alkyl, TMTr (Trimethoxytrityl), DMTr (Dimethoxytrityl), MMTr</span>
        <meta itemprop="num_attr" content="0694">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R w</span>
        <span itemprop="definition">is independently selected from the group consisting of (Ci-C4)alkyl and aryl.</span>
        <meta itemprop="num_attr" content="0696">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is connected to R 2 through -0-.</span>
        <meta itemprop="num_attr" content="0702">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0703">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0705">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q 1</span>
        <span itemprop="definition">is hydrogen and Q 2 is R 2 ; or Q 1 is R 2 and Q 2 is hydrogen;</span>
        <meta itemprop="num_attr" content="0711">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is -I â -R 1 ;</span>
        <meta itemprop="num_attr" content="0712">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each m</span>
        <span itemprop="definition">is independently 1 or 2;</span>
        <meta itemprop="num_attr" content="0717">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula lb</span>
        <span itemprop="definition">is selected from the group consisting of: wherein:</span>
        <meta itemprop="num_attr" content="0719">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q 1</span>
        <span itemprop="definition">is hydrogen and Q 2 is R 2 ; or Q 1 is R 2 and Q 2 is hydrogen;</span>
        <meta itemprop="num_attr" content="0720">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is -V-R 1 ;</span>
        <meta itemprop="num_attr" content="0721">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula I</span>
        <span itemprop="definition">has the following formula (Ic):</span>
        <meta itemprop="num_attr" content="0723">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">E</span>
        <span itemprop="definition">is -O- or -CH 2 -;</span>
        <meta itemprop="num_attr" content="0727">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from the group consisting of 0, 1, 2, 3, and 4;</span>
        <meta itemprop="num_attr" content="0728">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nl and n2</span>
        <span itemprop="definition">are each independently selected from the group consisting of 0, 1, 2, and 3; or a salt thereof.</span>
        <meta itemprop="num_attr" content="0729">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula (Ic)</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0730">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q 1</span>
        <span itemprop="definition">is hydrogen and Q 2 is R 2 ; or Q 1 is R 2 and Q 2 is hydrogen;</span>
        <meta itemprop="num_attr" content="0737">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each q</span>
        <span itemprop="definition">is independently 0, 1, 2, 3, 4 or 5;</span>
        <meta itemprop="num_attr" content="0738">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is an oligonucleotide.</span>
        <meta itemprop="num_attr" content="0740">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is an siRNA</span>
        <meta itemprop="num_attr" content="0741">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula (I)</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0742">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">2, 3, or 4;</span>
        <meta itemprop="num_attr" content="0747">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">x</span>
        <span itemprop="definition">is 1 or 2.</span>
        <meta itemprop="num_attr" content="0748">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0750">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is absent, phenyl, pyrrolidinyl, or cyclopentyl.</span>
        <meta itemprop="num_attr" content="0751">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is Ci-4 alkylene-O- that is optionally substituted with hydroxy.</span>
        <meta itemprop="num_attr" content="0752">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is -CH 2 0-, -CH 2 CH 2 0-, or -CH(OH)CH 2 0-.</span>
        <meta itemprop="num_attr" content="0753">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R A</span>
        <span itemprop="definition">is independently hydroxy or Ci-8 alkyl that is optionally substituted with hydroxyl.</span>
        <meta itemprop="num_attr" content="0754">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R A</span>
        <span itemprop="definition">is independently selected from the group consisting of hydroxy, methyl and -CH2OH.</span>
        <meta itemprop="num_attr" content="0755">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula I</span>
        <span itemprop="definition">has the following formula (Ig):</span>
        <meta itemprop="num_attr" content="0756">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B</span>
        <span itemprop="definition">is -N- or -CH-</span>
        <meta itemprop="num_attr" content="0759">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or -NH-</span>
        <meta itemprop="num_attr" content="0760">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or hal</span>
        <meta itemprop="num_attr" content="0761">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, or 2;</span>
        <meta itemprop="num_attr" content="0762">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B</span>
        <span itemprop="definition">is -N- or -CH-</span>
        <meta itemprop="num_attr" content="0766">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or -NH-</span>
        <meta itemprop="num_attr" content="0767">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo;</span>
        <meta itemprop="num_attr" content="0768">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5, 6, or 7;</span>
        <meta itemprop="num_attr" content="0769">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of formula I</span>
        <span itemprop="definition">has the following formula (Ig):</span>
        <meta itemprop="num_attr" content="0771">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B</span>
        <span itemprop="definition">is -N- or -CH-</span>
        <meta itemprop="num_attr" content="0774">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1</span>
        <span itemprop="definition">is absent or -NH-</span>
        <meta itemprop="num_attr" content="0775">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo;</span>
        <meta itemprop="num_attr" content="0776">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, or 4;</span>
        <meta itemprop="num_attr" content="0777">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R&#39;</span>
        <span itemprop="definition">is C1-9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the C1.9 alkyl, C2-9 alkenyl 2-9 alkynyl are optionally substituted with halo or hydroxyl;</span>
        <meta itemprop="num_attr" content="0781">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the oligonucleotide</span>
        <span itemprop="definition">is an siRNA molecule.</span>
        <meta itemprop="num_attr" content="0796">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (I)</span>
        <span itemprop="definition">is,</span>
        <meta itemprop="num_attr" content="0796">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conjugate</span>
        <span itemprop="definition">is selected from the group of conjugates shown in the following table, wherein R 2 is the modified HBV siRNA shown and is attached through the oxygen of a phosphate at the 3 &#39;-end of the sense strand.</span>
        <meta itemprop="num_attr" content="0798">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compo nd of formula I</span>
        <span itemprop="definition">has the following formula (Id):</span>
        <meta itemprop="num_attr" content="0813">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from:</span>
        <meta itemprop="num_attr" content="0817">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X d</span>
        <span itemprop="definition">is C2-10 alkylene</span>
        <meta itemprop="num_attr" content="0820">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2d</span>
        <span itemprop="definition">is a nucleic acid</span>
        <meta itemprop="num_attr" content="0822">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3d</span>
        <span itemprop="definition">is H.</span>
        <meta itemprop="num_attr" content="0823">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X d</span>
        <span itemprop="definition">is Csalkylene</span>
        <meta itemprop="num_attr" content="0826">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n d</span>
        <span itemprop="definition">is 0.</span>
        <meta itemprop="num_attr" content="0827">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2d</span>
        <span itemprop="definition">is an siRNA</span>
        <meta itemprop="num_attr" content="0828">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound of (Id) or the salt thereof</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0829">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R ld</span>
        <span itemprop="definition">is selected from:</span>
        <meta itemprop="num_attr" content="0837">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X d</span>
        <span itemprop="definition">is C2-10 alkylene</span>
        <meta itemprop="num_attr" content="0839">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2d</span>
        <span itemprop="definition">is an oligonucleotide</span>
        <meta itemprop="num_attr" content="0841">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3d</span>
        <span itemprop="definition">is H.</span>
        <meta itemprop="num_attr" content="0842">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound</span>
        <span itemprop="definition">is a compound of formula (Ig):</span>
        <meta itemprop="num_attr" content="0843">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B</span>
        <span itemprop="definition">is -N- or -CH-</span>
        <meta itemprop="num_attr" content="0849">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 2</span>
        <span itemprop="definition">is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo; and n is 0, 1, 2, 3, 4, 5, 6, or 7;</span>
        <meta itemprop="num_attr" content="0850">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R&#39;</span>
        <span itemprop="definition">is Ci-9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the C1-9 alkyl, C2-9 alkenyl or C2-9 alkynyl are optionally substituted with halo or hydroxyl;</span>
        <meta itemprop="num_attr" content="0856">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Wood Science &amp; Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Proteomics, Peptides &amp; Aminoacids</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Microbiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Analytical Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Virology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Botany</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Plant Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Immunology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicines That Contain Protein Lipid Enzymes And Other Medicines</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmaceuticals Containing Other Organic And Inorganic Compounds</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Measuring Or Testing Involving Enzymes Or Micro-Organisms</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA288537662" lang="EN" load-source="patent-office">
    <div num="0000" class="abstract">Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient&#39;s genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><div mxw-id="PDES186822211" lang="EN" load-source="WIPO-OCR" class="description">
    
    <div id="p0001" num="0001" class="description-paragraph"> METHODS FOR TREATING HEPATITIS B INFECTIONS</div>
    <div id="p0002" num="0002" class="description-paragraph">CROSS-REFERENCE TO RELATED APPLICATION </div>
    <div id="p0003" num="0003" class="description-paragraph"> This patent application claims the benefit of priority of U. S. Application Serial No. 62/556,870 filed September 11, 2017, which application is herein incorporated by reference. </div>
    <div id="p0004" num="0004" class="description-paragraph">BACKGROUND </div>
    <div id="p0005" num="0005" class="description-paragraph"> Hepatitis B virus (abbreviated as &#34;HBV&#34;) is a member of the Hepadnavirus family. The virus particle (sometimes referred to as a virion) includes an outer lipid envelope and an icosahedral nucleocapsid core composed of protein. The nucleocapsid encloses the viral DNA and a DNA polymerase that has reverse transcriptase activity. The outer envelope contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells, typically liver hepatocytes. In addition to the infectious viral particles, filamentous and spherical bodies lacking a core can be found in the serum of infected individuals. These particles are not infectious and are composed of the lipid and protein that forms part of the surface of the virion, which is called the surface antigen (HBsAg), and is produced in excess during the life cycle of the virus. </div>
    <div id="p0006" num="0006" class="description-paragraph"> The genome of HBV is made of circular DNA, but it is unusual because the DNA is not fully double-stranded. One end of the full length strand is linked to the viral DNA polymerase. The genome is 3020-3320 nucleotides long (for the full-length strand) and 1700-2800 nucleotides long (for the shorter strand). The negative-sense (non-coding) is complementary to the viral mRNA. The viral DNA is found in the nucleus soon after infection of the cell. There are four known genes encoded by the genome, called C, X, P, and S. The core protein is coded for by gene C (HBcAg), and its start codon is preceded by an upstream in-frame AUG start codon from which the pre-core protein is produced. HBeAg is produced by proteolytic processing of the pre-core protein. The DNA polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigen (HBsAg). The HBsAg gene is one long open reading frame but contains three in frame &#34;start&#34; (ATG) codons that divide the gene into three sections, pre-S l, pre-S2, and S. Because of the multiple start codons, polypeptides of three different sizes called large, middle, and small are produced. The function of the protein coded for by gene X is not fully understood but it is associated with the development of liver cancer. Replication of</div>
    <div id="p0007" num="0007" class="description-paragraph">HBV is a complex process. Although replication takes place in the liver, the virus spreads to the blood where viral proteins and antibodies against them are found in infected people. The 

 structure, replication and biology of HBV is reviewed in D. Glebe and C.M.Bremer, Seminars in Liver Disease, Vol. 33, No. 2, pages 103-112 (2013). </div>
    <div id="p0008" num="0008" class="description-paragraph"> Infection of humans with HBV can cause an infectious inflammatory illness of the liver. Infected individuals may not exhibit symptoms for many years. It is estimated that about a third of the world population has been infected at one point in their lives, including 350 million who are chronic carriers. The virus is transmitted by exposure to infectious blood or body fluids. Perinatal infection can also be a major route of infection. The acute illness causes liver inflammation, vomiting, jaundice, and possibly death. Chronic hepatitis B may eventually cause cirrhosis and liver cancer. </div>
    <div id="p0009" num="0009" class="description-paragraph"> Although most people who are infected with HBV clear the infection through the action of their immune system, some infected people suffer an aggressive course of infection </div>
    <div id="p0010" num="0010" class="description-paragraph">(fulminant hepatitis); while others are chronically infected thereby increasing their chance of liver disease. Several medications are currently approved for treatment of HBV infection, but infected individuals respond with various degrees of success to these medications. Over the past few decades, several host and viral factors have been found to be associated with differences in HBV clearance or persistence. However, an unexplained variability in treatment outcome still exists, suggesting that the genetic background of the host plays an important role. </div>
    <div id="p0011" num="0011" class="description-paragraph"> Thus, there is a need to identify new biomarkers that can be used to assess the likelihood that an HBV infected patient will respond positively to a particular treatment regimen. </div>
    <div id="p0012" num="0012" class="description-paragraph">BRIEF SUMMARY </div>
    <div id="p0013" num="0013" class="description-paragraph"> Accordingly, certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, wherein a C/C genotype at rs 12079860 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having a different genotype at rsl2079860. </div>
    <div id="p0014" num="0014" class="description-paragraph"> Certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising: </div>
    <div id="p0015" num="0015" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; and </div>
    <div id="p0016" num="0016" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860. 

 Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0017" num="0017" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; and </div>
    <div id="p0018" num="0018" class="description-paragraph"> b) administering an effective amount of an HBV antigen inhibitor to a patient having a</div>
    <div id="p0019" num="0019" class="description-paragraph">C/C genotype at rsl2079860. </div>
    <div id="p0020" num="0020" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0021" num="0021" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; </div>
    <div id="p0022" num="0022" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0023" num="0023" class="description-paragraph"> c) administering an effective amount of an HBV antigen inhibitor to the patient. </div>
    <div id="p0024" num="0024" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus</div>
    <div id="p0025" num="0025" class="description-paragraph">(HBV) infected patient comprising: </div>
    <div id="p0026" num="0026" class="description-paragraph"> a) analyzing a biological sample from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; </div>
    <div id="p0027" num="0027" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0028" num="0028" class="description-paragraph"> c) administering an effective amount of an HBV antigen inhibitor to the patient, wherein the HBV inhibitor comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    <div id="p0029" num="0029" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus</div>
    <div id="p0030" num="0030" class="description-paragraph">(HBV) infected patient comprising: </div>
    <div id="p0031" num="0031" class="description-paragraph"> a) obtaining a biological sample from the hepatitis B virus (HBV) infected patient; b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; </div>
    <div id="p0032" num="0032" class="description-paragraph"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and 

 d) administering an effective amount of an HBV antigen inhibitor to the patient, wherein the HBV inhibitor comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    <div id="p0033" num="0033" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient, comprising administering to the patient an effective amount of an HBV antigen inhibitor, wherein the patient had been determined to have a C/C genotype at rsl2079860. </div>
    <div id="p0034" num="0034" class="description-paragraph"> Certain embodiments of the invention provide an HBV antigen inhibitor for the prophylactic or therapeutic treatment of a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860. </div>
    <div id="p0035" num="0035" class="description-paragraph"> Certain embodiments of the invention provide the use of an HBV antigen inhibitor to prepare a medicament for treating a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860. </div>
    <div id="p0036" num="0036" class="description-paragraph"> Certain embodiments of the invention provide a kit comprising: </div>
    <div id="p0037" num="0037" class="description-paragraph"> a) an HBV antigen inhibitor; </div>
    <div id="p0038" num="0038" class="description-paragraph"> b) instructions for administering the inhibitor to a hepatitis B virus (HBV) infected patient determined to have a C/C genotype at rsl2079860. </div>
    <div id="p0039" num="0039" class="description-paragraph"> Other objects, features, and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and any figures. </div>
    <div id="p0040" num="0040" class="description-paragraph">BRIEF DESCRIPTION OF THE FIGURES </div>
    <div id="p0041" num="0041" class="description-paragraph"> Figure 1 : Illustrates an intermediate compound of formula Ie, wherein a targeting ligand/linker is bound to a solid phase support, and wherein Pg<sup>1</sup> is the protecting group DMTr. </div>
    <div id="p0042" num="0042" class="description-paragraph"> Figure 2: Illustrates a representative compound of formula Id wherein a targeting ligand is bound to a solid phase support, with a nucleic acid covalently bound. </div>
    <div id="p0043" num="0043" class="description-paragraph"> Figure 3: Illustrates a representative compound of formula Id, wherein a targeting ligand-nucleic acid conjugate has been cleaved from a solid phase support and deprotected to provide the compound of formula I. </div>
    <div id="p0044" num="0044" class="description-paragraph">DETAILED DESCRIPTION </div>
    <div id="p0045" num="0045" class="description-paragraph"> As described herein, a series of single nucleotide polymorphisms (SNPs) have been identified as biomarkers that may be used to detect patients infected with HBV that have a higher likelihood of responding to an HBV antigen inhibitor. These SNPs are located near 

 the inter leukin 28B (IL-28B) and the inter leukin 28 A (IL-28A) genes on chromosome 19 (National Center for Biotechnology Information, Entrez Gene Entry for IL28B, Gene ID: </div>
    <div id="p0046" num="0046" class="description-paragraph">282617; Entrez Gene Entry for IL28A, Gene ID: 282616). IL28B encodes ÎÎÎ-Î»3, which induces antiviral activity by itself and through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) complex, which induces IFN-stimulated genes (ISGs). </div>
    <div id="p0047" num="0047" class="description-paragraph"> IL28A encodes IFN-X2. In certain embodiments, there is a correlation between such SNPs associated with these genes and with increased IFN- 2 and/or IFN- 3 expression. The table shown below includes a non-limiting list of these IL28A/B SNPs, which may be used in methods of the invention described herein. </div>
    <div id="p0048" num="0048" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/20/4e/ec/6b8a57a015f2d4/imgf000006_0001.png"><img id="imgf000006_0001" he="91" wi="82" file="imgf000006_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="328" height="364" alt="Figure imgf000006_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/20/4e/ec/6b8a57a015f2d4/imgf000006_0001.png"/></a></div>
    </div>
    <div id="p0049" num="0049" class="description-paragraph">* combination of: rsl2979860CT/rs8099917TG; or rsl297980CT/rs809917TT. + indicates that these SNPs have been reported to be in high linkage disequilibrium with rsl2979860. <sup>Î</sup> rs368234815 is located upstream of IFNL3/IL28B; a frameshift variant gives rise to IFNL4. See, e.g., Tanaka et al, Nat Genet 2009, 41 : 1 105-1 109; Fischer et al., Hepatol. 2012, </div>
    <div id="p0050" num="0050" class="description-paragraph">55(6): 1700-10; Aziz et al., Int J Infect Dis 2015, 30:91 -7; Shaikh et al., J Med Virol, 2015, 87(5):814-20; Karatayli et al., Liver Int. 2015, 35(3):846-53; Juniastuti et al., J Clin Microbiol 2014, 52(6): 2193-2195; Prokunina-Olsson et al., Nat Gen 2013, 45(2): 164-71. </div>
    <div id="p0051" num="0051" class="description-paragraph">Accordingly, certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at any one or a combination of the SNPs listed in the table above, wherein a patient having the relevant genotype or combination of genotypes has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations. In certain 

 embodiments, at least one SNP from the above table is detected. In certain embodiments, a combination of at least 2 SNPs from the above table are detected. In certain embodiments, a combination of at least 3 SNPs from the above table are detected. In certain embodiments, a combination of at least 4 SNPs from the above table are detected. In certain embodiments, a combination of at least 5 SNPs from the above table are detected. </div>
    <div id="p0052" num="0052" class="description-paragraph"> In certain embodiments of the invention, a patient&#39; s genotype at the rsl2979860 SNP is detected. The rsl2979860 SNP is located approximately 3 kb upstream of the IL-28B gene {see, e.g., Ge et al, Nature 2009, 461 :399-401). As described in the Examples, it has been advantageously shown that individuals having a C/C genotype at rsl2979860 have a higher likelihood of positively responding to an HBV antigen inhibitor treatment than individuals having another genotype at this location. Additionally, patients having a combination of a CT genotype at rsl2979860 and a TG or TT genotype at rs8099917 may also have a higher likelihood of positively responding to an HBV antigen inhibitor treatment. </div>
    <div id="p0053" num="0053" class="description-paragraph"> In certain embodiments of the invention, a patient&#39; s genotype at the rs8099917 SNP is detected. The rs8099917 SNP is located in an intergenic region between IL28A and IL28B, ~8kb downstream from IL28B and ~16kb upstream from IL28A {see, e.g., Suppiah et al., Nat Genet 2009, 41 : 1 100-1 104; Tanaka et al., Nat Genet 2009, 41 : 1 105-1109). In certain embodiments, a T/T genotype at rs8099917 is indicative of a HBV infected patient that has a higher likelihood of responding to an HBV antigen inhibitor, as compared to an HBV infected patient having a different genotype at this location. Additionally, in certain embodiments, a patient having combination of a T/G genotype at rs8099917 and C/T genotype at rsl2979860 may also have a higher likelihood of positively responding to an HBV antigen inhibitor treatment. </div>
    <div id="p0054" num="0054" class="description-paragraph"> In certain embodiments of the invention, a patient&#39;s genotype at the rsl2980275 SNP is detected. rsl2980275 is also located near the IL28B gene {see, e.g., Tanaka et al., Nat Genet</div>
    <div id="p0055" num="0055" class="description-paragraph">2009, 41 : 1105-1109). In certain embodiments, an A/A genotype at rsl2980275 is indicative of a HBV infected patient that has a higher likelihood of responding to an HBV antigen inhibitor, as compared to an HBV infected patient having a different genotype at this location. </div>
    <div id="p0056" num="0056" class="description-paragraph"> Thus, certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, rs8099917 and/or rsl2980275, wherein a C/X genotype at rsl2079860, a T/Z genotype at rs8099917 and/or an A/A genotype at rsl2980275 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes 

 at rsl2079860, rs8099917 and/or rsl2980275, wherein X is C or T; and Z is T or G. In certain embodiments, X is C. In certain embodiments, Z is T. In certain embodiments, X is T and Z is G. In certain embodiments, X is T and Z is T. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860 is detected. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rs8099917 is detected. In certain embodiments, the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2980275 is detected. </div>
    <div id="p0057" num="0057" class="description-paragraph"> Certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising detecting the hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, wherein a C/C genotype at rsl2079860 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having a different genotype at rsl2079860. </div>
    <div id="p0058" num="0058" class="description-paragraph"> Certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising: </div>
    <div id="p0059" num="0059" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; and </div>
    <div id="p0060" num="0060" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860. </div>
    <div id="p0061" num="0061" class="description-paragraph"> In certain embodiments of the invention, a method described herein further comprises obtaining a biological sample from the hepatitis B virus (HBV) infected patient. </div>
    <div id="p0062" num="0062" class="description-paragraph"> Thus, certain embodiments of the invention provide a method of identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor comprising: </div>
    <div id="p0063" num="0063" class="description-paragraph"> a) obtaining a biological sample from the hepatitis B virus (HBV) infected patient; and b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; and </div>
    <div id="p0064" num="0064" class="description-paragraph"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860. </div>
    <div id="p0065" num="0065" class="description-paragraph"> In certain embodiments, a method described herein further comprises administering an effective amount of an HBV antigen inhibitor to the HBV infected patient having a C/C genotype at rsl2079860. </div>
    <div id="p0066" num="0066" class="description-paragraph"> In certain embodiments, an effective amount of an HBV antigen inhibitor for a patient having a C/C genotype at rsl2079860 is less than an effective amount of an HBV antigen inhibitor for a patient having a different genotype at rsl2079860. Thus, in certain embodiments, 

 an HBV infected patient having a C/C genotype at rsl2079860 is administered a different HBV antigen inhibitor treatment regimen than an HBV infected patient having a different genotype at rsl2079860. In certain embodiments, the HBV infected patient having a C/C genotype at rsl2079860 is administered a lower dosage of the HBV antigen inhibitor and/or is administered the HBV antigen inhibitor for a shorter period of time as compared to an HBV infected patient having a different genotype at rsl2079860. </div>
    <div id="p0067" num="0067" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0068" num="0068" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; and </div>
    <div id="p0069" num="0069" class="description-paragraph"> b) administering an effective amount of an HBV antigen inhibitor to a patient having a C/C genotype at rsl2079860. </div>
    <div id="p0070" num="0070" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0071" num="0071" class="description-paragraph"> a) obtaining a biological sample from the hepatitis B virus (HBV) infected patient; b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; and </div>
    <div id="p0072" num="0072" class="description-paragraph"> c) administering an effective amount of an HBV antigen inhibitor to a patient having a C/C genotype at rsl2079860. </div>
    <div id="p0073" num="0073" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0074" num="0074" class="description-paragraph"> a) analyzing a biological sample obtained from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; </div>
    <div id="p0075" num="0075" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0076" num="0076" class="description-paragraph"> c) administering an effective amount of an HBV antigen inhibitor to the patient. </div>
    <div id="p0077" num="0077" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus</div>
    <div id="p0078" num="0078" class="description-paragraph">(HBV) infected patient comprising: </div>
    <div id="p0079" num="0079" class="description-paragraph"> a) obtaining a biological sample from the hepatitis B virus (HBV) infected patient; b) analyzing the sample to detect the patient&#39;s genotype at rsl2079860; </div>
    <div id="p0080" num="0080" class="description-paragraph"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0081" num="0081" class="description-paragraph"> d) administering an effective amount of an HBV antigen inhibitor to the patient. 

 Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0082" num="0082" class="description-paragraph"> a) analyzing a biological sample from the hepatitis B virus (HBV) infected patient to detect the patient&#39;s genotype at rsl2079860; </div>
    <div id="p0083" num="0083" class="description-paragraph"> b) identifying the HBV infected patient as having a higher likelihood of responding to an</div>
    <div id="p0084" num="0084" class="description-paragraph">HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0085" num="0085" class="description-paragraph"> c) administering an effective amount of an HBV antigen inhibitor to the patient, wherein the HBV inhibitor comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    <div id="p0086" num="0086" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient comprising: </div>
    <div id="p0087" num="0087" class="description-paragraph"> a) obtaining a biological sample from the hepatitis B virus (HBV) infected patient; b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; </div>
    <div id="p0088" num="0088" class="description-paragraph"> c) identifying the HBV infected patient as having a higher likelihood of responding to an</div>
    <div id="p0089" num="0089" class="description-paragraph">HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
    <div id="p0090" num="0090" class="description-paragraph"> d) administering an effective amount of an HBV antigen inhibitor to the patient, wherein the HBV inhibitor comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    <div id="p0091" num="0091" class="description-paragraph"> Certain embodiments of the invention provide a method of treating a hepatitis B virus (HBV) infected patient, comprising administering to the patient an effective amount of an HBV antigen inhibitor, wherein the patient had been determined to have a C/C genotype at rsl2079860. </div>
    <div id="p0092" num="0092" class="description-paragraph"> HBV antigen inhibitors are described in detail below. Thus, in certain embodiments, the</div>
    <div id="p0093" num="0093" class="description-paragraph">HBV antigen inhibitor is an agent described herein. </div>
    <div id="p0094" num="0094" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is a core antigen inhibitor. </div>
    <div id="p0095" num="0095" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is a surface antigen inhibitor. </div>
    <div id="p0096" num="0096" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is selected from an oligonucleotide, a small molecule or a polypeptide. </div>
    <div id="p0097" num="0097" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is a small molecule. </div>
    <div id="p0098" num="0098" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is an oligonucleotide. </div>
    <div id="p0099" num="0099" class="description-paragraph"> In certain embodiments, the oligonucleotide is a siRNA molecule. 

 In certain embodiments, the HBV antigen inhibitor is an siRNA molecule selected from the siRNA molecules described in Tables A and B. </div>
    <div id="p0100" num="0100" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor comprises a combination of two or more siRNA molecules selected from the siRNA molecules described in Tables A and B or the Examples. </div>
    <div id="p0101" num="0101" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor comprises a combination of three or more siRNA molecules selected from the siRNA molecules described in Tables A and B or the Examples. </div>
    <div id="p0102" num="0102" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor comprises siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    <div id="p0103" num="0103" class="description-paragraph"> In certain embodiments, the oligonucleotide (e.g., siRNA) is comprised in a lipid nanoparticle formulation, wherein the lipid nanoparticle formulation comprises a cationic lipid and a non-cationic lipid. </div>
    <div id="p0104" num="0104" class="description-paragraph"> In certain embodiments, the cationic lipid is selected from the group consisting of 1,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane (Î³- DLenDMA; Compound (515)) , 3-((6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19- yloxy)-N,N-dimethylpropan-l -amine (DLin-MP-DMA; Compound (508)), (6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate) (Compound (507)), </div>
    <div id="p0105" num="0105" class="description-paragraph"> (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)), a salt thereof, and a mixture thereof. </div>
    <div id="p0106" num="0106" class="description-paragraph"> In certain embodiments the cationic lipid is: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/34/95/46ea1f8fae73c0/imgf000011_0001.png"><img id="imgf000011_0001" he="15" wi="97" file="imgf000011_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="388" height="60" alt="Figure imgf000011_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/34/95/46ea1f8fae73c0/imgf000011_0001.png"/></a></div>
 </div>
    <div id="p0107" num="0107" class="description-paragraph">3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (508). </div>
    <div id="p0108" num="0108" class="description-paragraph"> In certain embodiments, the non-cationic lipid is cholesterol or a derivative thereof. In certain embodiments, the non-cationic lipid is a phospholipid. </div>
    <div id="p0109" num="0109" class="description-paragraph"> In certain embodiments, the non-cationic lipid is a mixture of a phospholipid and cholesterol or a derivative thereof. 

 In certain embodiments, the phospholipid is selected from the group consisting of dipalmitoyl phosphatidylcholine (DPPC), distearoylphosphatidyl choline (DSPC), and a mixture thereof. In certain embodiments, the phospholipid is DSPC. </div>
    <div id="p0110" num="0110" class="description-paragraph"> In certain embodiments, the lipid formulation further comprises a conjugated lipid that inhibits aggregation of particles. In certain embodiments, the conjugated lipid that inhibits aggregation of particles is a polyethyleneglycol (PEG)-lipid conjugate. In certain embodiments, the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG- DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, a PEG- dimyristyloxypropyl (PEG-DMA) conjugate and a mixture thereof. In certain embodiments, the PEG-lipid conjugate is a PEG-CDMA conjugate. </div>
    <div id="p0111" num="0111" class="description-paragraph"> In certain embodiments, the cationic lipid comprises from about 48 mol % to about 62 mol % of the total lipid present in each particle within the formulation. In certain embodiments, the lipid nanoparticle formulation comprises a phospholipid and cholesterol or cholesterol derivative, wherein the phospholipid comprises from about 7 mol % to about 17 mol % of the total lipid present in each particle within the formulation and the cholesterol or derivative thereof comprises from about 25 mol % to about 40 mol % of the total lipid present in each particle within the formulation. In certain embodiments, the conjugated lipid that inhibits aggregation of particles comprises from about 0.5 mol % to about 3 mol % of the total lipid present in each particle within the formulation. </div>
    <div id="p0112" num="0112" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is conjugated to a targeting moiety. In certain embodiments, the HBV antigen inhibitor is an oligonucleotide, such as an siRNA, and the oligonucleotide is conjugated to a targeting moiety. For example, in certain embodiments, the oligonucleotide (e.g., siRNA) is com rised within a compound of formula I 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/9f/fc/d26cc3c01bbf12/imgf000012_0001.png"><img id="imgf000012_0001" he="18" wi="43" file="imgf000012_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="172" height="72" alt="Figure imgf000012_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/9f/fc/d26cc3c01bbf12/imgf000012_0001.png"/></a></div>
 </div>
    <div id="p0113" num="0113" class="description-paragraph"> (I) </div>
    <div id="p0114" num="0114" class="description-paragraph">wherein: </div>
    <div id="p0115" num="0115" class="description-paragraph"> R a is targeting ligand; </div>
    <div id="p0116" num="0116" class="description-paragraph"> L<sup>1</sup> is absent or a linking group; </div>
    <div id="p0117" num="0117" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p0118" num="0118" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; 

 the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
    <div id="p0119" num="0119" class="description-paragraph"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup>, Ci-io alkyl C2-io alkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
    <div id="p0120" num="0120" class="description-paragraph"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
    <div id="p0121" num="0121" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; </div>
    <div id="p0122" num="0122" class="description-paragraph"> or a salt thereof . </div>
    <div id="p0123" num="0123" class="description-paragraph"> In certain embodiments, methods of the invention further comprise administering at least one additional therapeutic agent. In certain embodiments, the at least one additional therapeutic agent is selected from the group consisting of: </div>
    <div id="p0124" num="0124" class="description-paragraph"> (A) an agent that controls viral replication; </div>
    <div id="p0125" num="0125" class="description-paragraph"> (B) an agent that reduces viral Ags; </div>
    <div id="p0126" num="0126" class="description-paragraph"> (C) an immune enhancer; and </div>
    <div id="p0127" num="0127" class="description-paragraph"> (D) an immune stimulant. </div>
    <div id="p0128" num="0128" class="description-paragraph"> These classes of additional therapeutic agents are further described below as Category I, II and III agents. </div>
    <div id="p0129" num="0129" class="description-paragraph"> In certain embodiments, the HBV infected patient is further infected with hepatitis D virus (HDV). </div>
    <div id="p0130" num="0130" class="description-paragraph">HBV Antigen Inhibitors </div>
    <div id="p0131" num="0131" class="description-paragraph"> The term &#34;HBV antigen inhibitor&#34; refers to a compound that can inhibit the expression and/or function of an HBV antigen {i.e., core or surface antigen), either directly or indirectly. The inhibitor may be of natural or synthetic origin. For example, HBV antigen inhibitors, include but are not limited to, e.g., oligonucleotides, small molecules and polypeptides. The term &#34;small molecule&#34; includes organic molecules having a molecular weight of less than about, e.g., 1000 amu. In one embodiment a small molecule can have a molecular weight of less than about 800 amu. In another embodiment a small molecule can have a molecular weight of less than about 500 amu. In certain embodiments, the HBV inhibitor does not comprise interferon (TFN). 

 In certain embodiments, the HBV antigen inhibitor is a core antigen inhibitor. As used herein, the term &#34;core antigen inhibitor&#34; refers to a compound that can inhibit the expression and/or function of an HBV core antigen. </div>
    <div id="p0132" num="0132" class="description-paragraph"> For example, in certain embodiments, the HBV core antigen inhibitor is a capsid inhibitor. As described herein the term &#34;capsid inhibitor&#34; includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly. For example, a capsid inhibitor may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA. Capsid inhibitors also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like). For example, in certain embodiments, the inhibitor detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, at least 90%, at least 95% or at least 99%. </div>
    <div id="p0133" num="0133" class="description-paragraph"> The term capsid inhibitor includes compounds described in International Patent Applications Publication Numbers WO2013006394, WO2014106019, and WO2014089296, including the following compounds: </div>
    <div id="p0134" num="0134" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/b8/3b/b1da8c71e07795/imgf000014_0001.png"><img id="imgf000014_0001" he="22" wi="110" file="imgf000014_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="440" height="88" alt="Figure imgf000014_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/b8/3b/b1da8c71e07795/imgf000014_0001.png"/></a></div>
    </div>
    <div id="p0135" num="0135" class="description-paragraph"> The term capsid inhibitor also includes the compounds Bay-41-4109 (see International Patent Application Publication Number WO/2013/144129), AT-61 (see International Patent Application Publication Number WO/1998/33501 ; and King, RW, et al., Antimicrob Agents Chemother., 1998, 42, 12, 3179-3186), DVR-01 and DVR-23 (see International Patent Application Publication Number WO 2013/006394; and Campagna, MR, et al., J. of Virology, 2013, 87, 12, 6931, and pharmaceutically acceptable salts thereof: 


<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/ed/75/02a8813724d0be/imgf000015_0001.png"><img id="imgf000015_0001" he="75" wi="111" file="imgf000015_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="444" height="300" alt="Figure imgf000015_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/ed/75/02a8813724d0be/imgf000015_0001.png"/></a></div>
 </div>
    <div id="p0136" num="0136" class="description-paragraph"> DVR-01 </div>
    <div id="p0137" num="0137" class="description-paragraph"> The term capsid inhibitor also includes the compounds Compound 3, GLS-4, and NVR</div>
    <div id="p0138" num="0138" class="description-paragraph">3-778. </div>
    <div id="p0139" num="0139" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is a surface antigen inhibitor (sAg inhibitor). As described herein the term &#34;surface antigen inhibitor&#34; includes compounds that are capable of inhibiting the expression and/or function of a surface antigen either directly or indirectly. </div>
    <div id="p0140" num="0140" class="description-paragraph"> For example, in certain embodiments, the surface antigen inhibitor is a sAg secretion inhibitor. As described herein the term &#34;sAg secretion inhibitor&#34; includes compounds that are capable of inhibiting, either directly or indirectly, the secretion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells. For example, in certain embodiments, the inhibitor detectably inhibits the secretion of sAg as measured, e.g., using assays known in the art or described herein, e.g., ELISA assay or by Western Blot. In certain embodiments, the inhibitor inhibits the secretion of sAg by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. In certain embodiments, the inhibitor reduces serum levels of sAg in a patient by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. </div>
    <div id="p0141" num="0141" class="description-paragraph"> The term sAg secretion inhibitor includes compounds described in United States Patent Number 8,921,381, as well as compounds described in United States Patent Application Publication Numbers 2015/0087659 and 2013/0303552. For example, the term includes the compounds PBHBV-001 and PBHBV-2-15, and pharmaceutically acceptable salts thereof: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/af/fe/dc/b2c4540bab60ad/imgf000016_0001.png"><img id="imgf000016_0001" he="33" wi="85" file="imgf000016_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="340" height="132" alt="Figure imgf000016_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/af/fe/dc/b2c4540bab60ad/imgf000016_0001.png"/></a></div>
 </div>
    <div id="p0142" num="0142" class="description-paragraph"> PBHBV-001 PBHBV-2-15 </div>
    <div id="p0143" num="0143" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is an anti-HBsAg antibody, e.g., mAbs. Certain aspects of the invention are directed to the use of hepatitis B immune globulin (HBIG). </div>
    <div id="p0144" num="0144" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is an oligonucleotide. Oligomeric nucleotides can be designed to target one or more genes and/or transcripts of the HBV genome, thereby inhibiting HBV antigen either directly or indirectly. The term &#34;oligonucleotide&#34; or &#34;oligomeric nucleotide&#34; refers to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally- or non-naturally occurring bases, sugars and intersugar (backbone) linkages. </div>
    <div id="p0145" num="0145" class="description-paragraph"> In certain embodiments, the oligonucleotide is an antisense molecule. In certain embodiments, the oligonucleotide is a small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA) or microRNA (miRNA). </div>
    <div id="p0146" num="0146" class="description-paragraph"> In certain embodiments, the oligonucleotide is a siRNA molecule. The term &#34;small- interfering RNA&#34; or &#34;siRNA&#34; as used herein refers to double stranded RNA (i.e., duplex RNA) that is capable of reducing or inhibiting the expression of a target gene or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the siRNA sequence) when the siRNA is in the same cell as the target gene or sequence. The siRNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif). In certain embodiments, the siRNAs may be about 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21- 23 (duplex) nucleotides in length. siRNA duplexes may comprise 3 &#39; overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5&#39; phosphate termini. Examples of siRNA include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand. </div>
    <div id="p0147" num="0147" class="description-paragraph"> Preferably, siRNA are chemically synthesized. siRNA can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coli RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, 

 e.g., Yang et al, Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al, Proc. Natl. Acad. Sci. USA, 99: 14236 (2002); Byrom et al, Ambion TechNotes, 10(1) 4-6 (2003); Kawasaki et al, Nucleic Acids Res., 31 :981-987 (2003); Knight et al , Science, 293 :2269-2271 (2001); and Robertson et al, J. Biol. Chem., 243 :82 (1968)). Preferably, dsRNA are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length. A dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer. The dsRNA can encode for an entire gene transcript or a partial gene transcript. In certain instances, siRNA may be encoded by a plasmid {e.g. , transcribed as sequences that automatically fold into duplexes with hairpin loops). </div>
    <div id="p0148" num="0148" class="description-paragraph"> In certain embodiments, the siRNA may comprise one or more modified ribonucleotides and/or one or more backbone modifications (e.g., one or more ribonucleotides with a 2 -0- methyl modification, one or more UNA moieties, one or more 2&#39;-Fluoro nucleotides, and/or one or more phosphorothioate linkers). </div>
    <div id="p0149" num="0149" class="description-paragraph"> In certain embodiments, the 5&#39; and/or 3&#39; overhang on one or both strands of the siRNA comprises 1-4 {e.g., 1, 2, 3, or 4) modified and/or unmodified deoxythymidine (t or dT) nucleotides, 1-4 {e.g., 1, 2, 3, or 4) modified {e.g., 2&#39;OMe) and/or unmodified uridine (U) ribonucleotides, and/or 1-4 {e.g., 1, 2, 3, or 4) modified {e.g., 2&#39;OMe) and/or unmodified ribonucleotides or deoxyribonucleotides having complementarity to the target sequence (e.g., 3&#39;overhang in the antisense strand) or the complementary strand thereof (e.g., 3&#39; overhang in the sense strand). </div>
    <div id="p0150" num="0150" class="description-paragraph"> In certain embodiments, the oligonucleotide is an isolated, double stranded, siRNA molecule, that includes a sense strand and an antisense strand that is hybridized to the sense strand. The siRNA target one or more genes and/or transcripts of the HBV genome. In certain embodiments, the HBV inhibitor may be a composition comprising a combination {e.g., a cocktail, pool, or mixture) of siRNAs that target different regions of the HBV genome, and thereby inhibit HBV antigen. </div>
    <div id="p0151" num="0151" class="description-paragraph"> Examples of such siRNA molecules are the siRNA molecules set forth in Tables A and B. Thus, in certain embodiments, the HBV antigen inhibitor is an siRNA molecule selected from the siRNA molecules described in Tables A and B. </div>
    <div id="p0152" num="0152" class="description-paragraph"> These sense and antisense strands, shown in Tables A and B, are useful, for example, for making siRNA molecules that are useful to reduce the expression of one or more HBV genes in vivo or in vitro. These sense and antisense strands are also useful, for example, as hybridization probes for identifying and measuring the amount of HBV genome in a biological material, such as a tissue or blood sample from a human being infected with HBV or HBV/HDV. 

 In particular embodiments, an oligonucleotide (such as the sense and antisense RNA strands set forth in Tables A and B) of the invention specifically hybridizes to or is </div>
    <div id="p0153" num="0153" class="description-paragraph">complementary to a target polynucleotide sequence. The terms &#34;specifically hybridizable&#34; and &#34;complementary&#34; as used herein indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. In preferred embodiments, an oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target sequence interferes with the normal function of the target sequence to cause a loss of utility or expression therefrom, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or, in the case of in vitro assays, under conditions in which the assays are conducted. Thus, the oligonucleotide may include 1, 2, 3, or more base substitutions as compared to the region of a gene or mRNA sequence that it is targeting or to which it specifically hybridizes. </div>
    <div id="p0154" num="0154" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor comprises a combination of two or more different siRNA molecules (e.g., a cocktail) selected from the siRNA molecules described in Tables A and B. In certain embodiments, the HBV antigen inhibitor comprises a combination of three or more different siRNA molecules selected from the siRNA molecules described in Tables A and B. Thus, in one aspect, the present invention provides compositions {e.g., pharmaceutical compositions) that include one of the two way or three way combinations of the siRNAs set forth in Tables A and B (see, e.g., Examples 26 and 27). In one aspect, the present invention provides combinations of two or three siRNA molecules, such as the combinations disclosed in the Examples, and compositions comprising such combinations, and uses of such combinations. </div>
    <div id="p0155" num="0155" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is a pharmaceutical composition comprising one or more {e.g., a cocktail) of the siRNAs described herein and a pharmaceutically acceptable carrier. 

 Table A. </div>
    <div id="p0156" num="0156" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/c1/7b/c4aeee8583a492/imgf000019_0001.png"><img id="imgf000019_0001" he="227" wi="176" file="imgf000019_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="704" height="908" alt="Figure imgf000019_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/c1/7b/c4aeee8583a492/imgf000019_0001.png"/></a></div>
 siRNA sense sense sequence (5&#39;-3&#39;) antisense antisense sequence (5&#39;-3&#39;) SEQ SEQ ID ID </div>
    <div id="p0157" num="0157" class="description-paragraph"> 44m 60 xGrCmCmGrAmUrCmCrAmUrArCmUmGrCrGmGrArArUxU 97 rUrUrCrCmGrCrAmGrUrAmUrGmGrAmUmCrGmGrCrUrU</div>
    <div id="p0158" num="0158" class="description-paragraph">45m 61 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGrUrGrUxU 98 rCrArCrUrAmGrUrArArArCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0159" num="0159" class="description-paragraph">46m 62 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGrUrGrUxU 99 rCrArCrUrAmGrUrArArArCmUmGrAmGrCrCrArGrUrU</div>
    <div id="p0160" num="0160" class="description-paragraph">47m 63 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGrUrGrUxU 100 rCrAmCrUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0161" num="0161" class="description-paragraph">48m 64 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGmUrGrUxU 101 rCrArCrUrAmGrUrArArArCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0162" num="0162" class="description-paragraph">49m 65 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGmUrGrUxU 102 rCrArCrUrAmGrUrArArArCmUmGrAmGrCrCrArGrUrU</div>
    <div id="p0163" num="0163" class="description-paragraph">50m 66 xCmUmGmGrCmUrCrArGrUrUrUrArCmUrAmGmUrGrUxU 103 rCrAmCrUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0164" num="0164" class="description-paragraph">51m 67 xCmUmGmGrCmUrCrArGrUrUmUrAmCmUrAmGmUrGrUxU 104 rCrArCrUrAmGrUrArArArCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0165" num="0165" class="description-paragraph">52m 68 xCmUmGmGrCmUrCrArGrUrUmUrAmCmUrAmGmUrGrUxU 105 rCrArCrUrAmGrUrArArArCmUmGrAmGrCrCrArGrUrU</div>
    <div id="p0166" num="0166" class="description-paragraph">53m 69 xCmUmGmGrCmUrCrArGrUrUmUrAmCmUrAmGmUrGrUxU 106 rCrAmCrUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0167" num="0167" class="description-paragraph">54m 107 xArCmCmUrCmUrGrCrCrUrArAmUrCrArUrCrUrCxUT 120 rGrArGrArUrGrArUmUrArGrGmCrArGrArGrGrUxUT</div>
    <div id="p0168" num="0168" class="description-paragraph">55m 108 xAmCrCmUrCmUrGmCrCmUrAmArUmCrArUrCrUrCxUT 121 rGrArGrArUrGmArUmUrArGrGmCrAmGrAmGrGrUxUT</div>
    <div id="p0169" num="0169" class="description-paragraph">56m 109 xGmCrCmUrCmUrGmCrCmUrAmArUmCrArUrCrUrCxUrU 74 rGrArGrArUrGmArUmUrArGrGmCrAmGrAmGrGrUxUrU</div>
    <div id="p0170" num="0170" class="description-paragraph">57m 110 xGrCrCmGrAmUrCrCrArUrArCmUmGrCrGmGrArATxU 122 rUrUrCrCrGrCrAmGrUrArUrGmGrArUrCrGmGrCTT</div>
    <div id="p0171" num="0171" class="description-paragraph">58m 111 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUrGrUxU 123 rCrArCrUrAmGmUrArArAmCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0172" num="0172" class="description-paragraph">59m 112 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUrGrUxU 124 rCrArCmUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0173" num="0173" class="description-paragraph">60m 113 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUrGrUxU 125 rCrArCmUrAmGmUrArArAmCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0174" num="0174" class="description-paragraph">61m 114 xCmUmGmGrCmUrCrArGmUrUmUrAmCmUrAmGmUmGrUxU 126 rCrArCrUrAmGmUrArArAmCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0175" num="0175" class="description-paragraph">62m 115 xCmUmGmGrCmUrCrArGmUrUmUrAmCmUrAmGmUmGrUxU 127 rCrArCmUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0176" num="0176" class="description-paragraph">63m 116 xCmUmGmGrCmUrCrArGmUrUmUrAmCmUrAmGmUmGrUxU 128 rCrArCmUrAmGmUrArArAmCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0177" num="0177" class="description-paragraph">64m 117 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUmGrUxU 129 rCrArCrUrAmGmUrArArAmCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0178" num="0178" class="description-paragraph">65m 118 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUmGrUxU 130 rCrArCmUrAmGrUrArArArCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0179" num="0179" class="description-paragraph">66m 119 xCmUmGmGrCmUrCrAmGmUrUmUrAmCmUrAmGmUmGrUxU 131 rCrArCmUrAmGmUrArArAmCmUmGrAmGrCmCrArGrUrU</div>
    <div id="p0180" num="0180" class="description-paragraph">67m 142 xCrCrGrUmGmUrGrCrArCrUmUrCrGrCmUmUrCrAxUxU 143 rUrGrArArGrCrGrArArGrUmGrCrArCrArCmGrGxUxU</div>
    <div id="p0181" num="0181" class="description-paragraph">68m 132 rCrCmGrUmGmUrGrCrArCrUmUrCmGrCmUmUrCrArUrU 133 rUrGrArAmGrCmGrArArGmUmGrCrAmCrAmCmGrGrUrU</div>
    <div id="p0182" num="0182" class="description-paragraph">69m 134 rGrCmCmGrAmUrCrCrAmUrArCmUmGrCrGmGrArArUrU 135 rUrUrCrCrGrCrAmGrUrArUrGmGrArUrCrGmGrCrUrU</div>
    <div id="p0183" num="0183" class="description-paragraph">70m 136 xGrCmCmGrAmUrCrCrAmUrArCmUmGrCrGmGrArArUxU 135 rUrUrCrCrGrCrAmGrUrArUrGmGrArUrCrGmGrCrUrU</div>
    <div id="p0184" num="0184" class="description-paragraph">71m 144 xCmUmGmGrCrUrCrArGrUrUrUrArCmUrAmGrUrGrUxU 145 rCrArCrUrAmGrUrArArArCrUmGrAmGrCrCrArGrUrU</div>
    <div id="p0185" num="0185" class="description-paragraph">72m 138 rCmUmGmGrCmUrCrArGmUrUmUrAmCmUrAmGmUmGrUrU 126 rCrArCrUrAmGmUrArArAmCrUmGrAmGrCmCrArGrUrU</div>
    <div id="p0186" num="0186" class="description-paragraph">73m 140 rAmCrCmUrCmUrGmCrCmUrAmArUmCrArUrCrUrCrUrU 141 rGrArGrArUrGmArUmUrArGrGmCrAmGrAmGrGrUrUrU</div>
    <div id="p0187" num="0187" class="description-paragraph">74m 10 xGrCrCmGrAmUrCrCrArUrArCmUmGrCrGmGrArArUxU 24 rUrUrCrCrGrCrAmGrUrArUrGmGrArUrCrGmGrCrUrU</div>
    <div id="p0188" num="0188" class="description-paragraph">75m 146 xCrArArGrGmUrArUrGrUrUrGmCrCmCrGmUrUrUxUxU 152 rArArArCrGrGrGmCrArAmCrAmUrArCrCrUrUrGxUxU</div>
    <div id="p0189" num="0189" class="description-paragraph">76m 147 xGrCmUrCrAmGrUrUrUrArCmUrAmGrUrGrCrCrArUxU 153 rUrGrGrCrArCrUrArGrUrArArArCmUrGrArGrCrUrU</div>
    <div id="p0190" num="0190" class="description-paragraph">77m 148 rCmUrGmUrArGmGrCrArUrArArArUmUrGrGrUrCrUrU 154 rGrArCrCrArArUrUmUrArUrGrCrCmUrAmCrArGrUrU</div>
    <div id="p0191" num="0191" class="description-paragraph">78m 149 xUrCrUmGrCmGrGrCrGrUrUmUrUrArUmCrAmUrAxUrU 155 rUrAmUrGrArUrArArArArCrGmCrCmGrCrArGrAxUrU</div>
    <div id="p0192" num="0192" class="description-paragraph">79m 150 xUmUrUrArCmUrAmGrUrGrCrCrAmUrUrUrGmUrUxUrU 17 rGrArGrArUrGrArUmUrArGrGmCrArGrArGrGrUxUrU</div>
    <div id="p0193" num="0193" class="description-paragraph">80m 151 rArCmCmUrCmUrGrCrCrUrArAmUrCrArUrCrUrCrUrU 156 rGrArGrArUrGrArUmUrArGrGmCrArGrArGrGrUrUrU rN = RNA of base N </div>
    <div id="p0194" num="0194" class="description-paragraph">mN = 2&#39;0-methyl modification of base N </div>
    <div id="p0195" num="0195" class="description-paragraph">xN = unlocked nucleoside analog moiety of base N </div>
    <div id="p0196" num="0196" class="description-paragraph"> T = deoxythymidine 

 Table B. </div>
    <div id="p0197" num="0197" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/83/47/e52f5e1384b826/imgf000021_0001.png"><img id="imgf000021_0001" he="224" wi="177" file="imgf000021_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="708" height="896" alt="Figure imgf000021_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/83/47/e52f5e1384b826/imgf000021_0001.png"/></a></div>
 siRNA Sense strand Sense strand Antisense strand Antisense strand </div>
    <div id="p0198" num="0198" class="description-paragraph">Number SEQ ID NO 5&#39; - 3&#39; SEQ ID NO 5&#39;-3&#39; </div>
    <div id="p0199" num="0199" class="description-paragraph"> 135 SEQ ID NO:225 ususuaCuAgUGCcaUuuguuca SEQ ID NO:226 us GsAaCaAauGgcaCuAgUaAas csuUU</div>
    <div id="p0200" num="0200" class="description-paragraph">136 SEQ ID NO:227 ususuacuAgUGCcauuuguuca SEQ ID NO:228 usGsaacAaAUggcaCuAguaaas csuUU</div>
    <div id="p0201" num="0201" class="description-paragraph">137 SEQ ID NO:229 ususuaCuAgUgCcauuuguuca SEQ ID NO:230 usGsaacAaAUggcaCuAguaaas csuUU</div>
    <div id="p0202" num="0202" class="description-paragraph">2&#39;-0-Methyl nucleotides = lower case </div>
    <div id="p0203" num="0203" class="description-paragraph"> 2&#39;-Fluoro nucleotides = UPPER CASE </div>
    <div id="p0204" num="0204" class="description-paragraph"> Phosphorothioate linker = s </div>
    <div id="p0205" num="0205" class="description-paragraph"> Unmodified = UPPER CASE </div>
    <div id="p0206" num="0206" class="description-paragraph">In certain embodiments, the oligonucleotide is Arrowhead-ARC-520 (see United States Patent Number 8,809,293; and Wooddell CI, et al., Molecular Therapy, 2013, 21, 5, 973-985). </div>
    <div id="p0207" num="0207" class="description-paragraph"> In another aspect, term oligonucleotide includes siRNA molecules that target GalNAc 5 and REP 2139, REP-2165 (see, e.g., WO 2016/077321, Al-Mathtab et al., PLoS ONE </div>
    <div id="p0208" num="0208" class="description-paragraph"> l l(6):e0156667. doi: 10.1371/journal.pone.0156667 and Guillot et al., Poster P0556, EASL, 2015). </div>
    <div id="p0209" num="0209" class="description-paragraph"> In certain embodiments, an HBV antigen inhibitor (e.g., an oligonucleotide, such as an siRNA) is comprised within a lipid nanoparticle formulation.</div>
    <div id="p0210" num="0210" class="description-paragraph">0 In certain embodiments, an HBV antigen inhibitor (e.g., an oligonucleotide, such as an </div>
    <div id="p0211" num="0211" class="description-paragraph"> siRNA) is conjugated to a targeting moiety. Accordingly, in certain embodiments, an HBV antigen inhibitor (e.g., an oligonucleotide, such as an siRNA) is comprised within a compound of formula (I) or compound of formula (XX). </div>
    <div id="p0212" num="0212" class="description-paragraph">Description of Additional Therapeutic Agents </div>
    <div id="p0213" num="0213" class="description-paragraph"> In certain embodiments, methods of the invention further comprise administering at least one additional therapeutic agent. In certain embodiments, the at least one additional therapeutic agent is selected from the group consisting of: </div>
    <div id="p0214" num="0214" class="description-paragraph"> (A) an agent that controls viral replication; </div>
    <div id="p0215" num="0215" class="description-paragraph"> (B) an agent that reduces viral Ags; </div>
    <div id="p0216" num="0216" class="description-paragraph"> (C) an immune enhancer; and </div>
    <div id="p0217" num="0217" class="description-paragraph"> (D) an immune stimulant. </div>
    <div id="p0218" num="0218" class="description-paragraph"> In certain embodiments, a combination of additional therapeutic agents is administered. In certain embodiments, an additional therapeutic agent may be an HBV antigen inhibitor described herein. 

 I. Agents that Control Viral Replication </div>
    <div id="p0219" num="0219" class="description-paragraph"> Category I treatments are directed to the use of agents that control, e.g., inhibit, viral replication. </div>
    <div id="p0220" num="0220" class="description-paragraph"> A. Reverse Transcriptase Inhibitors </div>
    <div id="p0221" num="0221" class="description-paragraph"> In certain embodiments, the reverse transcriptase inhibitor is a nucleoside analog. </div>
    <div id="p0222" num="0222" class="description-paragraph"> In certain embodiments, the reverse transcriptase inhibitor is a nucleoside analog reverse-transcriptase inhibitor (NARTI or NRTI). </div>
    <div id="p0223" num="0223" class="description-paragraph"> In certain embodiments, the reverse transcriptase inhibitor is a nucleotide analog reverse- transcriptase inhibitor (NtARTI or NtRTI). </div>
    <div id="p0224" num="0224" class="description-paragraph"> The term reverse transcriptase inhibitor includes, but is not limited to: entecavir, clevudine, telbivudine, lamivudine, adefovir, and tenofovir, tenofovir disoproxil, tenofovir alafenamide, tenofovir disoproxil fumarate, adefovir dipivoxil, (lR,2R,3R,5R)-3-(6-amino-9H- 9-purinyl)-2-fluoro-5-(hydroxymethyl)-4-methylenecyclopentan-l-ol (described in U. S. Patent No. 8,816,074), emtricitabine, abacavir, elvucitabine, ganciclovir, lobucavir, famciclovir, penciclovir, amdoxovir and CMX157 (tenofovir exalidex). </div>
    <div id="p0225" num="0225" class="description-paragraph"> The term reverse transcriptase inhibitor includes, but is not limited to, entecavir, lamivudine, and (lR,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5-(hydroxymethyl)-4- methylenecyclopentan- 1 -ol . </div>
    <div id="p0226" num="0226" class="description-paragraph"> The term reverse transcriptase inhibitor includes, but is not limited to a covalently bound phosphoramidate or phosphonamidate moiety of the above-mentioned reverse transcriptase inhibitors, or as described in, for example, U.S. Patent No. 8,816,074, US 2011/0245484 Al, and US 2008/0286230A1. </div>
    <div id="p0227" num="0227" class="description-paragraph"> The term reverse transcriptase inhibitor includes, but is not limited to, nucleotide analogs that comprise a phosphoramidate moiety, such as, methyl ((((lR,3R,4R,5R)-3-(6-amino-9H- purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl ((((lR,2R,3R,4R)-3-fluoro-2-hydroxy-5-methylene-4-(6-oxo-l,6- dihydro-9H-purin-9-yl)cyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate. Also included are the individual diastereomers thereof, which includes, for example, methyl ((R)- ((( 1 R, 3R,4R, 5R)-3 -(6-amino-9H-purin-9-yl)-4-fluoro-5 -hydroxy-2- methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl ((S)- ((( 1 R, 3R,4R, 5R)-3 -(6-amino-9H-purin-9-yl)-4-fluoro-5 -hydroxy-2- methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate. </div>
    <div id="p0228" num="0228" class="description-paragraph"> The term reverse transcriptase inhibitor includes, but is not limited to a phosphonamidate moiety, such as, tenofovir alafenamide, as well as those described in US 2008/0286230 Al . 

 Methods for preparing stereoselective phosphoramidate or phosphonamidate containing actives are described in, for example, U.S. Patent No. 8,816,074, as well as US 201 1/0245484 Al and US 2008/0286230 Al . </div>
    <div id="p0229" num="0229" class="description-paragraph"> B. Capsid Inhibitors </div>
    <div id="p0230" num="0230" class="description-paragraph"> As described herein the term &#34;capsid inhibitor&#34; includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly. </div>
    <div id="p0231" num="0231" class="description-paragraph">Examples of capsid inhibitors which may be used in methods of the invention are described above. </div>
    <div id="p0232" num="0232" class="description-paragraph"> C. cccDNA Formation Inhibitors </div>
    <div id="p0233" num="0233" class="description-paragraph"> Covalently closed circular DNA (cccDNA) is generated in the cell nucleus from viral rcDNA and serves as the transcription template for viral mRNAs. As described herein, the term &#34;cccDNA formation inhibitor&#34; includes compounds that are capable of inhibiting the formation and/or stability of cccDNA either directly or indirectly. For example, a cccDNA formation inhibitor may include, but is not limited to, any compound that inhibits capsid disassembly, rcDNA entry into the nucleus, and/or the conversion of rcDNA into cccDNA. For example, in certain embodiments, the inhibitor detectably inhibits the formation and/or stability of the cccDNA as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the formation and/or stability of cccDNA by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. </div>
    <div id="p0234" num="0234" class="description-paragraph"> The term cccDNA formation inhibitor includes compounds described in International Patent Application Publicati the following compound: </div>
    <div id="p0235" num="0235" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e6/21/ef/0b60155e453dcf/imgf000024_0001.png"><img id="imgf000024_0001" he="23" wi="70" file="imgf000024_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="280" height="92" alt="Figure imgf000024_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e6/21/ef/0b60155e453dcf/imgf000024_0001.png"/></a></div>
    </div>
    <div id="p0236" num="0236" class="description-paragraph">The term cccDNA formation inhibitor includes, but is not limited to those generally and specifically described in United States Patent Application Publication Number US </div>
    <div id="p0237" num="0237" class="description-paragraph">2015/0038515 Al . The term cccDNA formation inhibitor includes, but is not limited to, 1- (phenylsulfonyl)-N-(pyridin-4-ylmethyl)-lH-indole-2-carboxamide; 1-Benzenesulfonyl- pyrrolidine-2-carboxylic acid (pyridin-4-ylmethyl)-amide; 2-(2-chloro-N-(2-chloro-5- (trifluoromethyl)phenyl)-4-(trifluoromethyl)phenylsulfonamido)-N-(pyridin-4- ylmethyl)acetamide; 2-(4-chloro-N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N- (pyridin-4-ylmethyl)acetamide; 2-(N-(2-chloro-5-(trifluoromethyl)phenyl)-4- 

 (trifluoromethyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide; 2-(N-(2-chloro-5- (trifluoromethyl)phenyl)-4-methoxyphenylsulfonamido)-N-(pyridin-4-ylmethyl)acetamide; 2- (N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-((l-methylpiperidin-4- yl)methyl)acetamide; 2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N- (piperidin-4-ylmethyl)acetamide; 2-( -(2-chloro-5-</div>
    <div id="p0238" num="0238" class="description-paragraph">(trifluoromethyl)phenyl)phenylsulfonamido)-N-(pyridin-4-ylmethyl)propanamide; 2-(N-(2- chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(pyridin-3-ylmethyl)acetamide; 2-(N- (2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(pyrimidin-5-ylmethyl)acetamide; 2-(N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)-N-(pyrimidin-4- ylmethyl)acetamide; 2-(N-(5-chloro-2-fluorophenyl)phenylsulfonamido)-N-(pyridin-4- ylmethyl)acetamide; 2-[(2-chloro-5-trifluoromethyl-phenyl)-(4-fluoro-benzenesulfonyl)-amino] N-pyridin-4-ylmethyl-acetamide; 2-[(2-c loro-5-trifluoromethyl-phenyl)-(toluene-4-sulfonyl)- amino]-N-pyridin-4-ylmethyl-acetamide; 2-[benzenesulfonyl-(2-bromo-5-trifluoromethyl- phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide; 2-[benzenesulfonyl-(2-chloro-5- trifluoromethyl-phenyl)-amino]-N-(2-methyl-benzothiazol-5-yl)-acetamide; 2-[benzenesulfonyl (2-chloro-54rifluoromethyl-phenyl)-amino]-N-[4-(4-methyl-piperazin-l-yl)-benzyl]-acetamide; 2-[benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-[3-(4-methyl-piperazin-l-yl) benzyl]-acetamide; 2-[benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-benzyl- acetamide; 2-[benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4- ylmethyl-acetamide; 2-[benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin</div>
    <div id="p0239" num="0239" class="description-paragraph">4- ylmethyl-propionamide; 2-[benzenesulfonyl-(2-fluoro-5-trifluoromethyl-phenyl)-amino]-N- pyridin-4-ylmethyl-acetamide; 4 ( -(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)- N-(pyridin-4-yl- methyl)butanamide; 4-((2-(N-(2-chloro-5-</div>
    <div id="p0240" num="0240" class="description-paragraph">(trifluoromethyl)phenyl)phenylsulfonamido)-acetamido)-methyl)-l, l-dimethylpiperidin-1 um chloride; 4-(benzyl-methyl-sulfamoyl)-N-(2-chloro-5-trifluoromethyl-phenyl)-benzamide; 4- (benzyl -methyl-sulfamoyl)-N-(2 -methyl- lH-indol-5-yl)-benzamide; 4-(benzyl-methyl- sulfamoyl)-N-(2 -methyl- lH-indol-5-yl)-benzamide; 4-(benzyl-methyl-sulfamoyl)-N-(2-methyl- benzothiazol-5-yl)-benzamide; 4-(benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)- benzamide; 4-(benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-6-yl)-benzamide; 4- (benzyl-methyl-sulfamoyl)-N-pyridin-4-ylmethyl-benzamide; N-(2-aminoethyl)-2-(N-(2-chloro-</div>
    <div id="p0241" num="0241" class="description-paragraph">5- (trifluoromethyl)phenyl)phenylsulfonamido)-acetamide; N-(2-chloro-5- (trifluoromethyl)phenyl)-N-(2-(3,4-dihydro-2,6-naphthyridin-2(lH)-yl)-2- oxoethyl)benzenesulfonamide; N-benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide; N-benzothiazol-6-yl-4-(benzyl-methyl-sulfamoyl)-benzamide; tert-butyl (2-(2-(N-(2-chloro-5- 

 (trifluoromethyl)phenyl)phenylsulfonamido)acetamido)-ethyl)carbamate; and tert-butyl 4-((2- (N-(2-chloro-5-(trifluoromethyl)phenyl)phenylsulfonamido)- acetamido)-methyl)piperidine-l- carboxylate, and optionally, combinations thereof. </div>
    <div id="p0242" num="0242" class="description-paragraph"> D. Entry Inhibitors </div>
    <div id="p0243" num="0243" class="description-paragraph"> Certain embodiments of the invention are directed to the use of agents that are HBV entry inhibitors. Entry inhibitors include Myrcludex-B, NTCP inhibitor small molecules, and FXR agonist EYP001 (see, e.g., Gripon, P., Cannie, I. and Urban, S. Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein. Journal of Virology, 79(3): 1613-1622; Volz, T., Allweiss, L., MBarek, M, Warlich, M., Lohse, A., Pollok, J., Alexandrov, A., Urban, S., Petersen, J., Lutgehetmann, M., Dandri, M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology, 58(5): 861-867; Radreau, P., Procherot, M., Vonderscher, J., Lotteau, V., Andre, P. Effect of a novel synthetic FXR agonist EYP001 on hepatitis B virus replication in HepaRG cell line and primary human hepatocytes. AASLD LiverLeaming, Abstract 1652, November 16, 2015; WO 2015/036442; WO 00/37077; US2007/0015796). For example, the hepatitis B virus uses its surface lipopeptide pre-Sl for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S l that can also dock to NTCP, blocking the virus&#39;s entry mechanism. </div>
    <div id="p0244" num="0244" class="description-paragraph">II. Agents that Reduce Viral Ags </div>
    <div id="p0245" num="0245" class="description-paragraph"> Category II treatments are directed to the use of agents that reduce viral antigens. </div>
    <div id="p0246" num="0246" class="description-paragraph"> A. Oligomeric Nucleotides </div>
    <div id="p0247" num="0247" class="description-paragraph"> Examples of oligomeric nucleotides that may be used in methods of the invention are described above (e.g., an HBV antigen inhibitor described herein). </div>
    <div id="p0248" num="0248" class="description-paragraph"> B. sAg Secretion Inhibitors </div>
    <div id="p0249" num="0249" class="description-paragraph"> As described herein, the term &#34;sAg secretion inhibitor&#34; includes compounds that are capable of inhibiting, either directly or indirectly, the secretion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells. Examples of sAg secretion inhibitors that may be used in methods of the invention are described above (e.g., an HBV antigen inhibitor described herein). </div>
    <div id="p0250" num="0250" class="description-paragraph"> C. Anti-HBsAg agents </div>
    <div id="p0251" num="0251" class="description-paragraph"> As described herein, the term &#34;anti-HBsAg agents&#34; include anti-HBsAg antibodies, e.g., mAbs. This term also includes hepatitis B immune globulin (HBIG). </div>
    <div id="p0252" num="0252" class="description-paragraph">III. Agents that Improve Immune Response 

 Category III treatments are directed to the use of agents that improve the immune response against viral infection. In certain embodiments, at least one &#39;immune enhancer&#39; agent is used in combination with at least one &#39;immune stimulant agent&#39; . Such a combination can be used in further combination with at least one agent that controls viral replication and/or at least one agent that reduces the viral antigens. </div>
    <div id="p0253" num="0253" class="description-paragraph"> A. Immune Enhancers </div>
    <div id="p0254" num="0254" class="description-paragraph"> Certain aspects of the invention are directed to the use of agents that act to improve an immune response by reducing or eliminating immune exhaustion, e.g. , by using checkpoint inhibitors, thereby enhancing the immune response. </div>
    <div id="p0255" num="0255" class="description-paragraph"> In certain embodiments, an immune enhancer is a PD-L1 inhibitor. PD-L1 inhibitors are a group of agents that act to inhibit the association of the programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein 1 (PD-1). </div>
    <div id="p0256" num="0256" class="description-paragraph"> Immune enhancers include the following: </div>
    <div id="p0257" num="0257" class="description-paragraph"> anti-PD-1 mAbs (e.g., Nivolumab, Pembrolizumab; </div>
    <div id="p0258" num="0258" class="description-paragraph"> anti-PD-Ll mAbs (e.g., Atezolizumab, Avelumab); </div>
    <div id="p0259" num="0259" class="description-paragraph"> anti-PD-L2 mAbs; </div>
    <div id="p0260" num="0260" class="description-paragraph"> anti-CTLA4 mAbs (e.g., Ipilimumab); </div>
    <div id="p0261" num="0261" class="description-paragraph"> anti-VISTA mAbs (e.g., JNJ-61610588); </div>
    <div id="p0262" num="0262" class="description-paragraph"> anti-LAG3 mAbs (e.g., BMS-986016); </div>
    <div id="p0263" num="0263" class="description-paragraph"> anti-TEVB mAbs (e.g., TSR-022); </div>
    <div id="p0264" num="0264" class="description-paragraph"> peptidomimetics (e.g., AU P-12); and </div>
    <div id="p0265" num="0265" class="description-paragraph"> small molecule compounds (see, e.g., Zak et al., Oncotarget, 2016, 7(21):30323-35) </div>
    <div id="p0266" num="0266" class="description-paragraph">B. Immune Stimulants </div>
    <div id="p0267" num="0267" class="description-paragraph"> The term &#34;immune stimulant&#34; includes compounds that are capable of modulating an immune response (e.g., stimulating an innate and/or adaptive immune response (e.g., an adjuvant)). The term immune stimulant includes polyinosinic:polycytidylic acid (poly I:C) and interferons. </div>
    <div id="p0268" num="0268" class="description-paragraph"> The term immune stimulant includes agonists of stimulator of IFN genes (STING) and interleukins. The term also includes HBsAg release inhibitors, TLR-7 agonists (GS-9620, RG- 7795), T-cell and/or B-cell stimulators (GS-4774, OX-40 agonists (BMS 986178), anti-GITR agonists (BMS-986156)), RIG-1 inhibitors (SB-9200), and SMAC-mimetics (Birinapant). </div>
    <div id="p0269" num="0269" class="description-paragraph"> The term also includes the following: </div>
    <div id="p0270" num="0270" class="description-paragraph"> anti-HBV vaccines (Engerix-B, RECOMBIVAX HB, GS-4744, Heplisav-B); 

 interferons (Pegylated IFN-a2a, Peglyated IFN-a2b, IFN-a, IFN-Î»); </div>
    <div id="p0271" num="0271" class="description-paragraph"> RIG-I agonists (SB-9200); </div>
    <div id="p0272" num="0272" class="description-paragraph"> STING agonists (cGAMP, cGAMP bisphosphorot ioate, ADU S I 00, and other small molecule compounds); </div>
    <div id="p0273" num="0273" class="description-paragraph"> TLR9 agonists (CYT-009, CpG dinucleotides); </div>
    <div id="p0274" num="0274" class="description-paragraph"> TLR7 agonists (GS-9620); </div>
    <div id="p0275" num="0275" class="description-paragraph"> TLR8 agonists (GS-9688); </div>
    <div id="p0276" num="0276" class="description-paragraph"> TLR3 agonists (Ampligen/poly I:C12U); </div>
    <div id="p0277" num="0277" class="description-paragraph"> IL-7 (CYT107); and </div>
    <div id="p0278" num="0278" class="description-paragraph"> IL-2 (aldesleukin). </div>
    <div id="p0279" num="0279" class="description-paragraph">Certain Definitions </div>
    <div id="p0280" num="0280" class="description-paragraph"> As used herein, the following terms have the meanings ascribed to them unless specified otherwise. </div>
    <div id="p0281" num="0281" class="description-paragraph"> The term &#34;Hepatitis B virus&#34; (abbreviated as HBV) refers to a virus species of the genus</div>
    <div id="p0282" num="0282" class="description-paragraph">Orthohepadnavirus, which is a part of the Hepadnaviridae family of viruses, and that is capable of causing liver inflammation in humans. </div>
    <div id="p0283" num="0283" class="description-paragraph"> The term &#34;Hepatitis D virus&#34; (abbreviated as HDV) refers to a virus species of the genus Deltaviridae, which is capable of causing liver inflammation in humans. HDV is a small circular enveloped RNA virus that can propagate only in the presence HBV. In particular, HDV requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone. These </div>
    <div id="p0284" num="0284" class="description-paragraph">complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. In combination with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis infections. The routes of transmission of HDV are similar to those for HBV. </div>
    <div id="p0285" num="0285" class="description-paragraph"> A &#34;gene,&#34; for the purposes of the present disclosure, includes a DNA region encoding a gene product, as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. The term &#34;gene&#34; is used broadly to refer to any segment of nucleic acid associated with a biological function. Genes include coding sequences and/or the regulatory sequences required for their expression. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and 

 internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions. For example, &#34;gene&#34; refers to a nucleic acid fragment that expresses mRNA, functional RNA, or specific protein, including regulatory sequences. &#34;Functional RNA&#34; refers to sense RNA, antisense RNA, ribozyme RNA, siRNA, or other RNA that may not be translated but yet has an effect on at least one cellular process. &#34;Genes&#34; also include nonexpressed DNA segments that, for example, form recognition sequences for other proteins. &#34;Genes&#34; can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters. The term &#34;endogenous gene&#34; refers to a native gene in its natural location in the genome of an organism. </div>
    <div id="p0286" num="0286" class="description-paragraph"> The term &#34;single nucleotide polymorphism (SNP)&#34; refers to a DNA sequence variation that occurs when a single nucleotide in the genome differs between members of a species or paired chromosomes in an individual. As used herein, references to SNPs and SNP genotypes include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. The disclosure of U. S. Pat. No. 7,820,380, which is incorporated by reference, provides a detailed discussion on a variety of methods that employ SNP genotyping. For example, it is disclosed that various methods for detecting polymorphisms include, but are not limited to, sequencing, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230: 1242 (1985); Cotton et al., PNAS 85 :4397 (1988); and Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules (Orita et al, PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285 : 125-144 (1993); and Hayashi et al., Genet. Anal. Tech. App 9:73-79 (1992)), and assaying the movement of polymorphic or wild type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE) (Myers et al., Nature 313 :495 (1985)).</div>
    <div id="p0287" num="0287" class="description-paragraph">Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and 51 protection or chemical cleavage methods. In certain embodiments, sequence variations may be detected using a real-time PCR assay (e.g., employing a fluorescent probe). US. Pat. No. 7,820,380 also discloses that SNP genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the 

 nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent). </div>
    <div id="p0288" num="0288" class="description-paragraph"> The term &#34;detecting&#34; is used in the broadest sense to include both qualitative and quantitative measurements of a specific molecule, for example, measurements of a specific molecule such as a chromosome, a DNA sequence, individual nucleic acids, etc. </div>
    <div id="p0289" num="0289" class="description-paragraph"> The term &#34;obtaining a biological sample from a hepatitis B patient&#34; is used to refer to obtaining the sample directly from the patient, as well as obtaining the sample indirectly from an intermediary individual (e.g., obtaining the sample from a courier who obtained the sample from a nurse who obtained the sample from the patient). </div>
    <div id="p0290" num="0290" class="description-paragraph"> The term &#34;biological sample&#34; refers to a body sample from any animal, but preferably is from a mammal, more preferably from a human. Such samples include biological fluids such as serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, whole blood, biopsy material, urine, cerebro-spinal fluid, saliva, sputum, tears, perspiration, and mucus. The term also refers to tissue extracts, such as homogenized tissue and cellular extracts, and cellular samples (e.g., oral epithelial cells). </div>
    <div id="p0291" num="0291" class="description-paragraph"> The terms &#34;a higher likelihood of responding to an HBV antigen inhibitor&#34; refers to the likelihood of a patient having a favorable response to the HBV antigen inhibitor. Favorable responses include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In certain embodiments, a favorable response is a reduction in HBV DNA or RNA (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more; or e.g., is undetectable after e.g., 1, 2, 3, 4, 5, 6 months, etc. after cessation of HBV therapy). In certain embodiments, a favorable response is sustained virological response (SVR). In certain embodiments, a favorable response is a reduction in HBV core protein (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more). In certain </div>
    <div id="p0292" num="0292" class="description-paragraph">embodiments, a favorable response is a reduction in surface antigen (e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 709%, 80%, 90% or more). In certain embodiments, a favorable response is seroconversion (e.g., HBsAg seroconversion). For example, in certain embodiments, patients that have a C/C genotype at rsl2079860 may have a faster rate of surface antigen decline in response to the administration of an HBV antigen inhibitor as compared to a patient having a different genotype. In certain embodiments, patients that have a C/C genotype at rsl2079860 may have greater decline in surface antigen in response to the administration of an 

 HBV antigen inhibitor as compared to a patient having a different genotype. In certain embodiments, patients that have a C/C genotype at rsl2079860 may have a higher likelihood of seroconverting in response to an HBV inhibitor as compared to a patient having a different genotype. Methods of measuring a response to an HBV antigen inhibitor are known in the art, for example, an assay described in Example 27 may be used. </div>
    <div id="p0293" num="0293" class="description-paragraph"> As used herein, &#34;treatment&#34; (and grammatical variations thereof such as &#34;treat&#34; or &#34;treating&#34;) refers to clinical intervention in an attempt to alter the typical disease course of the individual being treated. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, treatments described herein are used to delay development of a disease or to slow the progression of a disease. </div>
    <div id="p0294" num="0294" class="description-paragraph"> The term &#34;patient&#34; as used herein refers to any animal including mammals such as humans, higher non-human primates, rodents domestic and farm animals such as cow, horses, dogs and cats. In one embodiment, the patient is a human patient. </div>
    <div id="p0295" num="0295" class="description-paragraph"> The phrase &#34;effective amount&#34; means an amount of a compound described herein that (i) treats or prevents a hepatitis B virus infection, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a hepatitis B virus infection, or (iii) prevents or delays the onset of one or more symptoms of a hepatitis B virus infection. </div>
    <div id="p0296" num="0296" class="description-paragraph"> The phrase &#34;inhibiting expression of a target gene&#34; refers to the ability of a siRNA described herein to silence, reduce, or inhibit expression of a target gene (e.g., a gene within the HBV genome). To examine the extent of gene silencing, a test sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) is contacted with a siRNA that silences, reduces, or inhibits expression of the target gene. Expression of the target gene in the test sample is compared to expression of the target gene in a control sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) that is not contacted with the siRNA. Control samples (e.g. , samples expressing the target gene) may be assigned a value of 100%. In particular embodiments, silencing, inhibition, or reduction of expression of a target gene is achieved when the value of the test sample relative to the control sample (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.) is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 

 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, </div>
    <div id="p0297" num="0297" class="description-paragraph">immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art. An &#34;effective amount&#34; or &#34;therapeutically effective amount&#34; of a therapeutic nucleic acid such as a siRNA is an amount sufficient to produce the desired effect, e.g., an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of a siRNA. In particular embodiments, inhibition of expression of a target gene or target sequence is achieved when the value obtained with a siRNA relative to the control {e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.) is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays for measuring the expression of a target gene or target sequence include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art. </div>
    <div id="p0298" num="0298" class="description-paragraph"> The term &#34;nucleic acid&#34; as used herein refers to a polymer containing at least two nucleotides (i.e., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form and includes DNA and RNA. &#34;Nucleotides&#34; contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. &#34;Bases&#34; include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs and/or modified residues include, without limitation, </div>
    <div id="p0299" num="0299" class="description-paragraph">phosphorothioates, phosphoramidates, methyl phosphonates, chiral -methyl phosphonates, 2&#39;-0- methyl ribonucleotides, and peptide-nucleic acids (PNAs). Additionally, nucleic acids can include one or more UNA moieties. </div>
    <div id="p0300" num="0300" class="description-paragraph"> The term &#34;nucleic acid&#34; includes any oligonucleotide or polynucleotide, with fragments containing up to 60 nucleotides generally termed oligonucleotides, and longer fragments termed 

 polynucleotides. A deoxyribooligonucleotide consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5&#39; and 3&#39; carbons of this sugar to form an alternating, unbranched polymer. DNA may be in the form of, e.g., antisense molecules, plasmid DNA, pre- condensed DNA, a PCR product, vectors, expression cassettes, chimeric sequences, </div>
    <div id="p0301" num="0301" class="description-paragraph">chromosomal DNA, or derivatives and combinations of these groups. A ribooligonucleotide consists of a similar repeating structure where the 5-carbon sugar is ribose. RNA may be in the form, for example, of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Accordingly, in the context of this invention, the terms &#34;polynucleotide&#34; and &#34;oligonucleotide&#34; refer to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally-occurring bases, sugars and intersugar (backbone) linkages. The terms &#34;polynucleotide&#34; and &#34;oligonucleotide&#34; also include polymers or oligomers comprising non -naturally occurring monomers, or portions thereof, which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of properties such as, for example, enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases. </div>
    <div id="p0302" num="0302" class="description-paragraph"> Unless otherwise indicated, a particular nucleic acid sequence also implicitly </div>
    <div id="p0303" num="0303" class="description-paragraph">encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes, 8:91-98 (1994)). </div>
    <div id="p0304" num="0304" class="description-paragraph"> Described herein are isolated or substantially purified nucleic acid molecules and compositions containing those molecules, which may be used in methods of the invention. In the context of the present invention, an &#34;isolated&#34; or &#34;purified&#34; DNA molecule or RNA molecule is a DNA molecule or RNA molecule that exists apart from its native environment. An isolated DNA molecule or RNA molecule may exist in a purified form or may exist in a non- native environment such as, for example, a transgenic host cell. For example, an &#34;isolated&#34; or &#34;purified&#34; nucleic acid molecule or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In one embodiment, an &#34;isolated&#34; nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5&#39; and 3&#39; ends of the nucleic acid) in the genomic DNA of the 

 organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. </div>
    <div id="p0305" num="0305" class="description-paragraph"> The term &#34;gene&#34; refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide. </div>
    <div id="p0306" num="0306" class="description-paragraph"> &#34;Gene product,&#34; as used herein, refers to a product of a gene such as an RNA transcript or a polypeptide. </div>
    <div id="p0307" num="0307" class="description-paragraph"> The term &#34;unlocked nucleobase analogue&#34; (abbreviated as &#34;UNA&#34;) refers to an acyclic nucleobase in which the C2&#39; and C3&#39; atoms of the ribose ring are not covalently linked. The term &#34;unlocked nucleobase analogue&#34; includes nucleobase analogues having the following structure identified as Structure A: </div>
    <div id="p0308" num="0308" class="description-paragraph"> Structure A </div>
    <div id="p0309" num="0309" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/56/24/86/a9b95316fa2764/imgf000034_0001.png"><img id="imgf000034_0001" he="28" wi="103" file="imgf000034_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="412" height="112" alt="Figure imgf000034_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/56/24/86/a9b95316fa2764/imgf000034_0001.png"/></a></div>
    </div>
    <div id="p0310" num="0310" class="description-paragraph"> wherein R is hydroxyl, and Base is any natural or unnatural base such as, for example, adenine (A), cytosine (C), guanine (G) and thymine (T). UNA useful in the practice of the present invention include the molecules identified as acyclic 2&#39;-3 &#39;-seco-nucleotide monomers in U. S. patent serial number 8,314,227 which is incorporated by reference herein in its entirety. </div>
    <div id="p0311" num="0311" class="description-paragraph"> The term &#34;lipid&#34; refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) &#34;simple lipids,&#34; which include fats and oils as well as waxes; (2) &#34;compound lipids,&#34; which include phospholipids and glycolipids; and (3) &#34;derived lipids&#34; such as steroids. </div>
    <div id="p0312" num="0312" class="description-paragraph"> The term &#34;lipid particle&#34; includes a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., siRNA) to a target site of interest (e.g., cell, tissue, organ, and the like). In preferred embodiments, the lipid particle of the invention is typically formed from a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle. A lipid particle that includes a nucleic acid molecule (e.g. , siRNA molecule) is 

 referred to as a nucleic acid-lipid particle. Typically, the nucleic acid is fully encapsulated within the lipid particle, thereby protecting the nucleic acid from enzymatic degradation. </div>
    <div id="p0313" num="0313" class="description-paragraph"> In certain instances, nucleic acid-lipid particles are extremely useful for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (e.g., sites physically separated from the administration site), and they can mediate silencing of target gene expression at these distal sites. The nucleic acid may be complexed with a condensing agent and encapsulated within a lipid particle as set forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0314" num="0314" class="description-paragraph"> The lipid particles of the invention typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm, and are substantially non-toxic. In addition, nucleic acids, when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0315" num="0315" class="description-paragraph"> As used herein, &#34;lipid encapsulated&#34; can refer to a lipid particle that provides a therapeutic nucleic acid such as a siRNA, with full encapsulation, partial encapsulation, or both. In a preferred embodiment, the nucleic acid (e.g., siRNA) is fully encapsulated in the lipid particle (e.g., to form a nucleic acid-lipid particle). </div>
    <div id="p0316" num="0316" class="description-paragraph"> The term &#34;lipid conjugate&#34; refers to a conjugated lipid that inhibits aggregation of lipid particles. Such lipid conjugates include, but are not limited to, PEG-lipid conjugates such as, e.g., PEG coupled to dialkyloxypropyls (e.g., PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see, e.g., U. S. Patent No. </div>
    <div id="p0317" num="0317" class="description-paragraph">5,885,613), cationic PEG lipids, polyoxazoline (POZ)-lipid conjugates (e.g., POZ-DAA conjugates), polyamide oligomers (e.g., ATTA-lipid conjugates), and mixtures thereof. </div>
    <div id="p0318" num="0318" class="description-paragraph">Additional examples of POZ-lipid conjugates are described in PCT Publication No. WO </div>
    <div id="p0319" num="0319" class="description-paragraph">2010/006282. PEG or POZ can be conjugated directly to the lipid or may be linked to the lipid 

 via a linker moiety. Any linker moiety suitable for coupling the PEG or the POZ to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties. In certain preferred embodiments, non-ester containing linker moieties, such as amides or carbamates, are used. </div>
    <div id="p0320" num="0320" class="description-paragraph"> The term &#34;amphipathic lipid&#34; refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase. Hydrophilic characteristics derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids. </div>
    <div id="p0321" num="0321" class="description-paragraph"> Representative examples of phospholipids include, but are not limited to, </div>
    <div id="p0322" num="0322" class="description-paragraph">phosphatidylcholine, phosphatidyl ethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, </div>
    <div id="p0323" num="0323" class="description-paragraph">lysophosphatidylethanolamine, dipalmitoylphosphatidyl choline, dioleoylphosphatidyl choline, distearoylphosphatidylcholine, and dilinoleoylphosphatidylcholine. Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacyl glycerols, and Î²- acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids described above can be mixed with other lipids including triglycerides and sterols. </div>
    <div id="p0324" num="0324" class="description-paragraph"> The term &#34;neutral lipid&#34; refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols. </div>
    <div id="p0325" num="0325" class="description-paragraph"> The term &#34;non-cationic lipid&#34; refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid. </div>
    <div id="p0326" num="0326" class="description-paragraph"> The term &#34;anionic lipid&#34; refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, </div>
    <div id="p0327" num="0327" class="description-paragraph">diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, </div>
    <div id="p0328" num="0328" class="description-paragraph">lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and other anionic modifying groups joined to neutral lipids. 

 The term &#34;hydrophobic lipid&#34; refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N- dialkylamino, l,2-diacyloxy-3-aminopropane, and l,2-dialkyl-3-aminopropane. </div>
    <div id="p0329" num="0329" class="description-paragraph"> The terms &#34;cationic lipid&#34; and &#34;amino lipid&#34; are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group). The cationic lipid is typically protonated (i.e., positively charged) at a pH below the pK<sub>a</sub> of the cationic lipid and is substantially neutral at a pH above the pK<sub>a</sub>. The cationic lipids of the invention may also be termed titratable cationic lipids. In some embodiments, the cationic lipids comprise: a protonatable tertiary amine (e.g., pH-titratable) head group; C<sub>18</sub> alkyl chains, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and ether, ester, or ketal linkages between the head group and alkyl chains. Such cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA, Î³-DLenDMA, DLin-K-DMA, DLin-K- C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4- DMA, DLen-C2K-DMA, y-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), and DLin-M-C3 -DMA (also known as MC3). </div>
    <div id="p0330" num="0330" class="description-paragraph"> The term &#34;salts&#34; includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions. Non-limiting examples of anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate, perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite, iodate, an alkyl sulfonate, an aryl sulfonate, arsenate, arsenite, chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide, peroxide, permanganate, and mixtures thereof. In particular embodiments, the salts of the cationic lipids disclosed herein are crystalline salts. </div>
    <div id="p0331" num="0331" class="description-paragraph"> The term &#34;alkyl&#34; includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, w-propyl, Â«-butyl, ft-pentyl, w-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, 

 isobutyl, tert-b tyl, isopentyl, and the like. Representative saturated cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like. </div>
    <div id="p0332" num="0332" class="description-paragraph"> The term &#34;alkenyl&#34; includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers. </div>
    <div id="p0333" num="0333" class="description-paragraph"> Representative straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1 -butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-l-butenyl, 2- methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like. </div>
    <div id="p0334" num="0334" class="description-paragraph"> The term &#34;alkynyl&#34; includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched alkynyls include, without limitation, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1- pentynyl, 2-pentynyl, 3 -methyl- 1 butynyl, and the like. </div>
    <div id="p0335" num="0335" class="description-paragraph"> The term &#34;acyl&#34; includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. The following are non-limiting examples of acyl groups: -C(=0)alkyl, -C(=0)alkenyl, and -C(=0)alkynyl. </div>
    <div id="p0336" num="0336" class="description-paragraph"> The term &#34;heterocycle&#34; includes a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like. </div>
    <div id="p0337" num="0337" class="description-paragraph"> The terms &#34;optionally substituted alkyl&#34;, &#34;optionally substituted alkenyl&#34;, &#34;optionally substituted alkynyl&#34;, &#34;optionally substituted acyl&#34;, and &#34;optionally substituted heterocycle&#34; mean that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (=0), two hydrogen atoms are replaced. In this regard, substituents include, but are not limited to, oxo, halogen, heterocycle, -CN, -OR<sup>x</sup>, </div>
    <div id="p0338" num="0338" class="description-paragraph">-NR<sup>x</sup>R<sup>y</sup>, -NR<sup>x</sup>C(=0)R<sup>y</sup> -NR<sup>x</sup>S0<sub>2</sub>R<sup>y</sup>, -C(=0)R<sup>x</sup>, -C(=0)OR<sup>x</sup>, -C(=0)NR<sup>x</sup>R<sup>y</sup>, -SO<sub>n</sub>R<sup>x</sup>, and -SO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>, wherein n is 0, 1, or 2, R<sup>x</sup> and R<sup>y</sup> are the same or different and are independently hydrogen, alkyl, or heterocycle, and each of the alkyl and heterocycle substituents may be 

 further substituted with one or more of oxo, halogen, -OH, -CN, alkyl, -OR<sup>x</sup>, heterocycle, -NR<sup>x</sup>R<sup>y</sup>, -NR<sup>x</sup>C(=0)R<sup>y</sup> - R<sup>x</sup>S0<sub>2</sub>R<sup>y</sup>, -C(=0)R<sup>x</sup>, -C(=0)OR<sup>x</sup>, -C(=0) R<sup>x</sup>R<sup>y</sup> -SO<sub>n</sub>R<sup>x</sup>, and -SO<sub>n</sub>NR<sup>x</sup>R<sup>y</sup>. The term &#34;optionally substituted,&#34; when used before a list of substituents, means that each of the substituents in the list may be optionally substituted as described herein. </div>
    <div id="p0339" num="0339" class="description-paragraph"> The term &#34;halogen&#34; includes fluoro, chloro, bromo, and iodo. </div>
    <div id="p0340" num="0340" class="description-paragraph"> The term &#34;fusogenic&#34; refers to the ability of a lipid particle to fuse with the membranes of a cell. The membranes can be either the plasma membrane or membranes surrounding organelles, e.g., endosome, nucleus, etc. </div>
    <div id="p0341" num="0341" class="description-paragraph"> As used herein, the term &#34;aqueous solution&#34; refers to a composition comprising in whole, or in part, water. </div>
    <div id="p0342" num="0342" class="description-paragraph"> As used herein, the term &#34;organic lipid solution&#34; refers to a composition comprising in whole, or in part, an organic solvent having a lipid. </div>
    <div id="p0343" num="0343" class="description-paragraph"> The term &#34;electron dense core&#34;, when used to describe a lipid particle described herein, refers to the dark appearance of the interior portion of a lipid particle when visualized using cryo transmission electron microscopy (&#34;cyroTEM&#34;). Some lipid particles of the present invention have an electron dense core and lack a lipid bilayer structure. Some lipid particles of the present invention have an electron dense core, lack a lipid bilayer structure, and have an inverse Hexagonal or Cubic phase structure. While not wishing to be bound by theory, it is thought that the non-bilayer lipid packing provides a 3-dimensional network of lipid cylinders with water and nucleic acid on the inside, i.e., essentially a lipid droplet interpenetrated with aqueous channels containing the nucleic acid. </div>
    <div id="p0344" num="0344" class="description-paragraph"> &#34;Distal site,&#34; as used herein, refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism. </div>
    <div id="p0345" num="0345" class="description-paragraph"> &#34;Serum-stable&#34; in relation to nucleic acid-lipid particles means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or RNA. Suitable assays include, for example, a standard serum assay, a DNAse assay, or an R Ase assay. </div>
    <div id="p0346" num="0346" class="description-paragraph"> &#34;Systemic delivery,&#34; as used herein, refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as a siRNA within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration. 

 Systemic delivery of lipid particles can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery. </div>
    <div id="p0347" num="0347" class="description-paragraph"> &#34;Local delivery,&#34; as used herein, refers to delivery of an active agent such as a siRNA directly to a target site within an organism. For example, an agent can be locally delivered by direct injection into a disease site, other target site, or a target organ such as the liver, heart, pancreas, kidney, and the like. </div>
    <div id="p0348" num="0348" class="description-paragraph"> The term &#34;virus particle load&#34;, as used herein, refers to a measure of the number of virus particles (e.g., HBV and/or HDV) present in a bodily fluid, such as blood. For example, particle load may be expressed as the number of virus particles per milliliter of, e.g., blood. Particle load testing may be performed using nucleic acid amplification based tests, as well as non-nucleic acid-based tests (see, e.g., Puren et al., The Journal of Infectious Diseases, 201 :S27-36 (2010)). </div>
    <div id="p0349" num="0349" class="description-paragraph"> The term &#34;mammal&#34; refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like. </div>
    <div id="p0350" num="0350" class="description-paragraph">Generating siRNA Molecules </div>
    <div id="p0351" num="0351" class="description-paragraph"> siRNA can be provided in several forms including, e.g., as one or more isolated small- interfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid. In some embodiments, siRNA may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis. In certain instances, each strand is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein. </div>
    <div id="p0352" num="0352" class="description-paragraph"> Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25 :263-269 (1983); Sambrook et al, supra; Ausubel et al, supra), as are PCR methods (see, U.S. Patent Nos. 4,683, 195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al , eds., 1994). The disclosures of these references are herein incorporated by reference in their entirety for all purposes. 

 Preferably, siRNA are chemically synthesized. The oligonucleotides that comprise the siRNA molecules of the invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al, J. Am. Chem. Soc, 109:7845 (1987); Scaringe et al, Nucl. Acids Res. , 18:5433 (1990); Wincott et al. , Nucl. Acids Res., 23 :2677-2684 (1995); and Wincott et al, Methods Mol. Bio., 74:59 (1997). The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5&#39;-end and phosphoramidites at the 3&#39;-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 Î¼Î¹Î·Î¿Î scale protocol. Alternatively, syntheses at the 0.2 Î¼Î¹Î·Î¿Î scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, CA). However, a larger or smaller scale of synthesis is also within the scope of this invention. Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification are known to those of skill in the art. </div>
    <div id="p0353" num="0353" class="description-paragraph"> siRNA molecules can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA. For example, each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection. </div>
    <div id="p0354" num="0354" class="description-paragraph">Carrier Systems Containing Therapeutic Nucleic Acids </div>
    <div id="p0355" num="0355" class="description-paragraph">A. Lipid Particles </div>
    <div id="p0356" num="0356" class="description-paragraph"> In certain aspects, lipid particles comprising one or more oligonucleotides {e.g. , one or more siRNA molecules, such as one or more siRNA molecules described in Tables A and B) and one or more of cationic (amino) lipids or salts thereof, may be administered. In some embodiments, the lipid particles described herein further comprise one or more non-cationic lipids. In other embodiments, the lipid particles further comprise one or more conjugated lipids capable of reducing or inhibiting particle aggregation. The lipid particles of the invention are useful, for example, for delivering a therapeutically effective amount of siRNA into cells (e.g. , liver cells) of a human body infected with HBV or HBV/HDV, thereby treating the HBV infection and/or HDV infection and/or ameliorating one or more symptoms of HBV infection and/or HDV infection. </div>
    <div id="p0357" num="0357" class="description-paragraph"> With respect to formulations that include a cocktail of siRNAs encapsulated within lipid particles, the different siRNA molecules may be co-encapsulated in the same lipid particle, or each type of siRNA species present in the cocktail may be encapsulated in its own particle, or some siRNA species may be coencapsulated in the same particle while other siRNA species are encapsulated in different particles within the formulation. Typically, the siRNA molecules of the invention are fully encapsulated in the lipid particle. 

 The lipid particles described herein preferably comprise one or more siRNA (e.g., siRNA molecules described in Tables A and B), a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles. In some embodiments, the siRNA molecule is fully encapsulated within the lipid portion of the lipid particle such that the siRNA molecule in the lipid particle is resistant in aqueous solution to nuclease degradation. In other embodiments, the lipid particles described herein are substantially non-toxic to mammals such as humans. The lipid particles typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 1 10 nm, or from about 70 to about 90 nm. In certain embodiments, the lipid particles have a median diameter of from about 30 nm to about 150 nm. The lipid particles also typically have a lipid:nucleic acid ratio (e.g., a lipid:siRNA ratio) (mass/mass ratio) of from about 1 : 1 to about 100: 1, from about 1 : 1 to about 50: 1, from about 2 : 1 to about 25 : 1, from about 3 : 1 to about 20: 1, from about 5 : 1 to about 15 : 1 , or from about 5 : 1 to about 10: 1. In certain embodiments, the nucleic acid-lipid particle has a lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1. </div>
    <div id="p0358" num="0358" class="description-paragraph"> In preferred embodiments, the lipid particles are serum-stable nucleic acid-lipid particles which comprise one or more siRNA molecules (e.g., a siRNA molecule as described in Tables A and B), a cationic lipid {e.g., one or more cationic lipids of Formula ZI-ZIII or salts thereof as set forth herein), a non-cationic lipid (e.g., mixtures of one or more phospholipids and cholesterol), and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates). The lipid particle may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more siRNA molecules (e.g., siRNA molecules described in Tables A and B) that target one or more of the genes described herein. Nucleic acid-lipid particles and their method of preparation are described in, e.g., U. S. Patent Nos. 5,753,613; 5,785,992; 5,705,385; 5,976,567; 5,981,501 ; 6, 110,745; and 6,320,017; and PCT Publication No. WO 96/40964, the disclosures of which are each herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0359" num="0359" class="description-paragraph"> In the nucleic acid-lipid particles described herein, the one or more siRNA molecules (e.g., an siRNA molecule as described in Tables A and B) may be fully encapsulated within the lipid portion of the particle, thereby protecting the siRNA from nuclease degradation. In certain instances, the siRNA in the nucleic acid-lipid particle is not substantially degraded after exposure of the particle to a nuclease at 37Â°C for at least about 20, 30, 45, or 60 minutes. In certain other instances, the siRNA in the nucleic acid-lipid particle is not substantially degraded after incubation of the particle in serum at 37Â°C for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. In 

 other embodiments, the siRNA is complexed with the lipid portion of the particle. One of the benefits of the formulations of the present invention is that the nucleic acid-lipid particle compositions are substantially non-toxic to mammals such as humans. </div>
    <div id="p0360" num="0360" class="description-paragraph"> The term &#34;fully encapsulated&#34; indicates that the siRNA (e.g., a siRNA molecule as described in Tables A and B) in the nucleic acid-lipid particle is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free DNA or RNA. In a fully encapsulated system, preferably less than about 25% of the siRNA in the particle is degraded in a treatment that would normally degrade 100% of free siRNA, more preferably less than about 10%, and most preferably less than about 5% of the siRNA in the particle is degraded. &#34;Fully encapsulated&#34; also indicates that the nucleic acid-lipid particles are serum- stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration. </div>
    <div id="p0361" num="0361" class="description-paragraph"> In the context of nucleic acids, full encapsulation may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid. Specific dyes such as OliGreen<sup>Â®</sup> and </div>
    <div id="p0362" num="0362" class="description-paragraph"> RiboGreen<sup>Â®</sup> (Invitrogen Corp.; Carlsbad, CA) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and/or single- or double-stranded ribonucleotides. Encapsulation is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent. Detergent-mediated disruption of the liposomal bilayer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation may be calculated as E = (I<sub>0</sub> - I)/I<sub>0</sub>, where / and I<sub>0</sub> refer to the fluorescence intensities before and after the addition of detergent (see, Wheeler et al., Gene Ther., 6:271-281 (1999)). </div>
    <div id="p0363" num="0363" class="description-paragraph"> In other embodiments, the present invention provides a nucleic acid-lipid particle composition comprising a plurality of nucleic acid-lipid particles. </div>
    <div id="p0364" num="0364" class="description-paragraph"> In some instances, the nucleic acid-lipid particle composition comprises a siRNA molecule that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, 

 from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction thereof or range therein) of the particles have the siRNA encapsulated therein. </div>
    <div id="p0365" num="0365" class="description-paragraph"> In other instances, the nucleic acid-lipid particle composition comprises siRNA that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any fraction thereof or range therein) of the input siRNA is encapsulated in the particles. </div>
    <div id="p0366" num="0366" class="description-paragraph"> Depending on the intended use of the lipid particles of the invention, the proportions of the components can be varied and the delivery efficiency of a particular formulation can be measured using, e.g., an endosomal release parameter (ERP) assay. </div>
    <div id="p0367" num="0367" class="description-paragraph"> The nucleic acid-lipid particles described herein are useful for the prophylactic or therapeutic delivery, into a human infected with HBV or HBV/HDV, of siRNA molecules that silence the expression of one or more HBV genes, thereby ameliorating at least one symptom of HBV infection and/or HDV infection in the human. In some embodiments, one or more of the siRNA molecules described herein are formulated into nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment. In certain instances, a therapeutically effective amount of the nucleic acid-lipid particle can be </div>
    <div id="p0368" num="0368" class="description-paragraph">administered to the mammal, (e.g., for treating HBV and/or HDV infection in a human being). The nucleic acid-lipid particles described herein are particularly useful for targeting liver cells in humans which is the site of most HBV gene expression. Administration of the nucleic acid-lipid particle can be by any route known in the art, such as, e.g., oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, or intradermal. In particular embodiments, the nucleic acid-lipid particle is administered systemically, e.g., via enteral or parenteral routes of administration. 

 In some embodiments, downregulation of HBV gene expression is determined by detecting HBV RNA or protein levels in a biological sample from a mammal after nucleic acid- lipid particle administration. In other embodiments, downregulation of HBV gene expression is determined by detecting HBV mRNA or protein levels in a biological sample from a mammal after nucleic acid-lipid particle administration. In certain embodiments, downregulation of HBV gene expression is detected by monitoring symptoms associated with HBV infection in a mammal after particle administration. </div>
    <div id="p0369" num="0369" class="description-paragraph">1. Cationic Lipids </div>
    <div id="p0370" num="0370" class="description-paragraph"> Any of a variety of cationic lipids or salts thereof may be used in the lipid particles of the present invention either alone or in combination with one or more other cationic lipid species or non-cationic lipid species. The cationic lipids include the (R) and/or (S) enantiomers thereof. </div>
    <div id="p0371" num="0371" class="description-paragraph"> In one aspect of the invention, the cationic lipid is a dialkyl lipid. For example, dialkyl lipids may include lipids that comprise two saturated or unsaturated alkyl chains, wherein each of the alkyl chains may be substituted or unsubstituted. In certain embodiments, each of the two alkyl chains comprise at least, e.g., 8 carbon atoms, 10 carbon atoms, 12 carbon atoms, 14 carbon atoms, 16 carbon atoms, 18 carbon atoms, 20 carbon atoms, 22 carbon atoms or 24 carbon atoms. </div>
    <div id="p0372" num="0372" class="description-paragraph"> In one aspect of the invention, the cationic lipid is a trialkyl lipid. For example, trialkyl lipids may include lipids that comprise three saturated or unsaturated alkyl chains, wherein each of the alkyl chains may be substituted or unsubstituted. In certain embodiments, each of the three alkyl chains comprise at least, e.g., 8 carbon atoms, 10 carbon atoms, 12 carbon atoms, 14 carbon atoms, 16 carbon atoms, 18 carbon atoms, 20 carbon atoms, 22 carbon atoms or 24 carbon atoms. </div>
    <div id="p0373" num="0373" class="description-paragraph"> In one aspect, cationic lipids of Formula ZI having the following structure are useful in the present invention: </div>
    <div id="p0374" num="0374" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/18/78/82b15cdaf4db4f/imgf000045_0001.png"><img id="imgf000045_0001" he="25" wi="53" file="imgf000045_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="212" height="100" alt="Figure imgf000045_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/18/78/82b15cdaf4db4f/imgf000045_0001.png"/></a></div>
    </div>
    <div id="p0375" num="0375" class="description-paragraph">(ZI), </div>
    <div id="p0376" num="0376" class="description-paragraph">or salts thereof, wherein: </div>
    <div id="p0377" num="0377" class="description-paragraph"> R<sup>1</sup> and R<sup>2</sup> are either the same or different and are independently hydrogen (H) or an optionally substituted Ci-Ce alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R<sup>1</sup> and R<sup>2</sup> may j oin to 

 form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof; </div>
    <div id="p0378" num="0378" class="description-paragraph"> R<sup>3</sup> is either absent or is hydrogen (H) or a C1-C6 alkyl to provide a quaternary amine;</div>
    <div id="p0379" num="0379" class="description-paragraph">R<sup>4</sup> and R<sup>5</sup> are either the same or different and are independently an optionally substituted C10-C24 alkyl, C10-C24 alkenyl, C10-C24 alkynyl, or C10-C24 acyl, wherein at least one of R<sup>4</sup> and R<sup>5</sup> comprises at least two sites of unsaturation; and </div>
    <div id="p0380" num="0380" class="description-paragraph"> n is 0, 1, 2, 3, or 4. </div>
    <div id="p0381" num="0381" class="description-paragraph"> In some embodiments, R<sup>1</sup> and R<sup>2</sup> are independently an optionally substituted C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl. In one preferred embodiment, R<sup>1</sup> and R<sup>2</sup> are both methyl groups. In other preferred embodiments, n is 1 or 2. In other embodiments, R<sup>3</sup> is absent when the pH is above the pK<sub>a</sub> of the cationic lipid and R<sup>3</sup> is hydrogen when the pH is below the pK<sub>a</sub> of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R<sup>3</sup> is an optionally substituted C1-C4 alkyl to provide a quaternary amine. In further </div>
    <div id="p0382" num="0382" class="description-paragraph">embodiments, R<sup>4</sup> and R<sup>5</sup> are independently an optionally substituted C12-C20 or C14-C22 alkyl, C12-C20 or C14-C22 alkenyl, C12-C20 or C14-C22 alkynyl, or C12-C20 or C14-C22 acyl, wherein at least one of R<sup>4</sup> and R<sup>5</sup> comprises at least two sites of unsaturation. </div>
    <div id="p0383" num="0383" class="description-paragraph"> In certain embodiments, R<sup>4</sup> and R<sup>5</sup> are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, an arachidonyl moiety, and a docosahexaenoyl moiety, as well as acyl derivatives thereof (e.g., linoleoyl, linolenoyl, Î³-linolenoyl, etc.). In some instances, one of R<sup>4</sup> and R<sup>5</sup> comprises a branched alkyl group (e.g., a phytanyl moiety) or an acyl derivative thereof (e.g., a phytanoyl moiety). In certain instances, the octadecadienyl moiety is a linoleyl moiety. In certain other instances, the octadecatrienyl moiety is a linolenyl moiety or a Î³-linolenyl moiety. In certain embodiments, R<sup>4</sup> and R<sup>5</sup> are both linoleyl moieties, linolenyl moieties, or Î³-linolenyl moieties. In particular embodiments, the cationic lipid of Formula ZI is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), l,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-dilinoleyloxy- (N,N-dimethyl)-butyl-4-amine (C2-DLinDMA), 1 ,2-dilinoleoyloxy-(N,N-dimethyl)-butyl-4- amine (C2-DLinDAP), or mixtures thereof. </div>
    <div id="p0384" num="0384" class="description-paragraph"> In some embodiments, the cationic lipid of Formula ZI forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula ZI is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt. 

 The synthesis of cationic lipids such as DLinDMA and DLenDMA, as well as additional cationic lipids, is described in U.S. Patent Publication No. 20060083780, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as C2-DLinDMA and C2-DLinDAP, as well as additional cationic lipids, is described in international patent application number WO2011/000106 the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0385" num="0385" class="description-paragraph"> In another aspect, cationic lipids of Formula ZII having the following structure (or thereof) are useful in the present invention: </div>
    <div id="p0386" num="0386" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a6/4d/de/0b7dc117811c65/imgf000047_0001.png"><img id="imgf000047_0001" he="28" wi="70" file="imgf000047_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="280" height="112" alt="Figure imgf000047_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a6/4d/de/0b7dc117811c65/imgf000047_0001.png"/></a></div>
    </div>
    <div id="p0387" num="0387" class="description-paragraph">wherein R<sup>1</sup> and R<sup>2</sup> are either the same or different and are independently an optionally substituted C12-C24 alkyl, C12-C24 alkenyl, C12-C24 alkynyl, or C12-C24 acyl; R<sup>3</sup> and R<sup>4</sup> are either the same or different and are independently an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R<sup>3</sup> and R<sup>4</sup> mayjoin to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen; R<sup>5</sup> is either absent or is hydrogen (H) or a C 1-C6 alkyl to provide a quaternary amine; m, n, and p are either the same or different and are independently either 0, 1, or 2, with the proviso that m, n, and p are not simultaneously 0; q is 0, 1, 2, 3, or 4; and Y and Z are either the same or different and are independently O, S, or NH. In a preferred embodiment, q is 2. </div>
    <div id="p0388" num="0388" class="description-paragraph"> In some embodiments, the cationic lipid of Formula ZII is 2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[l,3]-dioxolane (DLin-K-C2-DMA; &#34;XTC2&#34; or &#34;C2K&#34;), 2,2-dilinoleyl-4- (3-dimethylaminopropyl)-[l,3]-dioxolane (DLin-K-C3 -DMA; &#34;C3K&#34;), 2,2-dilinoleyl-4-(4- dimethylaminobutyl)-[l,3]-dioxolane (DLin-K-C4-DMA; &#34;C4K&#34;), 2,2-dilinoleyl-5- dimethylaminomethyl-[l,3]-dioxane (DLin-K6-DMA), 2,2-dilinoleyl-4-N-methylpepiazino- [l,3]-dioxolane (DLin-K-MPZ), 2,2-dilinoleyl-4-dimethylaminomethyl-[l,3]-dioxolane (DLin- K-DMA), 2,2-dioleoyl-4-dimethylaminomethyl-[l,3]-dioxolane (DO-K-DMA), 2,2-distearoyl- 4-dimethylaminomethyl-[l,3]-dioxolane (DS-K-DMA), 2,2-dilinoleyl-4-N-morpholino-[l,3]- dioxolane (DLin-K-MA), 2,2-Dilinoleyl-4-trimethylamino-[l,3]-dioxolane chloride (DLin-K- TMA.C1), 2,2-dilinoleyl-4,5-bis(dimethylaminomethyl)-[l,3]-dioxolane (DLin-K<sup>2</sup>-DMA), 2,2- dilinoleyl-4-methylpiperzine-[l,3]-dioxolane (D-Lin-K-N-methylpiperzine), or mixtures thereof. In preferred embodiments, the cationic lipid of Formula ZII is DLin-K-C2-DMA. 

 In some embodiments, the cationic lipid of Formula ZII forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula ZII is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt. </div>
    <div id="p0389" num="0389" class="description-paragraph"> The synthesis of cationic lipids such as DLin-K-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DLin-K-C2-DMA, DLin-K-C3-DMA, DLin-K-C4-DMA, DLin-K6-DMA, DLin-K-MPZ, DO- K-DMA, DS-K-DMA, DLin-K-MA, DLin-K-TMA.Cl, DLin-K<sup>2</sup>-DMA, and D-Lin-K-N- methylpiperzine, as well as additional cationic lipids, is described in PCT Application No. PCT/US2009/060251, entitled &#34;Improved Amino Lipids and Methods for the Delivery of Nucleic Acids,&#34; filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes. </div>
    <div id="p0390" num="0390" class="description-paragraph"> In a further aspect, cationic lipids of Formula ZIII having the following structure are useful in the present invention: </div>
    <div id="p0391" num="0391" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/2a/92/bf9f30324d51e5/imgf000048_0001.png"><img id="imgf000048_0001" he="26" wi="129" file="imgf000048_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="516" height="104" alt="Figure imgf000048_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/2a/92/bf9f30324d51e5/imgf000048_0001.png"/></a></div>
 or salts thereof, wherein: R<sup>1</sup> and R<sup>2</sup> are either the same or different and are independently an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, or R<sup>1</sup> and R<sup>2</sup> may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof; R<sup>3</sup> is either absent or is hydrogen (H) or a C1-C6 alkyl to provide a quaternary amine; R<sup>4</sup> and R<sup>5</sup> are either absent or present and when present are either the same or different and are independently an optionally substituted C1-C10 alkyl or C2-C10 alkenyl; and n is 0, 1, 2, 3, or 4. </div>
    <div id="p0392" num="0392" class="description-paragraph"> In some embodiments, R<sup>1</sup> and R<sup>2</sup> are independently an optionally substituted C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl. In a preferred embodiment, R<sup>1</sup> and R<sup>2</sup> are both methyl groups. In another preferred embodiment, R<sup>4</sup> and R<sup>5</sup> are both butyl groups. In yet another preferred embodiment, n is 1. In other embodiments, R<sup>3</sup> is absent when the pH is above the pK<sub>a</sub> of the cationic lipid and R<sup>3</sup> is hydrogen when the pH is below the pK<sub>a</sub> of the cationic lipid such that the amino head group is protonated. In an alternative embodiment, R<sup>3</sup> is an optionally substituted C1-C4 alkyl to provide a quaternary amine. In further embodiments, R<sup>4</sup> and R<sup>5</sup> are independently an optionally substituted C2-C6 or C2-C4 alkyl or C2-C6 or C2-C4 alkenyl. 

 In an alternative embodiment, the cationic lipid of Formula ZIII comprises ester linkages between the amino head group and one or both of the alkyl chains. In some embodiments, the cationic lipid of Formula ZIII forms a salt (preferably a crystalline salt) with one or more anions. In one particular embodiment, the cationic lipid of Formula ZIII is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt. </div>
    <div id="p0393" num="0393" class="description-paragraph"> Although each of the alkyl chains in Formula ZIII contains cis double bonds at positions 6, 9, and 12 (i.e., cis,cis,cis-A<sup>6</sup>,A<sup>9</sup>, <sup>w</sup>), in an alternative embodiment, one, two, or three of these double bonds in one or both alkyl chains may be in the trans configuration. </div>
    <div id="p0394" num="0394" class="description-paragraph"> In a particularly preferred embodiment, the cationic lipid of Formula ZIII has the structur 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/15/9d/47eab52362a330/imgf000049_0001.png"><img id="imgf000049_0001" he="15" wi="130" file="imgf000049_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="520" height="60" alt="Figure imgf000049_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/15/9d/47eab52362a330/imgf000049_0001.png"/></a></div>
 </div>
    <div id="p0395" num="0395" class="description-paragraph"> Î³-DLenDMA (515) </div>
    <div id="p0396" num="0396" class="description-paragraph">The synthesis of cationic lipids such as Î³-DLenDMA (515), as well as additional cationic lipids, is described in U.S. Provisional Application No. 61/222,462, entitled &#34;Improved Cationic Lipids and Methods for the Delivery of Nucleic Acids,&#34; filed July 1, 2009, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0397" num="0397" class="description-paragraph"> The synthesis of cationic lipids such as DLin-M-C3-DMA (&#34;MC3&#34;), as well as additional cationic lipids (e.g., certain analogs of MC3), is described in U.S. Provisional Application No. 61/185,800, entitled &#34;Novel Lipids and Compositions for the Delivery of Therapeutics,&#34; filed June 10, 2009, and U. S. Provisional Application No. 61/287,995, entitled &#34;Methods and Compositions for Delivery of Nucleic Acids,&#34; filed December 18, 2009, the disclosures of which are herein incorporated by reference in their entirety for all purposes. Examples of other cationic lipids or salts thereof which may be included in the lipid particles of the present invention include, but are not limited to, cationic lipids such as those described in WO2011/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes, as well as cationic lipids such as N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), l,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), l,2-distearyloxy-N,N- dimethylaminopropane (DSDMA), N-(l-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(l-(2,3- dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3 -(Î-(Î&#39;,Î&#39;- dimethylaminoethane)-carbamoyl)cholesterol (DC-Choi), N-(l,2-dimyristyloxyprop-3-yl)-N,N- dimethyl-N-hydroxy ethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(spermine- 

 carboxamido)ethyl]-N,N-dimethyl-l-propanaminiumtrifluoroacetate (DOSPA), dioctadecylamidoglycyl spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan- 4-oxy)-l-(cis,cis-9, 12-octadecadienoxy)propane (CLinDMA), 2-[5&#39;-(cholest-5-en-3-beta-oxy)- 3 &#39;-oxapentoxy)-3-dimethy-l-(cis,cis-9&#39;, l-2&#39;-octadecadienoxy)propane (CpLinDMA), N,N- dimethyl-3,4-dioleyloxybenzylamine (DMOBA), l,2-N,N&#39;-dioleylcarbamyl-3- dimethylaminopropane (DOcarbDAP), l,2-N,N&#39;-dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP), l,2-dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2- dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), l,2-dilinoleyoxy-3- morpholinopropane (DLin-MA), l,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2- dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), l-linoleoyl-2-linoleyloxy-3- dimethylaminopropane (DLin-2-DMAP), l,2-dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), l,2-dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), l,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-dilinoleylamino)-l,2- propanediol (DLinAP), 3-(N,N-dioleylamino)-l,2-propanedio (DOAP), l,2-dilinoleyloxo-3-(2- N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), l,2-dioeylcarbamoyloxy-3- dimethylaminopropane (DO-C-DAP), l,2-dimyristoleoyl-3-dimethylaminopropane (DMDAP), l,2-dioleoyl-3-trimethylaminopropane chloride (DOTAP.Cl), dilinoleylmethyl-3- dimethylaminopropionate (DLin-M-C2-DMA; also known as DLin-M-K-DMA or DLin-M- DMA), and mixtures thereof. Additional cationic lipids or salts thereof which may be included in the lipid particles of the present invention are described in U. S. Patent Publication No. </div>
    <div id="p0398" num="0398" class="description-paragraph"> 20090023673, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0399" num="0399" class="description-paragraph"> The synthesis of cationic lipids such as CLinDMA, as well as additional cationic lipids, is described in U. S. Patent Publication No. 20060240554, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DLin-C-DAP, DLinDAC, DLinMA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLinTMA.Cl, DLinTAP.Cl, DLinMPZ, DLinAP, DOAP, and DLin-EG-DMA, as well as additional cationic lipids, is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. The synthesis of cationic lipids such as DO-C-DAP, DMDAP, DOTAP.Cl, DLin-M-C2-DMA, as well as additional cationic lipids, is described in PCT Application No. PCT US2009/060251, entitled &#34;Improved Amino Lipids and Methods for the Delivery of Nucleic Acids,&#34; filed October 9, 2009, the disclosure of which is incorporated herein by reference in its entirety for all purposes. The synthesis of a number of other cationic lipids and related analogs has been described in U.S. Patent Nos. 5,208,036; 

 5,264,618; 5,279,833; 5,283, 185; 5,753,613; and 5,785,992; and PCT Publication No. WO 96/10390, the disclosures of which are each herein incorporated by reference in their entirety for all purposes. Additionally, a number of commercial preparations of cationic lipids can be used, such as, e.g., LIPOFECTIN<sup>Â®</sup> (including DOTMA and DOPE, available from Invitrogen); </div>
    <div id="p0400" num="0400" class="description-paragraph">LIPOFECTAMINE<sup>Â®</sup> (including DOSPA and DOPE, available from Invitrogen); and </div>
    <div id="p0401" num="0401" class="description-paragraph">TRANSFECTAM<sup>Â®</sup> (including DOGS, available from Promega Corp.). </div>
    <div id="p0402" num="0402" class="description-paragraph"> In some embodiments, the cationic lipid comprises from about 50 mol % to about 90 mol %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 mol %, or from about 55 mol % to about 70 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In particular embodiments, the cationic lipid comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof) of the total lipid present in the particle. </div>
    <div id="p0403" num="0403" class="description-paragraph"> In other embodiments, the cationic lipid comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0404" num="0404" class="description-paragraph"> Additional percentages and ranges of cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U. S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0405" num="0405" class="description-paragraph"> It should be understood that the percentage of cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by Â± 5 mol %. For example, in one exemplary lipid particle formulation, the target amount of cationic lipid is 57.1 mol %, but the actual amount of cationic lipid may be Â± 5 mol %, Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle; however, one skilled in the art will understand that the total mol % may deviate slightly from 100% due to rounding, for example, 99.9 mol % or 100.1 mol %.). 

 Further examples of cationic lipids useful for inclusion in lipid particles used in the present invention are shown below: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/43/83/5c/8604285bf264d5/imgf000052_0001.png"><img id="imgf000052_0001" he="10" wi="90" file="imgf000052_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="360" height="40" alt="Figure imgf000052_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/43/83/5c/8604285bf264d5/imgf000052_0001.png"/></a></div>
 </div>
    <div id="p0406" num="0406" class="description-paragraph">N,N-dimethyl-2,3-bis((9Z,12Z)-octadeca-9, 12-dienyloxy)propan-l-amine (505) 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f8/e8/aa/62d2d26c1f610a/imgf000052_0002.png"><img id="imgf000052_0002" he="14" wi="87" file="imgf000052_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="348" height="56" alt="Figure imgf000052_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f8/e8/aa/62d2d26c1f610a/imgf000052_0002.png"/></a></div>
 </div>
    <div id="p0407" num="0407" class="description-paragraph">2-(2,2-di((9Z,12Z)-octadeca-9, 12-dienyl)-l,3-dioxolan-4-yl)-N,N-dimethylethanamine (506) 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/49/26/c0c7182e3aaf88/imgf000052_0003.png"><img id="imgf000052_0003" he="12" wi="106" file="imgf000052_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="424" height="48" alt="Figure imgf000052_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5b/49/26/c0c7182e3aaf88/imgf000052_0003.png"/></a></div>
 </div>
    <div id="p0408" num="0408" class="description-paragraph"> (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate (507) 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/1f/f1/82f458ddf70d60/imgf000052_0004.png"><img id="imgf000052_0004" he="15" wi="97" file="imgf000052_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="388" height="60" alt="Figure imgf000052_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/1f/f1/82f458ddf70d60/imgf000052_0004.png"/></a></div>
 </div>
    <div id="p0409" num="0409" class="description-paragraph">3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (508) </div>
    <div id="p0410" num="0410" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d2/7f/a6/0da37b7501dab4/imgf000052_0005.png"><img id="imgf000052_0005" he="21" wi="96" file="imgf000052_0005.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="384" height="84" alt="Figure imgf000052_0005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d2/7f/a6/0da37b7501dab4/imgf000052_0005.png"/></a></div>
    </div>
    <div id="p0411" num="0411" class="description-paragraph">(Z)-12-((Z)-dec-4-enyl)docos-16-en-l 1-yl 5-(dimethylamino)pentanoate (553) </div>
    <div id="p0412" num="0412" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c1/67/ea/0cef53263802b6/imgf000052_0006.png"><img id="imgf000052_0006" he="18" wi="86" file="imgf000052_0006.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="344" height="72" alt="Figure imgf000052_0006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c1/67/ea/0cef53263802b6/imgf000052_0006.png"/></a></div>
    </div>
    <div id="p0413" num="0413" class="description-paragraph">(6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 6-(dimethylamino)hexanoate (511) 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/3b/76/ae180252f11c80/imgf000053_0001.png"><img id="imgf000053_0001" he="18" wi="82" file="imgf000053_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="328" height="72" alt="Figure imgf000053_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/3b/76/ae180252f11c80/imgf000053_0001.png"/></a></div>
 </div>
    <div id="p0414" num="0414" class="description-paragraph">(6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (513) </div>
    <div id="p0415" num="0415" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/69/44/27/9fab7794a74beb/imgf000053_0002.png"><img id="imgf000053_0002" he="23" wi="103" file="imgf000053_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="412" height="92" alt="Figure imgf000053_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/69/44/27/9fab7794a74beb/imgf000053_0002.png"/></a></div>
    </div>
    <div id="p0416" num="0416" class="description-paragraph">12-decyldocosan-l l-yl 5-(dimethylamino)pentanoate (514). </div>
    <div id="p0417" num="0417" class="description-paragraph">2. Non-cationic Lipids </div>
    <div id="p0418" num="0418" class="description-paragraph"> The non-cationic lipids used in the lipid particles of the invention can be any of a variety of neutral uncharged, zwitterionic, or anionic lipids capable of producing a stable complex. </div>
    <div id="p0419" num="0419" class="description-paragraph"> Non-limiting examples of non-cationic lipids include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), </div>
    <div id="p0420" num="0420" class="description-paragraph">dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), </div>
    <div id="p0421" num="0421" class="description-paragraph">dioleoylphosphatidyl ethanolamine (DOPE), palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyloleoyl -phosphatidyl ethanolamine (POPE), palmitoyloleyol-phosphatidylglycerol (POPG), dioleoylphosphatidyl ethanolamine 4-(N-maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl- phosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), </div>
    <div id="p0422" num="0422" class="description-paragraph">monomethyl -phosphatidyl ethanolamine, dimethyl -phosphatidyl ethanolamine, dielaidoyl- phosphatidylethanolamine (DEPE), stearoyloleoyl-phosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. Other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. 

 The acyl groups in these lipids are preferably acyl groups derived from fatty acids having C io- C24 carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl. </div>
    <div id="p0423" num="0423" class="description-paragraph"> Additional examples of non-cationic lipids include sterols such as cholesterol and derivatives thereof. Non-limiting examples of cholesterol derivatives include polar analogues such as 5a-cholestanol, 5 -coprostanol, cholesteryl-(2&#39; -hydroxy)-ethyl ether, cholesteryl-(4&#39;- hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5p-cholestanone, and cholesteryl decanoate; and mixtures thereof. In preferred embodiments, the cholesterol derivative is a polar analogue such as cholesteryl-(4&#39;-hydroxy)-butyl ether. The synthesis of cholesteryl-(2&#39;-hydroxy)-ethyl ether is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0424" num="0424" class="description-paragraph"> In some embodiments, the non-cationic lipid present in the lipid particles comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the non-cationic lipid present in the lipid particles comprises or consists of one or more phospholipids, e.g., a cholesterol -free lipid particle formulation. In yet other embodiments, the non-cationic lipid present in the lipid particles comprises or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation. </div>
    <div id="p0425" num="0425" class="description-paragraph"> Other examples of non-cationic lipids suitable for use in the present invention include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like. </div>
    <div id="p0426" num="0426" class="description-paragraph"> In some embodiments, the non-cationic lipid comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 45 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0427" num="0427" class="description-paragraph"> In embodiments where the lipid particles contain a mixture of phospholipid and cholesterol or a cholesterol derivative, the mixture may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle. 

 In some embodiments, the phospholipid component in the mixture may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In an certain embodiments, the phospholipid component in the mixture comprises from about 5 mol % to about 17 mol %, from about 7 mol % to about 17 mol %, from about 7 mol % to about 15 mol %, from about 8 mol % to about 15 mol %, or about 8 mol %, 9 mol %, 10 mol %, 11 mol %, 12 mol %, 13 mol %, 14 mol %, or 15 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle. </div>
    <div id="p0428" num="0428" class="description-paragraph"> By way of further example, a lipid formulation useful in the practice of the invention has a lipid to drug (e.g., siRNA) ratio of about 10: 1 (e.g., a lipid:drug ratio of from 9.5: 1 to 1 1 : 1, or from 9.9: 1 to 11 : 1, or from 10: 1 to 10.9: 1). In certain other embodiments, a lipid formulation useful in the practice of the invention has a lipid to drug (e.g., siRNA) ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5 : 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0429" num="0429" class="description-paragraph"> In other embodiments, the cholesterol component in the mixture may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. In certain preferred embodiments, the cholesterol component in the mixture comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. 

 In embodiments where the lipid particles are phospholipid-free, the cholesterol or derivative thereof may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle. </div>
    <div id="p0430" num="0430" class="description-paragraph"> In some embodiments, the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, or 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. As a non-limiting example, a lipid particle formulation may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle. As another non-limiting example, a lipid particle formulation may comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle. </div>
    <div id="p0431" num="0431" class="description-paragraph"> In other embodiments, the non-cationic lipid comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative thereof) (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0432" num="0432" class="description-paragraph"> Additional percentages and ranges of non-cationic lipids suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U. S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0433" num="0433" class="description-paragraph"> It should be understood that the percentage of non-cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by Â± 5 mol %, Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %. </div>
    <div id="p0434" num="0434" class="description-paragraph">3. Lipid Conjugates </div>
    <div id="p0435" num="0435" class="description-paragraph"> In addition to cationic and non-cationic lipids, the lipid particles may further comprise a lipid conjugate. The conjugated lipid is useful in that it prevents the aggregation of particles. Suitable conjugated lipids include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer-lipid conjugates (CPLs), and mixtures 

 thereof. In certain embodiments, the particles comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL. </div>
    <div id="p0436" num="0436" class="description-paragraph"> In a preferred embodiment, the lipid conjugate is a PEG-lipid. Examples of PEG-lipids include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and 2005008689, PEG coupled to phospholipids such as phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof. The disclosures of these patent documents are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0437" num="0437" class="description-paragraph"> Additional PEG-lipids suitable for use in the invention include, without limitation, mPEG2000-l,2-di-O-alkyl-^3-carbomoylglyceride (PEG-C-DOMG). The synthesis of PEG-C- DOMG is described in PCT Publication No. WO 09/086558, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Yet additional suitable PEG-lipid conjugates include, without limitation, l-[8&#39;-(l,2-dimyristoyl-3-propanoxy)-carboxamido-3 &#39;,6&#39;- dioxaoctanyl]carbamoyl-ro-methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0438" num="0438" class="description-paragraph"> PEG is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co. and other companies and include, but are not limited to, the following: </div>
    <div id="p0439" num="0439" class="description-paragraph">monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene glycol-succinate (MePEG-S), monomethoxypolyethylene glycol-succinimidyl succinate (MePEG-S-NHS), monomethoxypolyethylene glycol-amine (MePEG-NHi), monomethoxypolyethylene glycol- tresylate (MePEG-TRES), monomethoxypolyethylene glycol-imidazolyl-carbonyl (MePEG- EVI), as well as such compounds containing a terminal hydroxyl group instead of a terminal methoxy group (e.g., HO-PEG-S, HO-PEG-S-NHS, HO-PEG-NH<sub>2</sub>, etc.). Other PEGs such as those described in U. S. Patent Nos. 6,774, 180 and 7,053, 150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention. The disclosures of these patents are herein incorporated by reference in their entirety for all purposes. In addition, monomethoxypolyethyleneglycol-acetic acid (MePEG-ClHhCOOH) is particularly useful for preparing PEG-lipid conjugates including, e.g., PEG-DAA conjugates. 

 The PEG moiety of the PEG-lipid conjugates described herein may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG moiety has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1 ,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc. ). In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons. </div>
    <div id="p0440" num="0440" class="description-paragraph"> In certain instances, the PEG can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group. The PEG can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety. Any linker moiety suitable for coupling the PEG to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties. In a preferred embodiment, the linker moiety is a non-ester containing linker moiety. As used herein, the term &#34;non-ester containing linker moiety&#34; refers to a linker moiety that does not contain a carboxylic ester bond (-OC(O)-). Suitable non-ester containing linker moieties include, but are not limited to, amido (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (- HC(O)O-), urea (-</div>
    <div id="p0441" num="0441" class="description-paragraph">NHC(O)NH-), disulphide (-S-S-), ether (-0-), succinyl (-(0)CCH<sub>2</sub>CH<sub>2</sub>C(0)-), succinamidyl (- NHC(0)CH2CH2C(0)NH-), ether, disulphide, as well as combinations thereof (such as a linker containing both a carbamate linker moiety and an amido linker moiety). In a preferred embodiment, a carbamate linker is used to couple the PEG to the lipid. </div>
    <div id="p0442" num="0442" class="description-paragraph"> In other embodiments, an ester containing linker moiety is used to couple the PEG to the lipid. Suitable ester containing linker moieties include, e.g., carbonate (-OC(O)O-), succinoyl, phosphate esters (-O-(O)POH-O-), sulfonate esters, and combinations thereof. </div>
    <div id="p0443" num="0443" class="description-paragraph"> Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation can be conjugated to PEG to form the lipid conjugate. Such phosphatidylethanolamines are commercially available, or can be isolated or synthesized using conventional techniques known to those of skill in the art. Phosphatidyl-ethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of Cio to C20 are preferred. Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable </div>
    <div id="p0444" num="0444" class="description-paragraph">phosphatidylethanolamines include, but are not limited to, dimyristoyl- phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE). </div>
    <div id="p0445" num="0445" class="description-paragraph"> The term &#34;ATTA&#34; or &#34;polyamide&#34; includes, without limitation, compounds described in U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated 

 by reference in their entirety for all purposes. These compounds include a compound having the formula: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e1/b2/37/1bb2f9bf6f9b13/imgf000059_0001.png"><img id="imgf000059_0001" he="21" wi="104" file="imgf000059_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="416" height="84" alt="Figure imgf000059_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e1/b2/37/1bb2f9bf6f9b13/imgf000059_0001.png"/></a></div>
 wherein R is a member selected from the group consisting of hydrogen, alkyl and acyl; R<sup>1</sup> is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R<sup>1</sup> and the nitrogen to which they are bound form an azido moiety; R<sup>2</sup> is a member of the group selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and a side chain of an amino acid; R<sup>3</sup> is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and R<sup>4</sup>R<sup>5</sup>, wherein R<sup>4</sup> and R<sup>5</sup> are independently hydrogen or alkyl; n is 4 to 80; m is 2 to 6; p is 1 to 4; and q is 0 or 1. It will be apparent to those of skill in the art that other polyamides can be used in the compounds of the present invention. </div>
    <div id="p0446" num="0446" class="description-paragraph"> The term &#34;diacylglycerol&#34; or &#34;DAG&#34; includes a compound having 2 fatty acyl chains,</div>
    <div id="p0447" num="0447" class="description-paragraph">R<sup>1</sup> and R<sup>2</sup>, both of which have independently between 2 and 30 carbons bonded to the 1 - and 2- position of glycerol by ester linkages. The acyl groups can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C12), myristoyl</div>
    <div id="p0448" num="0448" class="description-paragraph">(C14), palmitoyl (Ci<sub>6</sub>), stearoyl (Cis), and icosoyl (C20). In preferred embodiments, R<sup>1</sup> and R<sup>2</sup> are the same, i.e., R<sup>1</sup> and R<sup>2</sup> are both myristoyl (i.e., dimyristoyl), R<sup>1</sup> and R<sup>2</sup> are both stearoyl</div>
    <div id="p0449" num="0449" class="description-paragraph">(i.e., distearoyl), etc. Diacylglycerols have the following general formula: </div>
    <div id="p0450" num="0450" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2d/df/f5/c56fbeb707c600/imgf000059_0002.png"><img id="imgf000059_0002" he="49" wi="28" file="imgf000059_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="112" height="196" alt="Figure imgf000059_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2d/df/f5/c56fbeb707c600/imgf000059_0002.png"/></a></div>
 The term &#34;dialkyloxypropyl&#34; or &#34;DAA&#34; includes a compound having 2 alkyl chains,</div>
    <div id="p0451" num="0451" class="description-paragraph">R<sup>1</sup> and R<sup>2</sup>, both of which have independently between 2 and 30 carbons. The alkyl groups can be saturated or have varying degrees of unsaturation. Di alkyl oxypropyls have the following general formula: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/89/ec/68116dd1935836/imgf000060_0001.png"><img id="imgf000060_0001" he="31" wi="31" file="imgf000060_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="124" height="124" alt="Figure imgf000060_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/89/ec/68116dd1935836/imgf000060_0001.png"/></a></div>
 </div>
    <div id="p0452" num="0452" class="description-paragraph">In a preferred embodiment, the PEG-lipid is a PEG-DAA conjugate having the following formula: </div>
    <div id="p0453" num="0453" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/bd/d9/693eccc8b5344a/imgf000060_0002.png"><img id="imgf000060_0002" he="22" wi="38" file="imgf000060_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="152" height="88" alt="Figure imgf000060_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/bd/d9/693eccc8b5344a/imgf000060_0002.png"/></a></div>
    </div>
    <div id="p0454" num="0454" class="description-paragraph"> CH<sub>2</sub>-L-PEG (zvil), wherein R<sup>1</sup> and R<sup>2</sup> are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyethyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above. The long-chain alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (do), lauryl (Co), myristyl (CM), palmityl (CÂ½), stearyl (C<sub>18</sub>), and icosyl (do). In preferred embodiments, R<sup>1</sup> and R<sup>2</sup> are the same, i.e., R<sup>1</sup> and R<sup>2</sup> are both myristyl (i.e., dimyristyl), R<sup>1</sup> and R<sup>2</sup> are both stearyl (i.e., distearyl), etc. </div>
    <div id="p0455" num="0455" class="description-paragraph"> In Formula ZVII above, the PEG has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.). In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons. The PEG can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group. </div>
    <div id="p0456" num="0456" class="description-paragraph"> In a preferred embodiment, &#34;L&#34; is a non-ester containing linker moiety. Suitable non- ester containing linkers include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and combinations thereof. In a preferred embodiment, the non-ester containing linker moiety is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate). In another preferred embodiment, the non-ester containing linker moiety is an amido linker moiety (i.e. , a PEG- 4-DAA conjugate). In yet another 

 preferred embodiment, the non-ester containing linker moiety is a succinamidyl linker moiety (i.e., a PEG-^-DAA conjugate). </div>
    <div id="p0457" num="0457" class="description-paragraph"> In particular embodiments, the PEG-lipid conjugate is selected from: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/7f/3b/5ecbacb2ec61b5/imgf000061_0001.png"><img id="imgf000061_0001" he="16" wi="152" file="imgf000061_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="608" height="64" alt="Figure imgf000061_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/7f/3b/5ecbacb2ec61b5/imgf000061_0001.png"/></a></div>
 </div>
    <div id="p0458" num="0458" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9e/ed/8f/c808e7d7489d91/imgf000061_0002.png"><img id="imgf000061_0002" he="21" wi="145" file="imgf000061_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="580" height="84" alt="Figure imgf000061_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9e/ed/8f/c808e7d7489d91/imgf000061_0002.png"/></a></div>
    </div>
    <div id="p0459" num="0459" class="description-paragraph">The PEG-DAA conjugates are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock,</div>
    <div id="p0460" num="0460" class="description-paragraph">COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furaiss, VOGEL&#39; S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989). It will also be appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the PEG-DAA conjugates. Those of skill in the art will recognize that such techniques are well known. See, e.g., Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991). </div>
    <div id="p0461" num="0461" class="description-paragraph"> Preferably, the PEG-DAA conjugate is a PEG-didecyloxypropyl (Cio) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG-dimyristyloxypropyl (CM) conjugate, a PEG- dipalmityloxypropyl (C<sub>16</sub>) conjugate, or a PEG-distearyloxypropyl (C<sub>18</sub>) conjugate. In these embodiments, the PEG preferably has an average molecular weight of about 750 or about 2,000 daltons. In one particularly preferred embodiment, the PEG-lipid conjugate comprises </div>
    <div id="p0462" num="0462" class="description-paragraph">PEG2000-C-DMA, wherein the &#34;2000&#34; denotes the average molecular weight of the PEG, the &#34;C&#34; denotes a carbamate linker moiety, and the &#34;DMA&#34; denotes dimyristyloxypropyl. In another particularly preferred embodiment, the PEG-lipid conjugate comprises PEG750-C- DMA, wherein the &#34;750&#34; denotes the average molecular weight of the PEG, the &#34;C&#34; denotes a carbamate linker moiety, and the &#34;DMA&#34; denotes dimyristyloxypropyl. In particular embodiments, the terminal hydroxyl group of the PEG is substituted with a methyl group. </div>
    <div id="p0463" num="0463" class="description-paragraph">Those of skill in the art will readily appreciate that other dialkyloxypropyls can be used in the PEG-DAA conjugates of the present invention. 

 In addition to the foregoing, it will be readily apparent to those of skill in the art that other hydrophilic polymers can be used in place of PEG. Examples of suitable polymers that can be used in place of PEG include, but are not limited to, polyvinylpyrrolidone, </div>
    <div id="p0464" num="0464" class="description-paragraph">polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, </div>
    <div id="p0465" num="0465" class="description-paragraph">polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethyl cellulose or hydroxyethylcellulose. </div>
    <div id="p0466" num="0466" class="description-paragraph"> In addition to the foregoing components, the lipid particles of the present invention can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et al, Bioconj. Chem., 11 :433-437 (2000); U. S. Patent No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes). </div>
    <div id="p0467" num="0467" class="description-paragraph"> Suitable CPLs include compounds of Formula ZVIII: </div>
    <div id="p0468" num="0468" class="description-paragraph"> A-W-Y (ZVIII), </div>
    <div id="p0469" num="0469" class="description-paragraph">wherein A, W, and Y are as described below. </div>
    <div id="p0470" num="0470" class="description-paragraph"> With reference to Formula ZVIII, &#34;A&#34; is a lipid moiety such as an amphipathic lipid, a neutral lipid, or a hydrophobic lipid that acts as a lipid anchor. Suitable lipid examples include, but are not limited to, diacylglycerolyls, dialkylglycerolyls, N-N-dialkylaminos, 1,2-diacyloxy- 3-aminopropanes, and l,2-dialkyl-3-aminopropanes. </div>
    <div id="p0471" num="0471" class="description-paragraph"> &#34;W&#34; is a polymer or an oligomer such as a hydrophilic polymer or oligomer. </div>
    <div id="p0472" num="0472" class="description-paragraph">Preferably, the hydrophilic polymer is a biocompatable polymer that is nonimmunogenic or possesses low inherent immunogenicity. Alternatively, the hydrophilic polymer can be weakly antigenic if used with appropriate adjuvants. Suitable nonimmunogenic polymers include, but are not limited to, PEG, polyamides, polylactic acid, polyglycolic acid, polylactic </div>
    <div id="p0473" num="0473" class="description-paragraph">acid/polyglycolic acid copolymers, and combinations thereof. In a preferred embodiment, the polymer has a molecular weight of from about 250 to about 7,000 daltons. </div>
    <div id="p0474" num="0474" class="description-paragraph"> &#34;Y&#34; is a polycationic moiety. The term polycationic moiety refers to a compound, derivative, or functional group having a positive charge, preferably at least 2 positive charges at a selected pH, preferably physiological pH. Suitable polycationic moieties include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine, and histidine; </div>
    <div id="p0475" num="0475" class="description-paragraph">spermine; spermidine; cationic dendrimers; polyamines; polyamine sugars; and amino polysaccharides. The polycationic moieties can be linear, such as linear tetralysine, branched or dendrimeric in structure. Polycationic moieties have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between 

 about 2 to about 8 positive charges at selected pH values. The selection of which polycationic moiety to employ may be determined by the type of particle application which is desired. </div>
    <div id="p0476" num="0476" class="description-paragraph"> The charges on the polycationic moieties can be either distributed around the entire particle moiety, or alternatively, they can be a discrete concentration of charge density in one particular area of the particle moiety e.g., a charge spike. If the charge density is distributed on the particle, the charge density can be equally distributed or unequally distributed. All variations of charge distribution of the polycationic moiety are encompassed by the present invention. </div>
    <div id="p0477" num="0477" class="description-paragraph"> The lipid &#34;A&#34; and the nonimmunogenic polymer &#34;W&#34; can be attached by various methods and preferably by covalent attachment. Methods known to those of skill in the art can be used for the covalent attachment of &#34;A&#34; and &#34;W.&#34; Suitable linkages include, but are not limited to, amide, amine, carboxyl, carbonate, carbamate, ester, and hydrazone linkages. It will be apparent to those skilled in the art that &#34;A&#34; and &#34;W&#34; must have complementary functional groups to effectuate the linkage. The reaction of these two groups, one on the lipid and the other on the polymer, will provide the desired linkage. For example, when the lipid is a diacyl glycerol and the terminal hydroxyl is activated, for instance with NHS and DCC, to form an active ester, and is then reacted with a polymer which contains an amino group, such as with a polyamide (see, e.g., U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes), an amide bond will form between the two groups. </div>
    <div id="p0478" num="0478" class="description-paragraph"> In certain instances, the polycationic moiety can have a ligand attached, such as a targeting ligand or a chelating moiety for complexing calcium. Preferably, after the ligand is attached, the cationic moiety maintains a positive charge. In certain instances, the ligand that is attached has a positive charge. Suitable ligands include, but are not limited to, a compound or device with a reactive functional group and include lipids, amphipathic lipids, carrier compounds, bioaffinity compounds, biomaterials, biopolymers, biomedical devices, analytically detectable compounds, therapeutically active compounds, enzymes, peptides, proteins, antibodies, immune stimulators, radiolabels, fluorogens, biotin, drugs, haptens, DNA, RNA, polysaccharides, liposomes, virosomes, micelles, immunoglobulins, functional groups, other targeting moieties, or toxins. </div>
    <div id="p0479" num="0479" class="description-paragraph"> In some embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 0.1 mol % to about 3 mol %, from about 0.5 mol % to about 3 mol %, or about 0.6 mol %, 0.7 mol %, 0.8 mol %, 0.9 mol %, 1.0 mol %, 1.1 mol %, 1.2 mol %, 1.3 mol %, 1.4 mol %, 1.5 mol %, 1.6 mol %, 1.7 mol %, 1.8 mol %, 1.9 mol %, 2.0 mol %, 2.1 mol%, 2.2 mol%, 2.3 mol %, 2.4 

 mol %, 2.5 mol %, 2.6 mol %, 2.7 mol %, 2.8 mol %, 2.9 mol % or 3 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0480" num="0480" class="description-paragraph"> In other embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0481" num="0481" class="description-paragraph"> In further embodiments, the lipid conjugate (e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle. </div>
    <div id="p0482" num="0482" class="description-paragraph"> It should be understood that the percentage of lipid conjugate present in the lipid particles of the invention is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by Â± 5 mol %, Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %. </div>
    <div id="p0483" num="0483" class="description-paragraph"> Additional percentages and ranges of lipid conjugates suitable for use in the lipid particles of the present invention are described in PCT Publication No. WO 09/127060, U. S. Published Application No. US 2011/0071208, PCT Publication No. WO2011/000106, and U.S. Published Application No. US 2011/0076335, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0484" num="0484" class="description-paragraph"> One of ordinary skill in the art will appreciate that the concentration of the lipid conjugate can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic. </div>
    <div id="p0485" num="0485" class="description-paragraph"> By controlling the composition and concentration of the lipid conjugate, one can control the rate at which the lipid conjugate exchanges out of the lipid particle and, in turn, the rate at which the lipid particle becomes fusogenic. For instance, when a PEG-DAA conjugate is used as the lipid conjugate, the rate at which the lipid particle becomes fusogenic can be varied, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate. In addition, other variables including, for example, pH, temperature, ionic strength, etc. can be used to vary and/or control the rate at which the lipid particle becomes fusogenic. Other methods which can be used to control the rate at which the 

 lipid particle becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure. Also, by controlling the composition and concentration of the lipid conjugate, one can control the lipid particle size. </div>
    <div id="p0486" num="0486" class="description-paragraph">B. Additional Carrier Systems </div>
    <div id="p0487" num="0487" class="description-paragraph"> Non-limiting examples of additional lipid-based carrier systems suitable for use in the present invention include lipoplexes (see, e.g., U.S. Patent Publication No. 20030203865; and Zhang et al., J. Control Release, 100: 165-180 (2004)), pH-sensitive lipoplexes (see, e.g., U. S. Patent Publication No. 20020192275), reversibly masked lipoplexes (see, e.g., U.S. Patent Publication No. 20030180950), cationic lipid-based compositions (see, e.g., U.S. Patent No. 6,756,054; and U. S. Patent Publication No. 20050234232), cationic liposomes (see, e.g., U. S. Patent Publication Nos. 20030229040, 20020160038, and 20020012998; U. S. Patent No. 5,908,635; and PCT Publication No. WO 01/72283), anionic liposomes (see, e.g., U. S. Patent Publication No. 20030026831), pH-sensitive liposomes (see, e.g., U. S. Patent Publication No. 20020192274; and AU 2003210303), antibody-coated liposomes (see, e.g., U.S. Patent Publication No. 20030108597; and PCT Publication No. WO 00/50008), cell-type specific liposomes (see, e.g., U.S. Patent Publication No. 20030198664), liposomes containing nucleic acid and peptides (see, e.g., U.S. Patent No. 6,207,456), liposomes containing lipids derivatized with releasable hydrophilic polymers (see, e.g., U.S. Patent Publication No. 20030031704), lipid-entrapped nucleic acid (see, e.g., PCT Publication Nos. WO 03/057190 and WO </div>
    <div id="p0488" num="0488" class="description-paragraph">03/059322), lipid-encapsulated nucleic acid (see, e.g., U. S. Patent Publication No. </div>
    <div id="p0489" num="0489" class="description-paragraph"> 20030129221; and U.S. Patent No. 5,756, 122), other liposomal compositions (see, e.g., U. S. Patent Publication Nos. 20030035829 and 20030072794; and U.S. Patent No. 6,200,599), stabilized mixtures of liposomes and emulsions (see, e.g., EP1304160), emulsion compositions (see, e.g., U.S. Patent No. 6,747,014), and nucleic acid micro-emulsions (see, e.g., U.S. Patent Publication No. 20050037086). </div>
    <div id="p0490" num="0490" class="description-paragraph"> Examples of polymer-based carrier systems suitable for use in the present invention include, but are not limited to, cationic polymer-nucleic acid complexes (i.e., polypi exes). To form a polyplex, a nucleic acid (e.g., a siRNA molecule, such as an siRNA molecule described in Tables A and B) is typically complexed with a cationic polymer having a linear, branched, star, or dendritic polymeric structure that condenses the nucleic acid into positively charged particles capable of interacting with anionic proteoglycans at the cell surface and entering cells by endocytosis. In some embodiments, the polyplex comprises nucleic acid (e.g., a siRNA molecule, such as an siRNA molecule described in Tables A and B) complexed with a cationic polymer such as polyethylenimine (PEI) (see, e.g., U.S. Patent No. 6,013,240; commercially 

 available from Qbiogene, Inc. (Carlsbad, CA) as In vivo jetPEIâ¢, a linear form of PEI), polypropylenimine (PPI), polyvinylpyrrolidone (PVP), poly-L-lysine (PLL), diethylaminoethyl (DEAE)-dextran, poly(p-amino ester) (PAE) polymers (see, e.g., Lynn et al., J. Am. Chem. Soc, 123 :8155-8156 (2001)), chitosan, polyamidoamine (PAMAM) dendrimers (see, e.g., Kukowska- Latallo et al, Proc. Natl. Acad. Sci. USA, 93 :4897-4902 (1996)), porphyrin (see, e.g., U. S. Patent No. 6,620,805), polyvinyl ether (see, e.g., U.S. Patent Publication No. 20040156909), polycyclic amidinium (see, e.g., U. S. Patent Publication No. 20030220289), other polymers comprising primary amine, imine, guanidine, and/or imidazole groups (see, e.g., U.S. Patent No. 6,013,240; PCT Publication No. WO/9602655; PCT Publication No. W095/21931 ; Zhang et al, J. Control Release, 100: 165-180 (2004); and Tiera et al, Curr. Gene Ther., 6:59-71 (2006)), and a mixture thereof. In other embodiments, the polyplex comprises cationic polymer-nucleic acid complexes as described in U. S. Patent Publication Nos. 2006021 1643, 20050222064, </div>
    <div id="p0491" num="0491" class="description-paragraph">20030125281, and 20030185890, and PCT Publication No. WO 03/066069; biodegradable poly(P-amino ester) polymer-nucleic acid complexes as described in U.S. Patent Publication No. 20040071654; microparticles containing polymeric matrices as described in U.S. Patent</div>
    <div id="p0492" num="0492" class="description-paragraph">Publication No. 20040142475; other microparticle compositions as described in U. S. Patent Publication No. 20030157030; condensed nucleic acid complexes as described in U.S. Patent Publication No. 20050123600; and nanocapsule and microcapsule compositions as described in AU 2002358514 and PCT Publication No. WO 02/096551. </div>
    <div id="p0493" num="0493" class="description-paragraph"> In certain instances, the siRNA may be complexed with cyclodextrin or a polymer thereof. Non-limiting examples of cyclodextrin-based carrier systems include the cyclodextrin- modified polymer-nucleic acid complexes described in U.S. Patent Publication No. </div>
    <div id="p0494" num="0494" class="description-paragraph">20040087024; the linear cyclodextrin copolymer-nucleic acid complexes described in U.S. Patent Nos. 6,509,323, 6,884,789, and 7,091, 192; and the cyclodextrin polymer-complexing agent-nucleic acid complexes described in U.S. Patent No. 7,018,609. In certain other instances, the siRNA may be complexed with a peptide or polypeptide. An example of a protein-based carrier system includes, but is not limited to, the cationic oligopeptide-nucleic acid complex described in PCT Publication No. W095/21931. </div>
    <div id="p0495" num="0495" class="description-paragraph">Preparation of Lipid Particles </div>
    <div id="p0496" num="0496" class="description-paragraph"> Nucleic acid-lipid particles, in which a nucleic acid (e.g., a siRNA as described in</div>
    <div id="p0497" num="0497" class="description-paragraph">Tables A and B) is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a continuous mixing method, a direct dilution process, and an in-line dilution process. 

 In particular embodiments, the cationic lipids may comprise lipids of Formula ZI-III or salts thereof, alone or in combination with other cationic lipids. In other embodiments, the non- cationic lipids are egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidyl choline (DOPC), l -palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC), monomethyl-phosphatidylethanolamine, dimethyl- phosphatidylethanolamine, 14:0 PE (1,2-dimyristoyl-phosphatidylethanolamine (DMPE)), 16:0 PE (1,2-dipalmitoyl -phosphatidylethanolamine (DPPE)), 18:0 PE (1,2-distearoyl- phosphatidylethanolamine (DSPE)), 18: 1 PE (1,2-dioleoyl-phosphatidylethanolamine (DOPE)), 18: 1 trans PE (1,2-dielaidoyl -phosphatidylethanolamine (DEPE)), 18:0-18: 1 PE (l-stearoyl-2- oleoyl-phosphatidylethanolamine (SOPE)), 16:0-18: 1 PE (l-palmitoyl-2-oleoyl- phosphatidylethanolamine (POPE)), polyethylene glycol-based polymers (e.g., PEG 2000, PEG 5000, PEG-modified diacylglycerols, or PEG-modified dialkyloxypropyls), cholesterol, derivatives thereof, or combinations thereof. </div>
    <div id="p0498" num="0498" class="description-paragraph"> In certain embodiments, the present invention provides nucleic acid-lipid particles produced via a continuous mixing method, e.g., a process that includes providing an aqueous solution comprising a siRNA in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (e.g., liposome) encapsulating the siRNA within the lipid vesicle. This process and the apparatus for carrying out this process are described in detail in U.S. Patent Publication No. 20040142025, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0499" num="0499" class="description-paragraph"> The action of continuously introducing lipid and buffer solutions into a mixing environment, such as in a mixing chamber, causes a continuous dilution of the lipid solution with the buffer solution, thereby producing a lipid vesicle substantially instantaneously upon mixing. As used herein, the phrase &#34;continuously diluting a lipid solution with a buffer solution&#34; (and variations) generally means that the lipid solution is diluted sufficiently rapidly in a hydration process with sufficient force to effectuate vesicle generation. By mixing the aqueous solution comprising a nucleic acid with the organic lipid solution, the organic lipid solution undergoes a continuous stepwise dilution in the presence of the buffer solution (i.e., aqueous solution) to produce a nucleic acid-lipid particle. </div>
    <div id="p0500" num="0500" class="description-paragraph"> The nucleic acid-lipid particles formed using the continuous mixing method typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from 

 about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 1 10 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 1 10 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 1 10 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or range therein). The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size. </div>
    <div id="p0501" num="0501" class="description-paragraph"> In another embodiment, the present invention provides nucleic acid-lipid particles produced via a direct dilution process that includes forming a lipid vesicle (e.g., liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer. In preferred aspects, the collection vessel includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution. In one aspect, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of lipid vesicle solution introduced thereto. As a non-limiting example, a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer will advantageously yield smaller particles. </div>
    <div id="p0502" num="0502" class="description-paragraph"> In yet another embodiment, the present invention provides nucleic acid-lipid particles produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region. In this embodiment, the lipid vesicle (e.g., liposome) solution formed in a first mixing region is immediately and directly mixed with dilution buffer in the second mixing region. In preferred aspects, the second mixing region includes a T- connector arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 180Â° flows; however, connectors providing shallower angles can be used, e.g., from about 27Â° to about 180Â° (e.g., about 90Â°). A pump mechanism delivers a controllable flow of buffer to the second mixing region. In one aspect, the flow rate of dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region. This embodiment advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also the concentration of lipid vesicle solution in buffer throughout the second mixing process. Such control of the dilution buffer flow rate </div>
    <div id="p0503" num="0503" class="description-paragraph">advantageously allows for small particle size formation at reduced concentrations. 

 These processes and the apparatuses for carrying out these direct dilution and in-line dilution processes are described in detail in U.S. Patent Publication No. 20070042031, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0504" num="0504" class="description-paragraph"> The nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 1 10 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 1 10 nm, 1 15 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm (or any fraction thereof or range therein). The particles thus formed do not aggregate and are optionally sized to achieve a uniform particle size. </div>
    <div id="p0505" num="0505" class="description-paragraph"> If needed, the lipid particles of the invention can be sized by any of the methods available for sizing liposomes. The sizing may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes. </div>
    <div id="p0506" num="0506" class="description-paragraph"> Several techniques are available for sizing the particles to a desired size. One sizing method, used for liposomes and equally applicable to the present particles, is described in U. S. Patent No. 4,737,323, the disclosure of which is herein incorporated by reference in its entirety for all purposes. Sonicating a particle suspension either by bath or probe sonication produces a progressive size reduction down to particles of less than about 50 nm in size. Homogenization is another method which relies on shearing energy to fragment larger particles into smaller ones. In a typical homogenization procedure, particles are recirculated through a standard emulsion homogenizer until selected particle sizes, typically between about 60 and about 80 nm, are observed. In both methods, the particle size distribution can be monitored by conventional laser-beam particle size discrimination, or QELS. </div>
    <div id="p0507" num="0507" class="description-paragraph"> Extrusion of the particles through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing particle sizes to a relatively well-defined size distribution. Typically, the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved. The particles may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size. 

 In some embodiments, the nucleic acids present in the particles (e.g., the siRNA molecules) are precondensed as described in, e.g., U.S. Patent Application No.09/744,103, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0508" num="0508" class="description-paragraph"> In other embodiments, the methods may further comprise adding non-lipid polycations which are useful to effect the lipofection of cells using the present compositions. Examples of suitable non-lipid polycations include, hexadimethrine bromide (sold under the brand name POLYBRENE<sup>Â®</sup>, from Aldrich Chemical Co., Milwaukee, Wisconsin, USA) or other salts of hexadimethrine. Other suitable polycations include, for example, salts of poly-L-ornithine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and polyethyleneimine. Addition of these salts is preferably after the particles have been formed. </div>
    <div id="p0509" num="0509" class="description-paragraph"> In some embodiments, the nucleic acid (e.g., siRNA) to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1, from about 0.03 to about 0.1, or from about 0.01 to about 0.08. The ratio of the starting materials (input) also falls within this range. In other embodiments, the particle preparation uses about 400 Î¼g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50 Î¼g of nucleic acid. In other preferred embodiments, the particle has a nucleic acid ipid mass ratio of about 0.08. </div>
    <div id="p0510" num="0510" class="description-paragraph"> In other embodiments, the lipid to nucleic acid (e.g., siRNA) ratios (mass/mass ratios) in a formed nucleic acid-lipid particle will range from about 1 (1:1) to about 100 (100: 1), from about 5 (5:1) to about 100 (100:1), from about 1 (1:1) to about 50 (50:1), from about 2 (2:1) to about 50 (50:1), from about 3 (3:1) to about 50 (50:1), from about 4 (4:1) to about 50 (50:1), from about 5 (5: 1) to about 50 (50:1), from about 1 (1:1) to about 25 (25: 1), from about 2 (2: 1) to about 25 (25:1), from about3 (3:l)to about 25 (25:1), from about 4 (4:1) to about 25 (25:1), from about 5 (5:1) to about 25 (25:1), from about 5 (5:1) to about 20 (20:1), from about 5 (5:1) to about 15 (15:1), from about 5 (5:1) to about 10 (10:1), or about 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), 15 (15:1), 16 (16:1), 17 (17:1), 18 (18:1), 19 (19:1), 20 (20:1), 21 (21:1), 22 (22:1), 23 (23:1), 24 (24:1), or 25 (25:1), or any fraction thereof or range therein. The ratio of the starting materials (input) also falls within this range. </div>
    <div id="p0511" num="0511" class="description-paragraph"> As previously discussed, the conjugated lipid may further include a CPL. A variety of general methods for making lipid particle-CPLs (CPL-containing lipid particles) are discussed herein. Two general techniques include the &#34;post-insertion&#34; technique, that is, insertion of a CPL into, for example, a pre-formed lipid particle, and the &#34;standard&#34; technique, wherein the 

 CPL is included in the lipid mixture during, for example, the lipid particle formation steps. The post-insertion technique results in lipid particles having CPLs mainly in the external face of the lipid particle bilayer membrane, whereas standard techniques provide lipid particles having CPLs on both internal and external faces. The method is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAAs and PEG-DAGs). Methods of making lipid particle-CPLs are taught, for example, in U.S. Patent Nos. 5,705,385; 6,586,410; 5,981,501 ; 6,534,484; and 6,852,334; U.S. Patent Publication No. 20020072121 ; and PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0512" num="0512" class="description-paragraph">Description of Certain LNP Embodiments </div>
    <div id="p0513" num="0513" class="description-paragraph"> As described herein, in certain embodiments, an HBV inhibitor may be an </div>
    <div id="p0514" num="0514" class="description-paragraph">oligonucleotide, such as an siRNA. In certain embodiments, the siRNA may be comprised within a lipid nanoparticle formulation. These nucleic acid-lipid particles may comprise one or more (e.g., a cocktail) of the double-stranded siRNA molecules described herein (e.g., as described in Tables A and B), a cationic lipid, and a non-cationic lipid. In certain instances, the nucleic acid-lipid particles further comprise a conjugated lipid that inhibits aggregation of particles. Preferably, the nucleic acid-lipid particles comprise one or more (e.g., a cocktail) of the double-stranded siRNA molecules described herein, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles. </div>
    <div id="p0515" num="0515" class="description-paragraph"> In certain embodiments, the nucleic acid-lipid particle comprises two different double stranded siRNA molecules. </div>
    <div id="p0516" num="0516" class="description-paragraph"> In certain embodiments, the nucleic acid-lipid particle comprises three different double stranded siRNA molecules. </div>
    <div id="p0517" num="0517" class="description-paragraph"> In some embodiments, the siRNAs are fully encapsulated in the nucleic acid-lipid particle. With respect to formulations comprising an siRNA cocktail, the different types of siRNA species present in the cocktail (e.g., siRNA compounds with different sequences) may be co-encapsulated in the same particle, or each type of siRNA species present in the cocktail may be encapsulated in a separate particle. The siRNA cocktail may be formulated in the particles described herein using a mixture of two, three or more individual siRNAs (each having a unique sequence) at identical, similar, or different concentrations or molar ratios. In one embodiment, a cocktail of siRNAs (corresponding to a plurality of siRNAs with different sequences) is formulated using identical, similar, or different concentrations or molar ratios of each siRNA species, and the different types of siRNAs are co-encapsulated in the same particle. In another embodiment, each type of siRNA species present in the cocktail is encapsulated in different 

 particles at identical, similar, or different siRNA concentrations or molar ratios, and the particles thus formed (each containing a different siRNA payload) are administered separately (e.g., at different times in accordance with a therapeutic regimen), or are combined and administered together as a single unit dose (e.g., with a pharmaceutically acceptable carrier). The particles described herein are serum-stable, are resistant to nuclease degradation, and are substantially non-toxic to mammals such as humans. </div>
    <div id="p0518" num="0518" class="description-paragraph"> The cationic lipid in the nucleic acid-lipid particles of the invention may comprise, e.g., one or more cationic lipids of Formula ZI-III described herein or any other cationic lipid species. In one embodiment, cationic lipid is a dialkyl lipid. In another embodiment, the cationic lipid is a trialkyl lipid. In one particular embodiment, the cationic lipid is selected from the group consisting of l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy- Î,Î-dimethylaminopropane (DLenDMA), l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA; Compound (515)), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[l,3]-dioxolane (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[l,3]-dioxolane (DLin-K-DMA), dilinoleylmethyl-3-dimethylaminopropionate (DLin-M-C2-DMA), (6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-M-C3-DMA; </div>
    <div id="p0519" num="0519" class="description-paragraph">Compound (507)), salts thereof, and mixtures thereof. </div>
    <div id="p0520" num="0520" class="description-paragraph"> In another particular embodiment, the cationic lipid is selected from the group consisting of l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane (Î³-</div>
    <div id="p0521" num="0521" class="description-paragraph">DLenDMA; Compound (515)), 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)- N,N-dimethylpropan-l -amine (DLin-MP-DMA; Compound (508)), (6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) (Compound (507)), </div>
    <div id="p0522" num="0522" class="description-paragraph">(6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)), a salt thereof, or a mixture thereof. </div>
    <div id="p0523" num="0523" class="description-paragraph"> In certain embodiments, the cationic lipid comprises from about 48 mol % to about 62 mol % of the total lipid present in the particle. </div>
    <div id="p0524" num="0524" class="description-paragraph"> The non-cationic lipid in the nucleic acid-lipid particles may comprise, e.g., one or more anionic lipids and/or neutral lipids. In some embodiments, the non-cationic lipid comprises one of the following neutral lipid components: (1) a mixture of a phospholipid and cholesterol or a derivative thereof; (2) cholesterol or a derivative thereof; or (3) a phospholipid. In certain preferred embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. In a preferred embodiment, the 

 non-cationic lipid is a mixture of DPPC and cholesterol. In a preferred embodiment, the non- cationic lipid is a mixture of DSPC and cholesterol. </div>
    <div id="p0525" num="0525" class="description-paragraph"> In certain embodiments, the non-cationic lipid comprises a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises from about 7 mol % to about 17 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from about 25 mol % to about 40 mol % of the total lipid present in the particle. </div>
    <div id="p0526" num="0526" class="description-paragraph"> The lipid conjugate in the nucleic acid-lipid particles inhibits aggregation of particles and may comprise, e.g., one or more of the lipid conjugates described herein. In one particular embodiment, the lipid conjugate comprises a PEG-lipid conjugate. Examples of PEG-lipid conjugates include, but are not limited to, PEG-DAG conjugates, PEG-DAA conjugates, and mixtures thereof. In certain embodiments, the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG- DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, and a mixture thereof. In certain embodiments, the PEG-lipid conjugate is a PEG-DAA conjugate. In certain embodiments, the PEG-DAA conjugate in the lipid particle may comprise a PEG- didecyloxypropyl (Cio) conjugate, a PEG-dilauryloxypropyl (C<sub>12</sub>) conjugate, a PEG- dimyristyloxypropyl (C<sub>14</sub>) conjugate, a PEG-dipalmityloxypropyl (Ci<sub>6</sub>) conjugate, a PEG- distearyloxypropyl (C<sub>18</sub>) conjugate, or mixtures thereof. In certain embodiments, wherein the PEG-DAA conjugate is a PEG-dimyristyloxypropyl (C<sub>14</sub>) conjugate. In another embodiment, the PEG-DAA conjugate is a compound (566) (PEG-C-DMA) conjugate. In another embodiment, the lipid conjugate comprises a POZ-lipid conjugate such as a POZ-DAA conjugate. </div>
    <div id="p0527" num="0527" class="description-paragraph"> In certain embodiments, the conjugated lipid that inhibits aggregation of particles comprises from about 0.5 mol % to about 3 mol % of the total lipid present in the particle. </div>
    <div id="p0528" num="0528" class="description-paragraph"> In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15: 1. </div>
    <div id="p0529" num="0529" class="description-paragraph"> In certain embodiments, the nucleic acid-lipid particle has a median diameter of from about 30 nm to about 150 nm. </div>
    <div id="p0530" num="0530" class="description-paragraph"> In certain embodiments, the nucleic acid-lipid particle has an electron dense core. </div>
    <div id="p0531" num="0531" class="description-paragraph"> In some embodiments, the nucleic acid-lipid particles comprising: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated 

 lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle. </div>
    <div id="p0532" num="0532" class="description-paragraph"> In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. In one particular embodiment, the formulation is a four- component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof). </div>
    <div id="p0533" num="0533" class="description-paragraph"> In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. In one particular embodiment, the formulation is a three-component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C- DMA), about 61.5 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof). </div>
    <div id="p0534" num="0534" class="description-paragraph"> Additional formulations are described in PCT Publication No. WO 09/127060 and published US patent application publication number US 2011/0071208 Al, the disclosures of which are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0535" num="0535" class="description-paragraph"> In other embodiments, the nucleic acid-lipid particles comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle. </div>
    <div id="p0536" num="0536" class="description-paragraph"> In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a 

 cationic lipid or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle. In one particular embodiment, the formulation is a four- component system which comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C- DMA), about 40 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof). </div>
    <div id="p0537" num="0537" class="description-paragraph"> In further embodiments, the nucleic acid-lipid particles comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) one or more cationic lipids or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. </div>
    <div id="p0538" num="0538" class="description-paragraph"> In one aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. In certain instances, the non-cationic lipid mixture in the formulation comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % to about 35 mol % of the total lipid present in the particle. In one particular embodiment, the formulation is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof). </div>
    <div id="p0539" num="0539" class="description-paragraph"> In another aspect of this embodiment, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate 

 comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle. In one particular embodiment, the formulation is a three-component system which is phospholipid- free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid (e.g., DLin-K-C2-DMA) or a salt thereof, and about 35 mol % cholesterol (or derivative thereof). </div>
    <div id="p0540" num="0540" class="description-paragraph"> Additional embodiments of useful formulations are described in published US patent application publication number US 2011/0076335 Al, the disclosure of which is herein incorporated by reference in its entirety for all purposes. </div>
    <div id="p0541" num="0541" class="description-paragraph"> In certain embodiments of the invention, the nucleic acid-lipid particle comprises: (a) one or more (e.g., a cocktail) siRNA molecules described herein (e.g., see, Tables A and B); (b) a cationic lipid or a salt thereof comprising from about 48 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the phospholipid comprises about 7 mol % to about 17 mol % of the total lipid present in the particle, and wherein the cholesterol or derivative thereof comprises about 25 mol % to about 40 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 0.5 mol % to about 3.0 mol % of the total lipid present in the particle. </div>
    <div id="p0542" num="0542" class="description-paragraph"> Exemplary lipid formulations A-Z are included below. </div>
    <div id="p0543" num="0543" class="description-paragraph"> Exemplary lipid formulation A includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.2%), cationic lipid (53.2%), phospholipid (9.3%), cholesterol (36.4%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.2%), the cationic lipid is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (53.2%), the phospholipid is DPPC (9.3%), and cholesterol is present at 36.4%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation A, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation A may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation A may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, 

 the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0544" num="0544" class="description-paragraph"> Exemplary lipid formulation B which includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.8%), cationic lipid</div>
    <div id="p0545" num="0545" class="description-paragraph">(59.7%), phospholipid (14.2%), cholesterol (25.3%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (0.8%), the cationic lipid is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (59.7%), the phospholipid is DSPC (14.2%), and cholesterol is present at 25.3%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation B, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation B may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation B may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratiooffrom 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0546" num="0546" class="description-paragraph"> Exemplary lipid formulation C includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.9%), cationic lipid</div>
    <div id="p0547" num="0547" class="description-paragraph">(52.5%), phospholipid (14.8%), cholesterol (30.8%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (1.9%), the cationic lipid is l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA; Compound (515)) (52.5%), the phospholipid is DSPC (14.8%), and cholesterol is present at 30.8%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation C, 

 which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation C may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation C may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0548" num="0548" class="description-paragraph"> Exemplary lipid formulation D includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.7%), cationic lipid (60.3%), phospholipid (8.4%), cholesterol (30.5%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (0.7%), the cationic lipid is 3- ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (DLin-MP-DMA; Compound (508) (60.3%), the phospholipid is DSPC (8.4%), and cholesterol is present at 30.5%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation D, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation D may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation D may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5:1 to about 15:1, orabout5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid: drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0549" num="0549" class="description-paragraph"> Exemplary lipid formulation E includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.8%), cationic lipid (52.1%), phospholipid (7.5%), cholesterol (38.5%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 

 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.8%), the cationic lipid is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate) </div>
    <div id="p0550" num="0550" class="description-paragraph">(Compound (507)) (52.1%), the phospholipid is DPPC (7.5%), and cholesterol is present at 38.5%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation E, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation E may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation E may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0551" num="0551" class="description-paragraph"> Exemplary formulation F includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.9%), cationic lipid (57.1%), phospholipid (8.1%), cholesterol (33.8%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (0.9%), the cationic lipid is 1,2-dilinolenyloxy- Î,Î-dimethylaminopropane (DLenDMA), l,2-di-Y-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA; Compound (515)) (57.1%), the phospholipid is DSPC (8.1%), and cholesterol is present at 33.8%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation F, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation F may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation F may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1 , 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any 

 fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0552" num="0552" class="description-paragraph"> Exemplary lipid formulation G includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.7%), cationic lipid (61.6%), phospholipid (1 1.2%), cholesterol (25.5%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (1.7%), the cationic lipid is 1 ,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1 ,2-di-y-linolenyloxy-N,N- dimethylaminopropane (Î³-DLenDMA; Compound (515)) (61.6%), the phospholipid is DPPC (11.2%), and cholesterol is present at 25.5%, wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g. , Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation G, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation G may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation G may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0553" num="0553" class="description-paragraph"> Exemplary lipid formulation H includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.1%), cationic lipid (55.0%), phospholipid (1 1.0%), cholesterol (33.0%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.1%), the cationic lipid is (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (55.0%), the phospholipid is DSPC (1 1.0%), and cholesterol is present at 33.0%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, 

 Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â±0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation H, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation H may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation H may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0554" num="0554" class="description-paragraph"> Exemplary lipid formulation I includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.6%), cationic lipid (53.1%), phospholipid (9.4%), cholesterol (35.0%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.6%), the cationic lipid is (6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (53.1%), the phospholipid is DSPC (9.4%), and cholesterol is present at 35.0%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â±0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation I, which comprises one or more siRNA molecules described herein. For example, in certain </div>
    <div id="p0555" num="0555" class="description-paragraph">embodiments, the nucleic acid lipid particle based on formulation I may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation I may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about5:l, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0556" num="0556" class="description-paragraph"> Exemplary lipid formulation J includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.6%), cationic lipid (59.4%), phospholipid (10.2%), cholesterol (29.8%), wherein the actual amounts of the lipids 

 present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (0.6%), the cationic lipid is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (59.4%), the phospholipid is DPPC (10.2%), and cholesterol is present at 29.8%, wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g. , Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation J, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation J may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation J may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0557" num="0557" class="description-paragraph"> Exemplary lipid formulation K includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.5%), cationic lipid (56.7%), phospholipid (13.1%), cholesterol (29.7%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (0.5%), the cationic lipid is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate) </div>
    <div id="p0558" num="0558" class="description-paragraph">(Compound (507)) (56.7%), the phospholipid is DSPC (13.1%), and cholesterol is present at 29.7%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation K, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation K may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation K may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any 

 fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0559" num="0559" class="description-paragraph"> Exemplary lipid formulation L includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.2%), cationic lipid (52.0%), phospholipid (9.7%), cholesterol (36.2%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (2.2%), the cationic lipid is l,2-di-y-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA; Compound (515)) (52.0%), the phospholipid is DSPC (9.7%), and cholesterol is present at 36.2%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation L, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation L may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation L may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0560" num="0560" class="description-paragraph"> Exemplary lipid formulation M includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.7%), cationic lipid (58.4%), phospholipid (13.1%), cholesterol (25.7%), wherein the actual amounts of the lipids present may vary by by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.7%), the cationic lipid is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (58.4%), the phospholipid is DPPC (13.1%), and cholesterol is present at 25.7%, wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g. , Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide 

 a nucleic acid-lipid particle based on formulation M, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation M may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation M may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0561" num="0561" class="description-paragraph"> Exemplary lipid formulation N includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (3.0%), cationic lipid (53.3%), phospholipid (12.1%), cholesterol (31.5%), wherein the actual amounts of the lipids present may vary by by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (3.0%), the cationic lipid is 1,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (53.3%), the phospholipid is DPPC (12.1%), and cholesterol is present at 31.5%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation N, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation N may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation N may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0562" num="0562" class="description-paragraph"> Exemplary lipid formulation O includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.5%), cationic lipid (56.2%), phospholipid (7.8%), cholesterol (34.7%), wherein the actual amounts of the lipids present may vary by by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 

 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.5%), the cationic lipid is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (56.2%), the phospholipid is DPPC (7.8%), and cholesterol is present at 34.7%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation O, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation O may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation O may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 {e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0563" num="0563" class="description-paragraph"> Exemplary lipid formulation P includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.1%), cationic lipid (48.6%), phospholipid (15.5%), cholesterol (33.8%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (2.1%), the cationic lipid is 3- ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31 -tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (DLin-MP-DMA; Compound (508)) (48.6%), the phospholipid is DSPC (15.5%), and cholesterol is present at 33.8%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g. , Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation P, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation P may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation P may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid 

 particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0564" num="0564" class="description-paragraph"> Exemplary lipid formulation Q includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.5%), cationic lipid (57.9%), phospholipid (9.2%), cholesterol (30.3%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.5%), the cationic lipid is (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (57.9%), the phospholipid is DSPC (9.2%), and cholesterol is present at 30.3%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation Q, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation Q may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation Q may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0565" num="0565" class="description-paragraph"> Exemplary lipid formulation R includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.6%), cationic lipid</div>
    <div id="p0566" num="0566" class="description-paragraph">(54.6%), phospholipid (10.9%), cholesterol (32.8%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.6%), the cationic lipid is 3- ((6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l -tetraen-19-yloxy)-N,N-dimethylpropan-l -amine (Compound (508)) (54.6%), the phospholipid is DSPC (10.9%), and cholesterol is present at 32.8%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based 

 on formulation R, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation R may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation R may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid: drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0567" num="0567" class="description-paragraph"> Exemplary lipid formulation S includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.9%), cationic lipid (49.6%), phospholipid (16.3%), cholesterol (31.3%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.9%), the cationic lipid is (6Z,16Z)-12-((Z)-dec-4-enyl)docosa-6,16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (49.6%), the phospholipid is DPPC (16.3%), and cholesterol is present at 31.3%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â±2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â±0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation S, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation S may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation S may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0568" num="0568" class="description-paragraph"> Exemplary lipid formulation T includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (0.7%), cationic lipid (50.5%), phospholipid (8.9%), cholesterol (40.0%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 

 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (0.7%), the cationic lipid is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (50.5%), the phospholipid is DPPC (8.9%), and cholesterol is present at 40.0%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation T, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation T may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation T may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 {e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0569" num="0569" class="description-paragraph"> Exemplary lipid formulation U includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.0%), cationic lipid (51.4%), phospholipid (15.0%), cholesterol (32.6%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (1.0%), the cationic lipid is l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (51.4%), the phospholipid is DSPC (15.0%), and cholesterol is present at 32.6%, wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g. , Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation U, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation U may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation U may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug 

 ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0570" num="0570" class="description-paragraph"> Exemplary lipid formulation V includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.3%), cationic lipid (60.0%), phospholipid (7.2%), cholesterol (31.5%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (1.3%), the cationic lipid is l,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA) (60.0%), the phospholipid is DSPC (7.2%), and cholesterol is present at 31.5%, wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation V, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation V may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation V may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 1 1 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5 : 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0571" num="0571" class="description-paragraph"> Exemplary lipid formulation W includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (1.8%), cationic lipid (51.6%), phospholipid (8.4%), cholesterol (38.3%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (1.8%), the cationic lipid is 1 ,2- dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) (51.6%), the phospholipid is DSPC (8.4%), and cholesterol is present at 38.3%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation W, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle 

 based on formulation W may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation W may comprise three different siRNA molecules, In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9:1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0572" num="0572" class="description-paragraph"> Exemplary lipid formulation X includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.4%), cationic lipid</div>
    <div id="p0573" num="0573" class="description-paragraph">(48.5%), phospholipid (10.0%), cholesterol (39.2%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.4%), the cationic lipid is 1,2- di-Y-linolenyloxy-N,N-dimethylaminopropane (Î³-DLenDMA; Compound (515)) (48.5%), the phospholipid is DPPC (10.0%), and cholesterol is present at 39.2%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â±0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation X, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation X may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation X may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of from about 5:1 to about 15:1, or about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, or 15:1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5:1 to 10:1, or from 8.9:1 to 10:1, or from 9:1 to 9.9:1, including 9.1:1, 9.2:1, 9.3:1, 9.4:1, 9.5:1, 9.6:1, 9.7:1, and 9.8:1). </div>
    <div id="p0574" num="0574" class="description-paragraph"> Exemplary lipid formulation Y includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.6%), cationic lipid</div>
    <div id="p0575" num="0575" class="description-paragraph">(61.2%), phospholipid (7.1%), cholesterol (29.2%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DMA (compound (566)) (2.6%), the cationic lipid is 

 (6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)) (61.2%), the phospholipid is DSPC (7.1%), and cholesterol is present at 29.2%, wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation Y, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation Y may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation Y may comprise three different siRNA molecules. In certain embodiments, the nucleic acid4ipid particle has a total lipid: siRNA mass ratio of from about 5: 1 to about 15: 1, or about 5 : 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, or 15 : 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid:drug ratio of from 8.5: 1 to 10: 1, or from 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0576" num="0576" class="description-paragraph"> Exemplary lipid formulation Z includes the following components (wherein the percentage values of the components are mole percent): PEG-lipid (2.2%), cationic lipid (49.7%), phospholipid (12.1%), cholesterol (36.0%), wherein the actual amounts of the lipids present may vary by, e.g. , Â± 5 % (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). For example, in one representative embodiment, the PEG-lipid is PEG-C-DOMG (compound (567)) (2.2%), the cationic lipid is (6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19-yl 4-(dimethylamino)butanoate) </div>
    <div id="p0577" num="0577" class="description-paragraph">(Compound (507)) (49.7%), the phospholipid is DPPC (12.1%), and cholesterol is present at 36.0%), wherein the actual amounts of the lipids present may vary by, e.g., Â± 5 %&gt; (or e.g., Â± 4 mol %, Â± 3 mol %, Â± 2 mol %, Â± 1 mol %, Â± 0.75 mol %, Â± 0.5 mol %, Â± 0.25 mol %, or Â± 0.1 mol %). Thus, certain embodiments of the invention provide a nucleic acid-lipid particle based on formulation Z, which comprises one or more siRNA molecules described herein. For example, in certain embodiments, the nucleic acid lipid particle based on formulation Z may comprise two different siRNA molecules. In certain other embodiments, the nucleic acid lipid particle based on formulation Z may comprise three different siRNA molecules. In certain embodiments, the nucleic acid-lipid particle has a total lipid:siRNA mass ratio of from about 5 : 1 to about 15 : 1, or about 5: l, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1 , 11 : 1, 12: 1, 13 : 1, 14: 1, or 15: 1, or any fraction thereof or range therein. In certain embodiments, the nucleic acid-lipid particle has a total lipid: siRNA mass ratio of about 9: 1 (e.g., a lipid: drug ratio of from 8.5 : 1 to 10: 1, or from 

 8.9: 1 to 10: 1, or from 9: 1 to 9.9: 1, including 9.1 : 1, 9.2: 1, 9.3 : 1, 9.4: 1, 9.5: 1, 9.6: 1, 9.7: 1, and 9.8: 1). </div>
    <div id="p0578" num="0578" class="description-paragraph"> Accordingly, described herein are nucleic acid-lipid particles, wherein the lipids are formulated as described in any one of formulations A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y or Z. </div>
    <div id="p0579" num="0579" class="description-paragraph"> Also described herein are pharmaceutical compositions comprising a nucleic acid-lipid particle and a pharmaceutically acceptable carrier. </div>
    <div id="p0580" num="0580" class="description-paragraph"> The nucleic acid-lipid particles described herein are useful, for example, for the therapeutic delivery of siRNAs that silence the expression of one or more HBV genes. In some embodiments, a cocktail of siRNAs that target different regions (e.g., overlapping and/or non- overlapping sequences) of an HBV gene or transcript is formulated into the same or different nucleic acid-lipid particles, and the particles are administered to a mammal (e.g., a human) requiring such treatment. In certain instances, a therapeutically effective amount of the nucleic acid-lipid particles can be administered to the mammal, e.g., for treating HBV and/or HDV infection in a human. </div>
    <div id="p0581" num="0581" class="description-paragraph"> In certain embodiments, one or more siRNA molecules described herein may be introduced into a cell by contacting the cell with a nucleic acid-lipid particle described herein. </div>
    <div id="p0582" num="0582" class="description-paragraph"> In certain embodiments, one or more siRNA molecules that silence expression of a Hepatitis B virus gene may be introduced into a cell by contacting the cell with a nucleic acid- lipid particle described herein under conditions whereby the siRNA enters the cell and silences the expression of the Hepatitis B virus gene within the cell. In certain embodiments, the cell is in a mammal, such as a human. In certain embodiments, the human has been diagnosed with a Hepatitis B virus infection or a Hepatitis B virus Hepatitis D virus infection. In certain embodiments, silencing of the Hepatitis B virus gene expression reduces Hepatitis B virus and/or Hepatitis D virus particle load in the mammal by at least about 50% (e.g., about 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100%) relative to Hepatitis B virus and/or Hepatitis D virus particle load in the absence of the nucleic acid-lipid particle. </div>
    <div id="p0583" num="0583" class="description-paragraph"> In certain embodiments, the expression of a Hepatitis B virus gene in a cell may be silenced by contacting a cell comprising an expressed Hepatitis B virus gene with a nucleic acid- lipid particle or a composition (e.g., a pharmaceutical composition) described herein under conditions whereby the siRNA enters the cell and silences the expression of the Hepatitis B virus gene within the cell. In certain embodiments, the cell is in a mammal, such as a human. In certain embodiments, the human has been diagnosed with a Hepatitis B virus infection or a Hepatitis B virus/Hepatitis D virus infection. In certain embodiments, the human has been 

 diagnosed with liver disease caused by a Hepatitis B virus infection or a Hepatitis B </div>
    <div id="p0584" num="0584" class="description-paragraph">virus/Hepatitis D virus infection. In certain embodiments, silencing of the Hepatitis B virus gene expression reduces Hepatitis B virus and/or Hepatitis D virus particle load in the mammal by at least about 50% (e.g., about 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100%) relative to Hepatitis B virus and/or Hepatitis D virus particle load in the absence of the nucleic acid-lipid particle. </div>
    <div id="p0585" num="0585" class="description-paragraph"> In some embodiments, the nucleic acid-lipid particles or compositions (e.g., a pharmaceutical composition) described herein are administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal. In particular embodiments, the nucleic acid-lipid particles are administered systemically, e.g., via enteral or parenteral routes of administration. </div>
    <div id="p0586" num="0586" class="description-paragraph"> In certain aspects, HBV gene expression may be silenced in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., one or more siRNAs shown in Tables A and B). In some embodiments, administration of nucleic acid-lipid particles comprising one or more siRNAs described herein reduces HBV RNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to HBV RNA levels detected in the absence of the siRNA (e.g., buffer control or irrelevant non-HBV targeting siRNA control). In other embodiments, administration of nucleic acid-lipid particles comprising one or more HBV- targeting siRNAs reduces HBV RNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control. </div>
    <div id="p0587" num="0587" class="description-paragraph"> In other aspects, HBV gene expression may be silenced in a mammal (e.g., human) in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNAs described herein (e.g., siRNAs described in Tables A and B). In some embodiments, administration of nucleic acid- lipid particles comprising one or more HBV siRNAs reduces HBV mRNA levels by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to HBV mRNA levels detected in the absence of the siRNA 

 (e.g., buffer control or irrelevant non-HBV targeting siRNA control). In other embodiments, administration of nucleic acid-lipid particles comprising one or more HBV-targeting siRNAs reduces HBV mRNA levels for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 days or more (or any range therein) relative to a negative control such as, e.g., a buffer control or an irrelevant non-HBV targeting siRNA control. </div>
    <div id="p0588" num="0588" class="description-paragraph"> Also described herein are methods for treating, preventing, reducing the risk or likelihood of developing (e.g., reducing the susceptibility to), delaying the onset of, and/or ameliorating one or more symptoms associated with HBV and/or HDV infection in a mammal (e.g., human) in need thereof. In certain embodiments, such methods comprise administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle comprising one or more siRNA molecules described herein {e.g., as described in Tables A and B) that target HBV gene expression. Examples of symptoms associated with HBV and/or HDV infection in a human include fever, abdominal pain, dark urine, joint pain, loss of appetite, nausea, vomiting, weakness, fatigue and yellowing of the skin (jaundice). </div>
    <div id="p0589" num="0589" class="description-paragraph"> In further aspects, HBV and/or HDV may be inactivated in a mammal (e.g., human) in need thereof {e.g., a human suffering from HBV infection or HBV/HDV infection), the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid- lipid particle comprising one or more siRNAs described herein that target HBV gene expression. In some embodiments, administration of nucleic acid-lipid particles comprising one or more HBV-targeting siRNAs lowers, reduces, or decreases HBV protein levels {e.g., HBV surface antigen protein) by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range therein) relative to the HBV protein levels detected in the absence of the siRNA {e.g., buffer control or irrelevant non-HBV targeting siRNA control). </div>
    <div id="p0590" num="0590" class="description-paragraph"> By way of example, HBV mRNA can be measured using a branched DNA assay (QuantiGeneÂ®; Affymetrix). The branched DNA assay is a sandwich nucleic acid hybridization method that uses bDNA molecules to amplify signal from captured target RNA. </div>
    <div id="p0591" num="0591" class="description-paragraph"> In addition to its utility in silencing the expression of any of the HBV genes for therapeutic purposes, the siRNA described herein are also useful in research and development applications as well as diagnostic, prophylactic, prognostic, clinical, and other healthcare applications. As a non-limiting example, the siRNA can be used in target validation studies 

 directed at testing whether a specific member of the HBV gene family has the potential to be a therapeutic target. </div>
    <div id="p0592" num="0592" class="description-paragraph">Administration of Lipid Particles </div>
    <div id="p0593" num="0593" class="description-paragraph"> Once formed, the lipid particles of the invention are particularly useful for the introduction of a siRNA molecule (e.g., a siRNA molecule as described in Tables A and B) into cells. Accordingly, the present invention also provides methods for introducing a siRNA molecule into a cell. In particular embodiments, the siRNA molecule is introduced into an infected cell. The methods may be carried out in vitro or in vivo by first forming the particles as described above and then contacting the particles with the cells for a period of time sufficient for delivery of siRNA to the cells to occur. </div>
    <div id="p0594" num="0594" class="description-paragraph"> The lipid particles of the invention (e.g., a nucleic-acid lipid particle) can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the siRNA portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid. </div>
    <div id="p0595" num="0595" class="description-paragraph"> The lipid particles of the invention (e.g., nucleic acid-lipid particles) can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (e.g., physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice. Generally, normal buffered saline (e.g., 135-150 mM NaCl) will be employed as the pharmaceutically acceptable carrier. Other suitable carriers include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Additional suitable carriers are described in, e.g. , REMINGTON&#39; S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). As used herein, &#34;carrier&#34; includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The phrase &#34;pharmaceutically acceptable&#34; refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. </div>
    <div id="p0596" num="0596" class="description-paragraph"> The pharmaceutically acceptable carrier is generally added following lipid particle formation. Thus, after the lipid particle is formed, the particle can be diluted into </div>
    <div id="p0597" num="0597" class="description-paragraph">pharmaceutically acceptable carriers such as normal buffered saline. 

 The concentration of particles in the pharmaceutical formulations can vary widely, i.e., from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, etc. , in accordance with the particular mode of administration selected. For example, the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension. Alternatively, particles composed of irritating lipids may be diluted to low concentrations to lessen </div>
    <div id="p0598" num="0598" class="description-paragraph">inflammation at the site of administration. </div>
    <div id="p0599" num="0599" class="description-paragraph"> The pharmaceutical compositions of the present invention may be sterilized by conventional, well-known sterilization techniques. Aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride. Additionally, the particle suspension may include lipid-protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable. </div>
    <div id="p0600" num="0600" class="description-paragraph"> In some embodiments, the lipid particles of the invention are particularly useful in methods for the therapeutic delivery of one or more siRNA molecules {e.g. , an siRNA molecule as described in Tables A and B). In particular, it is an object of this invention to provide in vivo methods for treatment of HBV and/or HDV infection in humans by downregulating or silencing the transcription and/or translation of one or more HBV genes. </div>
    <div id="p0601" num="0601" class="description-paragraph">A. In vivo Administration </div>
    <div id="p0602" num="0602" class="description-paragraph"> Systemic delivery for in vivo therapy, e.g. , delivery of a siRNA molecule described herein, such as an siRNA described in Tables A and B, to a distal target cell via body systems such as the circulation, has been achieved using nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes. The present invention also provides fully encapsulated lipid particles that protect the siRNA from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing. Additionally, the one or more siRNA molecules may be administered 

 alone in the lipid particles of the invention, or in combination (e.g., co-administered) with lipid particles comprising peptides, polypeptides, or small molecules such as conventional drugs. </div>
    <div id="p0603" num="0603" class="description-paragraph"> For in vivo administration, administration can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g. , intranasal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via single or divided doses. The pharmaceutical compositions can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical compositions are administered intravenously or intraperitoneally by a bolus injection (see, e.g. , U.S. Patent No. 5,286,634). Intracellular nucleic acid delivery has also been discussed in Straubringer et al. , Methods Enzymol. , 101 :512 (1983); Mannino et al. , </div>
    <div id="p0604" num="0604" class="description-paragraph"> Biotechniques, 6:682 (1988); Nicolau et al, Crit. Rev. Ther. Drug Carrier Sy St., 6:239 (1989); and Behr, Acc. Chem. Res., 26:274 (1993). Still other methods of administering lipid-based therapeutics are described in, for example, U.S. Patent Nos. 3,993,754; 4, 145,410; 4,235,871 ; 4,224, 179; 4,522,803; and 4,588,578. The lipid particles can be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, Mary Ann Liebert, Inc., Publishers, New York. pp.70-71(1994)). The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0605" num="0605" class="description-paragraph"> In embodiments where the lipid particles of the present invention are administered intravenously, at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In other embodiments, more than about 20%, 30%, 40% and as much as about 60%, 70% or 80% of the total injected dose of the lipid particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In certain instances, more than about 10% of a plurality of the particles is present in the plasma of a mammal about 1 hour after administration. In certain other instances, the presence of the lipid particles is detectable at least about 1 hour after administration of the particle. In some embodiments, the presence of a siRNA molecule is detectable in cells at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In other embodiments, downregulation of expression of a target sequence, such as a viral or host sequence, by a siRNA molecule is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration. In yet other embodiments, downregulation of expression of a target sequence, such as a viral or host sequence, by a siRNA molecule occurs preferentially in infected cells and/or cells capable of being infected. In further embodiments, the presence or effect of a siRNA molecule in cells at a site proximal or distal to the site of administration is detectable at about 12, 24, 48, 72, or 96 

 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration. In additional embodiments, the lipid particles of the invention are administered parenterally or intraperitoneally. </div>
    <div id="p0606" num="0606" class="description-paragraph"> The compositions of the present invention, either alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be &#34;nebulized&#34;) to be administered via inhalation (e.g. , intranasally or intratracheally) (see, Brigham et al. , Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. </div>
    <div id="p0607" num="0607" class="description-paragraph"> In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays have been described, e.g., in U.S. Patent Nos. 5,756,353 and 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins and lysophosphatidyl -glycerol compounds (U.S. Patent </div>
    <div id="p0608" num="0608" class="description-paragraph">5,725,871) are also well-known in the pharmaceutical arts. Similarly, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Patent No. 5,780,045. The disclosures of the above-described patents are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0609" num="0609" class="description-paragraph"> Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions are preferably administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally. </div>
    <div id="p0610" num="0610" class="description-paragraph"> Generally, when administered intravenously, the lipid particle formulations are formulated with a suitable pharmaceutical carrier. Many pharmaceutically acceptable carriers may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON&#39;S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). A variety of aqueous carriers may be used, for example, water, buffered water, 0.4% saline, 0.3%&gt; glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Generally, normal buffered saline (135-150 mM NaCl) will 

 be employed as the pharmaceutically acceptable carrier, but other suitable carriers will suffice. These compositions can be sterilized by conventional liposomal sterilization techniques, such as filtration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanol amine oleate, etc. These compositions can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. </div>
    <div id="p0611" num="0611" class="description-paragraph"> In certain applications, the lipid particles disclosed herein may be delivered via oral administration to the individual. The particles may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like {see, e.g., U.S. Patent Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes). These oral dosage forms may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents. When the unit dosage form is a capsule, it may contain, in addition to the materials described above, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. Of course, any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed. </div>
    <div id="p0612" num="0612" class="description-paragraph"> Typically, these oral formulations may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may </div>
    <div id="p0613" num="0613" class="description-paragraph">conveniently be between about 1% or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of particles in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable. </div>
    <div id="p0614" num="0614" class="description-paragraph"> Formulations suitable for oral administration can consist of: (a) liquid solutions, such as an effective amount of a packaged siRNA molecule {e.g., a siRNA molecule described in Tables A and B) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a siRNA molecule, as liquids, solids, 

 granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise a siRNA molecule in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic nucleic acid in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the siRNA molecule, carriers known in the art. </div>
    <div id="p0615" num="0615" class="description-paragraph"> In another example of their use, lipid particles can be incorporated into a broad range of topical dosage forms. For instance, a suspension containing nucleic acid-lipid particles can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like. </div>
    <div id="p0616" num="0616" class="description-paragraph"> When preparing pharmaceutical preparations of the lipid particles of the invention, it is preferable to use quantities of the particles which have been purified to reduce or eliminate empty particles or particles with therapeutic agents such as siRNA associated with the external surface. </div>
    <div id="p0617" num="0617" class="description-paragraph"> The methods of the present invention may be practiced in a variety of hosts. Preferred hosts include mammalian species, such as primates (e.g. , humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine. </div>
    <div id="p0618" num="0618" class="description-paragraph"> The amount of particles administered will depend upon the ratio of siRNA molecules to lipid, the particular siRNA used, the strain of HBV being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about 10<sup>8</sup>-10<sup>10</sup> particles per administration (e.g., injection). </div>
    <div id="p0619" num="0619" class="description-paragraph">B. In vitro Administration </div>
    <div id="p0620" num="0620" class="description-paragraph"> For in vitro applications, the delivery of siRNA molecules can be to any cell grown in culture. In preferred embodiments, the cells are animal cells, more preferably mammalian cells, and most preferably human cells. </div>
    <div id="p0621" num="0621" class="description-paragraph"> Contact between the cells and the lipid particles, when carried out in vitro, takes place in a biologically compatible medium. The concentration of particles varies widely depending on the particular application, but is generally between about 1 Î¼Î¹ÏÎ¹Î¿Î and about 10 mmol. Treatment 

 of the cells with the lipid particles is generally carried out at physiological temperatures (about 37Â°C) for periods of time of from about 1 to 48 hours, preferably of from about 2 to 4 hours. </div>
    <div id="p0622" num="0622" class="description-paragraph"> In one group of preferred embodiments, a lipid particle suspension is added to 60-80% confluent plated cells having a cell density of from about 10<sup>3</sup> to about 10<sup>5</sup> cells/ml, more preferably about 2 x 10<sup>4</sup> cells/ml. The concentration of the suspension added to the cells is preferably of from about 0.01 to 0.2 Î¼g/ml, more preferably about 0.1 Î¼g/ml. </div>
    <div id="p0623" num="0623" class="description-paragraph"> To the extent that tissue culture of cells may be required, it is well-known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley - Liss, New York (1994), Kuchler et al, Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1977), and the references cited therein provide a general guide to the culture of cells. Cultured cell systems often will be in the form of monolayers of cells, although cell suspensions are also used. </div>
    <div id="p0624" num="0624" class="description-paragraph"> Using an Endosomal Release Parameter (ERP) assay, the delivery efficiency of a nucleic acid-lipid particle of the invention can be optimized. An ERP assay is described in detail in U. S. Patent Publication No. 20030077829, the disclosure of which is herein </div>
    <div id="p0625" num="0625" class="description-paragraph">incorporated by reference in its entirety for all purposes. More particularly, the purpose of an ERP assay is to distinguish the effect of various cationic lipids and helper lipid components of the lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the endosomal membrane. This assay allows one to determine quantitatively how each component of the lipid particle affects delivery efficiency, thereby optimizing the lipid particle. Usually, an ERP assay measures expression of a reporter protein {e.g., luciferase, Î²- galactosidase, green fluorescent protein (GFP), etc.), and in some instances, a lipid particle formulation optimized for an expression plasmid will also be appropriate for encapsulating a siRNA. In other instances, an ERP assay can be adapted to measure downregulation of transcription or translation of a target sequence in the presence or absence of a siRNA. By comparing the ERPs for each of the various lipid particles, one can readily determine the optimized system, e.g., the lipid particle that has the greatest uptake in the cell. </div>
    <div id="p0626" num="0626" class="description-paragraph">C. Detection of Lipid Particles </div>
    <div id="p0627" num="0627" class="description-paragraph"> In some embodiments, the lipid particles of the present invention are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles. The presence of the particles can be detected in the cells, tissues, or other biological samples from the subject. The particles may be detected, e.g. , by direct detection of the particles, detection of 

 a siRNA sequence, detection of the target sequence of interest (i.e., by detecting expression or reduced expression of the sequence of interest), detection of a compound modulated by an EBOV protein (e.g., interferon), detection of viral load in the subject, or a combination thereof.</div>
    <div id="p0628" num="0628" class="description-paragraph">1. Detection of Particles </div>
    <div id="p0629" num="0629" class="description-paragraph"> Lipid particles of the invention can be detected using any method known in the art.</div>
    <div id="p0630" num="0630" class="description-paragraph">For example, a label can be coupled directly or indirectly to a component of the lipid particle using methods well-known in the art. A wide variety of labels can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions. Suitable labels include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon Greenâ¢; rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyesâ¢, and the like; radiolabels such as <sup>3</sup>H, <sup>125</sup>1, <sup>35</sup>S, <sup>14</sup>C, <sup>32</sup>P, <sup>33</sup>P, etc.; enzymes such as horse radish peroxidase, alkaline phosphatase, etc.; spectral colorimetnc labels such as colloidal gold or colored glass or plastic beads such as polystyrene, </div>
    <div id="p0631" num="0631" class="description-paragraph">polypropylene, latex, etc. The label can be detected using any means known in the art. </div>
    <div id="p0632" num="0632" class="description-paragraph"> 2. Detection of Nucleic Acids </div>
    <div id="p0633" num="0633" class="description-paragraph"> Nucleic acids (e.g., siRNA molecules) are detected and quantified herein by any of a number of means well-known to those of skill in the art. The detection of nucleic acids may proceed by well-known methods such as Southern analysis, Northern analysis, gel </div>
    <div id="p0634" num="0634" class="description-paragraph">electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. </div>
    <div id="p0635" num="0635" class="description-paragraph">Additional analytic biochemical methods such as spectrophotometry, radiography, </div>
    <div id="p0636" num="0636" class="description-paragraph">electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed. </div>
    <div id="p0637" num="0637" class="description-paragraph"> The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in, e.g., &#34;Nucleic Acid Hybridization, A Practical Approach,&#34; Eds. Hames and Higgins, IRL Press (1985). </div>
    <div id="p0638" num="0638" class="description-paragraph"> The sensitivity of the hybridization assays may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such in vitro amplification methods, 

 including the polymerase chain reaction (PCR), the ligase chain reaction (LCR), QP-replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBAâ¢) are found in Sambrook et al., n Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2000); and Ausubel et al , SHORT PROTOCOLS IN MOLECULAR BIOLOGY, eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley &amp; Sons, Inc. (2002); as well as U. S. Patent No. 4,683,202; PCR Protocols, A Guide to Methods and Applications (Innis et al. eds.) Academic Press Inc. San Diego, CA (1990); Arnheim &amp; Levinson (October 1, 1990), C&amp;EN 36; The Journal Of NIH Research, 3 :81 (1991); Kwoh et al, Proc. Natl. Acad. Sci. USA, 86: 1 173 (1989); Guatelli et al , Proc. Natl. Acad. Sci. USA, 87: 1874 (1990); Lomell et al, J. Clin. Chem., 35: 1826 (1989); Landegren et al , Science, 241 Î01Î (1988); Van Brunt, </div>
    <div id="p0639" num="0639" class="description-paragraph"> Biotechnology, 8:291 (1990); Wu and Wallace, Gene, 4:560 (1989); Barringer et al , Gene, 89: 1 17 (1990); and Sooknanan and Malek, Biotechnology, 13 :563 (1995). Improved methods of cloning in vitro amplified nucleic acids are described in U.S. Pat. No. 5,426,039. Other methods described in the art are the nucleic acid sequence based amplification (NASBAâ¢, Cangene, Mississauga, Ontario) and QP-replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation. The disclosures of the above-described references are herein incorporated by reference in their entirety for all purposes. </div>
    <div id="p0640" num="0640" class="description-paragraph"> Nucleic acids for use as probes, e.g., in in vitro amplification methods, for use as gene probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage et al, Tetrahedron Letts., 22: 1859 1862 (1981), e.g., using an automated synthesizer, as described in Needham </div>
    <div id="p0641" num="0641" class="description-paragraph">VanDevanter et al, Nucleic Acids Res., 12:6159 (1984). Purification of polynucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al, J. Chrom., 255: 137 149 (1983). The sequence of the synthetic polynucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65:499. </div>
    <div id="p0642" num="0642" class="description-paragraph"> An alternative means for determining the level of transcription is in situ hybridization. In situ hybridization assays are well-known and are generally described in Angerer et al , Methods Enzymol., 152:649 (1987). In an in situ hybridization assay, cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or 

 alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters. </div>
    <div id="p0643" num="0643" class="description-paragraph">Embodiments of Certain Conjugates </div>
    <div id="p0644" num="0644" class="description-paragraph"> As described herein, an HBV antigen inhibitor may be an oligonucleotide, such as an siRNA molecule. Such molecules (e.g., as described in Tables A and B) may be conjugated to a targeting moiety. For example, in certain embodiments, the oligonucleotide (e.g., siRNA molecule) may be comprised within a compound of formula I or XX. </div>
    <div id="p0645" num="0645" class="description-paragraph"> Accordingly, in one aspect an oligonucleotide is comprised within a compound of formula I: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/fc/c6/c67850c5124118/imgf000104_0001.png"><img id="imgf000104_0001" he="18" wi="44" file="imgf000104_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="176" height="72" alt="Figure imgf000104_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/fc/c6/c67850c5124118/imgf000104_0001.png"/></a></div>
 </div>
    <div id="p0646" num="0646" class="description-paragraph"> (I) </div>
    <div id="p0647" num="0647" class="description-paragraph">wherein: </div>
    <div id="p0648" num="0648" class="description-paragraph"> R<sup>1</sup> a is targeting ligand; </div>
    <div id="p0649" num="0649" class="description-paragraph"> L<sup>1</sup> is absent or a linking group; </div>
    <div id="p0650" num="0650" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p0651" num="0651" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; </div>
    <div id="p0652" num="0652" class="description-paragraph"> the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
    <div id="p0653" num="0653" class="description-paragraph"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup>, Ci-io alkyl C2-io lkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
    <div id="p0654" num="0654" class="description-paragraph"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
    <div id="p0655" num="0655" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; </div>
    <div id="p0656" num="0656" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0657" num="0657" class="description-paragraph"> In one embodiment of the compound of formula I, R<sup>1</sup> a is targeting ligand; </div>
    <div id="p0658" num="0658" class="description-paragraph"> L<sup>1</sup> is absent or a linking group; </div>
    <div id="p0659" num="0659" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p0660" num="0660" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; 

 the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
    <div id="p0661" num="0661" class="description-paragraph"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup> and Ci-s alkyl that is optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
    <div id="p0662" num="0662" class="description-paragraph"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
    <div id="p0663" num="0663" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. </div>
    <div id="p0664" num="0664" class="description-paragraph"> In one embodiment R<sup>1</sup> is -C(H)(3-<sub>P</sub>)(L -saccharide)<sub>p</sub>, wherein each L<sup>3</sup> is independently a linking group; p is 1, 2, or 3; and saccharide is a monosaccharide or disaccharide. </div>
    <div id="p0665" num="0665" class="description-paragraph"> In one embodiment the saccharide is: </div>
    <div id="p0666" num="0666" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/fb/0b/35ee3caf049249/imgf000105_0001.png"><img id="imgf000105_0001" he="26" wi="29" file="imgf000105_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="116" height="104" alt="Figure imgf000105_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/06/fb/0b/35ee3caf049249/imgf000105_0001.png"/></a></div>
    </div>
    <div id="p0667" num="0667" class="description-paragraph"> wherein: </div>
    <div id="p0668" num="0668" class="description-paragraph"> X is R<sup>3</sup>, and Y is selected from -(C=0)R<sup>4</sup>, -SO2R<sup>5</sup>, and -(C=0)NR<sup>6</sup>R<sup>7</sup>; or X is -(C=0)- and Y is NR<sup>8</sup>R<sup>9</sup>; </div>
    <div id="p0669" num="0669" class="description-paragraph"> R<sup>3</sup> is hydrogen or (Ci-C4)alkyl; </div>
    <div id="p0670" num="0670" class="description-paragraph"> R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> , R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of hydrogen, (Ci-Cs)alkyl, (Ci-Cg)haloalkyl, (Ci-C8)alkoxy and (C3-C6)cycloalkyl that is optionally substituted with one or more groups independently selected from the group consisting of halo, (Ci-C<sub>4</sub>)alkyl, (Ci-C<sub>4</sub>)haloalkyl, (Ci-C<sub>4</sub>)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy; </div>
    <div id="p0671" num="0671" class="description-paragraph"> R<sup>10</sup> is -OH, - R<sup>8</sup>R<sup>9</sup> or - F; and </div>
    <div id="p0672" num="0672" class="description-paragraph"> R<sup>11</sup> is -OH, -NR<sup>8</sup>R<sup>9</sup>, -F or 5 membered heterocycle that is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxyl, carboxyl, amino, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy; </div>
    <div id="p0673" num="0673" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0674" num="0674" class="description-paragraph"> In one embodiment the saccharide is selected from the roup consisting of: </div>
    <div id="p0675" num="0675" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9d/21/71/7666a7b093e1c3/imgf000105_0002.png"><img id="imgf000105_0002" he="28" wi="150" file="imgf000105_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="112" alt="Figure imgf000105_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9d/21/71/7666a7b093e1c3/imgf000105_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ca/7e/70/f88464bb614295/imgf000106_0001.png"><img id="imgf000106_0001" he="25" wi="146" file="imgf000106_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="584" height="100" alt="Figure imgf000106_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ca/7e/70/f88464bb614295/imgf000106_0001.png"/></a></div>
    </div>
    <div id="p0676" num="0676" class="description-paragraph"> and salts thereof. </div>
    <div id="p0677" num="0677" class="description-paragraph"> In one embodiment the saccharide is: </div>
    <div id="p0678" num="0678" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/30/8b/b18c1f760d381c/imgf000106_0002.png"><img id="imgf000106_0002" he="24" wi="80" file="imgf000106_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="320" height="96" alt="Figure imgf000106_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/30/8b/b18c1f760d381c/imgf000106_0002.png"/></a></div>
    </div>
    <div id="p0679" num="0679" class="description-paragraph"> N- Acetylgalactosamine (GalNAc) GalPro </div>
    <div id="p0680" num="0680" class="description-paragraph"> In one embodiment each L<sup>3</sup> is independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 0 to 50 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by - 0-, -NR<sup>X</sup>-, - R<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (Ci-Ce)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1 , 2, 3, or 4) substituents selected from (Ci-C6)alkoxy, (C3-C6)cycloalkyl, (Ci-C6)alkanoyl, (Ci- Ce)alkanoyloxy, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0681" num="0681" class="description-paragraph"> In one embodiment each L<sup>3</sup> is independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 20 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by - 0-, -NR<sup>X</sup>-, - R<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (Ci-C<sub>6</sub>)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1 , 2, 3, or 4) substituents selected from (Ci-Cs)alkoxy, (C3-Ce)cycloalkyl, (Ci-C6)alkanoyl, (Ci- C6)alkanoyloxy, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0682" num="0682" class="description-paragraph"> In one embodimen <sup>3</sup> is: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5e/0d/7a/117f6451c3ecd6/imgf000106_0003.png"><img id="imgf000106_0003" he="14" wi="71" file="imgf000106_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="284" height="56" alt="Figure imgf000106_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5e/0d/7a/117f6451c3ecd6/imgf000106_0003.png"/></a></div>
 </div>
    <div id="p0683" num="0683" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0684" num="0684" class="description-paragraph"> In one embodiment R<sup>1</sup> is: 

</div>
    <div id="p0685" num="0685" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/39/9b/5a2fa272d43746/imgf000107_0001.png"><img id="imgf000107_0001" he="67" wi="100" file="imgf000107_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="400" height="268" alt="Figure imgf000107_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/39/9b/5a2fa272d43746/imgf000107_0001.png"/></a></div>
    </div>
    <div id="p0686" num="0686" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/2b/62/08bf48cc0865d8/imgf000107_0002.png"><img id="imgf000107_0002" he="38" wi="129" file="imgf000107_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="516" height="152" alt="Figure imgf000107_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/2b/62/08bf48cc0865d8/imgf000107_0002.png"/></a></div>
    </div>
    <div id="p0687" num="0687" class="description-paragraph"> wherein G is -NH- or -0-; </div>
    <div id="p0688" num="0688" class="description-paragraph"> R<sup>c</sup> is hydrogen, (Ci-C<sub>8</sub>)alkyl, (Ci-C<sub>8</sub>)haloalkyl, (Ci-C<sub>8</sub>)alkoxy, (Ci-C<sub>6</sub>)alkanoyl, (C<sub>3</sub>- C2o)cycloalkyl, (C -C2o)heterocycle, aryl, heteroaryl, monosaccharide, disaccharide or trisacchande; and wherein the cycloalkyl, heterocyle, ary, heteroaryl and saccharide are optionally substituted with one or more groups independently selected from the group consisting of halo, carboxyl, hydroxyl, amino, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)alkoxy and (Ci- C4)haloalkoxy; </div>
    <div id="p0689" num="0689" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0690" num="0690" class="description-paragraph"> In one embodiment R<sup>c</sup> is: </div>
    <div id="p0691" num="0691" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/4d/42/35fff29224202c/imgf000107_0003.png"><img id="imgf000107_0003" he="41" wi="28" file="imgf000107_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="112" height="164" alt="Figure imgf000107_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/4d/42/35fff29224202c/imgf000107_0003.png"/></a></div>
    </div>
    <div id="p0692" num="0692" class="description-paragraph"> In one embodiment R is: 

</div>
    <div id="p0693" num="0693" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6c/36/ee/953b70f2634685/imgf000108_0001.png"><img id="imgf000108_0001" he="222" wi="156" file="imgf000108_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="624" height="888" alt="Figure imgf000108_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6c/36/ee/953b70f2634685/imgf000108_0001.png"/></a></div>
    </div>
    <div id="p0694" num="0694" class="description-paragraph">107 

 wherein each R is independently selected from the group consisting of hydrogen, (Ci- C<sub>6</sub>)alkyl, (C<sub>9</sub>-C<sub>2</sub>o)alkylsilyl, (R<sup>w</sup>)<sub>3</sub>Si-, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, tetrahydropyranyl, (Ci-C<sub>6</sub>)alkanoyl, benzoyl, aryl(Ci-C<sub>3</sub>)alkyl, TMTr (Trimethoxytrityl), DMTr (Dimethoxytrityl), MMTr </div>
    <div id="p0695" num="0695" class="description-paragraph">(Monomethoxytrityl), and Tr (Trityl); and </div>
    <div id="p0696" num="0696" class="description-paragraph"> each R<sup>w</sup> is independently selected from the group consisting of (Ci-C4)alkyl and aryl.</div>
    <div id="p0697" num="0697" class="description-paragraph">In one embodiment linking groups L<sup>1</sup> and L<sup>2</sup> are independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 50 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -0-, -NR<sup>X</sup>-, -NR<sup>x</sup>-C(=0)-, -C(=0)- R<sup>x</sup>- or -S-, and wherein R<sup>x</sup>is hydrogen or (Ci-C6)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from (Ci-C6)alkoxy, (C3-C6)cycloalkyl, (Ci- C6)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-C6)alkoxycarbonyl, (Ci-C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0698" num="0698" class="description-paragraph"> In one embodiment L<sup>1</sup> and L<sup>2</sup> are independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 20 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by - 0-, -NR<sup>X</sup>-, - R<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup>is hydrogen or (Ci-C<sub>6</sub>)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from (Ci-Cs)alkoxy, (C3-Ce)cycloalkyl, (Ci-C6)alkanoyl, (Ci- C6)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, (Ci-Ce)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0699" num="0699" class="description-paragraph"> In one embodiment L<sup>1</sup> and L<sup>2</sup> are independently, a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 14 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced -0-, -NR<sup>X</sup>-, - R -C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (Ci-C<sub>6</sub>)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from (Ci-C6)alkoxy, (C3-Ce)cycloalkyl, (Ci-C6)alkanoyl, (Ci- C6)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, (Ci-C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0700" num="0700" class="description-paragraph"> In one embodiment L<sup>1</sup> is connected to R<sup>1</sup> through -NH-, -0-, -S-, -(C=0)-, -(C=0)-NH-,</div>
    <div id="p0701" num="0701" class="description-paragraph">-NH-(C=0)-, -(C=0)-0-, -NH-(C=0)-NH-, or -NH-(S0<sub>2</sub>)-. </div>
    <div id="p0702" num="0702" class="description-paragraph"> In one embodiment L<sup>2</sup> is connected to R<sup>2</sup> through -0-. </div>
    <div id="p0703" num="0703" class="description-paragraph"> In one embodiment L<sup>1</sup> is selected from the group consisting of: 

</div>
    <div id="p0704" num="0704" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/5b/6c/6bca786260109f/imgf000110_0001.png"><img id="imgf000110_0001" he="60" wi="150" file="imgf000110_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="600" height="240" alt="Figure imgf000110_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/5b/6c/6bca786260109f/imgf000110_0001.png"/></a></div>
    </div>
    <div id="p0705" num="0705" class="description-paragraph">In one embodiment L<sup>1</sup> is selected from the group consisting of: </div>
    <div id="p0706" num="0706" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/79/8c/34/8cf056aa222cb9/imgf000110_0002.png"><img id="imgf000110_0002" he="105" wi="150" file="imgf000110_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="420" alt="Figure imgf000110_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/79/8c/34/8cf056aa222cb9/imgf000110_0002.png"/></a></div>
    </div>
    <div id="p0707" num="0707" class="description-paragraph"> wherein: each D is independently selected from the group consisting of C= and -N=; or a salt thereof. </div>
    <div id="p0708" num="0708" class="description-paragraph"> In one embodiment a compound of formula la is selected from the group consisting 

</div>
    <div id="p0709" num="0709" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/95/d1/9f619db836968c/imgf000111_0001.png"><img id="imgf000111_0001" he="105" wi="153" file="imgf000111_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="612" height="420" alt="Figure imgf000111_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8d/95/d1/9f619db836968c/imgf000111_0001.png"/></a></div>
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/2e/51/880829ba67041a/imgf000111_0002.png"><img id="imgf000111_0002" he="19" wi="154" file="imgf000111_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="76" alt="Figure imgf000111_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/2e/51/880829ba67041a/imgf000111_0002.png"/></a></div>
    </div>
    <div id="p0710" num="0710" class="description-paragraph"> wherein: </div>
    <div id="p0711" num="0711" class="description-paragraph"> Q<sup>1</sup> is hydrogen and Q<sup>2</sup> is R<sup>2</sup>; or Q<sup>1</sup> is R<sup>2</sup> and Q<sup>2</sup> is hydrogen; </div>
    <div id="p0712" num="0712" class="description-paragraph"> Z is -I^-R<sup>1</sup>; </div>
    <div id="p0713" num="0713" class="description-paragraph"> and salts thereof. </div>
    <div id="p0714" num="0714" class="description-paragraph"> In one embodiment a co lowing formula lb : 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/36/f6/fb/d948811a535ee2/imgf000111_0003.png"><img id="imgf000111_0003" he="24" wi="52" file="imgf000111_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="208" height="96" alt="Figure imgf000111_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/36/f6/fb/d948811a535ee2/imgf000111_0003.png"/></a></div>
 </div>
    <div id="p0715" num="0715" class="description-paragraph"> (lb) </div>
    <div id="p0716" num="0716" class="description-paragraph"> wherein: each D is independently selected from the group consisting of C I - and -N=; </div>
    <div id="p0717" num="0717" class="description-paragraph"> each m is independently 1 or 2; </div>
    <div id="p0718" num="0718" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0719" num="0719" class="description-paragraph"> In one embodiment a compound of formula lb is selected from the group consisting of: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9e/be/eb/4999548d792b9f/imgf000112_0001.png"><img id="imgf000112_0001" he="26" wi="122" file="imgf000112_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="488" height="104" alt="Figure imgf000112_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9e/be/eb/4999548d792b9f/imgf000112_0001.png"/></a></div>
 wherein: </div>
    <div id="p0720" num="0720" class="description-paragraph"> Q<sup>1</sup> is hydrogen and Q<sup>2</sup> is R<sup>2</sup>; or Q<sup>1</sup> is R<sup>2</sup> and Q<sup>2</sup> is hydrogen; </div>
    <div id="p0721" num="0721" class="description-paragraph">Z is -V-R<sup>1</sup>; </div>
    <div id="p0722" num="0722" class="description-paragraph">and salts thereof. </div>
    <div id="p0723" num="0723" class="description-paragraph"> In one embodiment a compound of formula I has the following formula (Ic): </div>
    <div id="p0724" num="0724" class="description-paragraph"> (R<sup>A</sup> </div>
    <div id="p0725" num="0725" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/79/fe/0899d8b0722b4c/imgf000112_0002.png"><img id="imgf000112_0002" he="29" wi="32" file="imgf000112_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="128" height="116" alt="Figure imgf000112_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/84/79/fe/0899d8b0722b4c/imgf000112_0002.png"/></a></div>
    </div>
    <div id="p0726" num="0726" class="description-paragraph"> (Ic) </div>
    <div id="p0727" num="0727" class="description-paragraph">Wherein E is -O- or -CH<sub>2</sub>-; </div>
    <div id="p0728" num="0728" class="description-paragraph">n is selected from the group consisting of 0, 1, 2, 3, and 4; and </div>
    <div id="p0729" num="0729" class="description-paragraph">nl and n2 are each independently selected from the group consisting of 0, 1, 2, and 3; or a salt thereof. </div>
    <div id="p0730" num="0730" class="description-paragraph"> In certain embodiments a compound of formula (Ic) is selected from the group consisting </div>
    <div id="p0731" num="0731" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8a/b5/5e/eebf780704738c/imgf000112_0003.png"><img id="imgf000112_0003" he="52" wi="131" file="imgf000112_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="524" height="208" alt="Figure imgf000112_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8a/b5/5e/eebf780704738c/imgf000112_0003.png"/></a></div>
    </div>
    <div id="p0732" num="0732" class="description-paragraph">wherein Z is -I^-R<sup>1</sup>; </div>
    <div id="p0733" num="0733" class="description-paragraph">and salts thereof. </div>
    <div id="p0734" num="0734" class="description-paragraph">I l l 

 In one embodiment the -A-L<sup>2</sup>-R<sup>2</sup> moiet is: </div>
    <div id="p0735" num="0735" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/99/e3/67c46a4da3b6e7/imgf000113_0001.png"><img id="imgf000113_0001" he="26" wi="104" file="imgf000113_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="416" height="104" alt="Figure imgf000113_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/99/e3/67c46a4da3b6e7/imgf000113_0001.png"/></a></div>
    </div>
    <div id="p0736" num="0736" class="description-paragraph"> wherein: </div>
    <div id="p0737" num="0737" class="description-paragraph"> Q<sup>1</sup> is hydrogen and Q<sup>2</sup> is R<sup>2</sup>; or Q<sup>1</sup> is R<sup>2</sup> and Q<sup>2</sup> is hydrogen; and </div>
    <div id="p0738" num="0738" class="description-paragraph"> each q is independently 0, 1, 2, 3, 4 or 5; </div>
    <div id="p0739" num="0739" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0740" num="0740" class="description-paragraph"> In one embodiment R<sup>2</sup> is an oligonucleotide. </div>
    <div id="p0741" num="0741" class="description-paragraph"> In one embodiment R<sup>2</sup> is an siRNA. </div>
    <div id="p0742" num="0742" class="description-paragraph"> In one embodiment a compound of formula (I) is selected from the group consisting of: </div>
    <div id="p0743" num="0743" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/bd/e1/4ba58032cdd791/imgf000113_0002.png"><img id="imgf000113_0002" he="58" wi="154" file="imgf000113_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="232" alt="Figure imgf000113_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/95/bd/e1/4ba58032cdd791/imgf000113_0002.png"/></a></div>
      
    </div>
    <div id="p0744" num="0744" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/ab/5f/c404eaa268708e/imgf000114_0001.png"><img id="imgf000114_0001" he="188" wi="153" file="imgf000114_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="612" height="752" alt="Figure imgf000114_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/ab/5f/c404eaa268708e/imgf000114_0001.png"/></a></div>
    </div>
    <div id="p0745" num="0745" class="description-paragraph">113 

</div>
    <div id="p0746" num="0746" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7c/ca/ef/d7a5eb6bcf33b4/imgf000115_0001.png"><img id="imgf000115_0001" he="153" wi="131" file="imgf000115_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="524" height="612" alt="Figure imgf000115_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7c/ca/ef/d7a5eb6bcf33b4/imgf000115_0001.png"/></a></div>
    </div>
    <div id="p0747" num="0747" class="description-paragraph"> n is 2, 3, or 4; </div>
    <div id="p0748" num="0748" class="description-paragraph"> x is 1 or 2. </div>
    <div id="p0749" num="0749" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/16/d9/46ce0a6ec067bd/imgf000115_0002.png"><img id="imgf000115_0002" he="58" wi="144" file="imgf000115_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="576" height="232" alt="Figure imgf000115_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/16/d9/46ce0a6ec067bd/imgf000115_0002.png"/></a></div>
    </div>
    <div id="p0750" num="0750" class="description-paragraph"> In one embodiment L<sup>1</sup> is selected from the group consisting of: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0c/61/80/708f27d3ae7afe/imgf000116_0001.png"><img id="imgf000116_0001" he="52" wi="131" file="imgf000116_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="524" height="208" alt="Figure imgf000116_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0c/61/80/708f27d3ae7afe/imgf000116_0001.png"/></a></div>
 </div>
    <div id="p0751" num="0751" class="description-paragraph"> In one embodiment A is absent, phenyl, pyrrolidinyl, or cyclopentyl. </div>
    <div id="p0752" num="0752" class="description-paragraph"> In one embodiment L<sup>2</sup> is Ci-4 alkylene-O- that is optionally substituted with hydroxy.</div>
    <div id="p0753" num="0753" class="description-paragraph">In one embodiment L<sup>2</sup> is -CH<sub>2</sub>0-, -CH<sub>2</sub>CH<sub>2</sub>0-, or -CH(OH)CH<sub>2</sub>0-. </div>
    <div id="p0754" num="0754" class="description-paragraph"> In one embodiment each R<sup>A</sup> is independently hydroxy or Ci-8 alkyl that is optionally substituted with hydroxyl. </div>
    <div id="p0755" num="0755" class="description-paragraph"> In one embodiment each R<sup>A</sup> is independently selected from the group consisting of hydroxy, methyl and -CH2OH. </div>
    <div id="p0756" num="0756" class="description-paragraph"> In one embodiment a compound of formula I has the following formula (Ig): </div>
    <div id="p0757" num="0757" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/61/5f/c8/21e692c9e0b795/imgf000116_0002.png"><img id="imgf000116_0002" he="32" wi="28" file="imgf000116_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="112" height="128" alt="Figure imgf000116_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/61/5f/c8/21e692c9e0b795/imgf000116_0002.png"/></a></div>
    </div>
    <div id="p0758" num="0758" class="description-paragraph">(ig) </div>
    <div id="p0759" num="0759" class="description-paragraph"> wherein B is -N- or -CH-; </div>
    <div id="p0760" num="0760" class="description-paragraph"> L<sup>1</sup> is absent or -NH-; </div>
    <div id="p0761" num="0761" class="description-paragraph"> L<sup>2</sup> is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or hal </div>
    <div id="p0762" num="0762" class="description-paragraph"> n is 0, 1, or 2; </div>
    <div id="p0763" num="0763" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0764" num="0764" class="description-paragraph"> In one embodiment a compound of formula I has the following formula </div>
    <div id="p0765" num="0765" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/7d/2e/f91ff1843b92fe/imgf000116_0003.png"><img id="imgf000116_0003" he="33" wi="28" file="imgf000116_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="112" height="132" alt="Figure imgf000116_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/7d/2e/f91ff1843b92fe/imgf000116_0003.png"/></a></div>
 (Ig) </div>
    <div id="p0766" num="0766" class="description-paragraph"> wherein B is -N- or -CH-; </div>
    <div id="p0767" num="0767" class="description-paragraph"> L<sup>1</sup> is absent or -NH-; </div>
    <div id="p0768" num="0768" class="description-paragraph"> L<sup>2</sup> is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo; </div>
    <div id="p0769" num="0769" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, or 7; </div>
    <div id="p0770" num="0770" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0771" num="0771" class="description-paragraph"> In one embodiment a compound of formula I has the following formula (Ig): </div>
    <div id="p0772" num="0772" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/b3/6e/c15b20e2d84e62/imgf000117_0001.png"><img id="imgf000117_0001" he="32" wi="27" file="imgf000117_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="108" height="128" alt="Figure imgf000117_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/b3/6e/c15b20e2d84e62/imgf000117_0001.png"/></a></div>
    </div>
    <div id="p0773" num="0773" class="description-paragraph">(ig) </div>
    <div id="p0774" num="0774" class="description-paragraph"> wherein B is -N- or -CH-; </div>
    <div id="p0775" num="0775" class="description-paragraph"> L<sup>1</sup> is absent or -NH-; </div>
    <div id="p0776" num="0776" class="description-paragraph"> L<sup>2</sup> is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo; </div>
    <div id="p0777" num="0777" class="description-paragraph"> n is 0, 1, 2, 3, or 4; </div>
    <div id="p0778" num="0778" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0779" num="0779" class="description-paragraph"> In one embodiment a compound of formula Ig is selected from the group consisting </div>
    <div id="p0780" num="0780" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6e/13/09/c6acd7010e33a1/imgf000117_0002.png"><img id="imgf000117_0002" he="66" wi="122" file="imgf000117_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="488" height="264" alt="Figure imgf000117_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6e/13/09/c6acd7010e33a1/imgf000117_0002.png"/></a></div>
    </div>
    <div id="p0781" num="0781" class="description-paragraph"> wherein R&#39; is C1-9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the C1.9 alkyl, C2-9 alkenyl 2-9 alkynyl are optionally substituted with halo or hydroxyl; </div>
    <div id="p0782" num="0782" class="description-paragraph"> and salts thereof. </div>
    <div id="p0783" num="0783" class="description-paragraph"> In one embodiment a compound of formula I is selected from the group consisting of: 

</div>
    <div id="p0784" num="0784" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/52/28/ebf5336a1a91df/imgf000118_0001.png"><img id="imgf000118_0001" he="75" wi="144" file="imgf000118_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="576" height="300" alt="Figure imgf000118_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/06/52/28/ebf5336a1a91df/imgf000118_0001.png"/></a></div>
    </div>
    <div id="p0785" num="0785" class="description-paragraph">and salts thereof. </div>
    <div id="p0786" num="0786" class="description-paragraph"> In one embodiment the compound of formula I or the salt thereof is selected from the group consisting of: </div>
    <div id="p0787" num="0787" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fe/f1/07/7383f0f921ceb3/imgf000118_0002.png"><img id="imgf000118_0002" he="105" wi="118" file="imgf000118_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="472" height="420" alt="Figure imgf000118_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fe/f1/07/7383f0f921ceb3/imgf000118_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/21/d9/aa34c65ed9d84a/imgf000119_0001.png"><img id="imgf000119_0001" he="40" wi="142" file="imgf000119_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="568" height="160" alt="Figure imgf000119_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/55/21/d9/aa34c65ed9d84a/imgf000119_0001.png"/></a></div>
    </div>
    <div id="p0788" num="0788" class="description-paragraph"> OH </div>
    <div id="p0789" num="0789" class="description-paragraph"> 173 Â° Â°-<sup>0li</sup>9Â° 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/69/f8/a8/d92d89f40edf8a/imgf000119_0002.png"><img id="imgf000119_0002" he="21" wi="133" file="imgf000119_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="84" alt="Figure imgf000119_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/69/f8/a8/d92d89f40edf8a/imgf000119_0002.png"/></a></div>
 </div>
    <div id="p0790" num="0790" class="description-paragraph"> 176 </div>
    <div id="p0791" num="0791" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/f7/58/90845fa5c5fe39/imgf000119_0003.png"><img id="imgf000119_0003" he="84" wi="143" file="imgf000119_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="572" height="336" alt="Figure imgf000119_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/f7/58/90845fa5c5fe39/imgf000119_0003.png"/></a></div>
      
    </div>
    <div id="p0792" num="0792" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/87/25/61e90d1e4921bc/imgf000120_0001.png"><img id="imgf000120_0001" he="192" wi="119" file="imgf000120_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="476" height="768" alt="Figure imgf000120_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9b/87/25/61e90d1e4921bc/imgf000120_0001.png"/></a></div>
      
    </div>
    <div id="p0793" num="0793" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/1a/b9/ecd2550edfa461/imgf000121_0001.png"><img id="imgf000121_0001" he="202" wi="132" file="imgf000121_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="528" height="808" alt="Figure imgf000121_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/1a/b9/ecd2550edfa461/imgf000121_0001.png"/></a></div>
    </div>
    <div id="p0794" num="0794" class="description-paragraph">120 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/f4/f0/2bf7dfb96407ca/imgf000122_0001.png"><img id="imgf000122_0001" he="207" wi="136" file="imgf000122_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="544" height="828" alt="Figure imgf000122_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/f4/f0/2bf7dfb96407ca/imgf000122_0001.png"/></a></div>
 </div>
    <div id="p0795" num="0795" class="description-paragraph">or pharmaceutically acceptable salts thereof. </div>
    <div id="p0796" num="0796" class="description-paragraph"> In certain embodiments, the oligonucleotide is an siRNA molecule. Thus, in one embodiment the compound of formula (I) is, 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/56/c6/7e/028775dd9f8989/imgf000123_0001.png"><img id="imgf000123_0001" he="64" wi="88" file="imgf000123_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="352" height="256" alt="Figure imgf000123_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/56/c6/7e/028775dd9f8989/imgf000123_0001.png"/></a></div>
 </div>
    <div id="p0797" num="0797" class="description-paragraph"> that is optionally associated with a counter cation. </div>
    <div id="p0798" num="0798" class="description-paragraph"> In one embodiment the conjugate is selected from the group of conjugates shown in the following table, wherein R<sup>2</sup> is the modified HBV siRNA shown and is attached through the oxygen of a phosphate at the 3 &#39;-end of the sense strand. </div>
    <div id="p0799" num="0799" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5e/72/5b/837aca3885e6a4/imgf000123_0002.png"><img id="imgf000123_0002" he="140" wi="179" file="imgf000123_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="716" height="560" alt="Figure imgf000123_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5e/72/5b/837aca3885e6a4/imgf000123_0002.png"/></a></div>
 Antisense </div>
    <div id="p0800" num="0800" class="description-paragraph"> Sense </div>
    <div id="p0801" num="0801" class="description-paragraph"> Formula siR A Sense strand strand Antisense strand </div>
    <div id="p0802" num="0802" class="description-paragraph"> strand SEQ </div>
    <div id="p0803" num="0803" class="description-paragraph"> (I) Number 5&#39; - 3&#39; SEQ ID 5 &#39;-3&#39; </div>
    <div id="p0804" num="0804" class="description-paragraph"> ID NO NO </div>
    <div id="p0805" num="0805" class="description-paragraph"> 215 134 223 ususuaCuAgUGCcaUuuguuca 224 us GsAaCaAauGgcaCuAgUaAas csu</div>
    <div id="p0806" num="0806" class="description-paragraph">236 103 161 usgs caCUUcgcuucaccu 162 as Gs gugaagcgaagUgCacas cs gU</div>
    <div id="p0807" num="0807" class="description-paragraph">236 114 183 cscsguguGcACUucgcuuCacc 184 gsGsugaAgCgaaguGcAcacGgsus cUU</div>
    <div id="p0808" num="0808" class="description-paragraph">236 120 195 cscsguguGcACUucgcuucaca 196 usGsugaAgCGaaguGcAcacggsus cUU</div>
    <div id="p0809" num="0809" class="description-paragraph">236 125 205 gsus gcACUucgcuucaca 206 us GsugaagcgaaguGcAcacsgs gU</div>
    <div id="p0810" num="0810" class="description-paragraph">236 134 223 ususuaCuAgUGCcaUuuguuca 224 us GsAaCaAauGgcaCuAgUaAas csu</div>
    <div id="p0811" num="0811" class="description-paragraph">2&#39;-0-Methyl nucleotides = lower case; 2&#39;-Fluoro nucleotides = UPPER CASE; </div>
    <div id="p0812" num="0812" class="description-paragraph"> Phosphor othioate linker = s; Unmodified = UPPER CASE </div>
    <div id="p0813" num="0813" class="description-paragraph"> In one embodiment a compo nd of formula I has the following formula (Id): </div>
    <div id="p0814" num="0814" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dc/8d/3a/f7268af5dc52db/imgf000124_0001.png"><img id="imgf000124_0001" he="25" wi="52" file="imgf000124_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="208" height="100" alt="Figure imgf000124_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dc/8d/3a/f7268af5dc52db/imgf000124_0001.png"/></a></div>
    </div>
    <div id="p0815" num="0815" class="description-paragraph"> (Id) </div>
    <div id="p0816" num="0816" class="description-paragraph"> wherein: </div>
    <div id="p0817" num="0817" class="description-paragraph"> R is selected from: </div>
    <div id="p0818" num="0818" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/be/1a/8c/918bbf5411086e/imgf000124_0002.png"><img id="imgf000124_0002" he="68" wi="101" file="imgf000124_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="404" height="272" alt="Figure imgf000124_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/be/1a/8c/918bbf5411086e/imgf000124_0002.png"/></a></div>
 and 

</div>
    <div id="p0819" num="0819" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/24/4e/8ed97a13deca89/imgf000125_0001.png"><img id="imgf000125_0001" he="72" wi="114" file="imgf000125_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="456" height="288" alt="Figure imgf000125_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/24/4e/8ed97a13deca89/imgf000125_0001.png"/></a></div>
    </div>
    <div id="p0820" num="0820" class="description-paragraph">X<sup>d</sup> is C2-10 alkylene; </div>
    <div id="p0821" num="0821" class="description-paragraph"> N<sup>d</sup>isOor 1; </div>
    <div id="p0822" num="0822" class="description-paragraph"> R<sup>2d</sup> is a nucleic acid; and</div>
    <div id="p0823" num="0823" class="description-paragraph">R<sup>3d</sup> is H. </div>
    <div id="p0824" num="0824" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1b/7f/95/f3d26290833214/imgf000125_0002.png"><img id="imgf000125_0002" he="74" wi="93" file="imgf000125_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="372" height="296" alt="Figure imgf000125_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1b/7f/95/f3d26290833214/imgf000125_0002.png"/></a></div>
    </div>
    <div id="p0825" num="0825" class="description-paragraph"> In one embodiment R is: 


<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/3a/47/a0b833115e67e1/imgf000126_0001.png"><img id="imgf000126_0001" he="64" wi="102" file="imgf000126_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="408" height="256" alt="Figure imgf000126_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/3a/47/a0b833115e67e1/imgf000126_0001.png"/></a></div>
 </div>
    <div id="p0826" num="0826" class="description-paragraph"> In one embodiment X<sup>d</sup> is Csalkylene. </div>
    <div id="p0827" num="0827" class="description-paragraph"> In one embodiment n<sup>d</sup> is 0. </div>
    <div id="p0828" num="0828" class="description-paragraph"> In one embodiment R<sup>2d</sup> is an siRNA. </div>
    <div id="p0829" num="0829" class="description-paragraph"> In another embodiment a compound of (Id) or the salt thereof is selected from the group consisting of: </div>
    <div id="p0830" num="0830" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/24/e9/6e/c39f91143af546/imgf000126_0002.png"><img id="imgf000126_0002" he="45" wi="118" file="imgf000126_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="472" height="180" alt="Figure imgf000126_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/24/e9/6e/c39f91143af546/imgf000126_0002.png"/></a></div>
      
    </div>
    <div id="p0831" num="0831" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/57/23/796c7d661e0276/imgf000127_0001.png"><img id="imgf000127_0001" he="109" wi="135" file="imgf000127_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="540" height="436" alt="Figure imgf000127_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/57/23/796c7d661e0276/imgf000127_0001.png"/></a></div>
    </div>
    <div id="p0832" num="0832" class="description-paragraph">and salts thereof. </div>
    <div id="p0833" num="0833" class="description-paragraph"> In one embodiment the compound is not a compound formula Id: </div>
    <div id="p0834" num="0834" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c7/45/02/cf19a96aa3f44f/imgf000127_0002.png"><img id="imgf000127_0002" he="25" wi="52" file="imgf000127_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="208" height="100" alt="Figure imgf000127_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c7/45/02/cf19a96aa3f44f/imgf000127_0002.png"/></a></div>
    </div>
    <div id="p0835" num="0835" class="description-paragraph"> (Id) </div>
    <div id="p0836" num="0836" class="description-paragraph">or a salt thereof, wherein: </div>
    <div id="p0837" num="0837" class="description-paragraph"> R<sup>ld</sup> is selected from: 

</div>
    <div id="p0838" num="0838" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/f2/8a/329465a79cf762/imgf000128_0001.png"><img id="imgf000128_0001" he="143" wi="107" file="imgf000128_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="428" height="572" alt="Figure imgf000128_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/f2/8a/329465a79cf762/imgf000128_0001.png"/></a></div>
    </div>
    <div id="p0839" num="0839" class="description-paragraph"> X<sup>d</sup> is C2-10 alkylene; </div>
    <div id="p0840" num="0840" class="description-paragraph"> N<sup>d</sup>isOor 1; </div>
    <div id="p0841" num="0841" class="description-paragraph"> R<sup>2d</sup> is an oligonucleotide; and </div>
    <div id="p0842" num="0842" class="description-paragraph"> R<sup>3d</sup> is H. </div>
    <div id="p0843" num="0843" class="description-paragraph"> In one embodiment the compound is a compound of formula (Ig): </div>
    <div id="p0844" num="0844" class="description-paragraph"> (R<sup>A</sup>)n </div>
    <div id="p0845" num="0845" class="description-paragraph">I </div>
    <div id="p0846" num="0846" class="description-paragraph"> L<sup>1</sup> </div>
    <div id="p0847" num="0847" class="description-paragraph"> R<sup>1</sup> </div>
    <div id="p0848" num="0848" class="description-paragraph"> (Ig) </div>
    <div id="p0849" num="0849" class="description-paragraph">wherein: 

 B is -N- or -CH-; </div>
    <div id="p0850" num="0850" class="description-paragraph"> L<sup>2</sup> is Ci-4 alkylene-O- that is optionally substituted with hydroxyl or halo; and n is 0, 1, 2, 3, 4, 5, 6, or 7; </div>
    <div id="p0851" num="0851" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0852" num="0852" class="description-paragraph"> In one embodiment the compound is a compound selected from the group consisting of: </div>
    <div id="p0853" num="0853" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/13/b2/ba/5ef87d2ebf56bb/imgf000129_0001.png"><img id="imgf000129_0001" he="62" wi="119" file="imgf000129_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="476" height="248" alt="Figure imgf000129_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/13/b2/ba/5ef87d2ebf56bb/imgf000129_0001.png"/></a></div>
    </div>
    <div id="p0854" num="0854" class="description-paragraph">wherein: </div>
    <div id="p0855" num="0855" class="description-paragraph"> Q is -V-R<sup>1</sup>; and </div>
    <div id="p0856" num="0856" class="description-paragraph"> R&#39; is Ci-9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the C1-9 alkyl, C2-9 alkenyl or C2-9 alkynyl are optionally substituted with halo or hydroxyl; </div>
    <div id="p0857" num="0857" class="description-paragraph"> and salts thereof. </div>
    <div id="p0858" num="0858" class="description-paragraph"> In one embodiment the compound is a compound selected from the group consisting of: </div>
    <div id="p0859" num="0859" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/17/25/e3/d03df2effd9094/imgf000129_0002.png"><img id="imgf000129_0002" he="70" wi="133" file="imgf000129_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="280" alt="Figure imgf000129_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/17/25/e3/d03df2effd9094/imgf000129_0002.png"/></a></div>
    </div>
    <div id="p0860" num="0860" class="description-paragraph">wherein: Q is -I^-R<sup>1</sup>; and salts thereof. </div>
    <div id="p0861" num="0861" class="description-paragraph"> In one embodiment L<sup>1</sup> is a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 5 to 20 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of 

 the carbon atoms in the hydrocarbon chain is optionally replaced -0-, - H-, -NH-C(=0)-, - C(=0)-NH- or -S-. </div>
    <div id="p0862" num="0862" class="description-paragraph"> In one embodiment the compound is a compound of formula (XX): 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/ca/5d/ba6d8909d4aa2b/imgf000130_0001.png"><img id="imgf000130_0001" he="8" wi="46" file="imgf000130_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="184" height="32" alt="Figure imgf000130_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/ca/5d/ba6d8909d4aa2b/imgf000130_0001.png"/></a></div>
 </div>
    <div id="p0863" num="0863" class="description-paragraph"> (XX) </div>
    <div id="p0864" num="0864" class="description-paragraph">wherein: </div>
    <div id="p0865" num="0865" class="description-paragraph"> R<sup>1</sup> a is targeting ligand; </div>
    <div id="p0866" num="0866" class="description-paragraph"> L<sup>1</sup> is absent or a linking group; </div>
    <div id="p0867" num="0867" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p0868" num="0868" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; </div>
    <div id="p0869" num="0869" class="description-paragraph"> B is divalent and is selected from the group consisting </div>
    <div id="p0870" num="0870" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/59/39/f4d44a0735c47f/imgf000130_0002.png"><img id="imgf000130_0002" he="124" wi="154" file="imgf000130_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="496" alt="Figure imgf000130_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/59/39/f4d44a0735c47f/imgf000130_0002.png"/></a></div>
 wherein: </div>
    <div id="p0871" num="0871" class="description-paragraph"> each R&#39; is independently C1.9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the Ci-9 alkyl, C2-9 alkenyl or C2-9 alkynyl are optionally substituted with halo or hydroxyl; 

 the valence marked with * is attached to L<sup>1</sup> or is attached to R<sup>1</sup> if L<sup>1</sup> is absent; and the valence marked with ** is attached to L<sup>2</sup> or is attached to R<sup>2</sup> if L<sup>2</sup> is absent; </div>
    <div id="p0872" num="0872" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0873" num="0873" class="description-paragraph"> In one embodiment, the oligonucleotide is an siRNA molecule. Thus, one embodiment of the invention, the compound is a compound of formula (XX), </div>
    <div id="p0874" num="0874" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/2a/ba/7e2d17b45aded1/imgf000131_0001.png"><img id="imgf000131_0001" he="65" wi="90" file="imgf000131_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="360" height="260" alt="Figure imgf000131_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/2a/ba/7e2d17b45aded1/imgf000131_0001.png"/></a></div>
    </div>
    <div id="p0875" num="0875" class="description-paragraph">that is optionally associated with a counter cation. </div>
    <div id="p0876" num="0876" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 2-8 saccharides. </div>
    <div id="p0877" num="0877" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 2-6 saccharides. </div>
    <div id="p0878" num="0878" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 2-4 saccharides. </div>
    <div id="p0879" num="0879" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 3-8 saccharides. </div>
    <div id="p0880" num="0880" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 3-6 saccharides. </div>
    <div id="p0881" num="0881" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 3-4 saccharides. </div>
    <div id="p0882" num="0882" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 3 saccharides. </div>
    <div id="p0883" num="0883" class="description-paragraph"> In one embodiment R<sup>1</sup> comprises 4 saccharides. </div>
    <div id="p0884" num="0884" class="description-paragraph"> In one embodiment R<sup>1</sup> has the following formula: </div>
    <div id="p0885" num="0885" class="description-paragraph">ccharide 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/a1/b3/ed488a4424af65/imgf000131_0002.png"><img id="imgf000131_0002" he="46" wi="56" file="imgf000131_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="224" height="184" alt="Figure imgf000131_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/a1/b3/ed488a4424af65/imgf000131_0002.png"/></a></div>
 h id &#39; </div>
    <div id="p0886" num="0886" class="description-paragraph">wherein: 

 B<sup>1</sup> is a trivalent group comprising about 1 to about 20 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0887" num="0887" class="description-paragraph"> B<sup>2</sup> is a trivalent group comprising about 1 to about 20 atoms and is covalently bonded to T<sup>1</sup>, T<sup>3</sup>, and T<sup>4</sup>; </div>
    <div id="p0888" num="0888" class="description-paragraph"> B<sup>3</sup> is a trivalent group comprising about 1 to about 20 atoms and is covalently bonded to T<sup>2</sup>, T<sup>5</sup>, and T<sup>6</sup>; </div>
    <div id="p0889" num="0889" class="description-paragraph"> T<sup>1</sup> is absent or a linking group; </div>
    <div id="p0890" num="0890" class="description-paragraph"> T<sup>2</sup> is absent or a linking group; </div>
    <div id="p0891" num="0891" class="description-paragraph"> T<sup>3</sup> is absent or a linking group; </div>
    <div id="p0892" num="0892" class="description-paragraph"> T<sup>4</sup> is absent or a linking group; </div>
    <div id="p0893" num="0893" class="description-paragraph"> T<sup>5</sup> is absent or a linking group; and </div>
    <div id="p0894" num="0894" class="description-paragraph"> T<sup>6</sup> is absent or a linking group </div>
    <div id="p0895" num="0895" class="description-paragraph"> In one embodiment each saccharide is independently selected from: </div>
    <div id="p0896" num="0896" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b0/5d/51/92ab567d6866b4/imgf000132_0001.png"><img id="imgf000132_0001" he="25" wi="28" file="imgf000132_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="112" height="100" alt="Figure imgf000132_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b0/5d/51/92ab567d6866b4/imgf000132_0001.png"/></a></div>
    </div>
    <div id="p0897" num="0897" class="description-paragraph"> wherein: </div>
    <div id="p0898" num="0898" class="description-paragraph"> X is R<sup>3</sup>, and Y is selected from -(C=0)R<sup>4</sup>, -S0<sub>2</sub>R<sup>5</sup>, and -(C=0)NR<sup>6</sup>R<sup>7</sup>; or X is -(C=0)- and Y is NR<sup>8</sup>R<sup>9</sup>; </div>
    <div id="p0899" num="0899" class="description-paragraph"> R<sup>3</sup> is hydrogen or (Ci-C4)alkyl; </div>
    <div id="p0900" num="0900" class="description-paragraph"> R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> , R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of hydrogen, (Ci-Cs)alkyl, (Ci-Cg)haloalkyl, (Ci-Cs)alkoxy and (C3-C6)cycloalkyl that is optionally substituted with one or more groups independently selected from the group consisting of halo, (Ci-C<sub>4</sub>)alkyl, (Ci-C<sub>4</sub>)haloalkyl, (Ci-C<sub>4</sub>)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy; </div>
    <div id="p0901" num="0901" class="description-paragraph"> R<sup>10</sup> is -OH, - R<sup>8</sup>R<sup>9</sup> or - F; and </div>
    <div id="p0902" num="0902" class="description-paragraph"> R<sup>11</sup> is -OH, - R<sup>8</sup>R<sup>9</sup>, -F or 5 membered heterocycle that is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxyl, carboxyl, amino, (Ci-C<sub>4</sub>)alkyl, (Ci-C<sub>4</sub>)haloalkyl, (Ci-C<sub>4</sub>)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy. </div>
    <div id="p0903" num="0903" class="description-paragraph"> In one embodiment each saccharide is independently selected from the group consisting of: 

</div>
    <div id="p0904" num="0904" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/7a/a3/f1d429037da197/imgf000133_0001.png"><img id="imgf000133_0001" he="56" wi="151" file="imgf000133_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="604" height="224" alt="Figure imgf000133_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/7a/a3/f1d429037da197/imgf000133_0001.png"/></a></div>
    </div>
    <div id="p0905" num="0905" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/42/ee/ac0ba014950d46/imgf000133_0002.png"><img id="imgf000133_0002" he="24" wi="80" file="imgf000133_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="320" height="96" alt="Figure imgf000133_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/42/ee/ac0ba014950d46/imgf000133_0002.png"/></a></div>
    </div>
    <div id="p0906" num="0906" class="description-paragraph"> In one embodiment one of T<sup>1</sup> and T<sup>2</sup> is absent. </div>
    <div id="p0907" num="0907" class="description-paragraph"> In one embodiment both T<sup>1</sup> and T<sup>2</sup> are absent. </div>
    <div id="p0908" num="0908" class="description-paragraph"> In one embodiment each of T<sup>1</sup>, T<sup>2</sup>, T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently absent or a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 50 carbon atoms, wherein one or more (e.g. 1 , 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -0-, - R<sup>X</sup>-, -NR<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (C l -C6)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1 , 2, 3, or 4) substituents selected from (C 1 -C6)alkoxy, (C3- C6)cycloalkyl, (C l -C6)alkanoyl, (C l -C6)alkanoyloxy, (C l -C6)alkoxycarbonyl, (Cl - C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0909" num="0909" class="description-paragraph"> In one embodiment each of T<sup>1</sup>, T<sup>2</sup>, T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently absent or a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 20 carbon atoms, wherein one or more (e.g. 1 , 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -0-, - R<sup>X</sup>-, -NR<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (C l -C6)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1 , 2, 3, or 4) substituents selected from (C l -C6)alkoxy, (C3- C6)cycloalkyl, (C l -C6)alkanoyl, (C l -C6)alkanoyloxy, (C l -C6)alkoxycarbonyl, (Cl - 

 C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0910" num="0910" class="description-paragraph"> In one embodiment each of T<sup>1</sup>, T<sup>2</sup>, T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently absent or a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 50 carbon atoms, or a salt thereof, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -O- or -NR<sup>X</sup>-, and wherein R<sup>x</sup> is hydrogen or (Ci- C<sub>6</sub>)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from halo, hydroxy, and oxo (=0). </div>
    <div id="p0911" num="0911" class="description-paragraph"> In one embodiment each of T<sup>1</sup>, T<sup>2</sup>, T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently absent or a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 20 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -O- and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from halo, hydroxy, and oxo (=0). </div>
    <div id="p0912" num="0912" class="description-paragraph"> In one embodiment each of T<sup>1</sup>, T<sup>2</sup>, T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently absent or a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 20 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by -O- and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from halo, hydroxy, and oxo (=0). </div>
    <div id="p0913" num="0913" class="description-paragraph"> In one embodiment at least one of T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/44/dc/6a3f833b14e303/imgf000134_0001.png"><img id="imgf000134_0001" he="10" wi="38" file="imgf000134_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="152" height="40" alt="Figure imgf000134_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/44/dc/6a3f833b14e303/imgf000134_0001.png"/></a></div>
 </div>
    <div id="p0914" num="0914" class="description-paragraph"> wherein: </div>
    <div id="p0915" num="0915" class="description-paragraph"> n = l, 2, 3. </div>
    <div id="p0916" num="0916" class="description-paragraph"> In one embodiment each of T<sup>3</sup>, T<sup>4</sup>, T<sup>5</sup>, and T<sup>6</sup> is independently selected from the group consisting of: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/34/f5/2d/d3d450f50bd4b6/imgf000134_0002.png"><img id="imgf000134_0002" he="10" wi="39" file="imgf000134_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="156" height="40" alt="Figure imgf000134_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/34/f5/2d/d3d450f50bd4b6/imgf000134_0002.png"/></a></div>
 </div>
    <div id="p0917" num="0917" class="description-paragraph"> wherein: </div>
    <div id="p0918" num="0918" class="description-paragraph"> n = l, 2, 3. </div>
    <div id="p0919" num="0919" class="description-paragraph"> In one embodiment at least one of T<sup>1</sup> and T<sup>2</sup> is glycine </div>
    <div id="p0920" num="0920" class="description-paragraph"> In one embodiment each of T<sup>1</sup> and T<sup>2</sup> is glycine. </div>
    <div id="p0921" num="0921" class="description-paragraph"> In one embodiment B<sup>1</sup> is a trivalent group comprising 1 to 15 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. 

 In one embodiment B is a trivalent group comprising 1 to 10 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0922" num="0922" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a (Ci-C6)alkyl. </div>
    <div id="p0923" num="0923" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a C3-8 cycloalkyl. </div>
    <div id="p0924" num="0924" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a silyl group. </div>
    <div id="p0925" num="0925" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a D- or L-amino acid. </div>
    <div id="p0926" num="0926" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a saccharide. </div>
    <div id="p0927" num="0927" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a phosphate group. </div>
    <div id="p0928" num="0928" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a phosphonate group. </div>
    <div id="p0929" num="0929" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises an aryl. </div>
    <div id="p0930" num="0930" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a phenyl ring. </div>
    <div id="p0931" num="0931" class="description-paragraph"> In one embodiment B<sup>1</sup> is a phenyl ring. </div>
    <div id="p0932" num="0932" class="description-paragraph"> In one embodiment B<sup>1</sup> is CH. </div>
    <div id="p0933" num="0933" class="description-paragraph"> In one embodiment B<sup>1</sup> comprises a heteroaryl. </div>
    <div id="p0934" num="0934" class="description-paragraph"> In one embodiment B<sup>1</sup> is selected from the rou consistin of: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/02/ec/a9e788ec107c50/imgf000135_0001.png"><img id="imgf000135_0001" he="18" wi="107" file="imgf000135_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="428" height="72" alt="Figure imgf000135_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/02/ec/a9e788ec107c50/imgf000135_0001.png"/></a></div>
 </div>
    <div id="p0935" num="0935" class="description-paragraph">In one embodiment B is selected from the group consisting of: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/24/b8/cf/8e8bb14f611d6d/imgf000135_0002.png"><img id="imgf000135_0002" he="22" wi="108" file="imgf000135_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="432" height="88" alt="Figure imgf000135_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/24/b8/cf/8e8bb14f611d6d/imgf000135_0002.png"/></a></div>
 </div>
    <div id="p0936" num="0936" class="description-paragraph">In one embodiment B<sup>2</sup> is a trivalent group comprising 1 to 15 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0937" num="0937" class="description-paragraph"> In one embodiment B<sup>2</sup> is a trivalent group comprising 1 to 10 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0938" num="0938" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a (Ci-C6)alkyl </div>
    <div id="p0939" num="0939" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a C3-8 cycloalkyl. </div>
    <div id="p0940" num="0940" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a silyl group. </div>
    <div id="p0941" num="0941" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a D- or L-amino acid. </div>
    <div id="p0942" num="0942" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a saccharide. 

 In one embodiment B<sup>2</sup> comprises a phosphate group. </div>
    <div id="p0943" num="0943" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a phosphonate group. </div>
    <div id="p0944" num="0944" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises an aryl. </div>
    <div id="p0945" num="0945" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a phenyl ring. </div>
    <div id="p0946" num="0946" class="description-paragraph"> In one embodiment B<sup>2</sup> is a phenyl ring. </div>
    <div id="p0947" num="0947" class="description-paragraph"> In one embodiment B<sup>2</sup> is CH. </div>
    <div id="p0948" num="0948" class="description-paragraph"> In one embodiment B<sup>2</sup> comprises a heteroaryl. </div>
    <div id="p0949" num="0949" class="description-paragraph"> In one embodiment B<sup>2</sup> is selected from the group consisting of: </div>
    <div id="p0950" num="0950" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/3d/aa/a0f138c2025b7c/imgf000136_0001.png"><img id="imgf000136_0001" he="27" wi="134" file="imgf000136_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="536" height="108" alt="Figure imgf000136_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/3d/aa/a0f138c2025b7c/imgf000136_0001.png"/></a></div>
    </div>
    <div id="p0951" num="0951" class="description-paragraph">In one embodiment B<sup>2</sup> is selected from the group consisting of: </div>
    <div id="p0952" num="0952" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a8/e2/08/0afd2f2b8ff6e7/imgf000136_0002.png"><img id="imgf000136_0002" he="31" wi="136" file="imgf000136_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="544" height="124" alt="Figure imgf000136_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a8/e2/08/0afd2f2b8ff6e7/imgf000136_0002.png"/></a></div>
    </div>
    <div id="p0953" num="0953" class="description-paragraph">In one embodiment B<sup>3</sup> is a trivalent group comprising 1 to 15 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0954" num="0954" class="description-paragraph"> In one embodiment B<sup>3</sup> is a trivalent group comprising 1 to 10 atoms and is covalently bonded to L<sup>1</sup>, T<sup>1</sup>, and T<sup>2</sup>. </div>
    <div id="p0955" num="0955" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a (Ci-C<sub>6</sub>)alkyl. </div>
    <div id="p0956" num="0956" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a C3-8 cycloalkyl. </div>
    <div id="p0957" num="0957" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a silyl group. </div>
    <div id="p0958" num="0958" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a D- or L-amino acid </div>
    <div id="p0959" num="0959" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a saccharide. </div>
    <div id="p0960" num="0960" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a phosphate group. </div>
    <div id="p0961" num="0961" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a phosphonate group. </div>
    <div id="p0962" num="0962" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises an aryl. </div>
    <div id="p0963" num="0963" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a phenyl ring. 

 In one embodiment B<sup>3</sup> is a phenyl ring. </div>
    <div id="p0964" num="0964" class="description-paragraph"> In one embodiment B<sup>3</sup> is CH. </div>
    <div id="p0965" num="0965" class="description-paragraph"> In one embodiment B<sup>3</sup> comprises a heteroaryl. </div>
    <div id="p0966" num="0966" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/bf/2b/21787d9a4075e1/imgf000137_0001.png"><img id="imgf000137_0001" he="84" wi="135" file="imgf000137_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="540" height="336" alt="Figure imgf000137_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/bf/2b/21787d9a4075e1/imgf000137_0001.png"/></a></div>
    </div>
    <div id="p0967" num="0967" class="description-paragraph"> or a salt thereof. </div>
    <div id="p0968" num="0968" class="description-paragraph"> In one embodiment L<sup>1</sup> and L<sup>2</sup> are independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 50 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by - 0-, -NR<sup>X</sup>-, - R<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (Cl-C6)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents selected from (Cl-C6)alkoxy, (C3-C6)cycloalkyl, (Cl-C6)alkanoyl, (Cl-</div>
    <div id="p0969" num="0969" class="description-paragraph">C6)alkanoyloxy, (Cl-C6)alkoxycarbonyl, (Cl-C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p0970" num="0970" class="description-paragraph"> In one emb iment L<sup>1</sup> is selected from the group consisting of: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/54/b5/015233a8217412/imgf000137_0002.png"><img id="imgf000137_0002" he="13" wi="92" file="imgf000137_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="368" height="52" alt="Figure imgf000137_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/54/b5/015233a8217412/imgf000137_0002.png"/></a></div>
 </div>
    <div id="p0971" num="0971" class="description-paragraph">or a salt thereof. </div>
    <div id="p0972" num="0972" class="description-paragraph"> In one embodiment L<sup>1</sup> is connected to B<sup>1</sup> through a linkage selected from the group consisting of: -0-, -S-, -(C=0)-, -(C=0)-NH-, -NH-(C=0), -(C=0)-0-, -NH-(C=0)-NH-, or - NH-(S0<sub>2</sub>)-. </div>
    <div id="p0973" num="0973" class="description-paragraph"> In one embodiment L<sup>1</sup> is selected from the group consisting of: 


<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2f/ff/b2/35e6525c1d2cc2/imgf000138_0001.png"><img id="imgf000138_0001" he="52" wi="143" file="imgf000138_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="572" height="208" alt="Figure imgf000138_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2f/ff/b2/35e6525c1d2cc2/imgf000138_0001.png"/></a></div>
 </div>
    <div id="p0974" num="0974" class="description-paragraph"> In one embodiment L<sup>2</sup> is connected to R<sup>2</sup> through -0-. </div>
    <div id="p0975" num="0975" class="description-paragraph"> In one embodiment L<sup>2</sup> is Ci alkylene-O- that is optionally substituted with hydroxy. In one embodiment L<sup>2</sup> is connected to R<sup>2</sup> through -0-. </div>
    <div id="p0976" num="0976" class="description-paragraph"> In one embodiment L<sup>2</sup> is absent. </div>
    <div id="p0977" num="0977" class="description-paragraph"> In one embodiment the compound is a compound or salt selected from the group consisting of: </div>
    <div id="p0978" num="0978" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4b/8f/bc/ef02dce1a83a2c/imgf000138_0002.png"><img id="imgf000138_0002" he="124" wi="119" file="imgf000138_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="476" height="496" alt="Figure imgf000138_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4b/8f/bc/ef02dce1a83a2c/imgf000138_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/a9/57/03f0427897e2c1/imgf000139_0001.png"><img id="imgf000139_0001" he="195" wi="133" file="imgf000139_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="780" alt="Figure imgf000139_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/a9/57/03f0427897e2c1/imgf000139_0001.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/fd/a6/a46227550fc5c8/imgf000140_0001.png"><img id="imgf000140_0001" he="206" wi="134" file="imgf000140_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="536" height="824" alt="Figure imgf000140_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/fd/a6/a46227550fc5c8/imgf000140_0001.png"/></a></div>
    </div>
    <div id="p0979" num="0979" class="description-paragraph">and pharmaceutically acceptable salts thereof. </div>
    <div id="p0980" num="0980" class="description-paragraph"> In one embodiment the compound is: 

</div>
    <div id="p0981" num="0981" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/99/f2/4e/d7c03f8c5fb930/imgf000141_0001.png"><img id="imgf000141_0001" he="114" wi="137" file="imgf000141_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="548" height="456" alt="Figure imgf000141_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/99/f2/4e/d7c03f8c5fb930/imgf000141_0001.png"/></a></div>
    </div>
    <div id="p0982" num="0982" class="description-paragraph">or a salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein. </div>
    <div id="p0983" num="0983" class="description-paragraph"> In one embodiment the compound is z conjugate of Formula X: </div>
    <div id="p0984" num="0984" class="description-paragraph"> A-B-C </div>
    <div id="p0985" num="0985" class="description-paragraph"> (X) </div>
    <div id="p0986" num="0986" class="description-paragraph">wherein A is a targeting ligand; </div>
    <div id="p0987" num="0987" class="description-paragraph">B is an optional linker; and </div>
    <div id="p0988" num="0988" class="description-paragraph">C is an siRNA molecule described herein. </div>
    <div id="p0989" num="0989" class="description-paragraph"> In one embodiment, the compound is a compound of formula: 

</div>
    <div id="p0990" num="0990" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/e9/17/c94b3c468d91a9/imgf000142_0001.png"><img id="imgf000142_0001" he="70" wi="129" file="imgf000142_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="516" height="280" alt="Figure imgf000142_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/e9/17/c94b3c468d91a9/imgf000142_0001.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p0991" num="0991" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p0992" num="0992" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/82/1c/d6/bc19bd6c562ebf/imgf000142_0002.png"><img id="imgf000142_0002" he="70" wi="128" file="imgf000142_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="512" height="280" alt="Figure imgf000142_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/82/1c/d6/bc19bd6c562ebf/imgf000142_0002.png"/></a></div>
    </div>
    <div id="p0993" num="0993" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p0994" num="0994" class="description-paragraph"> In one embodiment the compound is a compound of formula: 

</div>
    <div id="p0995" num="0995" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/20/22/29694c34fc0d48/imgf000143_0001.png"><img id="imgf000143_0001" he="70" wi="129" file="imgf000143_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="516" height="280" alt="Figure imgf000143_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/20/22/29694c34fc0d48/imgf000143_0001.png"/></a></div>
    </div>
    <div id="p0996" num="0996" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p0997" num="0997" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p0998" num="0998" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cf/91/39/e4df8434e4003c/imgf000143_0002.png"><img id="imgf000143_0002" he="70" wi="128" file="imgf000143_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="512" height="280" alt="Figure imgf000143_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cf/91/39/e4df8434e4003c/imgf000143_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p0999" num="0999" class="description-paragraph"> In one embodiment, the compound is a compound of formula: 

</div>
    <div id="p1000" num="1000" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/89/79/8817a0427e8f42/imgf000144_0001.png"><img id="imgf000144_0001" he="70" wi="127" file="imgf000144_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="508" height="280" alt="Figure imgf000144_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/89/79/8817a0427e8f42/imgf000144_0001.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1001" num="1001" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p1002" num="1002" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c9/1c/c4/9adbe9c6b9a324/imgf000144_0002.png"><img id="imgf000144_0002" he="70" wi="146" file="imgf000144_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="584" height="280" alt="Figure imgf000144_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c9/1c/c4/9adbe9c6b9a324/imgf000144_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1003" num="1003" class="description-paragraph"> In one embodiment, the compound is a compound of formula: 

</div>
    <div id="p1004" num="1004" class="description-paragraph">
      <span class="patent-image-not-available"></span>
    </div>
    <div id="p1005" num="1005" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1006" num="1006" class="description-paragraph"> In one embodiment the compound is a compound of formula: </div>
    <div id="p1007" num="1007" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/e6/b1/99d281a98a0898/imgf000145_0002.png"><img id="imgf000145_0002" he="81" wi="142" file="imgf000145_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="568" height="324" alt="Figure imgf000145_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/e6/b1/99d281a98a0898/imgf000145_0002.png"/></a></div>
    </div>
    <div id="p1008" num="1008" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B) </div>
    <div id="p1009" num="1009" class="description-paragraph"> In one embodiment the compound is a compound of formula: 

</div>
    <div id="p1010" num="1010" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/36/ba/46658e5017c9f2/imgf000146_0001.png"><img id="imgf000146_0001" he="82" wi="142" file="imgf000146_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="568" height="328" alt="Figure imgf000146_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/36/ba/46658e5017c9f2/imgf000146_0001.png"/></a></div>
    </div>
    <div id="p1011" num="1011" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1012" num="1012" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p1013" num="1013" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/66/0e/3d757fd50eb823/imgf000146_0002.png"><img id="imgf000146_0002" he="70" wi="147" file="imgf000146_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="588" height="280" alt="Figure imgf000146_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/66/0e/3d757fd50eb823/imgf000146_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1014" num="1014" class="description-paragraph"> In one embodiment the compound is a compound of formula: 

</div>
    <div id="p1015" num="1015" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/3e/4c/1ae855fd69cece/imgf000147_0001.png"><img id="imgf000147_0001" he="82" wi="154" file="imgf000147_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="328" alt="Figure imgf000147_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/3e/4c/1ae855fd69cece/imgf000147_0001.png"/></a></div>
    </div>
    <div id="p1016" num="1016" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1017" num="1017" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p1018" num="1018" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/0c/e4/57691992ad361b/imgf000147_0002.png"><img id="imgf000147_0002" he="82" wi="154" file="imgf000147_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="328" alt="Figure imgf000147_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/0c/e4/57691992ad361b/imgf000147_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1019" num="1019" class="description-paragraph"> In one embodiment, the compound is a compound of formula: 

</div>
    <div id="p1020" num="1020" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/7e/d0/c80ecfbcc0e68b/imgf000148_0001.png"><img id="imgf000148_0001" he="82" wi="154" file="imgf000148_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="328" alt="Figure imgf000148_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/7e/d0/c80ecfbcc0e68b/imgf000148_0001.png"/></a></div>
    </div>
    <div id="p1021" num="1021" class="description-paragraph">or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is a double stranded siRNA molecule selected from the double stranded siRNA molecules described herein (e.g., in Tables A or B). </div>
    <div id="p1022" num="1022" class="description-paragraph"> In one embodiment, the compound is a compound of formula: and 162) </div>
    <div id="p1023" num="1023" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/58/3d/e6/19fc1fdb8dd42b/imgf000148_0002.png"><img id="imgf000148_0002" he="103" wi="147" file="imgf000148_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="588" height="412" alt="Figure imgf000148_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/58/3d/e6/19fc1fdb8dd42b/imgf000148_0002.png"/></a></div>
    </div>
    <div id="p1024" num="1024" class="description-paragraph">or a pharmaceutically acceptable salt thereof. 

 In one embodiment the compound is a compound of formula: siRNA 125 (SEQ ID NO:205 and 206) </div>
    <div id="p1025" num="1025" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/11/49/7f239e49ab42d7/imgf000149_0001.png"><img id="imgf000149_0001" he="102" wi="147" file="imgf000149_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="588" height="408" alt="Figure imgf000149_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/11/49/7f239e49ab42d7/imgf000149_0001.png"/></a></div>
    </div>
    <div id="p1026" num="1026" class="description-paragraph">or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1027" num="1027" class="description-paragraph"> In one embodiment the compound is a compound of formula: 

</div>
    <div id="p1028" num="1028" class="description-paragraph">siRNA 103 (SEQ ID NO:161 and 162) </div>
    <div id="p1029" num="1029" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cd/58/c9/eaca890e0a9d01/imgf000150_0001.png"><img id="imgf000150_0001" he="107" wi="154" file="imgf000150_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="428" alt="Figure imgf000150_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cd/58/c9/eaca890e0a9d01/imgf000150_0001.png"/></a></div>
    </div>
    <div id="p1030" num="1030" class="description-paragraph">or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1031" num="1031" class="description-paragraph"> In one embodiment the compound is a compound of formula: </div>
    <div id="p1032" num="1032" class="description-paragraph"> SiRNA 125 (SEQ ID NO:205 and 206) </div>
    <div id="p1033" num="1033" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e5/2e/69/4aa8bcf5a1c2f2/imgf000150_0002.png"><img id="imgf000150_0002" he="101" wi="145" file="imgf000150_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="580" height="404" alt="Figure imgf000150_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e5/2e/69/4aa8bcf5a1c2f2/imgf000150_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1034" num="1034" class="description-paragraph"> In one embodiment the compound is a compound of formula: </div>
    <div id="p1035" num="1035" class="description-paragraph"> 162) </div>
    <div id="p1036" num="1036" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e7/27/46/1288e75acbb619/imgf000151_0001.png"><img id="imgf000151_0001" he="99" wi="104" file="imgf000151_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="416" height="396" alt="Figure imgf000151_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e7/27/46/1288e75acbb619/imgf000151_0001.png"/></a></div>
    </div>
    <div id="p1037" num="1037" class="description-paragraph">or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1038" num="1038" class="description-paragraph"> In one embodiment the compound is a compound of formula: 

</div>
    <div id="p1039" num="1039" class="description-paragraph">siRNA 125 (SEQ ID NO:205 and 206) </div>
    <div id="p1040" num="1040" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/09/40/83/17f0c8a5d7631a/imgf000152_0001.png"><img id="imgf000152_0001" he="103" wi="110" file="imgf000152_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="440" height="412" alt="Figure imgf000152_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/09/40/83/17f0c8a5d7631a/imgf000152_0001.png"/></a></div>
    </div>
    <div id="p1041" num="1041" class="description-paragraph">rmaceutically acceptable salt thereof. </div>
    <div id="p1042" num="1042" class="description-paragraph"> In one embodiment the compound is a compound of formula: </div>
    <div id="p1043" num="1043" class="description-paragraph"> siRNA 103 (SEQ ID N0:161 and 162) </div>
    <div id="p1044" num="1044" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d7/8c/57/c83dcbaad7045b/imgf000152_0002.png"><img id="imgf000152_0002" he="100" wi="106" file="imgf000152_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="424" height="400" alt="Figure imgf000152_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d7/8c/57/c83dcbaad7045b/imgf000152_0002.png"/></a></div>
 or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1045" num="1045" class="description-paragraph"> In one embodiment, the compound is a compound of formula: </div>
    <div id="p1046" num="1046" class="description-paragraph"> 206) </div>
    <div id="p1047" num="1047" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/2d/8f/24e12f8041485a/imgf000153_0001.png"><img id="imgf000153_0001" he="99" wi="105" file="imgf000153_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="420" height="396" alt="Figure imgf000153_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/2d/8f/24e12f8041485a/imgf000153_0001.png"/></a></div>
    </div>
    <div id="p1048" num="1048" class="description-paragraph">or a pharmaceutically acceptable salt thereof. </div>
    <div id="p1049" num="1049" class="description-paragraph"> In one embodiment the compound is a compound of formula (I): </div>
    <div id="p1050" num="1050" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/36/fd/e98045de20634b/imgf000153_0002.png"><img id="imgf000153_0002" he="82" wi="154" file="imgf000153_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="328" alt="Figure imgf000153_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/36/fd/e98045de20634b/imgf000153_0002.png"/></a></div>
    </div>
    <div id="p1051" num="1051" class="description-paragraph"> (I) </div>
    <div id="p1052" num="1052" class="description-paragraph">wherein: 

 L<sup>1</sup> is absent or a linking group; </div>
    <div id="p1053" num="1053" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p1054" num="1054" class="description-paragraph"> R<sup>2</sup> is a nucleic acid; </div>
    <div id="p1055" num="1055" class="description-paragraph"> the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
    <div id="p1056" num="1056" class="description-paragraph"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup>, Ci-io alkyl C2-io alkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
    <div id="p1057" num="1057" class="description-paragraph"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
    <div id="p1058" num="1058" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; </div>
    <div id="p1059" num="1059" class="description-paragraph"> or a salt thereof. </div>
    <div id="p1060" num="1060" class="description-paragraph"> embodiment the compound is a compound of formula (Ih): </div>
    <div id="p1061" num="1061" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ee/db/22/b36f77564b0469/imgf000154_0001.png"><img id="imgf000154_0001" he="86" wi="154" file="imgf000154_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="344" alt="Figure imgf000154_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ee/db/22/b36f77564b0469/imgf000154_0001.png"/></a></div>
 wherein: </div>
    <div id="p1062" num="1062" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p1063" num="1063" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; </div>
    <div id="p1064" num="1064" class="description-paragraph"> the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
    <div id="p1065" num="1065" class="description-paragraph"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup>, Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl 

 C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
    <div id="p1066" num="1066" class="description-paragraph"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
    <div id="p1067" num="1067" class="description-paragraph"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; </div>
    <div id="p1068" num="1068" class="description-paragraph"> or a salt thereof. </div>
    <div id="p1069" num="1069" class="description-paragraph"> In one embodiment the compound is a compound of formula (II): </div>
    <div id="p1070" num="1070" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/0f/f5/a88bc8d3af25b3/imgf000155_0001.png"><img id="imgf000155_0001" he="86" wi="154" file="imgf000155_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="344" alt="Figure imgf000155_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/0f/f5/a88bc8d3af25b3/imgf000155_0001.png"/></a></div>
 wherein: </div>
    <div id="p1071" num="1071" class="description-paragraph"> L<sup>1</sup> is absent or a linking group; </div>
    <div id="p1072" num="1072" class="description-paragraph"> L<sup>2</sup> is absent or a linking group; </div>
    <div id="p1073" num="1073" class="description-paragraph"> R<sup>2</sup> is an oligonucleotide; </div>
    <div id="p1074" num="1074" class="description-paragraph"> B is divalent and is selected from the group consisting of: </div>
    <div id="p1075" num="1075" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/96/3d/05/144edd4ddf2431/imgf000155_0002.png"><img id="imgf000155_0002" he="27" wi="154" file="imgf000155_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="108" alt="Figure imgf000155_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/96/3d/05/144edd4ddf2431/imgf000155_0002.png"/></a></div>
      
    </div>
    <div id="p1076" num="1076" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6a/86/c9/57df055b9a16fc/imgf000156_0001.png"><img id="imgf000156_0001" he="92" wi="152" file="imgf000156_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="608" height="368" alt="Figure imgf000156_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6a/86/c9/57df055b9a16fc/imgf000156_0001.png"/></a></div>
    </div>
    <div id="p1077" num="1077" class="description-paragraph">wherein: </div>
    <div id="p1078" num="1078" class="description-paragraph"> each R&#39; is independently C1.9 alkyl, C2-9 alkenyl or C2-9 alkynyl; wherein the C1-9 alkyl,</div>
    <div id="p1079" num="1079" class="description-paragraph">C2-9 alkenyl or C2-9 alkynyl are optionally substituted with halo or hydroxyl; </div>
    <div id="p1080" num="1080" class="description-paragraph"> the valence marked with * is attached to L<sup>1</sup> or is attached to R<sup>1</sup> if L<sup>1</sup> is absent; and the valence marked with ** is attached to L<sup>2</sup> or is attached to R<sup>2</sup> if L<sup>2</sup> is absent; </div>
    <div id="p1081" num="1081" class="description-paragraph"> or a salt thereof. </div>
    <div id="p1082" num="1082" class="description-paragraph"> In one embodiment L<sup>1</sup> and L<sup>2</sup> are independently a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 50 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms in the hydrocarbon chain is optionally replaced by - 0-, -NR<sup>X</sup>-, - R<sup>x</sup>-C(=0)-, -C(=0)-NR<sup>x</sup>- or -S-, and wherein R<sup>x</sup> is hydrogen or (Cl-C6)alkyl, and wherein the hydrocarbon chain, is optionally substituted with one or more substituents selected from (Cl-C6)alkoxy, (C3-C6)cycloalkyl, (Cl-C6)alkanoyl, (Cl-C6)alkanoyloxy, (Cl- C6)alkoxycarbonyl, (Cl -C6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy. </div>
    <div id="p1083" num="1083" class="description-paragraph"> In one embodiment the compound is: 

</div>
    <div id="p1084" num="1084" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f5/e6/3f/52268271c46147/imgf000157_0001.png"><img id="imgf000157_0001" he="84" wi="156" file="imgf000157_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="624" height="336" alt="Figure imgf000157_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f5/e6/3f/52268271c46147/imgf000157_0001.png"/></a></div>
    </div>
    <div id="p1085" num="1085" class="description-paragraph"> or a salt thereof wherein R<sup>2</sup> is an oligonucleotide. </div>
    <div id="p1086" num="1086" class="description-paragraph"> In one embodiment, n is 2, 3, 4, 5 or 6. </div>
    <div id="p1087" num="1087" class="description-paragraph"> In one embodiment R<sup>2</sup> is attached through the oxygen of a phosphate at the 3 &#39;-end of the sense strand. </div>
    <div id="p1088" num="1088" class="description-paragraph"> In one embodiment the compound is: </div>
    <div id="p1089" num="1089" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/8e/45/59f98f59942b18/imgf000157_0002.png"><img id="imgf000157_0002" he="85" wi="154" file="imgf000157_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="340" alt="Figure imgf000157_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/8e/45/59f98f59942b18/imgf000157_0002.png"/></a></div>
    </div>
    <div id="p1090" num="1090" class="description-paragraph">or a salt thereof wherein R<sup>2</sup> is a double stranded siRNA molecule as described in Table B that is attached through the oxygen of a phosphate at the 3 &#39;-end of the sense strand. </div>
    <div id="p1091" num="1091" class="description-paragraph"> In one embodiment the compound is: 


<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/e8/57/f6286f9c58c5b4/imgf000158_0001.png"><img id="imgf000158_0001" he="82" wi="154" file="imgf000158_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="328" alt="Figure imgf000158_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/e8/57/f6286f9c58c5b4/imgf000158_0001.png"/></a></div>
 </div>
    <div id="p1092" num="1092" class="description-paragraph"> a salt thereof wherein R<sup>2</sup> is a nucleic acid. </div>
    <div id="p1093" num="1093" class="description-paragraph"> In one embodiment the compound is: </div>
    <div id="p1094" num="1094" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/00/76/5b/d66734e1f6bf29/imgf000158_0002.png"><img id="imgf000158_0002" he="82" wi="154" file="imgf000158_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="328" alt="Figure imgf000158_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/00/76/5b/d66734e1f6bf29/imgf000158_0002.png"/></a></div>
 or a salt thereof wherein R<sup>2</sup> is a nucleic acid. </div>
    <div id="p1095" num="1095" class="description-paragraph"> In one embodiment the compound is: 

</div>
    <div id="p1096" num="1096" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/6d/63/793fbbdd936be2/imgf000159_0001.png"><img id="imgf000159_0001" he="82" wi="154" file="imgf000159_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="328" alt="Figure imgf000159_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/6d/63/793fbbdd936be2/imgf000159_0001.png"/></a></div>
    </div>
    <div id="p1097" num="1097" class="description-paragraph">Certain Definitions for Conjugate Embodiments </div>
    <div id="p1098" num="1098" class="description-paragraph"> The term &#34;synthetic activating group&#34; refers to a group that can be attached to an atom to activate that atom to allow it to form a covalent bond with another reactive group. It is understood that the nature of the synthetic activating group may depend on the atom that it is activating. For example, when the synthetic activating group is attached to an oxygen atom, the synthetic activating group is a group that will activate that oxygen atom to form a bond (e.g. an ester, carbamate, or ether bond) with another reactive group. Such synthetic activating groups are known. Examples of synthetic activating groups that can be attached to an oxygen atom include, but are not limited to, acetate, succinate, triflate, and mesylate. When the synthetic activating group is attached to an oxygen atom of a carboxylic acid, the synthetic activating group can be a group that is derivable from a known coupling reagent (e.g. a known amide coupling reagent). Such coupling reagents are known. Examples of such coupling reagents include, but are not limited to, Î,Î&#39;-Dicyclohexylcarbodimide (DCC), hydroxybenzotriazole (HOBt), N-(3-Dimethylaminopropyl)-N&#39;-ethylcarbonate (EDC), (Benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol-l-yl- oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) or O-benzotriazol-l-yl- Î,Î,Î&#39;,Î&#39;-tetramethyluronium hexafluorophosphate (HBTU). </div>
    <div id="p1099" num="1099" class="description-paragraph"> As used herein, the term &#34;alkyl&#34;, by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon 

 atoms designated (i.e., Ci-8 means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, and the like. The term &#34;alkenyl&#34; refers to an unsaturated alkyl radical having one or more double bonds. Similarly, the term &#34;alkynyl&#34; refers to an unsaturated alkyl radical having one or more triple bonds. Examples of such unsaturated alkyl groups include vinyl, 2- propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. </div>
    <div id="p1100" num="1100" class="description-paragraph"> The term &#34;alkylene&#34; by itself or as part of another substituent means a divalent radical derived from an alkane (including straight and branched alkanes), as exemplified by </div>
    <div id="p1101" num="1101" class="description-paragraph">-CH2CH2CH2CH2- and -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>-. </div>
    <div id="p1102" num="1102" class="description-paragraph"> The term &#34;cycloalkyl,&#34; &#34;carbocyclic,&#34; or &#34;carbocycle&#34; refers to hydrocarbon ringsystem having 3 to 20 overall number of ring atoms (e.g., 3-20 membered cycloalkyl is a cycloalkyl with 3 to 20 ring atoms, or C3-20 cycloalkyl is a cycloalkyl with 3-20 carbon ring atoms) and for a 3-5 membered cycloalkyl being fully saturated or having no more than one double bond between ring vertices and for a 6 membered cycloalkyl or larger being fully saturated or having no more than two double bonds between ring vertices. As used herein, &#34;cycloalkyl,&#34; </div>
    <div id="p1103" num="1103" class="description-paragraph">&#34;carbocyclic,&#34; or &#34;carbocycle&#34; is also meant to refer to bicyclic, polycyclic and spirocyclic hydrocarbon ring system, such as, for example, bicyclo[2.2.1]heptane, pinane, </div>
    <div id="p1104" num="1104" class="description-paragraph">bicyclo[2.2.2]octane, adamantane, norborene, spirocyclic C5-12 alkane, etc. As used herein, the terms, &#34;alkenyl,&#34; &#34;alkynyl,&#34; &#34;cycloalkyl,&#34;, &#34;carbocycle,&#34; and &#34;carbocyclic,&#34; are meant to include mono and polyhalogenated variants thereof. </div>
    <div id="p1105" num="1105" class="description-paragraph"> The term &#34;heterocycloalkyl,&#34; &#34;heterocyclic,&#34; or &#34;heterocycle&#34; refers to a saturated or partially unsaturated ring system radical having the overall having from 3-20 ring atoms (e.g., 3- 20 membered heterocycloalkyl is a heterocycloalkyl radical with 3-20 ring atoms, a C2-19 heterocycloalkyl is a heterocycloalkyl having 3-10 ring atoms with between 2-19 ring atoms being carbon) that contain from one to ten heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, nitrogen atom(s) are optionally quaternized, as ring atoms. Unless otherwise stated, a &#34;heterocycloalkyl,&#34; &#34;heterocyclic,&#34; or &#34;heterocycle&#34; ring can be a monocyclic, a bicyclic, spirocyclic or a polycylic ring system. Non limiting examples of &#34;heterocycloalkyl,&#34; &#34;heterocyclic,&#34; or &#34;heterocycle&#34; rings include pyrrolidine, piperidine, N-methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4(lH,3H)-dione, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrhydrothiophene, 

 quinuclidine, tropane, 2-azaspiro[3.3]heptane, (lR,5S)-3-azabicyclo[3.2.1]octane, (l s,4s)-2- azabicyclo[2.2.2]octane, (lR,4R)-2-oxa-5-azabicyclo[2.2.2]octane and the like A </div>
    <div id="p1106" num="1106" class="description-paragraph">&#34;heterocycloalkyl,&#34; &#34;heterocyclic,&#34; or &#34;heterocycle&#34; group can be attached to the remainder of the molecule through one or more ring carbons or heteroatoms. A &#34;heterocycloalkyl,&#34; </div>
    <div id="p1107" num="1107" class="description-paragraph">&#34;heterocyclic,&#34; or &#34;heterocycle&#34; can include mono- and poly-halogenated variants thereof. </div>
    <div id="p1108" num="1108" class="description-paragraph"> The terms &#34;alkoxy,&#34; and &#34;alkylthio&#34;, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom (&#34;oxy&#34;) or thio group, and further include mono- and poly-halogenated variants thereof. </div>
    <div id="p1109" num="1109" class="description-paragraph"> The terms &#34;halo&#34; or &#34;halogen,&#34; by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. The term &#34;(halo)alkyl&#34; is meant to include both a &#34;alkyl&#34; and &#34;haloalkyl&#34; substituent. Additionally, the term &#34;haloalkyl,&#34; is meant to include monohaloalkyl and polyhaloalkyl. For example, the term &#34;C haloalkyl&#34; is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, and the like. </div>
    <div id="p1110" num="1110" class="description-paragraph"> The term &#34;aryl&#34; means a carbocyclic aromatic group having 6-14 carbon atoms, whether or not fused to one or more groups. Examples of aryl groups include phenyl, naphthyl, biphenyl and the like unless otherwise stated. </div>
    <div id="p1111" num="1111" class="description-paragraph"> The term &#34;heteroaryl&#34; refers to aryl ring(s) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, </div>
    <div id="p1112" num="1112" class="description-paragraph">benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like. </div>
    <div id="p1113" num="1113" class="description-paragraph"> The term saccharide includes monosaccharides, disaccharides and trisaccharides. The term includes glucose, sucrose fructose, galactose and ribose, as well as deoxy sugars such as deoxyribose and amino sugar such as galactosamine. Saccharide derivatives can conveniently be prepared as described in International Patent Applications Publication Numbers WO </div>
    <div id="p1114" num="1114" class="description-paragraph">96/34005 and 97/03995. A saccharide can conveniently be linked to the remainder of a compound of formula I through an ether bond, a thioether bond (e.g. an S-glycoside), an amine 

 nitrogen (e.g., an N-glycoside ), or a carbon-carbon bond (e.g. a C-glycoside). In one embodiment the saccharide can conveniently be linked to the remainder of a compound of formula I through an ether bond. In one embodiment the term saccharide includes a group of the formula: </div>
    <div id="p1115" num="1115" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/66/20/67c0c5d050130e/imgf000162_0001.png"><img id="imgf000162_0001" he="25" wi="29" file="imgf000162_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="116" height="100" alt="Figure imgf000162_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/66/20/67c0c5d050130e/imgf000162_0001.png"/></a></div>
    </div>
    <div id="p1116" num="1116" class="description-paragraph"> wherein </div>
    <div id="p1117" num="1117" class="description-paragraph"> X is R<sup>3</sup>, and Y is selected from -(C=0)R<sup>4</sup>, -S0<sub>2</sub>R<sup>5</sup>, and -(C=0)NR<sup>6</sup>R<sup>7</sup>; or X is -(C=0&gt; and Y is NR<sup>8</sup>R<sup>9</sup>; </div>
    <div id="p1118" num="1118" class="description-paragraph"> R<sup>3</sup> is hydrogen or (Ci-C4)alkyl; </div>
    <div id="p1119" num="1119" class="description-paragraph"> R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> , R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of hydrogen, (Ci-Cs)alkyl, (Ci-Cg)haloalkyl, (Ci-Cg)alkoxy and (C3-Ce)cycloalkyl that is optionally substituted with one or more groups independently selected from the group consisting of halo, (Ci-C<sub>4</sub>)alkyl, (Ci-C<sub>4</sub>)haloalkyl, (Ci-C<sub>4</sub>)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy; </div>
    <div id="p1120" num="1120" class="description-paragraph"> R<sup>10</sup> is -OH, - R<sup>8</sup>R<sup>9</sup> or - F; and </div>
    <div id="p1121" num="1121" class="description-paragraph"> R<sup>11</sup> is -OH, - R<sup>8</sup>R<sup>9</sup>, -F or 5 membered heterocycle that is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxyl, carboxyl, amino, (Ci-C<sub>4</sub>)alkyl, (Ci-C<sub>4</sub>)haloalkyl, (Ci-C<sub>4</sub>)alkoxy and (Ci-C<sub>4</sub>)haloalkoxy. In another embodiment the saccharide can be selected from the group consisting of: </div>
    <div id="p1122" num="1122" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/1e/f9/75f7098429e1fc/imgf000162_0002.png"><img id="imgf000162_0002" he="56" wi="150" file="imgf000162_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="224" alt="Figure imgf000162_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/1e/f9/75f7098429e1fc/imgf000162_0002.png"/></a></div>
    </div>
    <div id="p1123" num="1123" class="description-paragraph"> In another embodiment the saccharide can be: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/34/55/d0c34ed89fc904/imgf000163_0001.png"><img id="imgf000163_0001" he="23" wi="80" file="imgf000163_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="320" height="92" alt="Figure imgf000163_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3c/34/55/d0c34ed89fc904/imgf000163_0001.png"/></a></div>
 </div>
    <div id="p1124" num="1124" class="description-paragraph"> N-Acetylgalactosamine (GalNAc) GalPro. </div>
    <div id="p1125" num="1125" class="description-paragraph">Formulation and Administration of Conjugates and/or Additional Therapeutic Agents</div>
    <div id="p1126" num="1126" class="description-paragraph">The agents (i.e., conjugates and additional therapeutic agents) can be formulated for and administered using any acceptable route of administration depending on the agent selected. For example, suitable routes include, but are not limited to, oral, sublingual, buccal, topical, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. </div>
    <div id="p1127" num="1127" class="description-paragraph"> When a combination of agents is administered, it will be understood that the agents can be formulated together in a single preparation or that they can be formulated separately and, thus, administered separately, either simultaneously or sequentially. In one embodiment, when the agents are administered sequentially (e.g. at different times), the agents may be administered so that their biological effects overlap (i.e. each agent is producing a biological effect at a single given time). </div>
    <div id="p1128" num="1128" class="description-paragraph"> The agents can be individually formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed. The pH of the formulation depends mainly on the particular use and the concentration of compound, but may typically range anywhere from about 3 to about 8. The agents ordinarily will be stored as a solid composition, although lyophilized formulations or aqueous solutions are acceptable. </div>
    <div id="p1129" num="1129" class="description-paragraph"> Compositions comprising the agents can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular human being treated, the clinical condition of the individual patient, the cause of the disorder, the site of administration, the method of administration, the scheduling of administration, and other factors known to medical practitioners </div>
    <div id="p1130" num="1130" class="description-paragraph"> The agents may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, 

 and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. </div>
    <div id="p1131" num="1131" class="description-paragraph"> Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel&#39; s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams &amp; Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams &amp; Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug or aid in the manufacturing of the pharmaceutical product (i.e., medicament). </div>
    <div id="p1132" num="1132" class="description-paragraph"> The agents are typically dosed at least at a level to reach the desired biological effect. Thus, an effective dosing regimen will dose at least a minimum amount that reaches the desired biological effect, or biologically effective dose, however, the dose should not be so high as to outweigh the benefit of the biological effect with unacceptable side effects. Therefore, an effective dosing regimen will dose no more than the maximum tolerated dose (&#34;MTD&#34;). The maximum tolerated dose is defined as the highest dose that produces an acceptable incidence of dose-limiting toxicities (&#34;DLT&#34;). Doses that cause an unacceptable rate of DLT are considered non-tolerated. Typically, the MTD for a particular schedule is established in phase 1 clinical trials. These are usually conducted in patients by starting at a safe starting dose of 1/10 the severe toxic dose (&#34;STD10&#34;) in rodents (on a mg/m^ basis) and accruing patients in cohorts of three, escalating the dose according to a modified Fibonacci sequence in which ever higher escalation steps have ever decreasing relative increments (e.g., dose increases of 100%, 65%, 50%, 40%, and 30% to 35% thereafter). The dose escalation is continued in cohorts of three patients until a non-tolerated dose is reached. The next lower dose level that produces an acceptable rate of DLT is considered to be the MTD. </div>
    <div id="p1133" num="1133" class="description-paragraph"> The amount of the agents administered will depend upon the particular agent used, the strain of HBV being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.2 to 2.0 grams per day. </div>
    <div id="p1134" num="1134" class="description-paragraph">Kits </div>
    <div id="p1135" num="1135" class="description-paragraph"> The present invention also provides kits comprising: </div>
    <div id="p1136" num="1136" class="description-paragraph"> a) an HBV antigen inhibitor; 

 b) instructions for administering the inhibitor to a hepatitis B virus (HBV) infected patient determined to have a C/C genotype at rsl2079860. </div>
    <div id="p1137" num="1137" class="description-paragraph"> In certain embodiments the HBV antigen inhibitor is an oligonucleotide (e.g., an siRNA). In certain embodiments, the oligonucleotide is comprised within a lipid nanoparticle formulation. Thus, the present invention also provides lipid particles in kit form. In some embodiments, the kit comprises a container which is compartmentalized for holding the various elements of the lipid particles (e.g., the active agents, such as siRNA molecules and the individual lipid components of the particles). Preferably, the kit comprises a container (e.g., a vial or ampoule) which holds the lipid particles of the invention, wherein the particles are produced by one of the processes set forth herein. In certain embodiments, the kit may further comprise an endosomal membrane destabilizer (e.g., calcium ions). The kit typically contains the particle compositions of the invention, either as a suspension in a pharmaceutically acceptable carrier or in dehydrated form, with instructions for their rehydration (if lyophilized) and administration. </div>
    <div id="p1138" num="1138" class="description-paragraph"> The formulations of the present invention can be tailored to preferentially target particular cells, tissues, or organs of interest. Preferential targeting of a nucleic acid-lipid particle may be carried out by controlling the composition of the lipid particle itself. In particular embodiments, the kits of the invention comprise these lipid particles, wherein the particles are present in a container as a suspension or in dehydrated form. </div>
    <div id="p1139" num="1139" class="description-paragraph"> In certain instances, it may be desirable to have a targeting moiety attached to the surface of the lipid particle to further enhance the targeting of the particle. Methods of attaching targeting moieties (e.g., antibodies, proteins, etc.) to lipids (such as those used in the present particles) are known to those of skill in the art. </div>
    <div id="p1140" num="1140" class="description-paragraph"> In certain embodiments, the HBV antigen inhibitor is conjugated to a targeting moiety. Thus, the present invention also provides conjugates described herein in kit form. </div>
    <div id="p1141" num="1141" class="description-paragraph">Examples </div>
    <div id="p1142" num="1142" class="description-paragraph"> The present invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. 

 Example 1. Synthesis of coniugate 1 </div>
    <div id="p1143" num="1143" class="description-paragraph"> Scheme 1. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/14/b2/62bd753713fd1a/imgf000166_0001.png"><img id="imgf000166_0001" he="11" wi="133" file="imgf000166_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="44" alt="Figure imgf000166_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/14/b2/62bd753713fd1a/imgf000166_0001.png"/></a></div>
 </div>
    <div id="p1144" num="1144" class="description-paragraph"> 3 </div>
    <div id="p1145" num="1145" class="description-paragraph"> Scheme 2. </div>
    <div id="p1146" num="1146" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/26/12/48166f15d0afc7/imgf000166_0002.png"><img id="imgf000166_0002" he="41" wi="134" file="imgf000166_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="536" height="164" alt="Figure imgf000166_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/26/12/48166f15d0afc7/imgf000166_0002.png"/></a></div>
    </div>
    <div id="p1147" num="1147" class="description-paragraph">Scheme 3. </div>
    <div id="p1148" num="1148" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/72/d3/121b9e08beed52/imgf000166_0003.png"><img id="imgf000166_0003" he="134" wi="153" file="imgf000166_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="612" height="536" alt="Figure imgf000166_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/72/d3/121b9e08beed52/imgf000166_0003.png"/></a></div>
    </div>
    <div id="p1149" num="1149" class="description-paragraph"> 17 18 

 Scheme 5. </div>
    <div id="p1150" num="1150" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/59/5f/2a/cfabde51dc499e/imgf000167_0001.png"><img id="imgf000167_0001" he="25" wi="75" file="imgf000167_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="300" height="100" alt="Figure imgf000167_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/59/5f/2a/cfabde51dc499e/imgf000167_0001.png"/></a></div>
    </div>
    <div id="p1151" num="1151" class="description-paragraph"> 18 </div>
    <div id="p1152" num="1152" class="description-paragraph"> HBTU</div>
    <div id="p1153" num="1153" class="description-paragraph">DIPEA, </div>
    <div id="p1154" num="1154" class="description-paragraph"> DMF </div>
    <div id="p1155" num="1155" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/17/01/53/e74c8b002b45c8/imgf000167_0002.png"><img id="imgf000167_0002" he="80" wi="140" file="imgf000167_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="560" height="320" alt="Figure imgf000167_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/17/01/53/e74c8b002b45c8/imgf000167_0002.png"/></a></div>
    </div>
    <div id="p1156" num="1156" class="description-paragraph"> 1) 1000AlcaaCPG </div>
    <div id="p1157" num="1157" class="description-paragraph"> 2) Oligonucleotide synthesis</div>
    <div id="p1158" num="1158" class="description-paragraph">3) Deprotection </div>
    <div id="p1159" num="1159" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/47/1b/88/2ac0c7d660804b/imgf000167_0003.png"><img id="imgf000167_0003" he="27" wi="135" file="imgf000167_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="540" height="108" alt="Figure imgf000167_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/47/1b/88/2ac0c7d660804b/imgf000167_0003.png"/></a></div>
    </div>
    <div id="p1160" num="1160" class="description-paragraph">Step 1. Preparation of 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 4- methylbenzenesulfonate 3 </div>
    <div id="p1161" num="1161" class="description-paragraph"> HO&#39;^ ^&#39;<sup>0</sup>^^O&#39;^ ^<sup>0V</sup>^OTS 

 A solution of tetraethylene glycol (934 g, 4.8 mol) in THF (175mL) and aqueous NaOH (5M, 145 niL) was cooled (0Â°C) and treated with ?-Toluensulfonyl chloride (91.4 g, 480 mmol) dissolved in THF (605 mL) and then stirred for two hours (0Â°C). The reaction mixture was diluted with water (3L) and extracted (3x 500mL) with CH2CI2. The combined extracts were washed with water and brine then dried (MgS04), filtered and concentrated to afford 2-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 3 (140 g, 84%) as a pale yellow oil. R<sub>f</sub> (0.57, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1162" num="1162" class="description-paragraph">Step 2. Preparation of 2-(2-(2-(2- )ethan-l-ol 4</div>
    <div id="p1163" num="1163" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bf/a8/fe/ace333f90e93de/imgf000168_0001.png"><img id="imgf000168_0001" he="6" wi="47" file="imgf000168_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="188" height="24" alt="Figure imgf000168_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bf/a8/fe/ace333f90e93de/imgf000168_0001.png"/></a></div>
    </div>
    <div id="p1164" num="1164" class="description-paragraph"> A solution of 3 (140 g, 403 mmol) in DMF (880 mL) was treated with sodium azide (131 g, 2.02 mol) and heated (45Â°C) overnight. A majority of the DMF was removed under reduced pressure and the residue was dissolved in CH2CI2 (500 mL) and washed (3x 500 mL) with brine then dried (MgSC ), filtered and concentrated. The residue was passed through a short bed of silica (5% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) and concentrated to yield 2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)ethan-l-ol 4 (65g, 74%) as a yellow oil. Rf (0.56, 10% MeOH- </div>
    <div id="p1165" num="1165" class="description-paragraph">Step 3. Preparation of peracetylated galactosamine 6 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/76/14/a4/906f8525237068/imgf000168_0002.png"><img id="imgf000168_0002" he="14" wi="25" file="imgf000168_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="100" height="56" alt="Figure imgf000168_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/76/14/a4/906f8525237068/imgf000168_0002.png"/></a></div>
 </div>
    <div id="p1166" num="1166" class="description-paragraph"> D-Galactosamine hydrochloride 5 (250 g, 1.16 mol) in pyridine (1.5 L) was treated with acetic anhydride (1.25 L, 13.2 mol) over 45 minutes. After stirring overnight the reaction mixture was divided into three 1 L portions. Each 1 L portion was poured into 3 L of ice water and mixed for one hour After mixing the solids were filtered off, combined, frozen over liquid nitrogen and then lyophilized for five days to yield peracetylated galactosamine 6 (369.4 g, 82%) as a white solid. Rf (0.58, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1167" num="1167" class="description-paragraph">Step 4. Preparation of (3aR,5R,6R,7R,7aR)-5-(acetoxymethyl)-2-methyl-3a,6,7,7a- tetrahydro-5H-pyrano[3,2-d]oxazole-6,7-diyl diacetate 7 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/2e/1e/60654a53c6f916/imgf000168_0003.png"><img id="imgf000168_0003" he="19" wi="17" file="imgf000168_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="68" height="76" alt="Figure imgf000168_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/2e/1e/60654a53c6f916/imgf000168_0003.png"/></a></div>
 

 A solution of per-acetylated galactosamine 6 (8.45 g, 21.7 mmol) in CHCb (320 mL) was treated dropwise with TMSOTf (4.32 mL, 23.9 mmol). After stirring (1.5 hr, 40Â°C) the reaction was quenched by the addition of triethylamine (5 mL) and concentrated to dryness to afford compound 7 as a pale yellow glass (7.2 g, Quant.). The product was used without further purification. Rf (0.59, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1168" num="1168" class="description-paragraph">Step 5. Preparation of (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate 8 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/91/5c/546f341c486907/imgf000169_0001.png"><img id="imgf000169_0001" he="18" wi="70" file="imgf000169_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="280" height="72" alt="Figure imgf000169_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/91/5c/546f341c486907/imgf000169_0001.png"/></a></div>
 </div>
    <div id="p1169" num="1169" class="description-paragraph"> Compound 7 (7.2 g, 21.7 mmol) and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-l-ol 4 (2.65 g, 15.2 mmol) were azeotroped (3x) from toluene (150 mL) to remove traces of water. The dried material was dissolved in 1,2-dichloroethane (150 mL), cooled (~5Â°C) and treated with TMSOTf (784 Î¼Î¯, 4.34 mmol). After stirring overnight the reaction was quenched by the addition of triethylamine (5 mL) and concentrated. The residue was purified by chromatography (1%â 5% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford 8 (7.12 g, 85%) as a brown oil. Rf (0.3, 10% MeOH- CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1170" num="1170" class="description-paragraph">Step 6. Preparation of 2-(2-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6- (acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethan-l-aminium 2,2,2-trifluoroacetate 9 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/fe/06/2a60a6dd62a2b2/imgf000169_0002.png"><img id="imgf000169_0002" he="15" wi="81" file="imgf000169_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="324" height="60" alt="Figure imgf000169_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/95/fe/06/2a60a6dd62a2b2/imgf000169_0002.png"/></a></div>
 </div>
    <div id="p1171" num="1171" class="description-paragraph"> A solution of the azide 8 (7.12 g, 13 mmol) in EtOAc (150 mL) and trifluoroacetic acid (2 mL) was treated with palladium on charcoal (1.5 g, 10% w/w wet basis). The reaction mixture was then purged with hydrogen and stirred vigorously overnight. After purging with nitrogen, the mixture was filtered through Celite, rinsing with MeOH. The filtrate was concentrated and purified via chromatography (5%â 10%â 20% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford 9 (5.8 g, 72%) as a brown oil. Rf (0.34, 15% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). 

 Step 7. Preparation of di-tert-butyl 4-(((benzyloxy)carbonyl)amino)-4-(3-(tert-butoxy)-3- oxopropyl)heptanedioate 11 </div>
    <div id="p1172" num="1172" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/e3/6e/c9352aa99da7aa/imgf000170_0001.png"><img id="imgf000170_0001" he="34" wi="44" file="imgf000170_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="176" height="136" alt="Figure imgf000170_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/e3/6e/c9352aa99da7aa/imgf000170_0001.png"/></a></div>
    </div>
    <div id="p1173" num="1173" class="description-paragraph"> To a solution of di-tert-butyl 4-amino-4-(3-(tert-butoxy)-3-oxopropyl)heptanedioate 10 (13.5 g, 33 mmol), 25% Na2C03 (aq) (1 0 mL) and dichloromethane (300 mL) was added slowly benzyl chloroformate (14 mL, 98 mmol). The solution was stirred vigorously overnight (16h) at room temperature. Upon completion, additional dichloromethane (100 mL) was added and the dichloromethane layer was separated. The aqueous layer was extracted with dichloromethane (2 x 100 mL). The combine dichloromethane extracts were dried on magnesium sulfate, filtered and concentrated to dryness. The product 11 was isolated as a colorless oil that required no further purification (15.8 g, 88%). Rf (0.7, 1 : 1 EtOAc-Hexane). </div>
    <div id="p1174" num="1174" class="description-paragraph">Step 8. Preparation of 4-(((benzyloxy)carbonyl)amino)-4-(2-carboxyethyl)heptanedioic acid 12 </div>
    <div id="p1175" num="1175" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/20/1f/2dbc2eda9be25c/imgf000170_0002.png"><img id="imgf000170_0002" he="30" wi="46" file="imgf000170_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="184" height="120" alt="Figure imgf000170_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/20/1f/2dbc2eda9be25c/imgf000170_0002.png"/></a></div>
    </div>
    <div id="p1176" num="1176" class="description-paragraph"> A solution of 11 (15.6 g, 28.8 mmol) in formic acid (50 mL) was stirred at room temperature for 2 hours. The solution was concentrated to dryness and dissolved in ethyl acetate (-25 mL). Upon standing, the product crystallized as a colorless solid. The solid was filtered, washed with ethyl acetate and air dried to afford 12 as a colorless solid (10.2 g, 93%). Rf (0.1, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). 

 Step 9. Preparation of compound 13 </div>
    <div id="p1177" num="1177" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/19/8c/f543d5df14e31a/imgf000171_0001.png"><img id="imgf000171_0001" he="23" wi="92" file="imgf000171_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="368" height="92" alt="Figure imgf000171_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/19/8c/f543d5df14e31a/imgf000171_0001.png"/></a></div>
    </div>
    <div id="p1178" num="1178" class="description-paragraph"> A solution of 12 (793 mg, 2.08 mmol) and 9 (5.8 g, 9.36 mmol) in DMF (50mL) was treated with BOP (3.67 g, 8.32 mmol) then N,N-diisopropylethylamine (4.31 mL, 25 mmol). After stirring overnight the mixture was concentrated to dryness and subjected to </div>
    <div id="p1179" num="1179" class="description-paragraph">chromatography (1%â 2%â 5%â 10%â 15% MeOH-CH<sub>2</sub>Cb) to afford 13 (5.71 g </div>
    <div id="p1180" num="1180" class="description-paragraph">[crude], &gt;100% - contained coupling by-products that did not affect the next step). Rf (0.45, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1181" num="1181" class="description-paragraph">Step 10. Preparation of compound 14 </div>
    <div id="p1182" num="1182" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/91/75/f3/f84f2ee0280e25/imgf000171_0002.png"><img id="imgf000171_0002" he="22" wi="97" file="imgf000171_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="388" height="88" alt="Figure imgf000171_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/91/75/f3/f84f2ee0280e25/imgf000171_0002.png"/></a></div>
    </div>
    <div id="p1183" num="1183" class="description-paragraph"> Compound 13 (5.7 g) was dissolved in MeOH (150 mL) and TFA (1.5 mL) and treated with palladium on charcoal (1 g, 10% w/w wet basis). The reaction mixture was then purged with hydrogen and stirred vigorously overnight. After purging with nitrogen, the mixture was filtered through Celite, rinsing with MeOH. The filtrate was concentrated and purified via chromatography (5%â 10%â 20% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford 14 as a brown oil (2.15 g, 56% over two steps). Rf (0.32, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1184" num="1184" class="description-paragraph">Step 11. Preparation of (5-amino-l,3-p thanol 15 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/09/6b/9cf8096860dd15/imgf000171_0003.png"><img id="imgf000171_0003" he="24" wi="26" file="imgf000171_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="104" height="96" alt="Figure imgf000171_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/09/6b/9cf8096860dd15/imgf000171_0003.png"/></a></div>
 </div>
    <div id="p1185" num="1185" class="description-paragraph"> A solution of dimethyl 5-aminoisophthalate (20.0 g, 96 mmol) in THF (350 mL) was added, dropwise, to a refluxing mixture of 3.75 eq LiAlFL (13.6 g, 358 mmol) in THF (440 mL) over one hour. The mixture was stirred at reflux for a further two hours, then cooled to room temperature and quenched by the careful addition of MeOH (27 mL) then water (40 mL). After stirring the quenched mixture for two hours it was filtered and concentrated to dryness. The 

 residue was recrystallized (2X) from EtOAc to afford 15 as brownish-yellow crystals (10.2 g, 70 %). </div>
    <div id="p1186" num="1186" class="description-paragraph">Step 12. Preparation of methyl 10-((3,5-bis(hydroxymethyl)phenyl)amino)-10- oxodecanoate 16 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bb/fc/61/05e54a0924d53d/imgf000172_0001.png"><img id="imgf000172_0001" he="19" wi="36" file="imgf000172_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="144" height="76" alt="Figure imgf000172_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bb/fc/61/05e54a0924d53d/imgf000172_0001.png"/></a></div>
 </div>
    <div id="p1187" num="1187" class="description-paragraph"> A solution of methyl sebacate (3.8 g, 17 mmol), 15 (2.5 g, 17 mmol) and EEDQ (8.1 g, 33 mmol) in 2: 1 dichlorom ethane / methanol (200 mL) was stirred at room temperature for 2 hours. Upon completion the solution was concentrated to dryness. The solid obtained was triturated with dichloromethane (50 mL) and filtered. The solid was rinsed with cold </div>
    <div id="p1188" num="1188" class="description-paragraph">dichloromethane and air dried to afford 16 as a colorless solid (4.3 g, 72%). Rf (0.33, EtOAc). </div>
    <div id="p1189" num="1189" class="description-paragraph">Step 13. Preparation of methyl 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)phenyl)amino)-10-oxodecanoate 17 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/c2/30/89cac8d1923907/imgf000172_0002.png"><img id="imgf000172_0002" he="19" wi="37" file="imgf000172_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="148" height="76" alt="Figure imgf000172_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/c2/30/89cac8d1923907/imgf000172_0002.png"/></a></div>
 </div>
    <div id="p1190" num="1190" class="description-paragraph"> To a solution of 16 (4.3 g, 12 mmol) in pyridine (50 mL) was added 4,4&#39;- (chloro(phenyl)methylene)bis(methoxybenzene) (4.1 g, 12 mmol). The solution was stirred under nitrogen overnight at room temperature. Upon completion the solution was concentrated to dryness and the residue was purified by column chromatography (0.5%â 0.75%â 1%â 1.5% MeOH-CH<sub>2</sub>Cb) to afford 17 as a yellow solid (2.9 g, 35%). Rf (0.6, 10% MeOH-CH<sub>2</sub>Cb). </div>
    <div id="p1191" num="1191" class="description-paragraph">Step 14. Preparation of lithium 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)phenyl)amino)-10-oxodecanoate 18 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/47/72/e7/1b4891ed186423/imgf000172_0003.png"><img id="imgf000172_0003" he="19" wi="39" file="imgf000172_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="156" height="76" alt="Figure imgf000172_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/47/72/e7/1b4891ed186423/imgf000172_0003.png"/></a></div>
 </div>
    <div id="p1192" num="1192" class="description-paragraph"> To a solution of 17 (2.9 g, 4.3 mmol) in THF (60 mL) was added water (15 mL) and lithium hydroxide (112 mg, 4.7 mmol). The solution was stirred overnight at room temperature. Upon completion the solution was concentrated to remove the THF. The remaining aqueous 

 solution was flash frozen on liquid nitrogen and lyophilized overnight to afford a colorless solid (2.9 g, quant). Rf (0.3, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1193" num="1193" class="description-paragraph">Step 15. Preparation of compound 19 </div>
    <div id="p1194" num="1194" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/aa/9e/dafe51bb9450f4/imgf000173_0001.png"><img id="imgf000173_0001" he="29" wi="117" file="imgf000173_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="468" height="116" alt="Figure imgf000173_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/aa/9e/dafe51bb9450f4/imgf000173_0001.png"/></a></div>
    </div>
    <div id="p1195" num="1195" class="description-paragraph"> To a solution 14 (454 mg, 0.67 mmol), 18 (1.25 g, 0.67 mmol) and HBTU (381 mg, 1.0 mmol) in anhydrous DMF (25 mL) was added N,N-diisopropylethylamine (0.35 mL, 2.0 mmol). The solution was stirred overnight at room temperature. Upon completion, the solution was poured into ethyl acetate (250 mL) and washed with brine (3 x 200 mL). The ethyl acetate layer was dried on magnesium sulfate, filtered and concentration to dryness. Purification by column chromatography (5%â 7.5%â 10%â 15% MeOH in CH<sub>2</sub>C1<sub>2</sub>) afforded 19 as a pale orange foam (1.5 g, 94%). Rf (0.25, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1196" num="1196" class="description-paragraph">Step 16. Preparation of compound 20 </div>
    <div id="p1197" num="1197" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/63/c6/79977247d9b5f7/imgf000173_0002.png"><img id="imgf000173_0002" he="29" wi="141" file="imgf000173_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="564" height="116" alt="Figure imgf000173_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/63/c6/79977247d9b5f7/imgf000173_0002.png"/></a></div>
    </div>
    <div id="p1198" num="1198" class="description-paragraph"> A solution of compound 19 (1.5 g, 0.6 mmol), succinic anhydride (120 mg, 1.2 mmol),</div>
    <div id="p1199" num="1199" class="description-paragraph">DMAP (220 mg, 1.8 mmol) and trimethyl amine (250 Î¼Î,, 1.8 mmol) in anhydrous CH<sub>2</sub>C1<sub>2</sub> (50 mL) was stirred overnight at room temperature. Upon completion, the solution was concentrated to dryness and filtered through a short plug of silica (100% CH<sub>2</sub>C1<sub>2</sub>â 15% MeOH in CH<sub>2</sub>C1<sub>2</sub>) to afford the product 20 as a light beige foam (1.1 g, 70%). Mass m/z (ES-TOF MS) 727.7 [M + 3H - DMTr]<sup>+</sup>, 1091.1 [M + 2H - DMTr]. Â¾ NMR (400 MHz, CDCb) Î´ 8.92 (br s, 1H), 7.78 (s, 1H), 7.49-7.47 (m, 3H), 7.41 (br s, 1H), 7.38-7.34 (m, 5H), 7.32-7.26 (m, 4H), 7.24-7.08 (br s, 3H), 7.08 (s, 1H), 6.90-6.80 (m, 7H), 5.31 (d, 3H, J = 2.7Hz), 5.12 (s, 2H), 5.06 (dd, 3H, J = 1 1.2, 3.2 Hz), 4.78 (d, 3H, J= 8.5 Hz), 4.24-4.08 (m, 12H), 3.95-3.88 (m, 7H), 3.85-3.76 (m, 4H), 3.78 (s, 6H), 3.68-3.56 (m, 34H), 3.54-3.44 (m, 8H), 3.41-3.33 (m, 6H), 2.70-2.60 (m, 4H), 2.52-2.30 (m, 30H), 2.24-2.16 (m, 8H), 2.14 (s, 9H), 2.04 (s, 9H), 2.02-1.96 (m, 6H), 1.98 (s, 9H), 1.96 (s, 9H), 1.74-1.52 (m, 4H), 1.36-1.24 (m, 12H). 

 Step 17. Preparation of conjugate 1 </div>
    <div id="p1200" num="1200" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b6/76/f7/ec9b1bcda11ff2/imgf000174_0001.png"><img id="imgf000174_0001" he="33" wi="149" file="imgf000174_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="596" height="132" alt="Figure imgf000174_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b6/76/f7/ec9b1bcda11ff2/imgf000174_0001.png"/></a></div>
    </div>
    <div id="p1201" num="1201" class="description-paragraph"> The succinate 20 was loaded onto ÎÎÎÎ¸Î LCAA (long chain aminoalkyl) CPG (control pore glass) using standard amide coupling chemistry. A solution of diisopropylcarbodiimide (52.6 Î¼Î·Î¹Î¿Î), N-hydroxy succinimide (0.3 mg, 2.6 Î¼Î·Î¹Î¿Î) and pyridine (10 Î¼Î¯) in anhydrous acetonitrile (0.3 mL) was added to 20 (20.6 mg, 8 Î¼ÏÎ¹Î¿Î) in anhydrous dichloromethane (0.2 mL). This mixture was added to LCAA CPG (183 mg). The suspension was gently mixed overnight at room temperature. Upon disappearance of 20 (HPLC), the reaction mixture was filtered and the CPG was washed with 1 mL of each dichloromethane, acetonitrile, a solution of 5% acetic anhydride / 5% N-methylimidazole / 5% pyridine in THF, then THF, acetonitrile and dichloromethane. The CPG was then dried overnight under high vacuum. Loading was determined by standard DMTr assay by UV/Vis (504 nm) to be 25 Î¼Î¹Î·Î¿Î/g. The resulting GalNAc loaded CPG solid support was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded the GalNAc-oligonucleotide conjugate 1 as a representative example. 

</div>
    <div id="p1202" num="1202" class="description-paragraph">Example 2: Synthesis of coniugate 34 Scheme 6. </div>
    <div id="p1203" num="1203" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/2b/15/48fe5ffa6de92c/imgf000175_0001.png"><img id="imgf000175_0001" he="103" wi="130" file="imgf000175_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="520" height="412" alt="Figure imgf000175_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/2b/15/48fe5ffa6de92c/imgf000175_0001.png"/></a></div>
    </div>
    <div id="p1204" num="1204" class="description-paragraph"> Schem </div>
    <div id="p1205" num="1205" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/8b/b2/25990e4fd8a4cd/imgf000175_0002.png"><img id="imgf000175_0002" he="81" wi="133" file="imgf000175_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="324" alt="Figure imgf000175_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/8b/b2/25990e4fd8a4cd/imgf000175_0002.png"/></a></div>
 Scheme 8. </div>
    <div id="p1206" num="1206" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8e/ec/f7/b21d3e65386ebb/imgf000176_0001.png"><img id="imgf000176_0001" he="117" wi="158" file="imgf000176_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="468" alt="Figure imgf000176_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8e/ec/f7/b21d3e65386ebb/imgf000176_0001.png"/></a></div>
    </div>
    <div id="p1207" num="1207" class="description-paragraph"> R<sub>2</sub> = H </div>
    <div id="p1208" num="1208" class="description-paragraph">Step 1. Preparation of di-tert-butyl 4-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-(3- (tert-butoxy)-3-oxopropyl)heptanedioate 21 </div>
    <div id="p1209" num="1209" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/78/47/9b2d0a11c866f6/imgf000176_0002.png"><img id="imgf000176_0002" he="34" wi="55" file="imgf000176_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="220" height="136" alt="Figure imgf000176_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/78/47/9b2d0a11c866f6/imgf000176_0002.png"/></a></div>
    </div>
    <div id="p1210" num="1210" class="description-paragraph">A solution of di-tert-butyl 4-amino-4-(3-(tert-butoxy)-3-oxopropyl)heptanedioate (25 g, 60 mmol) and Z-glycine (18.9 g, 90.2 mmol,) in CH2CI2 (300 mL) was treated successively with EDC (23 g, 120 mmol), Diisopropylethylamine (32 mL, 180 mmol) and DMAP (Cat. 17 mg). After stirring (16h) the reaction mixture was poured into NaHCCb (Sat. Aq.), extracted with CH2CI2, washed with brine, dried (MgS04), filtered and concentrated to afford di-tert-butyl 4-(2- (((benzyloxy)carbonyl)amino)acetamido)-4-(3-(tert-butoxy)-3-oxopropyl)heptanedioate 21 as an 

 amorphous solid and was used without further processing (36 g, quant.). Rf (0.85, 10% MeOH- </div>
    <div id="p1211" num="1211" class="description-paragraph">Step 2. Preparation of 4-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-(2- carboxyethyl)heptanedioic acid 22 </div>
    <div id="p1212" num="1212" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/d6/34/6c007ac5a3bd27/imgf000177_0001.png"><img id="imgf000177_0001" he="30" wi="52" file="imgf000177_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="208" height="120" alt="Figure imgf000177_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/d6/34/6c007ac5a3bd27/imgf000177_0001.png"/></a></div>
    </div>
    <div id="p1213" num="1213" class="description-paragraph"> A solution of di-tert-butyl 4-(2-(((benzyloxy)carbonyl)amino)acetamido)-4-(3-(tert- butoxy)-3-oxopropyl)heptanedioate 21 (59.3mmol, 36g) was stirred in neat formic acid (150mL) for 72 hours. Upon completion, the formic acid was removed under reduced pressure and the crude solid was dried overnight on high-vacuum to yield 22 as a colorless solid (15.9 g, 61%). Rf (0.15, 10% MeOH-CH<sub>2</sub>Ch). </div>
    <div id="p1214" num="1214" class="description-paragraph">Step 3. Preparation of compound 23 </div>
    <div id="p1215" num="1215" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8a/f5/37/2ce0c24b12ef7b/imgf000177_0002.png"><img id="imgf000177_0002" he="25" wi="111" file="imgf000177_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="444" height="100" alt="Figure imgf000177_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8a/f5/37/2ce0c24b12ef7b/imgf000177_0002.png"/></a></div>
    </div>
    <div id="p1216" num="1216" class="description-paragraph"> A solution of 22 (6.2 g, 14.1 mmol) and 2-(2-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-</div>
    <div id="p1217" num="1217" class="description-paragraph">4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethan-l- aminium 2,2,2-trifluoroacetate (35 g, 56.5 mmol) in DMF (250mL) was treated with BOP (25 g, 56.5 mmol) then N,N-diisopropylethylamine (29 mL, 170 mmol). After stirring overnight the mixture was concentrated to dryness and subjected to chromatography (100% CH2CI2 to 15% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford compound 23 (24.6 g, 89%). Rf (0.55, 15% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1218" num="1218" class="description-paragraph">Step 4. Preparation of compound 24 </div>
    <div id="p1219" num="1219" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3b/06/84/a319a40d187d4d/imgf000177_0003.png"><img id="imgf000177_0003" he="25" wi="98" file="imgf000177_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="392" height="100" alt="Figure imgf000177_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3b/06/84/a319a40d187d4d/imgf000177_0003.png"/></a></div>
    </div>
    <div id="p1220" num="1220" class="description-paragraph"> Compound 23 (24.6 g) was dissolved in MeOH (200 mL) and TFA (1.5 mL) and purged with nitrogen. Palladium on charcoal (1 g, 10% w/w wet basis) was added and then the reaction 

 mixture was purged with hydrogen and stirred vigorously overnight. Upon completion, the reaction was purged with nitrogen, filtered through Celite and rinsed with MeOH. The filtrate was concentrated and purified by column chromatography on silica gel 60 (gradient: 5%â 10% â 20% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford 24 as a pale brown viscous oil (23 g). Rf (0.32, 10% MeOH- </div>
    <div id="p1221" num="1221" class="description-paragraph">Step 5. Preparation of (5-amino-l,3-p anol 26 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/57/a3/f1/fff8acfbbfbca2/imgf000178_0001.png"><img id="imgf000178_0001" he="22" wi="30" file="imgf000178_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="120" height="88" alt="Figure imgf000178_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/57/a3/f1/fff8acfbbfbca2/imgf000178_0001.png"/></a></div>
 </div>
    <div id="p1222" num="1222" class="description-paragraph"> A suspension of lithium aluminum hydride (13.6 g, 358 mmol) in anhydrous </div>
    <div id="p1223" num="1223" class="description-paragraph">tetrahydrofuran (450 mL) was brought to reflux under a nitrogen atmosphere and treated, dropwise, with a solution of dimethyl-5-aminoisophthalte 25 (20 g, 96 mmol) in anhydrous tetrahydrofuran (350 mL). After the addition was complete the mixture was heated to reflux for an additional 2 hours. Upon completion, the solution was cooled to room temperature and quenched by the slow addition of MeOH (27 mL) then water (40 mL). After stirring for 2 hours the mixture was filtered, concentrated and recrystallized from EtOAc to yield (5-amino-l,3- phenylene)dimethanol 26 as off-white crystals (10.2 g, 70%). Rf 0.5 (15% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1224" num="1224" class="description-paragraph">Step 6. Preparation of 3,5-bis(hydroxymethyl)benzonitrile 27 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/9d/b8/c888370daa8e94/imgf000178_0002.png"><img id="imgf000178_0002" he="18" wi="27" file="imgf000178_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="108" height="72" alt="Figure imgf000178_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/9d/b8/c888370daa8e94/imgf000178_0002.png"/></a></div>
 </div>
    <div id="p1225" num="1225" class="description-paragraph"> A solution of 26 (5 g, 33 mmol) in 2N hydrochloric acid (100 mL) was cooled to 0Â°C and treated with a cold solution of sodium nitrite (3.53 g, 36mmol) in water (50 mL). The reaction mixture was maintained at a temperature &lt; 5Â°C for 30min then treated with a solution of copper(I) cyanide (3.19 g, 35.6mmol) and sodium cyanide (3.53 g, 72mmol) in water (50 mL) in a single portion. After stirring overnight at room temperature the mixture was filtered, extracted with dichlorom ethane (3 x 100 mL), concentrated and used without further purification. The diol, 3,5-bis(hydroxymethyl)benzonitrile 27 was obtained as a yellow solid (2.19 g, 41%). Rf 0.75 (15% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). 

 Step 7. Preparation of 3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)benzonitrile 28 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/41/c0/e2/098520ad75e188/imgf000179_0001.png"><img id="imgf000179_0001" he="18" wi="32" file="imgf000179_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="128" height="72" alt="Figure imgf000179_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/41/c0/e2/098520ad75e188/imgf000179_0001.png"/></a></div>
 </div>
    <div id="p1226" num="1226" class="description-paragraph"> A solution of 3,5-bis(hydroxymethyl)benzonitrile 27 (538 mg, 3.3 mmol) in pyridine (14 mL) was treated with 4,4&#39;-Dimethoxytrityl chloride (1.17 g, 3.46 mmol) and stirred overnight at room temperature. Once complete, the mixture was concentrated and dispersed in diethyl ether (25 mL), filtered and concentrated. The crude product was purified by column chromatography of silica gel 60 (gradient: 10% to 50% EtOAc-Hexane) to yield the 28 as a yellow solid (725 mg, 47%). Rf 0.5 (1 : 1 EtOAc-hexane). </div>
    <div id="p1227" num="1227" class="description-paragraph">Step 8. Preparation of (3-(aminomethyl)-5-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)phenyl)methanol 29 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/6f/18/e32fd51161015b/imgf000179_0002.png"><img id="imgf000179_0002" he="16" wi="32" file="imgf000179_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="128" height="64" alt="Figure imgf000179_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/6f/18/e32fd51161015b/imgf000179_0002.png"/></a></div>
 </div>
    <div id="p1228" num="1228" class="description-paragraph"> A solution of the 28 (100 mg, 0.22 mmol) in methyl tetrahydrofuran (5 mL) was cooled to 0Â°C and treated slowly with lithium aluminum hydride (0.64 mmol = 0.28mL of a 2.3M solution in MeTHF). After stirring for one hour the reaction was quenched by the addition of methanol (1 mL) then water (0.3 mL) and stirred for 30min. The mixture was filtered and concentrated, to yield (3-(aminomethyl)-5-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)phenyl)methanol 29 (78 mg, 77%). Rf 0.15 (10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1229" num="1229" class="description-paragraph">Step 9. Preparation of methyl 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)benzyl)amino)-10-oxodecanoate 30 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a8/5e/34/a1126d5e1c59d3/imgf000179_0003.png"><img id="imgf000179_0003" he="20" wi="58" file="imgf000179_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="232" height="80" alt="Figure imgf000179_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a8/5e/34/a1126d5e1c59d3/imgf000179_0003.png"/></a></div>
 </div>
    <div id="p1230" num="1230" class="description-paragraph"> A solution of (3-(aminomethyl)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)- methyl)phenyl)methanol 29 (78 mg, 0.17 mmol) and monomethyl sebacate (38 mg, 0.17 mmol,) in dichloromethane (5 mL) were treated successively with EDC (48 mg, 0.25 mmol), DMAP (cat, 5 mg) and diisopropylethylamine (57 Î¼Î¯, 0.33 mmol). After stirring (3.5 hr) the reaction 

 mixture was poured into saturated sodium bicarbonate solution (50 mL). The sodium </div>
    <div id="p1231" num="1231" class="description-paragraph">bicarbonate solution was extracted with dichloromethane (3 x 50 mL), washed with brine (50 mL), dried on magnesium sulfate, filtered and concentrated to dryness. The crude material was purified by column chromatography on silica gel 60 (gradient: 2% to 5% MeOH-CH<sub>2</sub>Cl<sub>2</sub>) to afford methyl 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-</div>
    <div id="p1232" num="1232" class="description-paragraph">(hydroxymethyl)benzyl)amino)-10-oxodecanoate 30 as a yellow oil (57 mg, 53%). Rf 0.45 (10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1233" num="1233" class="description-paragraph">Step 10. Preparation of lithium 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)benzyl)amino)-10-oxodecanoate 31 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/2e/e6/4e2f2aa29e4297/imgf000180_0001.png"><img id="imgf000180_0001" he="20" wi="58" file="imgf000180_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="232" height="80" alt="Figure imgf000180_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/2e/e6/4e2f2aa29e4297/imgf000180_0001.png"/></a></div>
 </div>
    <div id="p1234" num="1234" class="description-paragraph"> Compound 30 (188 mg, 0.28 mmol) was dissolved in tetrahydrofuran (5 mL) and treated with a solution of LiOH (7mg, 0.30 mmol) in water (1 mL). Upon completion, the </div>
    <div id="p1235" num="1235" class="description-paragraph">tetrahydrofuran was removed in vacuo and the remaining aqueous mixture was frozen and lyophilized to afford lithium 10-((3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- (hydroxymethyl)benzyl)amino)-10-oxodecanoate 31 as a colorless solid (180 mg, 99%). Rf 0.45 (10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1236" num="1236" class="description-paragraph">Step 11. Preparation of compounds 32, 33, and 34 </div>
    <div id="p1237" num="1237" class="description-paragraph"> Compounds 32, 33 and 34 were prepared according to same procedure used to synthesize compounds 19, 20, and 1 respectfully. </div>
    <div id="p1238" num="1238" class="description-paragraph">Example 3. Synthesis of conjugate 36 </div>
    <div id="p1239" num="1239" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/c9/c1/2f56046200d725/imgf000180_0002.png"><img id="imgf000180_0002" he="31" wi="146" file="imgf000180_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="584" height="124" alt="Figure imgf000180_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/c9/c1/2f56046200d725/imgf000180_0002.png"/></a></div>
    </div>
    <div id="p1240" num="1240" class="description-paragraph"> Oligonucleotide </div>
    <div id="p1241" num="1241" class="description-paragraph"> H 

 Step 1. Preparation of conjugate 36 </div>
    <div id="p1242" num="1242" class="description-paragraph"> Conjugate 36 was prepared using identical procedures as used to synthesize compound 34 and all corresponding intermediates. The only exception being the synthesis of compound 6 where propanoic anhydride was used in place of acetic anhydride. </div>
    <div id="p1243" num="1243" class="description-paragraph">Example 4. Synthesis of coniugate 42 </div>
    <div id="p1244" num="1244" class="description-paragraph"> Scheme 9. </div>
    <div id="p1245" num="1245" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/5d/bb/778435035f4694/imgf000181_0001.png"><img id="imgf000181_0001" he="35" wi="143" file="imgf000181_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="572" height="140" alt="Figure imgf000181_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/5d/bb/778435035f4694/imgf000181_0001.png"/></a></div>
    </div>
    <div id="p1246" num="1246" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/83/55/5c/fd767540a4f5d8/imgf000181_0002.png"><img id="imgf000181_0002" he="30" wi="140" file="imgf000181_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="560" height="120" alt="Figure imgf000181_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/83/55/5c/fd767540a4f5d8/imgf000181_0002.png"/></a></div>
    </div>
    <div id="p1247" num="1247" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/f3/b6/dbe74d836a018d/imgf000181_0003.png"><img id="imgf000181_0003" he="63" wi="146" file="imgf000181_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="584" height="252" alt="Figure imgf000181_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7b/f3/b6/dbe74d836a018d/imgf000181_0003.png"/></a></div>
      
    </div>
    <div id="p1248" num="1248" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/46/81/87/3642c4ac4b7065/imgf000182_0001.png"><img id="imgf000182_0001" he="65" wi="142" file="imgf000182_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="568" height="260" alt="Figure imgf000182_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/46/81/87/3642c4ac4b7065/imgf000182_0001.png"/></a></div>
    </div>
    <div id="p1249" num="1249" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2c/fb/60/29a5f3a7b2d5fd/imgf000182_0002.png"><img id="imgf000182_0002" he="30" wi="59" file="imgf000182_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="236" height="120" alt="Figure imgf000182_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2c/fb/60/29a5f3a7b2d5fd/imgf000182_0002.png"/></a></div>
    </div>
    <div id="p1250" num="1250" class="description-paragraph"> A solution of 18 -glycyrrhetinic acid (2.5 g, 5.3 mmol), tert-butyl (3- aminopropyl)carbamate (1.1 g, 6.4 mmol) and HBTU (3.0 g, 8.0 mmol) in N,N- dimethylformamide (20 mL) was added diisopropylethylamine (2.75 mL, 15.9 mmol). The solution was stirred overnight at room temperature. Upon completion, the solution was concentrated in vacuo to dryness. The residue was purified by column chromatography on silica gel 60 (gradient: 2% to 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford the product as a colorless solid (2.1 g, 63%). </div>
    <div id="p1251" num="1251" class="description-paragraph">Step 2. Preparation of compound 38 </div>
    <div id="p1252" num="1252" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/48/36/64/9e94a69acc631b/imgf000182_0003.png"><img id="imgf000182_0003" he="30" wi="62" file="imgf000182_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="248" height="120" alt="Figure imgf000182_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/48/36/64/9e94a69acc631b/imgf000182_0003.png"/></a></div>
    </div>
    <div id="p1253" num="1253" class="description-paragraph">To a solution of 37 (2.1 g, 3.3 mmol) and triethylamine (3.5 mL, 10 mmol) in dichloromethane (25 mL) was added acetic anhydride (850 Î¼L, 5.3 mmol) and DMAP (5 mg). The solution was stirred overnight at room temperature. Upon completion, the solution was concentrated to dryness and dissolved in ethyl acetate (100 mL), washed with water (100 mL), 

 dried on magnesium sulfate, filtered and concentrated to dryness to afford a pale brown foam (1.9 g, 85%). </div>
    <div id="p1254" num="1254" class="description-paragraph">Step 3. Preparation of comp </div>
    <div id="p1255" num="1255" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/d5/0c/2fa1d499a81e8c/imgf000183_0001.png"><img id="imgf000183_0001" he="37" wi="61" file="imgf000183_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="244" height="148" alt="Figure imgf000183_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1f/d5/0c/2fa1d499a81e8c/imgf000183_0001.png"/></a></div>
    </div>
    <div id="p1256" num="1256" class="description-paragraph"> To a solution of 38 (1.5 g, 2.3 mmol) in anhydrous dioxane (25 mL) was added 2M Hydrogen chloride in dioxane (25 mL). The solution was stirred overnight at room temperature then concentrated in vacuo to dryness to afford a light brown solid (1.3 g, 96%&gt;). </div>
    <div id="p1257" num="1257" class="description-paragraph">Step 4. Preparation of compounds 40, 41 and 42 </div>
    <div id="p1258" num="1258" class="description-paragraph"> Compounds 40, 41 and 42 were prepared according to the same procedure used to synthesize compounds 19, 20, and 1 respectfully. </div>
    <div id="p1259" num="1259" class="description-paragraph">Example 5. Synthesis of Conjugate 43 </div>
    <div id="p1260" num="1260" class="description-paragraph"> Scheme 11. </div>
    <div id="p1261" num="1261" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a3/63/3a/7250c942f713ae/imgf000183_0002.png"><img id="imgf000183_0002" he="58" wi="137" file="imgf000183_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="548" height="232" alt="Figure imgf000183_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a3/63/3a/7250c942f713ae/imgf000183_0002.png"/></a></div>
      
    </div>
    <div id="p1262" num="1262" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/a8/99/1a33ac04b09be8/imgf000184_0001.png"><img id="imgf000184_0001" he="42" wi="138" file="imgf000184_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="552" height="168" alt="Figure imgf000184_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/84/a8/99/1a33ac04b09be8/imgf000184_0001.png"/></a></div>
    </div>
    <div id="p1263" num="1263" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/36/5f/f5e6520a903125/imgf000184_0002.png"><img id="imgf000184_0002" he="88" wi="148" file="imgf000184_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="592" height="352" alt="Figure imgf000184_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/36/5f/f5e6520a903125/imgf000184_0002.png"/></a></div>
    </div>
    <div id="p1264" num="1264" class="description-paragraph">Step 1. Preparation of methyl ll-(2,6-bis(hydroxymethyl)-4-methylphenoxy)undecanoate 44 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/46/2b/516a967eee1c71/imgf000184_0003.png"><img id="imgf000184_0003" he="19" wi="17" file="imgf000184_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="68" height="76" alt="Figure imgf000184_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/46/2b/516a967eee1c71/imgf000184_0003.png"/></a></div>
 </div>
    <div id="p1265" num="1265" class="description-paragraph"> To a solution of 2,6-bis(hydroxymethyl)-p-cresol (2.7 g, 16.3 mmol), methyl 11- bromoundecanoate (5.0 g, 17.9 mmol) and potassium carbonate (4.5 g, 32.6 mmol) in acetone (100 mL) was refluxed for 16 hours. Upon completion the solution was concentrated in vacuo to dryness, suspended in ethyl acetate (150 mL) and washed with water (2 x 100 mL) and brine (100 mL) The ethyl acetate layer was dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. The residue was purified by column chromatography on silica gel 60 (gradient 

 100 % Hex 50% EtO Ac/Hex) to afford methyl 1 l-(2,6-bis(hydroxymethyl)-4- methylphenoxy)undecanoate 44 as a colorless oil (1.6 g, 27%). </div>
    <div id="p1266" num="1266" class="description-paragraph">Step 2. Preparation of methyl ll-(2-((bis(4-methoxyphenyl)(phenyl)methoxy)i </div>
    <div id="p1267" num="1267" class="description-paragraph">(hydroxymethyl)-4-methylphenoxy)u 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a3/69/8f/0b7b1abd4945b5/imgf000185_0001.png"><img id="imgf000185_0001" he="27" wi="29" file="imgf000185_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="116" height="108" alt="Figure imgf000185_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a3/69/8f/0b7b1abd4945b5/imgf000185_0001.png"/></a></div>
 </div>
    <div id="p1268" num="1268" class="description-paragraph"> To a solution of methyl 1 l-(2,6-bis(hydroxymethyl)-4-methylphenoxy)undecanoate 44 (1.5 g, 4.1 mmol) in anhydrous pyridine (20 mL) was added 4,4&#39;-Dimethoxytrityl chloride (1.4 g, 4.1 mmol). The solution was stirred overnight at room temperature. Upon completion the solution was concentrated in vacuo to dryness and purified by column chromatography on silica gel 60 (0.5 to 1% MeOH in CH<sub>2</sub>C1<sub>2</sub>) to afford Methyl 1 l-(2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-6-(hydroxymethyl)-4-methylphenoxy)undecanoate 45 as a pale yellow solid (1.1 g, 40%). </div>
    <div id="p1269" num="1269" class="description-paragraph">Step 3. Preparation of lithium ll-(2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-6- (hydroxymethyl)-4-methylphenoxy)u 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/0b/a3/fad3bf55c3cc5a/imgf000185_0002.png"><img id="imgf000185_0002" he="27" wi="29" file="imgf000185_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="116" height="108" alt="Figure imgf000185_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/0b/a3/fad3bf55c3cc5a/imgf000185_0002.png"/></a></div>
 </div>
    <div id="p1270" num="1270" class="description-paragraph"> To a solution of Methyl 1 l -(2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-6- (hydroxymethyl)-4-methylphenoxy)undecanoate 45 (1.1 g, 1.7 mmol) in anhydrous </div>
    <div id="p1271" num="1271" class="description-paragraph">tetrahydrofuran (40 mL) and water (10 mL) was added lithium hydroxide (44 mg, 1.8 mmol). The solution was concentrated in vacuo to remove all tetrahydrofuran. The remaining aqueous solution was flash frozen on liquid nitrogen then lyophilized overnight to afford lithium 1 1 -(2- ((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-6-(hydroxymethyl)-4- methylphenoxy)undecanoate 46 as a pale pink solid (1.1 g, 94%). Step 4. Preparation of Compound 47 </div>
    <div id="p1272" num="1272" class="description-paragraph"> A solution of 10 (1.33 g, 0.66 mmol), 46 (0.5 g, 0.73 mmol), HBTU (400 mg, 1 mmol) in N,N-dimethylformamide (25 mL) was added diisopropylethylamine (0.35 mL, 2 mmol). The solution was stirred overnight (18 hours) at room temperature. Upon completion, the solvent was remove in vacuo and the residue was purified by column chromatography on silica gel (gradient: 

 100% CH2CI2 - 5% - 10% - 15% MeOH in CH<sub>2</sub>Ch) to afford 47 as a colorless solid (710 mg, 41%). </div>
    <div id="p1273" num="1273" class="description-paragraph">Step 5. Preparation of Compound 48 </div>
    <div id="p1274" num="1274" class="description-paragraph"> To a solution of 47 (0.71 g, 0.3 mmol), triethylamine (0.4 mL, 3.0 mmol) and polystyrene-DMAP (3 mmol/g loading, 200 mg, 0.6 mmol) in dichloromethane (15 mL) was added succinic anhydride (60 mg, 0.6 mmol). The solution was stirred overnight at room temperature and upon completion filtered and concentrated in vacuo to dryness. The residue was purified by column chromatography on silica gel 60 (gradient 5% to 20% MeOH in CH2CI2) to afford the 48 as a pale yellow solid (570 mg, 70%). Â¾ NMR (DMSO-d<sub>6</sub>, 400 MHz) Î´ 7.91 (m, 1H), 7.86-7.76 (m, 6H), 7.45-7.40 (m, 2H), 7.36-7.14 (m, 10H), 7.10 (s, 1H), 6.91 (d, J= 8.9 Hz, 4H), 5.21 (d, J = 3.3 Hz, 3H), 5.01 (s, 2H), 4.97 (dd, J = 11.2, 3.4 Hz, 3H), 4.56 (d, j = 8.5 Hz, 3H), 4.06-3.98 (m, 11H), 3.93-3.84 (m, 3H), 3.81-3.72 (m, 3H), 3.74 (s, 6H), 3.65-3.46 (m, 38H), 3.40-3.35 (m, 6H), 3.20-3.16 (m, 6H), 2.56-2.44 (m, 4H), 2.33 (s, 3H), 2.15-2.08 (m, 2H), 2.10 (s, 9H), 2.04-1.96 (m, 6H), 1.89 (s, 9H), 1.82-1.76 (m, 4H), 1.77 (s, 9H), 1.54-1.34 (m, 4H), 1.28-1.10 (m, 12H), </div>
    <div id="p1275" num="1275" class="description-paragraph">Step 6. Preparation of compound 49 </div>
    <div id="p1276" num="1276" class="description-paragraph"> To a solution of 48 (100 mg, 40 Î¼Î·Î¹Î¿Î), N-Hydroxysuccinimide (30 mg/mL soln in acetonitrile, 50 Î¼Î¯, 13 Î¼Î·Î¹Î¿Î), N,N-Diisopropylcarbodiimide (40 Î¼Î¯, 264 Î¼Î¹ÏÎ¹Î¿Î) and pyridine (50 Î¼Î.) in dichloromethane (2 mL) and acetonitrile (3 mL) was added 1000 A lcaa CPG (prime synthesis, 920 mg). The solution was stirred overnight at room temperature on an orbital shaker. TLC analysis of the reaction solution showed only partial consumption of the activated N- Hydroxysuccinic ester so additional CPG (500 mg) was added. The solution was stirred again overnight. Upon completion, the CPG was filtered and washed with dichloromethane (25 mL), acetonitrile (25 mL) and tetrahydrofuran (25 mL). The unreacted amine residues on the CPG were acetylated (capped) by adding a 1 : 1 solution of acetic anhydride in acetonitrile (3 mL) and 10%) N-methylimidazole / 10% pryridine in tetrahydrofuran (3 mL). The suspension was left for 2 hours then filtered and rinsed with equal parts tetrahydrofuran (25 mL), acetonitrile (25 mL) and dichloromethane (25 mL). The loaded CPG 49 was dried under high vacuum overnight. The ligand loading efficiency was determined to be 22
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/80/b2/28/bd126196c8df66/imgf000186_0001.png"><img id="imgf000186_0001" he="5" wi="14" file="imgf000186_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="56" height="20" alt="Figure imgf000186_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/80/b2/28/bd126196c8df66/imgf000186_0001.png"/></a></div>
 using a standard DMT loading assay (3% trichloroacetic acid in CH2CI2, UV-VIS, A504). 

 Step 7. Preparation of conjugate 43 </div>
    <div id="p1277" num="1277" class="description-paragraph"> The resulting GalNAc loaded CPG solid support 49 was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded a GalNAc-oligonucleotide conjugate 43. </div>
    <div id="p1278" num="1278" class="description-paragraph">Example 6. Synthesis of Conjugate 50 </div>
    <div id="p1279" num="1279" class="description-paragraph">Scheme 13. </div>
    <div id="p1280" num="1280" class="description-paragraph"> HO^-<sup>NH</sup>* </div>
    <div id="p1281" num="1281" class="description-paragraph"> reflux DMTrCI </div>
    <div id="p1282" num="1282" class="description-paragraph"> + ^ HO^ ^^.OTBDMS ^ DMTrO^^ ^^OTBDMS </div>
    <div id="p1283" num="1283" class="description-paragraph"> <sup>ACN</sup> H Et<sub>3</sub>N H </div>
    <div id="p1284" num="1284" class="description-paragraph"> <sup>Br</sup>^^OTBDMS 51 52 </div>
    <div id="p1285" num="1285" class="description-paragraph">
      <span class="patent-image-not-available"></span>
    </div>
    <div id="p1286" num="1286" class="description-paragraph"> 55 </div>
    <div id="p1287" num="1287" class="description-paragraph">Scheme 14. </div>
    <div id="p1288" num="1288" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/7f/44/eac4ab48c9406e/imgf000187_0002.png"><img id="imgf000187_0002" he="46" wi="136" file="imgf000187_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="544" height="184" alt="Figure imgf000187_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/7f/44/eac4ab48c9406e/imgf000187_0002.png"/></a></div>
      
    </div>
    <div id="p1289" num="1289" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/62/43/50/45ac5af9eb317a/imgf000188_0001.png"><img id="imgf000188_0001" he="102" wi="155" file="imgf000188_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="620" height="408" alt="Figure imgf000188_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/62/43/50/45ac5af9eb317a/imgf000188_0001.png"/></a></div>
    </div>
    <div id="p1290" num="1290" class="description-paragraph">Step 1. Preparation of 2-((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)ethan-l-ol 51 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dc/15/d8/f5eb26a59cf84e/imgf000188_0002.png"><img id="imgf000188_0002" he="8" wi="34" file="imgf000188_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="136" height="32" alt="Figure imgf000188_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dc/15/d8/f5eb26a59cf84e/imgf000188_0002.png"/></a></div>
 </div>
    <div id="p1291" num="1291" class="description-paragraph"> A solution of ethanolamine (77 mL, 1.25 mol) and (2-bromoethoxy)-/er/-butyl dimethylsilane (15 g, 62.7 mmol) in anhydrous acetonitrile (200 mL) was refluxed for 3 hours. Upon completion the reaction was cooled to room temperature, diluted with water (400 mL) and extracted with ethyl acetate (3 x 150 mL). The combined ethyl acetate extracts were dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. The residue was purified by filtration through a pad of silica first with 50% ethyl acetate/hexanes then 50% MeOH/EtOAc to afford 51 as a pale yellow oil (14 g, 100%). </div>
    <div id="p1292" num="1292" class="description-paragraph">Step 2. Preparation of 2-(bis(4-methoxyphenyl)(phenyl)methoxy)-N-(2-((tert- butyldiniethylsilyl)oxy)ethyl)ethan-l-amine 52 </div>
    <div id="p1293" num="1293" class="description-paragraph"> DMTrO. ^-\^OTBD S </div>
    <div id="p1294" num="1294" class="description-paragraph"> H </div>
    <div id="p1295" num="1295" class="description-paragraph"> To a solution of 2-((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)ethan-l-ol 51 (14 g, 64 mmol) and triethylamine (17.5 mL, 128 mmol) in anhydrous dichloromethane (250 mL) was added 4,4&#39;-Dimethoxytrityl chloride (24 g, 70 mmol). The solution was stirred overnight at room 

 temperature then concentrated in vacuo to dryness. The residue was dissolved in ethyl acetate (300 mL) and washed with water (250 mL) and brine (250 mL). The ethyl acetate was dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. Purification by column chromatography on silica gel 60 (1% to 5% MeOH in CH2CI2) afforded 52 as a pale yellow viscous oil (13 g, 39%). </div>
    <div id="p1296" num="1296" class="description-paragraph">Step 3. Preparation of methyl 10-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2- ((tert-butyldimethylsilyl)oxy)ethyl)amino)-10-oxodecanoate 53 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/bd/d2/c21c551711c954/imgf000189_0001.png"><img id="imgf000189_0001" he="18" wi="43" file="imgf000189_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="172" height="72" alt="Figure imgf000189_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/bd/d2/c21c551711c954/imgf000189_0001.png"/></a></div>
 </div>
    <div id="p1297" num="1297" class="description-paragraph"> A solution of 2-(bis(4-methoxyphenyl)(phenyl)methoxy)-N-(2-((tert- butyldimethylsilyl)oxy)ethyl)ethan-l -amine 52 (5.4 g, 10.3 mmol), monomethyl sebacate (2.2 g, 10.3 g), HBTU (4.9 g, 12.9 mmol), DIPEA (5.3 mL, 30.9 mmol) in N,N-dimethylformamide (100 mL) was stirred for 3 hours at room temperature. Upon completion, the solution was poured into water (400 mL) and extracted with ethyl acetate (1 x 500 mL). The ethyl acetate extract was washed with brine (2 x 250 mL), dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. Purification by column chromatography on silica gel 60 (10% to 25% ethyl acetate in hexanes) afforded 53 as a viscous yellow oil (6.5 g, 87%). </div>
    <div id="p1298" num="1298" class="description-paragraph">Step 4. Preparation of methyl 10-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2- hydroxyethyl)amino)-10-oxodecan 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/21/cf/c9/cc9733406eca14/imgf000189_0002.png"><img id="imgf000189_0002" he="22" wi="38" file="imgf000189_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="152" height="88" alt="Figure imgf000189_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/21/cf/c9/cc9733406eca14/imgf000189_0002.png"/></a></div>
 </div>
    <div id="p1299" num="1299" class="description-paragraph"> To a solution of methyl 10-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2-((tert- butyldimethylsilyl)oxy)ethyl)amino)-10-oxodecanoate 53 (2.0 g, 2.8 mmol) and triethylamine (1 mL) in anhydrous tetrahydrofuran (20 mL) was added TBAF (1M in THF, 3.4 mL, 3.3 mmol). The solution was stirred for 6h, but only partial conversion observed by TLC (5% MeOH in CH2CI2). Additional 1.7 mL TBAF added and the solution was stirred overnight at room temperature. Upon completion, the solution was concentrated in vacuo and purified by column chromatography on silica gel 60 (10%) to 50% EtOAc in hexanes then 100% EtOAc) to afford 54 as a viscous colorless oil (0.5 g, 29%). 

 Step 5. Preparation of lithium 10-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2- hydroxyethyl)amino)-10-oxodecan 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/de/02/8c4e6be716a60b/imgf000190_0001.png"><img id="imgf000190_0001" he="22" wi="38" file="imgf000190_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="152" height="88" alt="Figure imgf000190_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/de/02/8c4e6be716a60b/imgf000190_0001.png"/></a></div>
 </div>
    <div id="p1300" num="1300" class="description-paragraph"> To a solution of methyl 10-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2- hydroxyethyl)amino)-10-oxodecanoate 54 (0.5 g, 0.83 mmol) in THF (40 mL) was added water (10 mL) and lithium hydroxide (24 mg, 1.0 mmol). The solution was stirred overnight at room temperature then concentrated in vacuo to remove the THF. The remaining aqueous solution was flash frozen on liquid nitrogen and lyophilized to afford 55 as a colorless solid (485 mg,</div>
    <div id="p1301" num="1301" class="description-paragraph">95%). </div>
    <div id="p1302" num="1302" class="description-paragraph">Step 6. Preparation of compounds 56, 57, 58 and 50 </div>
    <div id="p1303" num="1303" class="description-paragraph"> Compounds 56, 57, 58 and 50 were prepared using the identical procedures to those used to synthesize compounds 47, 48, 49 and 43 respectfully. </div>
    <div id="p1304" num="1304" class="description-paragraph">Example 7. Synthesis of conjugate 59 </div>
    <div id="p1305" num="1305" class="description-paragraph">Scheme 15. </div>
    <div id="p1306" num="1306" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/98/e3/78/0568e57a3b4cb1/imgf000190_0002.png"><img id="imgf000190_0002" he="76" wi="155" file="imgf000190_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="304" alt="Figure imgf000190_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/98/e3/78/0568e57a3b4cb1/imgf000190_0002.png"/></a></div>
 Scheme 16 </div>
    <div id="p1307" num="1307" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/76/e9/6a/9cf7c9c76095e7/imgf000191_0001.png"><img id="imgf000191_0001" he="118" wi="151" file="imgf000191_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="604" height="472" alt="Figure imgf000191_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/76/e9/6a/9cf7c9c76095e7/imgf000191_0001.png"/></a></div>
    </div>
    <div id="p1308" num="1308" class="description-paragraph"> Step 1. Preparation of methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate 61 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/92/de/92/4f63fdec9d3a52/imgf000191_0002.png"><img id="imgf000191_0002" he="15" wi="25" file="imgf000191_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="100" height="60" alt="Figure imgf000191_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/92/de/92/4f63fdec9d3a52/imgf000191_0002.png"/></a></div>
 </div>
    <div id="p1309" num="1309" class="description-paragraph"> (2R,5R)-5-hydroxypiperidine-2-carboxylic acid 60 (3.5 g, 24.1 mmol) was stirred in MeOH (50 mL). HCl (g) was bubbled through the solution for 2 mins and the reaction stirred at reflux for 1.5 h. The reaction was concentrated in-vacuo to give methyl (2R,5R)-5- hydroxypiperidine-2-carboxylate 61 in quantitative yield which was used without further purification. </div>
    <div id="p1310" num="1310" class="description-paragraph">Step 2. Preparation of l-(tert-butyl) 2-methyl (2R,5R)-5-hydroxypiperidine-l,2- dicarboxylate 62 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/e0/47/fac560d4706b3a/imgf000191_0003.png"><img id="imgf000191_0003" he="17" wi="25" file="imgf000191_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="100" height="68" alt="Figure imgf000191_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/e0/47/fac560d4706b3a/imgf000191_0003.png"/></a></div>
 

 Methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate 61 (24.1 mmol) and TEA (7.2 mL, 53.02 mmol) were stirred in DCM (100 mL) at RT. Di-fert-butyl-di-carbonate (5.7 g, 26.5 mmol) was added in portions and the reaction stirred for 2 h. The reaction was diluted with DCM (100 mL) and washed sequentially with 1 M HCl (2 x 75 mL), saturated NaHC0<sub>3</sub> (2 x 75 mL), H2O (2 x 75 mL) and saturated NaCl solution (2 x75 mL). The organics were separated, dried (NaiSC ) and concentrated in-vacuo to give l-(tert-butyl) 2-methyl (2R,5R)-5- hydroxypiperidine-l,2-dicarboxylate 62 (5.53 g, 88%) which was used without further purification. Step 3. Preparation of tert-butyl (2R,5R)-5-hydroxy-2-(hydroxymethyl)piperidine-l- carboxylate 63 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/41/32/c4/446834c720dc5f/imgf000192_0001.png"><img id="imgf000192_0001" he="17" wi="24" file="imgf000192_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="96" height="68" alt="Figure imgf000192_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/41/32/c4/446834c720dc5f/imgf000192_0001.png"/></a></div>
 </div>
    <div id="p1311" num="1311" class="description-paragraph"> (2R,5R)-l-(tert-Butoxycarbonyl)-5-hydroxypiperidine-2-carboxylic acid 62 (5.53 g, 21.4 mmol) was stirred in THF at 0Â°C. LiBH<sub>4</sub> (3.0 M solution in THF)(8.9 mL, 27.7 mmol) was added dropwise over 1 hr. The reaction was allowed to warm to RT and stirring continued for 16 h. Reaction was quenched with 1M NaOH, THF removed in-vacuo and the aqueous </div>
    <div id="p1312" num="1312" class="description-paragraph">exhaustively extracted with EtOAc (10 x 100 mL). The combined organics were washed with H2O (50 mL), saturated NaCl solution (2 x 50 mL), dried (NaiSC ) and concentrated in-vacuo to give tert-buty\ (2R,5R)-5-hydroxy-2-(hydroxymethyl)piperidine-l-carboxylate 63 (2.4 g, 49.0 %) which was used without further purification. </div>
    <div id="p1313" num="1313" class="description-paragraph">Step 4. Preparation of (3R,6R)-6-(hydroxymethyl)piperidin 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ba/ec/5d/992e7dff647e4a/imgf000192_0002.png"><img id="imgf000192_0002" he="18" wi="26" file="imgf000192_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="104" height="72" alt="Figure imgf000192_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ba/ec/5d/992e7dff647e4a/imgf000192_0002.png"/></a></div>
 </div>
    <div id="p1314" num="1314" class="description-paragraph"> tert-Butyi (2R,5R)-5-hydroxy-2-(hydroxymethyl)piperidine-l-carboxylate 63 (2.4 g, 10.4 mmol) was stirred in ÎÎª2Î at RT. HCl (g) was bubbled through for 45 sees and the reaction stirred at RT for 45 mins. The reaction was concentrated in-vacuo and dried under hi-vac to afford (3R,6R)-6-(hydroxymethyl)piperidin-3-ol 64. The product was used without further purification. 

 Step 5. Preparation of 2,2,2-trifluoro-l-((2R,5R)-5-hydroxy-2-(hydroxymethyl)piperidin-l- yl)ethan-l-one 65 </div>
    <div id="p1315" num="1315" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b1/00/4f/fef6a055a5911f/imgf000193_0001.png"><img id="imgf000193_0001" he="22" wi="24" file="imgf000193_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="96" height="88" alt="Figure imgf000193_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b1/00/4f/fef6a055a5911f/imgf000193_0001.png"/></a></div>
    </div>
    <div id="p1316" num="1316" class="description-paragraph"> Crude (3R,6R)-6-(hydroxymethyl)piperidin-3-ol 64 from the previous reaction was stirred in MeCN (50 mL) with TEA (3.5 mL, 25.2 mmol) at RT. Ethyl trifluoroacetate (3 mL, 25.2 mmol) was added and the reaction stirred at RT for 16 hr, then concentrated in-vacuo to give 2,2,2-trifluoro-l-((2R,5R)-5-hydroxy-2-(hydroxymethyl)piperidin-l-yl)ethan-l-one 65. The product was used without further purification. </div>
    <div id="p1317" num="1317" class="description-paragraph">Step 6. Preparation of l-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)i </div>
    <div id="p1318" num="1318" class="description-paragraph">hydroxypiperidin-l-yl)-2,2,2-trifluor 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/ce/f7/e13d6533a465e1/imgf000193_0002.png"><img id="imgf000193_0002" he="27" wi="31" file="imgf000193_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="124" height="108" alt="Figure imgf000193_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/ce/f7/e13d6533a465e1/imgf000193_0002.png"/></a></div>
 </div>
    <div id="p1319" num="1319" class="description-paragraph"> Crude 2,2,2-trifluoro- 1 -((2R, R)-5 -hydroxy-2-(hy droxymethyl)piperidin- 1 -yl)ethan- 1 - one 65 from the previous reaction was stirred in DCM with TEA (50 mL) at RT. 4,4&#39;- Dimethoxytrityl chloride (DMTrCl) (3.87 g, 11.44 mmol) was added in one portion and the reaction stirred at RT for 3 hours. The reaction was diluted with DCM (50 mL) and washed sequentially with saturated NaHCCb (2 x 75 mL), H2O (2 x 75 mL) and saturated NaCl solution (2 x75 mL). The organics were separated, dried ( a2S04), concentrated in-vacuo and purified by column chromatography (100% hexanes - 60% EtOAc/Hexanes) (0.1 % TEA) to give 1- ((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-hydroxypiperidin-l-yl)-2,2,2- trifluoroethan-l-one 66 (3.14 g, 57%) Step 7. Preparation of (3R,6R)-6-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)- piperidin-3-ol 67 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1b/15/ce/9fc2695618ec80/imgf000193_0003.png"><img id="imgf000193_0003" he="12" wi="27" file="imgf000193_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="108" height="48" alt="Figure imgf000193_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1b/15/ce/9fc2695618ec80/imgf000193_0003.png"/></a></div>
 

 l-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-hydroxypiperidin-l- yl)-2,2,2-trifluoroethan-l-one 66 (3.14 g, 6.0 mmol) was stirred in MeOH (50 mL) at RT. KOH (672 mg, 12 mmol) was added and the reaction stirred at RT for 16 hours. Additional KOH (300 mg, 6 mmol) was added and stirring continued for an additional 24 h. The reaction was concentrated in-vacuo, taken up in DCM (150 mL), washed with H2O (4 x 50 mL), dried (Na2SC&gt;4) and concentrated in-vacuo to give (3R,6R)-6-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)piperidin-3-ol 67 (2.34 g, 90%) which was used without further purification. </div>
    <div id="p1320" num="1320" class="description-paragraph">Step 8. Preparation of methyl 12-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)- methoxy)methyl)-5-hydroxypiperidin-l-yl)-12-oxododecanoate 68 </div>
    <div id="p1321" num="1321" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/db/0e/41/9e367ff0c143fe/imgf000194_0001.png"><img id="imgf000194_0001" he="25" wi="67" file="imgf000194_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="268" height="100" alt="Figure imgf000194_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/db/0e/41/9e367ff0c143fe/imgf000194_0001.png"/></a></div>
    </div>
    <div id="p1322" num="1322" class="description-paragraph"> (3R,6R)-6-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)piperidin-3-ol 67 (2.34 g, 5.34 mmol) was stirred in DCM (75 mL) at RT. Triethylamine (2.2 mL, 16.2 mmol), HATU (3.5 g, 9.2 mmol) and 12-methoxy-12-oxododecanoic acid (1.32 g, 5.4 mmol) were added and the reaction stirred at RT for 3 h. The resultant solid precipitate was removed by filtration, the filtrate concentrated in-vacuo and the residue purified by column chromatography (2.5 </div>
    <div id="p1323" num="1323" class="description-paragraph">%MeOH/DCM, 0.1% TEA) to give methyl 12-((2R,5R)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-5-hydroxypiperidin-l-yl)-12-oxododecanoate 68 in quantitative yield. </div>
    <div id="p1324" num="1324" class="description-paragraph">Step 9. Preparation of lithium 12-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)- methyl)-5-hydroxypiperidi -l-yl)-12-oxododecanoate 69 </div>
    <div id="p1325" num="1325" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/6c/59/08a2a14e05c6b3/imgf000194_0002.png"><img id="imgf000194_0002" he="22" wi="63" file="imgf000194_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="252" height="88" alt="Figure imgf000194_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/6c/59/08a2a14e05c6b3/imgf000194_0002.png"/></a></div>
    </div>
    <div id="p1326" num="1326" class="description-paragraph"> Methyl 12-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5- hydroxypiperidin-l-yl)-12-oxododecanoate 68 (5.4 mmol) and LiOH (140 mg, 5.94 mmol) were stirred in THF:H<sub>2</sub>0 (1 :1, 100 mL) at RT for 48 h. The THF was removed in-vacuo, the aqueous frozen and lyophilized to give lithium 12-((2R,5R)-2-((bis(4- 

 methoxyphenyl)(phenyl)methoxy)methyl)-5-hydroxypiperidin-l-yl)-12-oxododecanoate 69 (3.2 g, 91 %). Which was used in subsequent reactions without additional purification. </div>
    <div id="p1327" num="1327" class="description-paragraph">Step 10. Preparation of compounds 70, 71, 72, and 59 </div>
    <div id="p1328" num="1328" class="description-paragraph"> Compounds 70, 71, 72 and 59 were prepared using the identical procedures to those used to synthesize compounds 47, 48, 49 and 43 respectfully. </div>
    <div id="p1329" num="1329" class="description-paragraph">Example 8. Synthesis of conjugate 142 </div>
    <div id="p1330" num="1330" class="description-paragraph">Scheme 17. </div>
    <div id="p1331" num="1331" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a7/b6/0e/1a9f35931da1c8/imgf000195_0001.png"><img id="imgf000195_0001" he="143" wi="155" file="imgf000195_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="572" alt="Figure imgf000195_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a7/b6/0e/1a9f35931da1c8/imgf000195_0001.png"/></a></div>
 Scheme 18. </div>
    <div id="p1332" num="1332" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9d/95/43/b6da5adc2efe0c/imgf000196_0001.png"><img id="imgf000196_0001" he="90" wi="154" file="imgf000196_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="360" alt="Figure imgf000196_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9d/95/43/b6da5adc2efe0c/imgf000196_0001.png"/></a></div>
    </div>
    <div id="p1333" num="1333" class="description-paragraph">Step 1. Preparation of 3,4,5-Triacetoxybenzoic acid 73 </div>
    <div id="p1334" num="1334" class="description-paragraph"> To a solution of Gallic acid (20 g) in pyridine (50 mL) and acetic anhydride (50 mL). The solution was stirred overnight at room temperature then poured into ice water (1 L). The solution was made acidic with concentrated hydrochloric acid where upon a colorless solid precipitated. The solid was collected via filtration and washed with water (5 x 100 mL). The wet solid was frozen on liquid nitrogen and freeze dried to afford 3,4,5-triacetoxybenzoic acid (26 g, 75%). </div>
    <div id="p1335" num="1335" class="description-paragraph">Step 2. Preparation of 5-((2-((2-Oxo-2-phenyl-lX<sup>2</sup>-ethyl)amino)ethyl)carbamoyl)benzene- 1,2,3-triyl triacetate 74 </div>
    <div id="p1336" num="1336" class="description-paragraph"> To a solution of 3,4,5-triacetoxybenzoic acid (10 g, 33.8 mmol), N-carbobenzoxy-1,2- diaminoethane hydrochloride (5.3 g, 33.8 mmol) and HBTU (13.5 g, 35.5 mmol) in DMF (200 mL) was added DIPEA (17.5 mL, 101 mmol). The solution was stirred for 16 hours then diluted with ethyl acetate (250 mL), washed with brine (3 x 200 mL), dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. The crude product was purified by column chromatography on silica gel (Gradient 1% to 5% MeOH in DCM) to afford 5-((2-((2-Oxo-2- phenyl-^<sup>2</sup>-ethyl)amino)ethyl)carbamoyl)benzene-l,2,3-triyl triacetate as an off white solid (5.5 g). 

 Step 3. Preparation of 3,4,5-Trihydroxy-N-(2-((2-oxo-2-phenyl-l <sup>2</sup>- ethyl)amino)ethyl)benzamide 75 </div>
    <div id="p1337" num="1337" class="description-paragraph"> A solution of 5-((2-((2-Oxo-2-phenyl- <sup>2</sup>-ethyl)amino)ethyl)carbamoyl)benzene-l,2,3- triyl triacetate (5 g, 1.1 mmol) in 1 : 1 MeOH / CH2CI2 (100 mL) was stirred for 3 days at room temperature. Upon completion the solvent was removed to afford 3,4,5-Trihydroxy-N-(2-((2- oxo-2-phenyl- <sup>2</sup>-ethyl)amino)ethyl)benzamide as a colorless solid (4 g, quantitative). </div>
    <div id="p1338" num="1338" class="description-paragraph">Step 4. Preparation of Trimethyl 2,2\2&#34;-((5-((2-((2-oxo-2-phenyl-l <sup>2</sup>- ethyl)amino)ethyl)carbamoyl)benzene-l,2,3-triyl)tris(oxy))triacetate 76 </div>
    <div id="p1339" num="1339" class="description-paragraph"> A solution of 3,4,5-Trihydroxy-N-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)ethyl)benzamide</div>
    <div id="p1340" num="1340" class="description-paragraph">(4 g, 11.6 mmol), methyl bromoacetate (7.7 g, 46.4 mmol) and potassium carbonate (9.6 g, 69.4 mmol) in DMF (100 mL) was stirred overnight at 60 Â°C. Upon completion the solution was cooled to room temperature, diluted with ethyl acetate (200 mL), washed with water (200 mL), brine (3 x 100 mL), dried on magnesium sulfate, filtered and concentrated in vacuo to dryness. The crude product was purified by column chromatography on silica gel (Gradient 2% to 10% MeOH in DCM) to afford trimethyl 2,2&#39;,2&#34;-((5-((2-((2-oxo-2-phenyl-U<sup>2</sup>- ethyl)amino)ethyl)carbamoyl)benzene-l,2,3-triyl)tris(oxy))-triacetate as a beige solid (5 g, 79%) </div>
    <div id="p1341" num="1341" class="description-paragraph">Step 5. Preparation of 2,2&#39;,2&#34;-((5-((2-((2-Oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)ethyl)- carbamoyl)benzene-l,2,3-triyl)tris(oxy))triacetic acid 77 </div>
    <div id="p1342" num="1342" class="description-paragraph"> A solution of trimethyl 2,2&#39;,2&#34;-((5-((2-((2-oxo-2-phenyl- <sup>2</sup>-ethyl)amino)ethyl)- carbamoyl)benzene-l,2,3-triyl)tris(oxy))triacetate (5 g, 9.2 mmol) and lM aOH (30 mL) in methanol (100 mL) was stirred for 2 hours at room temperature. Upon completion the reaction was concentrated to remove the methanol and diluted with water (75 mL). The mixture was cooled to 0Â°C, acidified with 2M HC1 and extracted with ethyl acetate (5 x 150 mL). The combined ethyl acetate extracts were dried on magnesium sulfate, filtered and concentrated in vacuo to dryness to afford 2,2&#39;,2&#34;-((5-((2-((2-Oxo-2-phenyl-a<sup>2</sup>- ethyl)amino)ethyl)carbamoyl)benzene-l,2,3-triyl)tris(oxy))triacetic acid as a colorless solid (2.3 g, 50%). </div>
    <div id="p1343" num="1343" class="description-paragraph">Step 6. Preparation of Compound 78 </div>
    <div id="p1344" num="1344" class="description-paragraph"> Compound 78 was prepared from compounds 9 (2.75 g, 4.3 mmol) and 77 (0.5 g, 0.96 mmol) using an identical procedure to that used for compound 13. Yield: 600 mg. 

 Step 7. Preparation of Compound 79 </div>
    <div id="p1345" num="1345" class="description-paragraph"> Compound 79 was prepared from compounds 78 (0.6 g) using an identical procedure to that used for compound 14. Yield: 500 mg. </div>
    <div id="p1346" num="1346" class="description-paragraph">Step 8. Preparation of compound 140 </div>
    <div id="p1347" num="1347" class="description-paragraph"> Compound 140 was prepared from compound 79 (500 mg, 0.25 mmol) and compound 18 (175 mg, 0.25 mmol) using an identical procedure to that used for compound 19. Yield: 250 mg, 44%. </div>
    <div id="p1348" num="1348" class="description-paragraph">Step 9. Preparation of compound 141 </div>
    <div id="p1349" num="1349" class="description-paragraph"> Compound 141 was prepared from compound 140 (250 mg, 0.11 mmol) using an identical procedure to that used for compound 20. Yield: 200 mg </div>
    <div id="p1350" num="1350" class="description-paragraph">Step 10. Preparation of conjugate 142 </div>
    <div id="p1351" num="1351" class="description-paragraph"> Conjugate 142 was prepared from compound 141 (200 mg) and 1000A lcaa CPG (1.8 g) using an identical procedure to that used for compound 1. Yield: 1.9 g, 22 Î¼Î¹Î·Î¿Î/g CPG loading. The resulting GalNAc loaded CPG solid support was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded the GalNAc- oligonucleotide conjugate 142. </div>
    <div id="p1352" num="1352" class="description-paragraph">Example 9. Synthesis of conjugate 145 </div>
    <div id="p1353" num="1353" class="description-paragraph">Scheme 19. </div>
    <div id="p1354" num="1354" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/00/e5/7b/bbb4eb692ef6db/imgf000198_0001.png"><img id="imgf000198_0001" he="57" wi="156" file="imgf000198_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="228" alt="Figure imgf000198_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/00/e5/7b/bbb4eb692ef6db/imgf000198_0001.png"/></a></div>
    </div>
    <div id="p1355" num="1355" class="description-paragraph"> 126 127 128 

 Scheme 20. </div>
    <div id="p1356" num="1356" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/bb/ae/3b615570104f57/imgf000199_0001.png"><img id="imgf000199_0001" he="48" wi="147" file="imgf000199_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="588" height="192" alt="Figure imgf000199_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/bb/ae/3b615570104f57/imgf000199_0001.png"/></a></div>
    </div>
    <div id="p1357" num="1357" class="description-paragraph"> 3) Deptrotection </div>
    <div id="p1358" num="1358" class="description-paragraph">Step 1. Preparation of (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4- c]pyrrole-l,3(3aH)-dione 123 </div>
    <div id="p1359" num="1359" class="description-paragraph"> To a cooled solution (0Â°C) of 3,4-dimethylfuran-2,5-dione (3 g, 24 mmol) and N-benzyl- l-methoxy-N-((trimethylsilyl)methyl)methanamine (7 g, 29.8 mmol) in dichloromethane (75 mL) was slowly added trifluoroacetic acid (75 Î¼Î,). Stir overnight allowing the solution to slowly warm to room temperature as the ice bath melted. The reaction mixture was concentrated to dryness, dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate (2 x lOOmL), dried on magnesium sulfate, filtered and concentrated to dryness. Purification by column chromatography on silica gel (gradient: 20% ethyl acetate in hexanes to 100% ethyl acetate) afforded (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4-c]pyrrole- l,3(3aH)-dione as a yellow oil (3.5 g, 56%) </div>
    <div id="p1360" num="1360" class="description-paragraph">Step 2. Preparation of ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4-diyl)dimethanol 124</div>
    <div id="p1361" num="1361" class="description-paragraph">To a cooled (0Â°C) solution of (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH- furo[3,4-c]pyrrole-l,3(3aH)-dione (3.5 g, 13.4 mmol) in anhydrous diethyl ether (50 mL) was added slowly lithium aluminum hydride pellets (1.5 g, 40 mmol) over three portions. The solution was stirred overnight warming to room temperature as the ice water bath melted. Upon completion, the reaction was cooled to 0Â°C and very slowly quenched with 1.5 mL of 5M NaOH followed by 1.5 mL of water. Stir for 30 minutes then add magnesium sulfate and filter. The filtrate was concentrated to afford ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4- diyl)dimethanol as a colorless oil (2.7 g) 

 Step 3. Preparation of ((3R,4S)-3,4-Dimethylpyrrolidine-3,4-diyl)dimethanol 125 </div>
    <div id="p1362" num="1362" class="description-paragraph"> To a solution of ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4-diyl)dimethanol (10 g, 40 mmol) in methanol (10 mL) was added 10% palladium on activated charcoal wet (1 g). The solution was stirred vigorously under a hydrogen atmosphere for 16 hours. Upon completion the solution was filtered through Celite, and concentrated to dryness to afford ((3R,4S)-3,4- Dimethylpyrrolidine-3,4-diyl)dimethanol as a colorless solid (5.5 g, 86%). </div>
    <div id="p1363" num="1363" class="description-paragraph">Step 4. Preparation of Methyl 10-((3R,4S)-3,4-bis(hydroxymethyl)-3,4-dimethylpyrrolidin- l-yl)-10-oxodecanoate 126 </div>
    <div id="p1364" num="1364" class="description-paragraph"> Compound 126 was prepared from compound 125 (1.3 g, 8.2 mmol) and monomethyl sebacate (1.8 g, 8.2 mmol) using an identical procedure to that used for compound 17. Yield: 1.8 g, 61%. </div>
    <div id="p1365" num="1365" class="description-paragraph">Step 5. Preparation of Methyl 10-((3R,4S)-3-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)- 10-oxodecanoate 127 </div>
    <div id="p1366" num="1366" class="description-paragraph"> Compound 127 was prepared from compound 126 (1.8 g, 5.0 mmol) and 4,4&#39;- Dimethoxytrityl chloride (1.7 g, 5.0 mmol) using an identical procedure to that used for compound 18. Yield: 1.4 g, 42%. </div>
    <div id="p1367" num="1367" class="description-paragraph">Step 6. Preparation of Lithium 10-((3R,4S)-3-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)- 10-oxodecanoate 128 </div>
    <div id="p1368" num="1368" class="description-paragraph"> To a solution of compound 127 (3.0 g, 4.6 mmol) in THF (50 mL) and water (50 mL) was added lithium hydroxide (121 mg, 5.0 mmol). The solution was stirred for 4 hours at room temperature then concentrated to remove the THF. The remaining aqueous solution was freeze dried overnight to afford a pale pink solid (2.9 g, quantitative) </div>
    <div id="p1369" num="1369" class="description-paragraph">Step 7. Preparation of compound 143 </div>
    <div id="p1370" num="1370" class="description-paragraph"> Compound 143 was prepared from compound 128 (270 mg, 0.42 mmol) and compound</div>
    <div id="p1371" num="1371" class="description-paragraph">14 (800 mg, 0.42 mmol) using an identical procedure to that used for compound 19. Yield: 900 mg, 87%. 

 Step 8. Preparation of compound 144 </div>
    <div id="p1372" num="1372" class="description-paragraph"> Compound 144 was prepared from compound 143 (500 mg, 0.2 mmol) using an identical procedure to that used for compound 20. Yield: 200 mg </div>
    <div id="p1373" num="1373" class="description-paragraph">Step 9. Preparation of conjugate 145 </div>
    <div id="p1374" num="1374" class="description-paragraph"> Conjugate 145 was prepared from compound 144 (200 mg) and 1000A lcaa CPG (1.8 g) using an identical procedure to that used for compound 1. Yield: 1.9 g, 20 Î¼Î¹Î·Î¿Î/g CPG loading. The resulting GalNAc loaded CPG solid support was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded the GalNAc- oligonucleotide conjugate 145. </div>
    <div id="p1375" num="1375" class="description-paragraph">Example 10. Synthesis of conjugate 150 </div>
    <div id="p1376" num="1376" class="description-paragraph">Scheme 21. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/83/a0/c8/d36c463a77fdbf/imgf000201_0001.png"><img id="imgf000201_0001" he="14" wi="74" file="imgf000201_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="296" height="56" alt="Figure imgf000201_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/83/a0/c8/d36c463a77fdbf/imgf000201_0001.png"/></a></div>
 </div>
    <div id="p1377" num="1377" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9f/b1/44/9095cae396fad8/imgf000201_0002.png"><img id="imgf000201_0002" he="35" wi="142" file="imgf000201_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="568" height="140" alt="Figure imgf000201_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9f/b1/44/9095cae396fad8/imgf000201_0002.png"/></a></div>
    </div>
    <div id="p1378" num="1378" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/2a/81/fd21326e81ba47/imgf000201_0003.png"><img id="imgf000201_0003" he="21" wi="115" file="imgf000201_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="460" height="84" alt="Figure imgf000201_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/2a/81/fd21326e81ba47/imgf000201_0003.png"/></a></div>
    </div>
    <div id="p1379" num="1379" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/80/6e/ed/eebc46aee1ada4/imgf000201_0004.png"><img id="imgf000201_0004" he="21" wi="155" file="imgf000201_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="84" alt="Figure imgf000201_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/80/6e/ed/eebc46aee1ada4/imgf000201_0004.png"/></a></div>
    </div>
    <div id="p1380" num="1380" class="description-paragraph"> 3) Deptrotection 

 Step 1. Preparation of 146-1 </div>
    <div id="p1381" num="1381" class="description-paragraph"> To a solution of mono methyl ester of dodecanedioic acid (12.2 g, 50.0 mmol) in dichloromethane (300 mL) was added N-hydroxysuccinimide (6.10g, 53.0 mmol) and 1 -ethyl -3- (3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (10.52g, 55.0 mmol). The cloudy mixture was stirred overnight at room temperature and the reaction became a clear solution. TLC indicated the reaction was completed. The organics were washed with saturated Â¾C1 (300 mL) and brine (100 mL). The organic layer was separated, dried over MgS04 and concentrated to dryness to pure l-(2,5-dioxopyrrolidin-l-yl) 12-methyl dodecanedioate 146-1 as a white solid (16.7g, 97.8%). </div>
    <div id="p1382" num="1382" class="description-paragraph">Step 2. Preparation of cyclopent-3-en-l-ylmethanol 146-2 </div>
    <div id="p1383" num="1383" class="description-paragraph"> To a suspension of lithium aluminum hydride (15.2g, 0.40 mol) in anhydrous ether (1 L) at 0Â°C under nitrogen, was added the solution of methyl cyclopent-3-enecarboxylate (50 g, 0.40 mol) in ether (300 mL) dropwise over 5 hrs. The suspension was stirred at room temperature overnight. TLC indicated the completion of the reaction. The reaction was re-cooled to 0Â°C. Saturated solution of Na2S04 (32 mL) was added dropwise to quench the reaction. After the addition was complete, the mixture was stirred for another 3 hrs and was filtered through a pad of celite. Evaporation of solvent afforded cyclopent-3-enylmethanol 146-2 (37.3 g, 95 %) as a colorless liquid. </div>
    <div id="p1384" num="1384" class="description-paragraph">Step 3. Preparation of (6-oxabicyclo[3.1.0]hexan-3-yl)methanol 146-3 </div>
    <div id="p1385" num="1385" class="description-paragraph"> To a solution of cyclopent-3-enylmethanol 146-2 (4.0 g, 41 mmol) in dichloromethane (150 mL) at 0Â°C was added 3-chloroperbenzoic acid (10 g, 45 mmol, 77% purity) by portion. The reaction was stirred overnight. Dichloromethane (150 mL) was added. The organics was washed with sodium thiosulfate (12 g in 10 mL water), followed by saturated NaHCCb (40 mL). This was repeated till all the remaining 3-chloroperbenzoic acid was washed away. The organic was dried over MgSC . Evaporation of solvent gave a mixture of cis- and trans- 6- oxabicyclo[3.1.0]hexan-3-ylmethanol 146-3 (2.6 g, 57 %) as a yellow oil. GC-MS: m/z 114 (5) (M<sup>+</sup>), 95 (15), 88 (100), 81 (15). </div>
    <div id="p1386" num="1386" class="description-paragraph">Step 4. Preparation of 2-amino-4-(hydroxymethyl)cyclopentan-l-ol 146-4 </div>
    <div id="p1387" num="1387" class="description-paragraph"> To a solution of 6-oxabicyclo[3.1.0]hexan-3-ylmethanol 146-3 (2.0g, 17.6 mmol) in methanol (20 mL) at 0Â°C was purged ammonia gas for 10 min. The reaction was stirred at room temperature overnight. TLC indicated the incompletion of the reaction. Methanol was removed 

 and Â¾ H2O (50 mL) was added and this was stirred at room temperature over a week. TLC confirmed the completion of the reaction. Water was removed by azeotropically with ethanol to afford 2-amino-4-(hydroxymethyl)cyclopentanol 146-4 (2.1 g, 91%) as a yellow oil. Step 5. Preparation of Methyl 12-(2-hydroxy-4-(hydroxymethyl)cyclopentylamino)-12- oxododecanoate 146-5 </div>
    <div id="p1388" num="1388" class="description-paragraph"> Compound 146-5 was prepared from 2-amino-4-(hydroxymethyl)cyclopentanol 146-4 and l-(2,5-dioxopyrrolidin-l-yl) 12-methyl dodecanedioate 146-1, using the same procedure as described in the synthesis of 12-(2-(/ert-butoxycarbonylamino)ethylamino)-12-oxododecanoate (3-2). Methyl 12-(2-hydroxy-4-(hydroxymethyl)cyclopentylamino)-12-oxododecanoate 146-5 was obtained in 87.4% yield as an off-white solid. </div>
    <div id="p1389" num="1389" class="description-paragraph">Step 6. Preparation of compound 147 </div>
    <div id="p1390" num="1390" class="description-paragraph"> Compound 147 was prepared quantitatively from compound 146 (1.4 g, 2.33mmol) using an identical procedure to that used for compound 18. </div>
    <div id="p1391" num="1391" class="description-paragraph">Step 7. Preparation of compound 148 </div>
    <div id="p1392" num="1392" class="description-paragraph"> Compound 148 was prepared from compound 147 (150mg, 0.23mmol) and compound 14 (43 lmg, 0.23mmol) using an identical procedure to that used for compound 19. Yield: </div>
    <div id="p1393" num="1393" class="description-paragraph">460mg, 84%. </div>
    <div id="p1394" num="1394" class="description-paragraph">Step 8. Preparation of compound 149 </div>
    <div id="p1395" num="1395" class="description-paragraph"> Compound 149 was prepared from compound 148 (460mg, 0.19mmol) using an identical procedure to that used for compound 20. Yield: 436mg, 91%. </div>
    <div id="p1396" num="1396" class="description-paragraph">Step 9. Preparation of conjugate 150 </div>
    <div id="p1397" num="1397" class="description-paragraph"> Compound 150 was prepared from compound 149 (436mg) and 1000A lcaa CPG (2.62g) using an identical procedure to that used for compound 1. Yield: 2.7g, 21.3 mol/g CPG loading. The resulting GalNAc loaded CPG solid support was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded the GalNAc- oligonucleotide conjugate 150. 

 Example 11. Synthesis of conjugates 153, 158, 163, 168 and 173 </div>
    <div id="p1398" num="1398" class="description-paragraph">Scheme 22. </div>
    <div id="p1399" num="1399" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b2/23/ad/c728f456629c04/imgf000204_0001.png"><img id="imgf000204_0001" he="117" wi="155" file="imgf000204_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="468" alt="Figure imgf000204_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b2/23/ad/c728f456629c04/imgf000204_0001.png"/></a></div>
    </div>
    <div id="p1400" num="1400" class="description-paragraph">Step 1. Preparation of l-(tert-butyl) 2-methyl (2S,4R)-4-hydroxypyrrolidine-l,2- dicarboxylate (133) </div>
    <div id="p1401" num="1401" class="description-paragraph"> Methyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate (25.9 g, 46 mmol), BOC anhydride (65.9 g, 302.5 mmol) and TEA (42 ml, 302.5 mmol) were stirred in DCM at RT for 16 h. The organics were washed sequentially with 1M HCl (x2), saturated NaHCC (x2), Î<sub>2</sub>0 and brine, dried and concentrated in-vacuo to give l-(tert-butyl) 2-methyl (2S,4R)-4-hydroxypyrrolidine- 1,2-dicarboxylate (133) (58. lg, 85%) </div>
    <div id="p1402" num="1402" class="description-paragraph">Step 2. Preparation of l-(tert-butyl) 2-methyl (4R)-4-hydroxy-2-methylpyrrolidine-l,2- dicarboxylate (134) </div>
    <div id="p1403" num="1403" class="description-paragraph"> l-(tert-butyl) 2-methyl (2S,4R)-4-hydroxypyrrolidine-l,2-dicarboxylate (133) (5g, 20.4 mmol) and Mel (12 g, 84.5 mmol) were stirred in anhydrous THF at -40Â°C. LDA (2.0 M solution in THF) (37.5 mL, 75 mmol) was added dropwise. The reaction was allowed to warm to RT and stirred for 4 h then quenched with saturated NH4CI. The reaction was extracted with EtOAc, washed with H2O and brine, dried (INfeSC ) and concentrated in-vacuo. The residue was 

 purified by column chromatography 50:50 EtOAc//hexanes to give 1 -(tert-butyl) 2-methyl (4R)- 4-hydroxy-2-methylpyrrolidine-l,2-dicarboxylate (134) as a racemic mixture (3.6 g, 68%) </div>
    <div id="p1404" num="1404" class="description-paragraph">Step 3. Preparation of tert-butyl (2S,4R)-4-hydroxy-2-(hydroxymethyl)-2- methylpyrrolidine-l-carboxylate (135a) </div>
    <div id="p1405" num="1405" class="description-paragraph"> 1 -(Tert-butyl) 2-methyl (4R)-4-hydroxy-2-methylpyrrolidine-l,2-dicarboxylate (134) (19g, 73.5 mmol) was stirred in anhydrous THF under N<sub>2</sub>. L1BH4 solution (48 ml, 96 mmol) was added dropwise and the reaction stirred at RT for 48 h. The reaction was quenched with 1M NaOH, the THF removed in-vacuo and the residual extracted with EtOAc (4 x 100ml). The organics were washed with H2O and brine, dried (Na2S04) and concentrated in-vacuo. The residue was purified by column chromatography (5% MeOH/DCM) to give tert-butyl (2S,4R)-4- hydroxy-2-(hydroxymethyl)-2-methylpyrrolidine-l-carboxylate (135a) as the major product (8g, 47%). Structure assigned according to literature references Step 4. Preparation of (3R,5S)-5-(hydroxymethyl)-5-methylpyrrolidin-3-ol hydrochloride (136) </div>
    <div id="p1406" num="1406" class="description-paragraph"> tert-Butyl (2S,4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidine- 1 -carboxylate (135a) (8g, 34.6 mmol) was stirred in EtOAc at RT and gaseous HC1 applied for approximately two minutes. The reaction was stirred for one hour then concentrated in-vacuo and dried under high vacuum to give (3R,5S)-5-(hydroxymethyl)-5-methylpyrrolidin-3-ol hydrochloride (136) in quantitative fashion. </div>
    <div id="p1407" num="1407" class="description-paragraph">Step 5. Preparation of methyl 12-((2S,4R)-4-hydroxy-2-(hydroxymethyl)-2- methylpyrrolidin-l-yl)-12-oxododecanoate (137) </div>
    <div id="p1408" num="1408" class="description-paragraph">(3R,5S)-5-(Hydroxymethyl)-5-methylpyrrolidin-3-ol hydrochloride (136) (7.9 g, 47.4 mmol), 12-methoxy-12-oxododecanoic acid (11.5 g, 47.4 mmol), HBTU (36 g, 76 mmol) and TEA 20 mL, 142.2 mmol) were stirred in DCM at RT for 16h. The precipitate was removed by filtration and the organics washed with 1M HC1 (x2), saturated NaHCC (x2), H<sub>2</sub>0 and brine. After drying the organics were concentrated in-vacuo and purified by column chromatography (5%MeOH/DCM) to give methyl 12-((2S,4R)-4-hydroxy-2-(hydroxymethyl)-2- methylpyrrolidin-l-yl)-12-oxododecanoate (137) (3.1 g, 18.3 %) 

 Step 6. Preparation of methyl 12-((2S,4R)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-2-methylpyrrolidin-l-yl)-12- oxododecanoate (138) </div>
    <div id="p1409" num="1409" class="description-paragraph"> Methyl 12-((2S,4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidin- 1 -yl)- 12- oxododecanoate (137) (3.1 g, 9.0 mmol), DMTr-Cl (2.8 g, 8.2 mmol) and TEA (1.1 ml, 8.2 mmol) were stirred in DC&lt; at RT for 16 h. The reaction was concentrated in-vacuo and the residue purified by column chromatography (5% MeOH DCM, 0.1%TEA) to give methyl 12- ((2S,4R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-2-methylpyrrolidin-l- yl)-12-oxododecanoate (138) (2.7 g, 45.5 mmol). </div>
    <div id="p1410" num="1410" class="description-paragraph">Scheme 23 </div>
    <div id="p1411" num="1411" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/6b/65/5b816010673c44/imgf000206_0001.png"><img id="imgf000206_0001" he="62" wi="121" file="imgf000206_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="484" height="248" alt="Figure imgf000206_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/6b/65/5b816010673c44/imgf000206_0001.png"/></a></div>
    </div>
    <div id="p1412" num="1412" class="description-paragraph"> Step 7. Preparation of Compound 154-1 </div>
    <div id="p1413" num="1413" class="description-paragraph"> To a solution of N-(2-hydroxyethyl)phthalimide (4.80 g, 25.0 mmol) and 4,4&#39;- dimethoxytrityl chloride (8.8 g, 26.0 mmol) in dichloromethane (200 mL) at 0Â°C under nitrogen, was added triethylamine (10.4 mL, 74.6 mmol) dropwise. The reaction mixture was stirred at room temperature for 3 hrs. TLC indicated the completion of the reaction. The organic layer was washed with brine (100 mL), dried over MgSC , and concentrated to dryness. This was used directly for the next reaction without purification. </div>
    <div id="p1414" num="1414" class="description-paragraph">Step 8. Preparation of Compound 154-2 </div>
    <div id="p1415" num="1415" class="description-paragraph"> 2-(2-(Bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)isoindoline-l,3-dione (154-1) obtained above and hydrazine monohydrate (3.6 mL, 74 mmol) in ethanol (100 mL) was stirred overnight at room temperature. TLC indicated the completion of the reaction. The precipitate was filtered out. The filtrate was evaporated. The residue was taken up by ethyl acetate (100 

 mL). The organic solution was washed with 10% NaOH, water and brine, and dried over MgS04. Evaporation of solvent afforded 2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine (154-2) as a yellow liquid (8.1 lg, 89.3% yield over two steps). This was used for the next reaction without further purification. </div>
    <div id="p1416" num="1416" class="description-paragraph">Step 9. Preparation of Compound 154-3 </div>
    <div id="p1417" num="1417" class="description-paragraph"> To a solution of L-threonine (1.19g, 10.0 mmol) and NaHCC (2.3g, 27 mmol) in water (20 mL) and dioxane (10 mL), was added l-(2,5-dioxopyrrolidin-l-yl) 12-methyl </div>
    <div id="p1418" num="1418" class="description-paragraph">dodecanedioate 146-1 (3. lg, 9.1 mmol) in dioxane (10 mL) dropwise. The reaction mixture was stirred at room temperature overnight. 4N HC1 (10 mL) was added. The precipitate was collected by filtration and washed with water (3 x 10 mL). The solid was dried over P2O5 in a desiccator to afford (2S,3R)-3-hydroxy-2-(12-methoxy-12-oxododecanamido)butanoic acid 154- 3 as an off-white solid (2.84g, 82.2%). LC-MS (ESI): m/z: 346 (100), (M + H<sup>+</sup>). Step 10. Preparation of Compound 154 </div>
    <div id="p1419" num="1419" class="description-paragraph"> (2S,3R)-3-hydroxy-2-(12-methoxy-12-oxododecanamido)butanoic acid 154-3 (2.47g, 7.15 mmol), 2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethanamine 154-2 (2.60g, 7.15 mmol), EDC (1.64g, 8.58 mmol), 1-hydroxybenzotriazole (HOBt) (1.16g, 8.58 mmol) and TEA (2.4 mL, 17.2 mmol) were stirred in dichloromethane (72 mL) at room temperature for 2 hrs. Water (30 mL) was added. The organic layer was separated and washed with brine (2 x30 mL). </div>
    <div id="p1420" num="1420" class="description-paragraph"> Evaporation of solvent followed by column chromatography (30% ethyl acetate/hexanes -50% ethyl acetate/hexanes) afforded methyl 12-((2S,3R)-l-(2-(bis(4- methoxyphenyl)(phenyl)methoxy)ethylamino)-3-hydroxy-l-oxobutan-2-ylamino)-12- oxododecanoate 154 as a waxy yellow semi-solid (2.60g, 52.6%). <sup>1</sup>HNMR (400MHz, acetone- d6, ppm): Î´ 7.51 (t, J = 5.5 Hz, 1H), 7.45-7.49 (m, 2H), 7.28-7.36 (m, 6H), 7.21 (tt, J = 7.2, 1.2 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 6.88 (dt, J = 8.9, 2.5 Hz, 4H), 4.39 (dd, J = 8.2, 3.0 Hz, 1H), 4.20-4.27 (m, 1H), 3.78 (s, 6H), 3.60 (s, 1H), 3.35-3.52 (m, 2H), 3.07-3.16 (m, 2H), 2.23-2.37 (m, 4H), 1.53-1.65 (m, 4H), 1.23-1.36 (m, 12H), 1.10 (d, J = 6.4 Hz, 3H). 

 cheme 24 </div>
    <div id="p1421" num="1421" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6a/3d/0f/1140e2d26e7458/imgf000208_0001.png"><img id="imgf000208_0001" he="55" wi="130" file="imgf000208_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="520" height="220" alt="Figure imgf000208_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6a/3d/0f/1140e2d26e7458/imgf000208_0001.png"/></a></div>
    </div>
    <div id="p1422" num="1422" class="description-paragraph"> 164-4 164 </div>
    <div id="p1423" num="1423" class="description-paragraph">Step 11. Preparation of Compound 164-1 </div>
    <div id="p1424" num="1424" class="description-paragraph"> To a suspension of potassium t-butoxide (14.6 g, 130 mol) in THF (120 mL)/ether (360 mL) was added methyltriphenylphosphonium bromide (46.6 g, 130 mmol). The mixture was refluxed for 2 hrs and then cooled to 0Â°C. tert-but l 2-formylpyrrolidine-l-carboxylate (13. Og, 65.2 mmol) in ether (50 mL) was added dropwise. The reaction mixture was stirred at 0Â°C and then quenched by the addition of water (250 mL). The organic layer was separated and the aqueous was extracted with ether (250 mL). The combined extract was dried over MgS04. Evaporation of solvent, followed by column chromatography purification (5% ethyl acetae/hexanes) gave fert-butyl 3-vinylpyrrolidine-l-carboxylate 164-1 (1 1.5g, 89.4%) as a colorless liquid. GC-MS: m/z: 197 (2) (M<sup>+</sup>), 141 (40), 124 (30), 57 (100). Step 12. Preparation of Compound 164-2 </div>
    <div id="p1425" num="1425" class="description-paragraph"> To a mixture of /-BuOH (140 mL) and water (70 mL), was charged AD-mix-Î² (47.4 g) and methanesulfonamide (2.89 g, 30.4 mmol). The mixture was stirred at room temperature for 30 min and was then cooled to 0Â°C. tert- utyl 3-vinylpyrrolidine-l -carboxylate 164-1 (6.00g, 30.4 mmol) was added. The reaction was stirred at room temperature overnight. The reaction mixture was cooled to 0Â°C. Sodium thiosulfate pentahydrate (96 g, 387 mmol) was added and the temperature was allowed to warm to room temperature. Water (700mL) was added and the mixture was extracted with ethyl acetate (500 mL). The extract was washed with water (2 x 50 mL) and brine (50 mL), and dried over MgSC . Evaporation of solvent, followed by column chromatography (2% methanol/dichloromethane - 7% methanol/dichloromethane) gave tert- butyl 3-(l,2-dihydroxyethyl)pyrrolidine-l-carboxylate 164-2 (5.4 g, 77%) as a light brown oil. 

 Step 13. Preparation of Compound 164-3 </div>
    <div id="p1426" num="1426" class="description-paragraph"> To a solution of ferZ-butyl 3-(l,2-dihydroxyethyl)pyrrolidine-l-carboxylate 164-2 (3.1g, 13.4 mmol) in ethanol (10 mL) was added 3N HCl (30 mL, 90 mmol). The reaction mixture was stirred at room temperature overnight. TLC indicated the completion of the reaction. Ethanol was evaporated. Toluene was added and evaporated. This was repeated three times to give 1- (pyrrolidin-3-yl)ethane-l ,2-diol hydrochloride 164-3 (2.0g, 89%) as a brown oil. LC-MS (ESI): m/z: 132 (100), (M + H<sup>+</sup>, free amine). </div>
    <div id="p1427" num="1427" class="description-paragraph">Step 14 Preparation of Compound 164-4 </div>
    <div id="p1428" num="1428" class="description-paragraph"> To a solution of l -(pyrrolidin-3-yl)ethane-l,2-diol hydrochloride 164-2 (2.0g, 12 mmol) in water (30 mL) was added NaHCCb (3.7g, 44 mmol) by portion. Dioxane (20 mL) was then added. To the above solution was added l-(2,5-dioxopyrrolidin-l-yl) 12-methyl dodecanedioate 146-1 (3.7g, 1 1 mmol) in dioxane (30 mL). The reaction mixture was stirred overnight. This was extracted with ethyl acetate (3 xlOO mL). The combined extract was washed with 0.5N HCl (50 mL) and brine (50 mL), and dried over MgSC . </div>
    <div id="p1429" num="1429" class="description-paragraph">Step 15. Preparation of Compound 164 </div>
    <div id="p1430" num="1430" class="description-paragraph"> This substance was prepared from methyl 12-(3-(l ,2-dihydroxyethyl)pyrrolidin-l-yl)-12- oxododecanoate 164-4 and 4,4-dimethoxytrityl chloride (1 eq) using the same procedure as described in the synthesis of 2-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)isoindoline-l,3- dione 138. The product was purified by column chromatography (1.5% </div>
    <div id="p1431" num="1431" class="description-paragraph">methanol/dichloromethane). Methyl 12-(3-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)-l- hydroxyethyl)pyrrolidin-l-yl)-12-oxododecanoate 164 was obtained in 51% yield as a yellow oil. <sup>1</sup>HNMR (400MHz, acetone-d6, ppm): Î´ 7.49-7.54 (m, 2H), 7.35-7.40 (m, 4H), 7.28-7.34 (m, 2H), 7.19-7.25 (m, 1H), 6.86-6.91 (m, 4H), 4.1 1-4.20 (m, 1H), 3.79 (s, 6H), 3.68-3.77 (m, 1H), 3.60 (s, 3H), 3.29-3.59 (m, 3H), 3.06-3.20 (m, 3H), 2.33-2.55 (m, 1H), 2.29 (t, J = 7.4 Hz, 2H), 2.19 (t, J = 7.6 Hz, 2H), 1.65-2.0 (m, 2H), 1.51-1.62 (m, 4H), 1.26-1.35 (m, 12H). 

 Scheme 25 </div>
    <div id="p1432" num="1432" class="description-paragraph"> NHBoc</div>
    <div id="p1433" num="1433" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/96/a4/b7b94ae97120fc/imgf000210_0001.png"><img id="imgf000210_0001" he="11" wi="103" file="imgf000210_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="412" height="44" alt="Figure imgf000210_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/96/a4/b7b94ae97120fc/imgf000210_0001.png"/></a></div>
    </div>
    <div id="p1434" num="1434" class="description-paragraph"> 170-1 170-2 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/7c/41/4fbc4a9f48055c/imgf000210_0002.png"><img id="imgf000210_0002" he="18" wi="156" file="imgf000210_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="624" height="72" alt="Figure imgf000210_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/7c/41/4fbc4a9f48055c/imgf000210_0002.png"/></a></div>
 </div>
    <div id="p1435" num="1435" class="description-paragraph"> 170-3 170-4 170-5 </div>
    <div id="p1436" num="1436" class="description-paragraph"> DDMMTTCCII - <sub>H</sub>H <sup>9</sup> V Â° V</div>
    <div id="p1437" num="1437" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/00/38/2633f934eea3d8/imgf000210_0003.png"><img id="imgf000210_0003" he="12" wi="65" file="imgf000210_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="260" height="48" alt="Figure imgf000210_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/00/38/2633f934eea3d8/imgf000210_0003.png"/></a></div>
    </div>
    <div id="p1438" num="1438" class="description-paragraph"> 170-6 170 </div>
    <div id="p1439" num="1439" class="description-paragraph">Step 16. Preparation of Compound 170-1 </div>
    <div id="p1440" num="1440" class="description-paragraph"> To a solution of /ert-butyl 2-aminoethylcarbamate (2.88g, 18.0 mmol) and triethylamine</div>
    <div id="p1441" num="1441" class="description-paragraph">(2.98g, 29.4 mmol) in dichloromethane (100 mL), was added l -(2,5-dioxopyrrolidin-l-yl) 12- methyl dodecanedioate (146-1) (5.09g, 14.9 mmol) in dichloromethane (50 mL) dropwise at room temperature. The reaction mixture was stirred overnight and TLC indicated the completion of the reaction. 100 mL brine was added and the organic layer was separated. The organic layer was washed with 0.5N HCI (150 mL), brine ( 2 x 100 mL) and dried over MgSC . Evaporation of solvent gave pure methyl 12-(2-(Â¾r?-butoxycarbonylamino)ethylamino)-12-oxododecanoate 170-1 (5.85g 100%) as a white solid. </div>
    <div id="p1442" num="1442" class="description-paragraph">Step 17. Preparation of Compound 170-2 </div>
    <div id="p1443" num="1443" class="description-paragraph"> To a solution of 12-(2-(teri-butoxycarbonylamino)ethylamino)-12-oxododecanoate 170-</div>
    <div id="p1444" num="1444" class="description-paragraph">1 (5.55g, 14.4 mmol) in methanol (100 mL) at 0Â°C, was added thionyl chloride (3.3 mL, 45.5 mmol) dropwise. The reaction was then stirred at room temperature overnight. TLC indicated the completion of the reaction. The solvent and volatile organics were evaporated. The residue was then co-evaporated with heptanes twice to give methyl 12-(2-aminoethylamino)-12- oxododecanoate hydrochloride 170-2 quantitatively as a white solid. LC-MS (ESI): m/z: 287 (100), (M + H<sup>+</sup>, free amine). </div>
    <div id="p1445" num="1445" class="description-paragraph">Step 18. Preparation of Compound 170-3 </div>
    <div id="p1446" num="1446" class="description-paragraph"> (-)-Methyl (S)-2,2-dimethyl-l,3-dioxolane-4-carboxylate (5.01g, 31.2 mmol) and LiOHEhO (2.55g, 60.8 mmol) in THF (50 mL) and water (50 mL) was stirred overnight. TLC 

 indicated the completion of the reaction. THF was evaporated and the aqueous was acidified with IN HC1 to pH = 1. This was extracted with ethyl acetate ( 5 x 50 mL). The combined extract was dried over MgSC . Evaporation of solvent gave (S)-2,2-dimethyl-l,3-dioxolane-4- carboxylic acid 170-3 (2.93g, 64.3%) as a light yellow liquid. </div>
    <div id="p1447" num="1447" class="description-paragraph">Step 19. Preparation of Compound 170-4 </div>
    <div id="p1448" num="1448" class="description-paragraph"> Compound 170-4 was synthesized from (S)-2,2-dimethyl-l,3-dioxolane-4-carboxylic acid 170-3 and N-hydroxysuccinimide in 86% yield, using the same procedure as described in the synthesis of l -(2,5-dioxopyrrolidin-l-yl) 12-methyl dodecanedioate 146-1. (S)-2,5- Dioxopyrrolidin-l-yl 2,2-dimethyl-l,3-dioxolane-4-carboxylate 170-4 was obtained in 86% yield as a white solid. </div>
    <div id="p1449" num="1449" class="description-paragraph">Step 20. Preparation of Compound 170-5 </div>
    <div id="p1450" num="1450" class="description-paragraph"> To a suspension of methyl 12-(2-aminoethylamino)-12-oxododecanoate hydrochloride 170-2 (14.4 mmol) and (S)-2,5-dioxopyrrolidin-l-yl 2,2-dimethyl-l,3-dioxolane-4-carboxylate 170-4 (3.80g, 15.6 mmol) in dichloromethane (100 mL) was added triethylamine (6 mL, 43.0 mmol) in dichloromethane (25 mL) over 4 hrs at 0Â°C. The reaction mixture was then stirred at room temperature overnight. LC-MS indicated that the starting material 170-2 was completely converted. The organic layer was washed with brine (50 mL), IN HC1 (50 mL), brine (50 mL), dried over MgSC and concentrated to dryness to afford (S)-methyl 12-(2-(2,2-dimethyl-l,3- dioxolane-4-carboxamido)ethylamino)-12-oxododecanoate 170-5 (5.93g, 99.3%) as a white solid. </div>
    <div id="p1451" num="1451" class="description-paragraph">Step 21. Preparation of Compound 170-6 </div>
    <div id="p1452" num="1452" class="description-paragraph"> To a solution of (S)-methyl 12-(2-(2,2-dimethyl-l,3-dioxolane-4- carboxamido)ethylamino)-12-oxododecanoate 170-5 (5.93g, 14.3 mmol) was added one drop of concentrated sulfuric acid. This was refluxed for 6 hrs and then cooled to room temperature. The solid was collected through filtration and washed twice with cold methanol. The solid was dried in the air (3.32g). The second crop (0.42g) was obtained from the mother liquid to give (S)- methyl 12-(2-(2,3-dihydroxypropanamido)ethylamino)-12-oxododecanoate 170-6 (3.74g in total, 69.4%) as a white crystal. LC-MS (ESI): m/z: 375 (100), (M + H<sup>+</sup>). <sup>1</sup>HNMR (400MHz, DMSO-d6, ppm): Î´ 7.79 (br, 2H), 5.49 (d, J = 5.3 Hz, 1H), 4.66 (t, J = 5.8 Hz, 1H), 3.83-3.88 (m, 1H), 3.55-3.61 (m, 4H), 3.41-3.47 (m, 1H), 3.05-3.15 (m, 4H), 2.29 (t, J = 7.4 Hz, 2H), 2.03 (t, J = 7.6 Hz, 2H), 1.42-1.52 (m, 4H), 1.18-1.29 (m, 12H). 

 Step 22. Preparation of Compound 170 </div>
    <div id="p1453" num="1453" class="description-paragraph"> To a solution of (S)-methyl 12-(2-(2,3-dihydroxypropanamido)ethylamino)-12- oxododecanoate 170-6 (2.99g, 7.99 mmol) in dry pyridine (57.5 mL) under nitrogen, was added 4,4&#39;-dimethoxytrityl chloride (2.84g, 8.38 mmol) in one portion. The reaction was stirred at room temperature for two days. Methanol (5 mL) was added to quench the reaction. Pyridine was evaporated. Toluene was added and then evaporated. This was repeated three times. Water (100 mL) was added and this was extracted with ethyl acetate (5 x 250 mL). The extracts were combined and dried over MgS04. Evaporation of solvent, followed by column chromatography (l%methanol/dichloromethane-3% methanol/dichloromethane) gave (S)-methyl 12-(2-(3-(bis(4- methoxyphenyl)(phenyl)methoxy)-2-hydroxypropanamido)ethylamino)-12-oxododecanoate 170 (1.70g, 31.4%) as a viscous oil. <sup>1</sup>HNMR (400MHz, acetone-d6, ppm): Î´ 7.64-7.70 (br, 1H), 7.47-7.51 (m, 2H), 7.33-7.37 (m, 4H), 7.26-7.32 (m, 2H), 7.20 (dt, J = 7.3, 2.1 Hz, 1H), 7.11 (br, 1H), 6.86 (d, J = 8.7 Hz, 4H), 4.84 (br, 1H), 4.21 (dd, J = 5.1, 3.8 Hz, 1H), 3.78 (s, 6H), 3.60 (s, 1H), 3.25-3.42 (m, 6H), 2.28 (t, J = 7.4 Hz, 2H), 1.48-1.62 (m, 4H), 1.21-1.34 (m, 12H). </div>
    <div id="p1454" num="1454" class="description-paragraph">Scheme 26. </div>
    <div id="p1455" num="1455" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/55/f4/6fb7a479bbfa84/imgf000212_0001.png"><img id="imgf000212_0001" he="61" wi="151" file="imgf000212_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="604" height="244" alt="Figure imgf000212_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/55/f4/6fb7a479bbfa84/imgf000212_0001.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/08/fc/79df8ba778a059/imgf000213_0001.png"><img id="imgf000213_0001" he="73" wi="153" file="imgf000213_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="612" height="292" alt="Figure imgf000213_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/08/fc/79df8ba778a059/imgf000213_0001.png"/></a></div>
    </div>
    <div id="p1456" num="1456" class="description-paragraph"> Step 23. Preparation of compounds 139, 155, 160, 165 and 170 </div>
    <div id="p1457" num="1457" class="description-paragraph"> Compounds 139, 155, 160, 165 and 170 were prepared from compounds 138, 154, 159, 164 and 169 using an identical procedure to that used for compound 18. </div>
    <div id="p1458" num="1458" class="description-paragraph">Step 24. Preparation of conjugates 153, 158, 163, 168 and 173 </div>
    <div id="p1459" num="1459" class="description-paragraph"> Conjugates 153, 158, 163, 168 and 173 were prepared from compound 139, 154, 159, 164 and 169 using an identical procedure to that used for compound 1. Example 12. Synthesis of conjugate 176 </div>
    <div id="p1460" num="1460" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2f/de/95/e5a2f2dc59087a/imgf000213_0002.png"><img id="imgf000213_0002" he="34" wi="139" file="imgf000213_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="556" height="136" alt="Figure imgf000213_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2f/de/95/e5a2f2dc59087a/imgf000213_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/8e/7e/ff8b83360061ac/imgf000214_0001.png"><img id="imgf000214_0001" he="53" wi="145" file="imgf000214_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="580" height="212" alt="Figure imgf000214_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/8e/7e/ff8b83360061ac/imgf000214_0001.png"/></a></div>
    </div>
    <div id="p1461" num="1461" class="description-paragraph"> 130 </div>
    <div id="p1462" num="1462" class="description-paragraph"> Scheme 28. </div>
    <div id="p1463" num="1463" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/b8/36/5ae6c385e40863/imgf000214_0002.png"><img id="imgf000214_0002" he="38" wi="156" file="imgf000214_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="152" alt="Figure imgf000214_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/b8/36/5ae6c385e40863/imgf000214_0002.png"/></a></div>
    </div>
    <div id="p1464" num="1464" class="description-paragraph"> 175 </div>
    <div id="p1465" num="1465" class="description-paragraph"> 1) lOOO A lcaa CPG </div>
    <div id="p1466" num="1466" class="description-paragraph"> 2) Oligonucleotide synthesis </div>
    <div id="p1467" num="1467" class="description-paragraph"> 3) Deptrotsction 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/54/7a/cb3453f454d787/imgf000214_0003.png"><img id="imgf000214_0003" he="19" wi="122" file="imgf000214_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="488" height="76" alt="Figure imgf000214_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/54/7a/cb3453f454d787/imgf000214_0003.png"/></a></div>
 </div>
    <div id="p1468" num="1468" class="description-paragraph"> 176 </div>
    <div id="p1469" num="1469" class="description-paragraph">Step. 1. Preparation of methyl 12-aminododecanoate 132 </div>
    <div id="p1470" num="1470" class="description-paragraph"> 12-aminoundecanoic acid (131) (10g, 4.64 mmol) was stirred in MeOH at RT. Acetyl chloride (856Î¼Î, 12 mmol) was added dropwise and the reaction stirred for 1.5 hr. The solvent was removed in-vacuo, the residue taken up in MTBE and chilled in the fridge overnight. The resultant precipitate was collected by filtration, washed with ice cold MTBE and dried under high vacuum to afford methyl 12-aminododecanoate 132. 

 Step 2. Preparation of Racemic (cis) Methyl 12-(12-(10-(3-((bis(4-methoxyphenyl)- (phenyl)methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10- oxodecanamido)dodecanamido)dodecanoate 129 </div>
    <div id="p1471" num="1471" class="description-paragraph"> Lithium racemic (cis) 10-(3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- (hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10-oxodecanoate (128) (2g, 3.1 mmol), of methyl 12-aminododecanoate (132) (778 mg, 3.1 mmol), HBTU (1.2 g, 3.1 mmol) and TEA (1.4 mL, 10 mmol) were stirred in DCM at RT O/N. The precipitate was removed by filtration, the filtrate concentrated in-vacuo and the residue purified by column chromatography (5% MeOH, DCM). TLC showed two close running spots with identical mass that were assigned as geometric isomers and pooled together to give of Methyl 12-(12-(10-((3R,4S)-3-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-(hydroxymethyl)-3 ,4-dimethylpyrrolidin- 1 -yl)- 10- oxodecanamido)dodecanamido)dodecanoate (129) in quantitative fashion. </div>
    <div id="p1472" num="1472" class="description-paragraph">Step 3. Preparation of Racemic (cis) Lithium 12-(12-(10-(-3-((bis(4- methoxyphenyl)(phenyl)-methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l- yl)-10-oxodecanamido)-dodecanamido)dodecanoate 130 </div>
    <div id="p1473" num="1473" class="description-paragraph"> Racemic (cis) methyl 12-(12-(10-(3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- (hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10-oxodecanamido)dodecanamido)dodecanoate (129) (3.1 mmol) was stirred in THF:H<sub>2</sub>0 (50:50) with LiOH (88 mg, 3.7 mmol) at RT O/N. Reaction was confirmed by TLC and the THF removed in-vacuo. The aqueous solution was frozen in liquid N<sub>2</sub> and lyophilized for 48 hours to give racemic (cis) Lithium 12-(12-(10-(3- ((bis(4-methoxyphenyl)(phenyl)-methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l- yl)-10-oxodecanamido)-dodecanamido)dodecanoate 130 quantitatively. </div>
    <div id="p1474" num="1474" class="description-paragraph">Step 4. Preparation of conjugate 176 </div>
    <div id="p1475" num="1475" class="description-paragraph"> Conjugate 176 was prepared from compounds 24 and 130 using an identical procedure to that used for compound 1. 

 Example 13. Synthesis of coniugate 179</div>
    <div id="p1476" num="1476" class="description-paragraph">Scheme 29.</div>
    <div id="p1477" num="1477" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/fa/e7/adb790d26e39ff/imgf000216_0001.png"><img id="imgf000216_0001" he="23" wi="144" file="imgf000216_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="576" height="92" alt="Figure imgf000216_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/fa/e7/adb790d26e39ff/imgf000216_0001.png"/></a></div>
    </div>
    <div id="p1478" num="1478" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3a/49/4a/27d5a33aec7bd5/imgf000216_0002.png"><img id="imgf000216_0002" he="24" wi="142" file="imgf000216_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="568" height="96" alt="Figure imgf000216_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3a/49/4a/27d5a33aec7bd5/imgf000216_0002.png"/></a></div>
    </div>
    <div id="p1479" num="1479" class="description-paragraph">Scheme 30. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/d2/a9/7151eed9876954/imgf000216_0003.png"><img id="imgf000216_0003" he="64" wi="132" file="imgf000216_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="528" height="256" alt="Figure imgf000216_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/d2/a9/7151eed9876954/imgf000216_0003.png"/></a></div>
 </div>
    <div id="p1480" num="1480" class="description-paragraph"> 1 ) 1000 A lcaa CPG</div>
    <div id="p1481" num="1481" class="description-paragraph">2) Oligonucleotide synthesis</div>
    <div id="p1482" num="1482" class="description-paragraph">3) Deptrotection </div>
    <div id="p1483" num="1483" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/b9/32/0da03bd3d254ce/imgf000216_0004.png"><img id="imgf000216_0004" he="36" wi="129" file="imgf000216_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="516" height="144" alt="Figure imgf000216_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/b9/32/0da03bd3d254ce/imgf000216_0004.png"/></a></div>
 Step 1. Preparation of compound 80 </div>
    <div id="p1484" num="1484" class="description-paragraph"> Compound 24 (2g, 0.86 mmol), N-carbobenzoxy-L-glutamic acid (120 mg, 0.43 mmol), HBTU (326 mg, 0.86 mmol) and TEA (353 Î¼Î_, 2.6 mmol) were stirred in DCM at RT O N. The mixture was concentrated in-vacuo and purified by column chromatography to give compound 80 (2.88 g, 83%). </div>
    <div id="p1485" num="1485" class="description-paragraph">Step 2. Preparation of compound 81 </div>
    <div id="p1486" num="1486" class="description-paragraph"> Compound 81 was prepared from compounds 80 (670 mg, 0.17 mmol) using an identical procedure to that used for compound 14. The compound was used crude in subsequent reactions and the yield taken as quantitative. </div>
    <div id="p1487" num="1487" class="description-paragraph">Step 3. Preparation of conjugatel79 </div>
    <div id="p1488" num="1488" class="description-paragraph"> Conjugate 179 was prepared from compounds 18 and 81 using an identical procedure to that used for compound 1. </div>
    <div id="p1489" num="1489" class="description-paragraph">Example 14. Synthesis of conjugate 182 </div>
    <div id="p1490" num="1490" class="description-paragraph"> Scheme 31. </div>
    <div id="p1491" num="1491" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/74/9b/ab/bffcc5f9184def/imgf000217_0001.png"><img id="imgf000217_0001" he="48" wi="153" file="imgf000217_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="612" height="192" alt="Figure imgf000217_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/74/9b/ab/bffcc5f9184def/imgf000217_0001.png"/></a></div>
    </div>
    <div id="p1492" num="1492" class="description-paragraph"> 94, n = 3, x = 1 </div>
    <div id="p1493" num="1493" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/73/15/77b3909d174b2d/imgf000217_0002.png"><img id="imgf000217_0002" he="42" wi="154" file="imgf000217_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="168" alt="Figure imgf000217_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/73/15/77b3909d174b2d/imgf000217_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/eb/71/d2ff5a23b60ffa/imgf000218_0001.png"><img id="imgf000218_0001" he="37" wi="154" file="imgf000218_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="148" alt="Figure imgf000218_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/31/eb/71/d2ff5a23b60ffa/imgf000218_0001.png"/></a></div>
    </div>
    <div id="p1494" num="1494" class="description-paragraph"> Step 1. Preparation of compound 93 </div>
    <div id="p1495" num="1495" class="description-paragraph"> Compound 93 was prepared from (2-oxo-2-phenyl-^<sup>2</sup>-ethyl)-D-glutamic acid (2.25 g, 8.1 mmol) and 9 (13 g, 21 mmol) using an identical procedure to that used for compound 89. Yield: 1 1.2 g. </div>
    <div id="p1496" num="1496" class="description-paragraph"> Step 2. Preparation of compound 94 </div>
    <div id="p1497" num="1497" class="description-paragraph"> Compound 94 was prepared from compound 93 (11.1 g) using an identical procedure to that used for compound 90. Yield: 10.2 g </div>
    <div id="p1498" num="1498" class="description-paragraph">Step 3. Preparation of conjugate 182 </div>
    <div id="p1499" num="1499" class="description-paragraph"> Conjugate 182 was prepared from compounds 18 and 94 using an identical procedure to that used for compound 1. </div>
    <div id="p1500" num="1500" class="description-paragraph">Example 15. Synthesis of conjugates 185 and 188 </div>
    <div id="p1501" num="1501" class="description-paragraph">Scheme 33. </div>
    <div id="p1502" num="1502" class="description-paragraph">ScOTf 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/12/f1/c3b749fdc5c16b/imgf000218_0002.png"><img id="imgf000218_0002" he="48" wi="106" file="imgf000218_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="424" height="192" alt="Figure imgf000218_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/12/f1/c3b749fdc5c16b/imgf000218_0002.png"/></a></div>
 

 Scheme 34. </div>
    <div id="p1503" num="1503" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/08/b1/a8/3074d757cca9a6/imgf000219_0001.png"><img id="imgf000219_0001" he="110" wi="156" file="imgf000219_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="440" alt="Figure imgf000219_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/08/b1/a8/3074d757cca9a6/imgf000219_0001.png"/></a></div>
    </div>
    <div id="p1504" num="1504" class="description-paragraph"> Scheme 35. </div>
    <div id="p1505" num="1505" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c0/0e/01/bebfde9cad7cf5/imgf000219_0002.png"><img id="imgf000219_0002" he="102" wi="155" file="imgf000219_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="408" alt="Figure imgf000219_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c0/0e/01/bebfde9cad7cf5/imgf000219_0002.png"/></a></div>
 Step 1. Preparation of 14-Hydroxy-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate 82 </div>
    <div id="p1506" num="1506" class="description-paragraph"> A solution of pentaethylene glycol (35g, 147mmol), TEA (41mL, 294mmol) and trimethylamine-HCl (1.4g, 14.7mmol) in CH2CI2 (600mL) was treated with tosyl chloride</div>
    <div id="p1507" num="1507" class="description-paragraph">(29.4g, 154mmol). After stirring (18h) the reaction mixture was washed with EhO-brine (1 : 1), dried (MgS04), filtered, concentrated and subjected to chromatography to yield 82 (24.6g, 43%) as a pale yellow oil. Rf 0.8 (10% CH3OH-CH2CI2). Step 2. 14-azido-3,6,9,12-tetraoxatetradecan-l-ol 83 </div>
    <div id="p1508" num="1508" class="description-paragraph"> 14-azido-3,6,9,12-tetraoxatetradecan-l-ol (83) was prepared from 82 (24.6g, 62.7mmol) and sodium azide (7.13g, 1 lOmmol) using an identical procedure to that used for compound 4. Yield: 14.8g, 90%. Step 3. Preparation of compound 84 </div>
    <div id="p1509" num="1509" class="description-paragraph"> A solution of GalNAc 6 (12.2g, 31.4mmol) and HO-PEG-N3 83 (9.2g, 35mmol) in 1,2- dichloroethane (150mL) was treated with Sc(OTf)3 (771mg, 1.6mmol). After stirring (85Â°C, 2hr) the reaction was cooled (RT), quenched by the addition of TEA (40mL) and concentrated. The crude material was subjected to chromatography to yield 84 (11.16g, 60%) as a pale yellow foam. Rf 0.7 (10% CH3OH-CH2CI2). </div>
    <div id="p1510" num="1510" class="description-paragraph">Step 4. Preparation of compound 85 </div>
    <div id="p1511" num="1511" class="description-paragraph"> A solution of 84 (11.16g, 18.8mmol) and Pd/C (l . lg, 10% - wet support) in EtOAc (120mL) was treated with TFA (4.32mL, 56.5mmol) and purged with Â¾. After stirring vigorously (4.5h) the reaction was purged with N<sub>2</sub>, filtered through Celite and concentrated. The crude material was subjected to chromatography to yield 85 (5.77g, 45%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). </div>
    <div id="p1512" num="1512" class="description-paragraph">Step 5. Preparation of compound 95 </div>
    <div id="p1513" num="1513" class="description-paragraph"> Compound 95 was prepared from (2-oxo-2-phenyl- <sup>2</sup>-ethyl)-D-glutamic acid (1.04 g,</div>
    <div id="p1514" num="1514" class="description-paragraph">3.7 mmol) and compound 94 (10.2 g) using an identical procedure to that used for compound 91. Yield: 7.2 g 

 Step 6. Preparation of compound 96 </div>
    <div id="p1515" num="1515" class="description-paragraph"> Compound 96 was prepared from compound 95 (11.1 g) using an identical procedure to that used for compound 92. Yield: 6.5 g </div>
    <div id="p1516" num="1516" class="description-paragraph">Step 7. Preparation of compound 97 </div>
    <div id="p1517" num="1517" class="description-paragraph"> Compound 97 was prepared from (2-oxo-2-phenyl- <sup>2</sup>-ethyl)-D-glutamic acid (2g, 7. Immol) and 85 (12. lg, 17.8mmol) using an identical procedure to that used for compound 89. Yield: lOg, quantitative. </div>
    <div id="p1518" num="1518" class="description-paragraph">Step 8. Preparation of compound 98 </div>
    <div id="p1519" num="1519" class="description-paragraph"> Compound 98 was prepared from compound 97 (lOg, 7.2mmol) using an identical procedure to that used for compound 90. Yield: 3.5g, 36%. </div>
    <div id="p1520" num="1520" class="description-paragraph">Step 9. Preparation of compound 99 </div>
    <div id="p1521" num="1521" class="description-paragraph"> Compound 99 was prepared quantitatively from (2-oxo-2-phenyl- <sup>2</sup>-ethyl)-D-glutamic acid (350 mg, 1.25 mmol) and compound 98 (2.86 mg, 2.5mmol) using an identical procedure to that used for compound 91. </div>
    <div id="p1522" num="1522" class="description-paragraph">Step 10. Preparation of compound 100 </div>
    <div id="p1523" num="1523" class="description-paragraph"> Compound 100 was prepared quantitatively from compound 99 (3.2 g, 1.25 mmol) using an identical procedure to that used for compound 92. </div>
    <div id="p1524" num="1524" class="description-paragraph">Step 11. Preparation of conjugates 185 and 188 </div>
    <div id="p1525" num="1525" class="description-paragraph"> Conjugate 185 and 188 were prepared from compounds 18 and 96 or 18 and 100 using an identical procedure to that used for compound 1. 

</div>
    <div id="p1526" num="1526" class="description-paragraph">Example 16. Synthesis of conjugates 191, 194, 197 and 200
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c9/b8/13/766cfc1ee001e7/imgf000222_0001.png"><img id="imgf000222_0001" he="44" wi="131" file="imgf000222_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="524" height="176" alt="Figure imgf000222_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c9/b8/13/766cfc1ee001e7/imgf000222_0001.png"/></a></div>
 </div>
    <div id="p1527" num="1527" class="description-paragraph"> Scheme 37. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ae/5b/9e/5116ae1b908eb8/imgf000222_0002.png"><img id="imgf000222_0002" he="55" wi="156" file="imgf000222_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="220" alt="Figure imgf000222_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ae/5b/9e/5116ae1b908eb8/imgf000222_0002.png"/></a></div>
 </div>
    <div id="p1528" num="1528" class="description-paragraph"> 90, n = 2, x = 1 </div>
    <div id="p1529" num="1529" class="description-paragraph"> 102, n = 3, x = 2 </div>
    <div id="p1530" num="1530" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b3/80/21/743cca09bda21d/imgf000222_0003.png"><img id="imgf000222_0003" he="50" wi="113" file="imgf000222_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="452" height="200" alt="Figure imgf000222_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b3/80/21/743cca09bda21d/imgf000222_0003.png"/></a></div>
 Scheme 38. </div>
    <div id="p1531" num="1531" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/2a/48/d73b53b02ba403/imgf000223_0001.png"><img id="imgf000223_0001" he="112" wi="161" file="imgf000223_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="644" height="448" alt="Figure imgf000223_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/2a/48/d73b53b02ba403/imgf000223_0001.png"/></a></div>
    </div>
    <div id="p1532" num="1532" class="description-paragraph">Step 1. Preparation of 2-(2-(2-azidoethoxy)ethoxy)ethan-l-ol 86 </div>
    <div id="p1533" num="1533" class="description-paragraph"> To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (13 g, 77 mmol) in water (200 mL) was added sodium azide (10 g, 154 mmol). The reaction was heated to 100Â°C for 18 hours. The reaction was cooled to room temperature and poured into a 1L separatory funnel and extracted with dichloromethane (3 x 200 mL). The combine dichloromethane extracts were dried on magnesium sulfate, filtered and concentrated to dryness to afford 2-(2-(2- azidoethoxy)ethoxy)ethan-l-ol as a colorless oil (11.7 g) </div>
    <div id="p1534" num="1534" class="description-paragraph">Step 2. Preparation of compound 87 </div>
    <div id="p1535" num="1535" class="description-paragraph"> Compound 87 was prepared from 86 (4.95g, 28.3mmol) and 6 (lOg, 25.7mmol) using an identical procedure to that used for compound 84. Yield: lOg, 77%. </div>
    <div id="p1536" num="1536" class="description-paragraph">Step 3. Preparation of compound 88 </div>
    <div id="p1537" num="1537" class="description-paragraph"> Compound 88 was prepared from 87 (lOg, 19.8mmol) using an identical procedure to that used for compound 85. Yield: 7.63g, 65%. 

 Step 4. Preparation of compound 89 </div>
    <div id="p1538" num="1538" class="description-paragraph"> A solution of 88 (2g, 3.38mmol) and Z-glutamic acid (427mg, 1.52mmol) in CH2CI2 (50mL) was treated with HBTU (1.41g, 3.7mmol) and Hunig&#39;s base (1.77mL, lO. lmmol). After stirring (18h) the mixture was concentrated and subjected to chromatography to yield 89 </div>
    <div id="p1539" num="1539" class="description-paragraph">(871mg, 48%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). </div>
    <div id="p1540" num="1540" class="description-paragraph">Step 5. Preparation of compound 90 </div>
    <div id="p1541" num="1541" class="description-paragraph"> A solution of 89 (870mg, 0.72mmol) and Pd/C (90mg, 10% - wet support) in EtOAc (lOmL) was treated with TFA (84Î¼Î<sub>^</sub>, 1. lmmol) and purged with Â¾. After stirring vigorously (2h) the reaction was purged with N2, filtered through Celite and concentrated. The crude material was used without further processing and yielded 90 (850mg, quantitative) as a colorless foam. Rf 0.25 (10% CH3OH-CH2CI2). Step 6. Preparation of compound 91 </div>
    <div id="p1542" num="1542" class="description-paragraph"> A solution of 90 (850mg, 0.72mmol) and Z-glutamic acid (91mg, 0.32mmol) in CH2CI2 (lOmL) was treated with HBTU (300mg, 0.79mmol) and Hunig&#39;s base (502uL, 2.9mmol). After stirring (1.5h) the mixture diluted with CH2CI2 and washed with NaHCCb (Sat. Aq.), dried (MgS04), filtered and concentrated. The crude material was subjected to chromatography to yield 91 (590mg, 76%) as a colorless foam. Rf 0.5 (10% CH<sub>3</sub>0H-CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1543" num="1543" class="description-paragraph">Step 7. Preparation of compound 92 </div>
    <div id="p1544" num="1544" class="description-paragraph"> A solution of 91 (590mg, 0.25mmol) and Pd/C (lOOmg, 10% - wet support) in CH3OH (30mL) was treated with TFA (29Î¼Î., 0.37mmol) and purged with Â¾. After stirring (3h) the mixture was purged with N2, then filtered through Celite and concentrated. The crude material was used without further processing and yielded 92 (600mg, quantitative) as a colorless foam. Rf O. l (10% CH3OH-CH2CI2). </div>
    <div id="p1545" num="1545" class="description-paragraph">Step 8. Preparation of compound 101 </div>
    <div id="p1546" num="1546" class="description-paragraph"> Compound 101 was prepared from (R)-2-((2-oxo-2-phenyl-112-ethyl)amino)hexanedioic acid (2.51g, 8.6 mmol) and 9 (1 lg, 17.2 mmol) using an identical procedure to that used for compound 89. Yield: 4.2 g, 37% 

 Step 9. Preparation of compound 102 </div>
    <div id="p1547" num="1547" class="description-paragraph"> Compound 102 was prepared from compound 101 (4.2g, 3.2 mmol) using an identical procedure to that used for compound 90. Yield: 2.1 g, 47% </div>
    <div id="p1548" num="1548" class="description-paragraph">Step 10. Preparation of compound 103 </div>
    <div id="p1549" num="1549" class="description-paragraph"> Compound 103 was prepared from (R)-2-((2-oxo-2-phenyl-112-ethyl)amino)hexanedioic acid (265 mg, 0.9 mmol) and compound 102 (2.1 g, 1.8 mmol) using an identical procedure to that used for compound 91. Yield: (560 mg, 24 %) </div>
    <div id="p1550" num="1550" class="description-paragraph">Step 11. Preparation of compound 104 </div>
    <div id="p1551" num="1551" class="description-paragraph"> Compound 104 was prepared quantitatively from compound 103 (560 mg) using an identical procedure to that used for compound 92. The compound was used without purification. </div>
    <div id="p1552" num="1552" class="description-paragraph">Step 12. Preparation of conjugates 191, 194, 197 and 200 </div>
    <div id="p1553" num="1553" class="description-paragraph"> Conjugates 191, 194, 197 and 200 were prepared from compound 128 and 92, 96, 100 or 104 using an identical procedure to that used for compound 1. </div>
    <div id="p1554" num="1554" class="description-paragraph">Example 16a. Synthesis of conjugates 191a </div>
    <div id="p1555" num="1555" class="description-paragraph">Scheme 36a </div>
    <div id="p1556" num="1556" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6a/4f/d5/24d0a3e65bb07d/imgf000225_0001.png"><img id="imgf000225_0001" he="44" wi="129" file="imgf000225_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="516" height="176" alt="Figure imgf000225_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6a/4f/d5/24d0a3e65bb07d/imgf000225_0001.png"/></a></div>
 Scheme 37a.</div>
    <div id="p1557" num="1557" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/94/3b/07cee0f63dde13/imgf000226_0001.png"><img id="imgf000226_0001" he="56" wi="156" file="imgf000226_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="224" alt="Figure imgf000226_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/94/3b/07cee0f63dde13/imgf000226_0001.png"/></a></div>
    </div>
    <div id="p1558" num="1558" class="description-paragraph"> 90a, n = 2, x = 1
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/1a/0c/eefa02f0811ad1/imgf000226_0002.png"><img id="imgf000226_0002" he="51" wi="113" file="imgf000226_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="452" height="204" alt="Figure imgf000226_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/1a/0c/eefa02f0811ad1/imgf000226_0002.png"/></a></div>
</div>
    <div id="p1559" num="1559" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/71/67/a1/da43fdc1101980/imgf000226_0003.png"><img id="imgf000226_0003" he="58" wi="157" file="imgf000226_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="628" height="232" alt="Figure imgf000226_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/71/67/a1/da43fdc1101980/imgf000226_0003.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/7c/16/d78c458e008933/imgf000227_0001.png"><img id="imgf000227_0001" he="49" wi="155" file="imgf000227_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="196" alt="Figure imgf000227_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/7c/16/d78c458e008933/imgf000227_0001.png"/></a></div>
    </div>
    <div id="p1560" num="1560" class="description-paragraph"> Step 1. Preparation of 2-(2-(2-azidoethoxy)ethoxy)ethan-l-ol 86a </div>
    <div id="p1561" num="1561" class="description-paragraph"> To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (13 g, 77 mmol) in water (200 mL) was added sodium azide (10 g, 154 mmol). The reaction was heated to 100Â°C for 18 hours. The reaction was cooled to room temperature and poured into a 1L separatory funnel and extracted with dichloromethane (3 x 200 mL). The combine dichloromethane extracts were dried on magnesium sulfate, filtered and concentrated to dryness to afford 2-(2-(2- azidoethoxy)ethoxy)ethan-l-ol as a colorless oil (11.7 g). </div>
    <div id="p1562" num="1562" class="description-paragraph">Step 2. Preparation of compound 87a </div>
    <div id="p1563" num="1563" class="description-paragraph"> Compound 87a was prepared from 86a (4.95g, 28.3mmol) and 6a (lOg, 25.7mmol) using an identical procedure to that used for compound 84. Yield: lOg, 77%. </div>
    <div id="p1564" num="1564" class="description-paragraph">Step 3. Preparation of compound 88a </div>
    <div id="p1565" num="1565" class="description-paragraph"> Compound 88a was prepared from 87a (lOg, 19.8mmol) using an identical procedure to that used for compound 85. Yield: 7.63g, 65%. </div>
    <div id="p1566" num="1566" class="description-paragraph">Step 4. Preparation of compound 89a </div>
    <div id="p1567" num="1567" class="description-paragraph"> A solution of 88a (2g, 3.38mmol) and Zâ L-glutamic acid (427mg, 1.52mmol) in </div>
    <div id="p1568" num="1568" class="description-paragraph">CH2CI2 (50mL) was treated with HBTU (1.41g, 3.7mmol) and Hunig&#39;s base (1.77mL, </div>
    <div id="p1569" num="1569" class="description-paragraph">10. Immol). After stirring (18h) the mixture was concentrated and subjected to chromatography to yield 89a (871mg, 48%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). </div>
    <div id="p1570" num="1570" class="description-paragraph">Step 5. Preparation of compound 90a </div>
    <div id="p1571" num="1571" class="description-paragraph"> A solution of 89a (870mg, 0.72mmol) and Pd/C (90mg, 10% - wet support) in EtOAc (lOmL) was treated with TFA (84Î¼Î, 1 Immol) and purged with Â¾. After stirring vigorously (2h) the reaction was purged with N<sub>2</sub>, filtered through Celite and concentrated. The crude 

 material was used without further processing and yielded 90a (850mg, quantitative) as a colorless foam. Rf 0.25 (10% CH3OH-CH2CI2). </div>
    <div id="p1572" num="1572" class="description-paragraph">Step 6. Preparation of compound 91a </div>
    <div id="p1573" num="1573" class="description-paragraph"> A solution of 90a (850mg, 0.72mmol) and Z-glutamic acid (91mg, 0.32mmol) in CH2CI2 (lOmL) was treated with HBTU (300mg, 0.79mmol) and Hunig&#39; s base (502Î¼Î-, 2.9mmol). After stirring (1.5h) the mixture diluted with CH2CI2 and washed with NaHC03 (Sat. Aq.), dried (MgSO t), filtered and concentrated. The crude material was subjected to chromatography to yield 91a (590mg, 76%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). </div>
    <div id="p1574" num="1574" class="description-paragraph">Step 7. Preparation of compound 92a </div>
    <div id="p1575" num="1575" class="description-paragraph"> A solution of 91a (590mg, 0.25mmol) and Pd/C (lOOmg, 10% - wet support) in CH3OH (30mL) was treated with TFA (29Î¼Î<sub>^</sub>, 0.37mmol) and purged with H<sub>2</sub>. After stirring (3h) the mixture was purged with N2, then filtered through Celite and concentrated. The crude material was used without further processing and yielded 92a (600mg, quantitative) as a colorless foam. Rf O. l (10% CH3OH-CH2CI2). </div>
    <div id="p1576" num="1576" class="description-paragraph">Step 8. Preparation of conjugate 191a, </div>
    <div id="p1577" num="1577" class="description-paragraph"> Conjugate 191a was prepared from compound 128 and compound 92a using an identical procedure to that used for compound 1. </div>
    <div id="p1578" num="1578" class="description-paragraph">Example 16b. Synthesis of conjugates 191b </div>
    <div id="p1579" num="1579" class="description-paragraph">Scheme 36b </div>
    <div id="p1580" num="1580" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/86/5a/203ff4695262ab/imgf000228_0001.png"><img id="imgf000228_0001" he="44" wi="131" file="imgf000228_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="524" height="176" alt="Figure imgf000228_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/86/5a/203ff4695262ab/imgf000228_0001.png"/></a></div>
 Scheme 37b.</div>
    <div id="p1581" num="1581" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/82/0a/36cf830dac4adb/imgf000229_0001.png"><img id="imgf000229_0001" he="55" wi="155" file="imgf000229_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="220" alt="Figure imgf000229_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/82/0a/36cf830dac4adb/imgf000229_0001.png"/></a></div>
    </div>
    <div id="p1582" num="1582" class="description-paragraph"> 90b, n = 2, x = 1
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/44/02/751b5d08d1a0a8/imgf000229_0002.png"><img id="imgf000229_0002" he="50" wi="113" file="imgf000229_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="452" height="200" alt="Figure imgf000229_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/44/02/751b5d08d1a0a8/imgf000229_0002.png"/></a></div>
</div>
    <div id="p1583" num="1583" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/44/9f/edf53412b9561e/imgf000229_0003.png"><img id="imgf000229_0003" he="51" wi="95" file="imgf000229_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="380" height="204" alt="Figure imgf000229_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/44/9f/edf53412b9561e/imgf000229_0003.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/71/35/5d8e00cd56e8d1/imgf000230_0001.png"><img id="imgf000230_0001" he="49" wi="155" file="imgf000230_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="196" alt="Figure imgf000230_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/eb/71/35/5d8e00cd56e8d1/imgf000230_0001.png"/></a></div>
    </div>
    <div id="p1584" num="1584" class="description-paragraph">Step 1. Preparation of 2-(2-(2-azidoethoxy)ethoxy)ethan-l-ol 86b </div>
    <div id="p1585" num="1585" class="description-paragraph"> To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (13 g, 77 mmol) in water (200 mL) is added sodium azide (10 g, 154 mmol). The reaction was heated to 100Â°C for 18 hours. The reaction was cooled to room temperature and poured into a 1L separatory funnel and extracted with dichloromethane (3 x 200 mL). The combine dichloromethane extracts were dried on magnesium sulfate, filtered and concentrated to dryness to afford 2-(2-(2- azidoethoxy)ethoxy)ethan-l-ol as a colorless oil (1 1.7 g). </div>
    <div id="p1586" num="1586" class="description-paragraph">Step 2. Preparation of compound 87b </div>
    <div id="p1587" num="1587" class="description-paragraph"> Compound 87a is prepared from 86b (4.95g, 28.3mmol) and 6b (lOg, 25.7mmol) using an identical procedure to that used for compound 84. Yield: lOg, 77%. </div>
    <div id="p1588" num="1588" class="description-paragraph">Step 3. Preparation of compound 88b </div>
    <div id="p1589" num="1589" class="description-paragraph"> Compound 88a is prepared from 87b (lOg, 19.8mmol) using an identical procedure to that used for compound 85. Yield: 7.63g, 65%. </div>
    <div id="p1590" num="1590" class="description-paragraph">Step 4. Preparation of compound 89b </div>
    <div id="p1591" num="1591" class="description-paragraph"> A solution of 88b (2g, 3.38mmol) and racemic Z-glutamic acid (427mg, 1.52mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50mL) is treated with HBTU (1.41g, 3.7mmol) and Hunig&#39; s base (1.77mL, lO. lmmol). After stirring (18h) the mixture was concentrated and subjected to chromatography to yield 89b (871mg, 48%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). 

 Step 5. Preparation of compound 90b </div>
    <div id="p1592" num="1592" class="description-paragraph"> A solution of 89b (870mg, 0.72mmol) and Pd/C (90mg, 10% - wet support) in EtOAc (lOmL) is treated with TFA (84Î¼Î¯, 1. lmmol) and purged with Â¾. After stirring vigorously (2h) the reaction is purged with N<sub>2</sub>, filtered through Celite and concentrated. The crude material is used without further processing and yielded 90b (850mg, quantitative) as a colorless foam. Rf 0.25 (10% CH3OH-CH2CI2). </div>
    <div id="p1593" num="1593" class="description-paragraph">Step 6. Preparation of compound 91b </div>
    <div id="p1594" num="1594" class="description-paragraph"> A solution of 90b (850mg, 0.72mmol) and Z-glutamic acid (91mg, 0.32mmol) in CH2CI2 (lOmL) is treated with HBTU (300mg, 0.79mmol) and Hunig&#39;s base (502pL, 2.9mmol). After stirring (1.5h) the mixture is diluted with CH2CI2 and washed with NaHCC (Sat. Aq.), dried (MgSC ), filtered and concentrated. The crude material is subjected to chromatography to yield 91b (590mg, 76%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). Step 7. Preparation of compound 92b </div>
    <div id="p1595" num="1595" class="description-paragraph"> A solution of 91b (590mg, 0.25mmol) and Pd/C (lOOmg, 10% - wet support) in CH3OH (30mL) is treated with TFA (29Î¼Î¯, 0.37mmol) and purged with H2. After stirring (3h) the mixture is purged with N<sub>2</sub>, then filtered through Celite and concentrated. The crude material is used without further processing and yielded 92b (600mg, quantitative) as a colorless foam. Rf 0.1 (10% CH<sub>3</sub>0H-CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1596" num="1596" class="description-paragraph">Step 8. Preparation of conjugate 191b </div>
    <div id="p1597" num="1597" class="description-paragraph"> Conjugate 191b is prepared from compound 128 and compound 92b using an identical procedure to that used for compound 1. 

</div>
    <div id="p1598" num="1598" class="description-paragraph">Example 16c. Synthesis of coniugates 191c </div>
    <div id="p1599" num="1599" class="description-paragraph">Scheme 36c 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/31/fc/5b36488bc047e8/imgf000232_0001.png"><img id="imgf000232_0001" he="16" wi="129" file="imgf000232_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="516" height="64" alt="Figure imgf000232_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/31/fc/5b36488bc047e8/imgf000232_0001.png"/></a></div>
 </div>
    <div id="p1600" num="1600" class="description-paragraph">ScOTf 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/09/04/459cb9832fed09/imgf000232_0002.png"><img id="imgf000232_0002" he="21" wi="67" file="imgf000232_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="268" height="84" alt="Figure imgf000232_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/09/04/459cb9832fed09/imgf000232_0002.png"/></a></div>
 </div>
    <div id="p1601" num="1601" class="description-paragraph">Scheme 37c. </div>
    <div id="p1602" num="1602" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/2b/c1/e64093063d2785/imgf000232_0003.png"><img id="imgf000232_0003" he="55" wi="155" file="imgf000232_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="220" alt="Figure imgf000232_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7b/2b/c1/e64093063d2785/imgf000232_0003.png"/></a></div>
    </div>
    <div id="p1603" num="1603" class="description-paragraph"> 90c, n = 2, x = 1 </div>
    <div id="p1604" num="1604" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/ff/e1/d4547f0d75e362/imgf000232_0004.png"><img id="imgf000232_0004" he="50" wi="113" file="imgf000232_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="452" height="200" alt="Figure imgf000232_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/ff/e1/d4547f0d75e362/imgf000232_0004.png"/></a></div>
      
    </div>
    <div id="p1605" num="1605" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/7b/18/f303fb4e6701af/imgf000233_0001.png"><img id="imgf000233_0001" he="111" wi="157" file="imgf000233_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="628" height="444" alt="Figure imgf000233_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/7b/18/f303fb4e6701af/imgf000233_0001.png"/></a></div>
    </div>
    <div id="p1606" num="1606" class="description-paragraph">Step 1. Preparation of 2-(2-(2-azidoethoxy)ethoxy)ethan-l-ol 86c </div>
    <div id="p1607" num="1607" class="description-paragraph"> To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (13 g, 77 mmol) in water (200 mL) is added sodium azide (10 g, 154 mmol). The reaction was heated to 100Â°C for 18 hours. The reaction was cooled to room temperature and poured into a 1L separatory funnel and extracted with dichloromethane (3 x 200 mL). The combine dichloromethane extracts were dried on magnesium sulfate, filtered and concentrated to dryness to afford 2-(2-(2- azidoethoxy)ethoxy)ethan-l-ol as a colorless oil (11.7 g). </div>
    <div id="p1608" num="1608" class="description-paragraph">Step 2. Preparation of compound 87c </div>
    <div id="p1609" num="1609" class="description-paragraph"> Compound 87c is prepared from 86c (4.95g, 28.3mmol) and 6c (lOg, 25.7mmol) using an identical procedure to that used for compound 84. Yield: lOg, 77%. </div>
    <div id="p1610" num="1610" class="description-paragraph">Step 3. Preparation of compound 88c </div>
    <div id="p1611" num="1611" class="description-paragraph"> Compound 88c is prepared from 87c (10g, 19.8mmol) using an identical procedure to that used for compound 85. Yield: 7.63g, 65%. 

 Step 4. Preparation of compound 89c </div>
    <div id="p1612" num="1612" class="description-paragraph"> A solution of 88c (2g, 3.38mmol) and racemic Z-glutamic acid (427mg, 1.52mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50mL) is treated with HBTU (1.41g, 3.7mmol) and Hunig&#39; s base (1.77mL, 10. Immol). After stirring (18h) the mixture was concentrated and subjected to chromatography to yield 89c (871mg, 48%) as a colorless foam. Rf 0.5 (10% CH<sub>3</sub>0H-CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1613" num="1613" class="description-paragraph">Step 5. Preparation of compound 90c </div>
    <div id="p1614" num="1614" class="description-paragraph"> A solution of 89c (870mg, 0.72mmol) and Pd/C (90mg, 10% - wet support) in EtOAc (lOmL) is treated with TFA (84Î¼Î<sub>^</sub>, 1. Immol) and purged with Â¾. After stirring vigorously (2h) the reaction is purged with N<sub>2</sub>, filtered through Celite and concentrated. The crude material is used without further processing and yielded 90c (850mg, quantitative) as a colorless foam. Rf 0.25 (10% CH3OH-CH2CI2). Step 6. Preparation of compound 91c </div>
    <div id="p1615" num="1615" class="description-paragraph"> A solution of 90c (850mg, 0.72mmol) and Z-glutamic acid (91mg, 0.32mmol) in CH2CI2 (lOmL) is treated with HBTU (300mg, 0.79mmol) and Hunig&#39;s base (502Î¼Î¯, 2.9mmol). After stirring (1.5h) the mixture is diluted with CH2CI2 and washed with NaHC0<sub>3</sub> (Sat. Aq.), dried (MgSO , filtered and concentrated. The crude material is subjected to chromatography to yield 91c (590mg, 76%) as a colorless foam. Rf 0.5 (10% CH3OH-CH2CI2). </div>
    <div id="p1616" num="1616" class="description-paragraph">Step 7. Preparation of compound 92c </div>
    <div id="p1617" num="1617" class="description-paragraph"> A solution of 91c (590mg, 0.25mmol) and Pd/C (lOOmg, 10% - wet support) in CH<sub>3</sub>OH (30mL) is treated with TFA (29Î¼Î¯, 0.37mmol) and purged with Â¾. After stirring (3h) the mixture is purged with N<sub>2</sub>, then filtered through Celite and concentrated. The crude material is used without further processing and yielded 92c (600mg, quantitative) as a colorless foam. Rf 0.1 (10% CH<sub>3</sub>0H-CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1618" num="1618" class="description-paragraph">Step 8. Preparation of conjugate 191c </div>
    <div id="p1619" num="1619" class="description-paragraph"> Conjugate 191c is prepared from compound 128 and compound 92c using an identical procedure to that used for compound 1. 

 Example 17. Synthesis of conjugates 203 and 206 </div>
    <div id="p1620" num="1620" class="description-paragraph">Scheme 39. </div>
    <div id="p1621" num="1621" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/4a/99/db36d7d20bdf52/imgf000235_0001.png"><img id="imgf000235_0001" he="99" wi="157" file="imgf000235_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="628" height="396" alt="Figure imgf000235_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/4a/99/db36d7d20bdf52/imgf000235_0001.png"/></a></div>
    </div>
    <div id="p1622" num="1622" class="description-paragraph">Step 1. Preparation of compound 69b </div>
    <div id="p1623" num="1623" class="description-paragraph"> Compound 69b was prepared from (2S,4R)-4-Hydroxypyrrolidine-2-carboxylic acid using an identical procedure to that used for compound 69. Step 2. Preparation of conjugates 203 and 206 </div>
    <div id="p1624" num="1624" class="description-paragraph"> Conjugates 203 and 206 were prepared from compound 96 and 100 using an identical procedure to that used for compound 1. 

</div>
    <div id="p1625" num="1625" class="description-paragraph">Example 18. Synthesis of coniugate 207 </div>
    <div id="p1626" num="1626" class="description-paragraph">Scheme 40. </div>
    <div id="p1627" num="1627" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/58/58/2c6ec8cb300228/imgf000236_0001.png"><img id="imgf000236_0001" he="101" wi="155" file="imgf000236_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="404" alt="Figure imgf000236_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/58/58/2c6ec8cb300228/imgf000236_0001.png"/></a></div>
    </div>
    <div id="p1628" num="1628" class="description-paragraph"> Step 1. Preparation of conjugate 209 </div>
    <div id="p1629" num="1629" class="description-paragraph"> Conjugate 209 was prepared from compound 96 and 160 using an identical procedure to that used for compound 1. 

</div>
    <div id="p1630" num="1630" class="description-paragraph">Example 18a. Synthesis of coniugate 209a </div>
    <div id="p1631" num="1631" class="description-paragraph">Scheme 40a. </div>
    <div id="p1632" num="1632" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b0/9f/36/598f068536accf/imgf000237_0001.png"><img id="imgf000237_0001" he="163" wi="155" file="imgf000237_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="652" alt="Figure imgf000237_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b0/9f/36/598f068536accf/imgf000237_0001.png"/></a></div>
    </div>
    <div id="p1633" num="1633" class="description-paragraph"> Step 1. Preparation of conjugate 209a </div>
    <div id="p1634" num="1634" class="description-paragraph"> Conjugate 209a is prepared from compound 96a and 160 using an identical procedure to that used for compound 1. 

 Example 19. Synthesis of coniugates 212 and 215 Scheme 41. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/14/81/384cc7c1106204/imgf000238_0001.png"><img id="imgf000238_0001" he="14" wi="146" file="imgf000238_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="584" height="56" alt="Figure imgf000238_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/14/81/384cc7c1106204/imgf000238_0001.png"/></a></div>
 105 106 </div>
    <div id="p1635" num="1635" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/aa/a0/5ec6da01d6118d/imgf000238_0002.png"><img id="imgf000238_0002" he="53" wi="127" file="imgf000238_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="508" height="212" alt="Figure imgf000238_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/aa/a0/5ec6da01d6118d/imgf000238_0002.png"/></a></div>
    </div>
    <div id="p1636" num="1636" class="description-paragraph"> Scheme 42. </div>
    <div id="p1637" num="1637" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/36/b5/1d/2577a6e99e55a5/imgf000238_0003.png"><img id="imgf000238_0003" he="98" wi="155" file="imgf000238_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="392" alt="Figure imgf000238_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/36/b5/1d/2577a6e99e55a5/imgf000238_0003.png"/></a></div>
    </div>
    <div id="p1638" num="1638" class="description-paragraph">Step 1. Preparation of Dimethyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>- ethyl)amino)acetamido)isophthalate 105 

 A solution of dimethyl 5-aminoisophthalate (5 g, 24 mmol), Z-Gly-OH (5 g, 24 mmol), EDC (5 g, 26.3 mmol), HOBt (3.6 g, 26.3 mmol), NMM (2.9 mL, 26.3 mmol) in DMF (50 mL) was stirred overnight at room temperature. Upon completion, the reaction mixture was diluted with ethyl acetate (250 mL) and washed with each 1M HC1 (2 x 100 mL), saturated sodium bicarbonate (1 x 100 mL) and brine (2 x 100 mL). Dry on magnesium sulfate, filter and concentrate to dryness to afford Dimethyl 5-(2-((2-oxo-2-phenyl- <sup>2</sup>- ethyl)amino)acetamido)isophthalate as a colorless solid (7.2 g, 79%). </div>
    <div id="p1639" num="1639" class="description-paragraph">Step 2. Preparation of 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)isophthalic acid 106 </div>
    <div id="p1640" num="1640" class="description-paragraph"> To a solution of methyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)isophthalate (7.2 g) in methanol (25 mL) and THF (25 mL) was added 1M NaOH (25 mL). The solution was stirred at room temperature for 2 hours then concentrated to remove THF and MeOH. The aqueous solution remaining was diluted with water (75 mL), cooled on an ice water bath and acidified to pH = 1 with 6M HC1. The solid was filtered and washed with water (3 x 100 mL). The solid was freeze dried to afford 5-(2-((2-oxo-2-phenyl- <sup>2</sup>- ethyl)amino)acetamido)isophthalic acid (6.9 g, quantitative) </div>
    <div id="p1641" num="1641" class="description-paragraph">Step 3. Preparation of compound 107 </div>
    <div id="p1642" num="1642" class="description-paragraph"> Compound 107 was prepared from 5-(2-((2-oxo-2-phenyl- <sup>2</sup>- ethyl)amino)acetamido)isophthalic acid 106 (200 mg, 0.54 mmol) and 94 (1.7 g, 1.3 mmol) using an identical procedure to that used for compound 95. Yield: 600 mg. </div>
    <div id="p1643" num="1643" class="description-paragraph">Step 4. Preparation of compound 108 </div>
    <div id="p1644" num="1644" class="description-paragraph"> Compound 108 was prepared from compound 107 (600 mg) using an identical procedure to that used for compound 96. Yield: 650 mg, quantitative. </div>
    <div id="p1645" num="1645" class="description-paragraph">Step 5. Preparation of compound 109 </div>
    <div id="p1646" num="1646" class="description-paragraph"> Compound 109 was prepared from 5-(2-((2-Î¿ÏÎ¿-2-ÏÎ·ÎµÎ·Î³1-1Î»<sup>2</sup>- ethyl)amino)acetamido)isophthalic acid 106 (180 mg, 0.48 mmol) and 98 (1.5 g, 1.1 mmol) using an identical procedure to that used for compound 99. Yield: 900 mg. 

 Step 6. Preparation of compound 110 </div>
    <div id="p1647" num="1647" class="description-paragraph"> Compound 110 was prepared from compound 109 (900 mg) using an identical procedure to that used for compound 100. Yield: 920 mg, quantitative. </div>
    <div id="p1648" num="1648" class="description-paragraph">Step 7. Preparation of conjugates 212 and 215 </div>
    <div id="p1649" num="1649" class="description-paragraph"> Conjugates 212 and 215 were prepared from compound 128 and 108 or 110 using an identical procedure to that used for compound 1. </div>
    <div id="p1650" num="1650" class="description-paragraph">Example 19a. Synthesis of coniugates 212a and 215a </div>
    <div id="p1651" num="1651" class="description-paragraph">Scheme 41a. </div>
    <div id="p1652" num="1652" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/f9/d1/90b60f626e0657/imgf000240_0001.png"><img id="imgf000240_0001" he="57" wi="127" file="imgf000240_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="508" height="228" alt="Figure imgf000240_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/f9/d1/90b60f626e0657/imgf000240_0001.png"/></a></div>
    </div>
    <div id="p1653" num="1653" class="description-paragraph"> 94a, n = 3, x = 1 </div>
    <div id="p1654" num="1654" class="description-paragraph"> 98a n = 4, x = 1 </div>
    <div id="p1655" num="1655" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/ba/70/302be8a6f96de1/imgf000240_0002.png"><img id="imgf000240_0002" he="64" wi="154" file="imgf000240_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="256" alt="Figure imgf000240_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/ba/70/302be8a6f96de1/imgf000240_0002.png"/></a></div>
      
    </div>
    <div id="p1656" num="1656" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3a/66/73/50b8905d20b8e8/imgf000241_0001.png"><img id="imgf000241_0001" he="99" wi="154" file="imgf000241_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="396" alt="Figure imgf000241_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3a/66/73/50b8905d20b8e8/imgf000241_0001.png"/></a></div>
    </div>
    <div id="p1657" num="1657" class="description-paragraph">Step 1. Preparation of Dimethyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)- isophthalate 105a </div>
    <div id="p1658" num="1658" class="description-paragraph"> A solution of dimethyl 5-aminoisophthalate (5 g, 24 mmol), Z-Gly-OH (5 g, 24 mmol), EDC (5 g, 26.3 mmol), HOBt (3.6 g, 26.3 mmol), NMM (2.9 mL, 26.3 mmol) in DMF (50 mL) is stirred overnight at room temperature. Upon completion, the reaction mixture is diluted with ethyl acetate (250 mL) and washed with each 1M HC1 (2 x 100 mL), saturated sodium bicarbonate (1 x 100 mL) and brine (2 x 100 mL). Dry on magnesium sulfate, filter and concentrate to dryness to afford Dimethyl 5-(2-((2-oxo-2-phenyl- <sup>2</sup>- ethyl)amino)acetamido)isophthalate as a colorless solid (7.2 g, 79%). </div>
    <div id="p1659" num="1659" class="description-paragraph">Step 2. Preparation of 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)isophthalic acid 106a </div>
    <div id="p1660" num="1660" class="description-paragraph"> To a solution of methyl 5-(2-((2-oxo-2-phenyl-^<sup>2</sup>-ethyl)amino)acetamido)isophthalate (7.2 g) in methanol (25 mL) and THF (25 mL) is added 1M NaOH (25 mL). The solution is stirred at room temperature for 2 hours then concentrated to remove THF and MeOH. The aqueous solution remaining is diluted with water (75 mL), cooled on an ice water bath and acidified to pH = 1 with 6M HC1. The solid is filtered and washed with water (3 x 100 mL). The 

 solid is freeze dried to afford 5-(2-((2-oxo-2-phenyl- <sup>2</sup>-ethyl)amino)acetamido)-isophthalic acid (6.9 g, quantitative) . </div>
    <div id="p1661" num="1661" class="description-paragraph">Step 3. Preparation of compound 107a </div>
    <div id="p1662" num="1662" class="description-paragraph"> Compound 107a is prepared from 5-(2-((2-Î¿ÏÎ¿-2-ÏÎ·ÎµÎ·Î½1-1Î»<sup>2</sup>- ethyl)amino)acetamido)isophthalic acid 106a (200 mg, 0.54 mmol) and 94a (1.7 g, 1.3 mmol) using an identical procedure to that used for compound 95. Yield: 600 mg. </div>
    <div id="p1663" num="1663" class="description-paragraph">Step 4. Preparation of compound 108a </div>
    <div id="p1664" num="1664" class="description-paragraph"> Compound 108a is prepared from compound 107a (600 mg) using an identical procedure to that used for compound 96a. Yield: 650 mg, quantitative. </div>
    <div id="p1665" num="1665" class="description-paragraph">Step 5. Preparation of compound 109a </div>
    <div id="p1666" num="1666" class="description-paragraph"> Compound 109a is prepared from 5-(2-((2-oxo-2-phenyl- <sup>2</sup>- ethyl)amino)acetamido)isophthalic acid 106a (180 mg, 0.48 mmol) and 9a8 (1.5 g, 1.1 mmol) using an identical procedure to that used for compound 99. Yield: 900 mg. </div>
    <div id="p1667" num="1667" class="description-paragraph">Step 6. Preparation of compound 110a </div>
    <div id="p1668" num="1668" class="description-paragraph"> Compound 110a is prepared from compound 109 (900 mg) using an identical procedure to that used for compound 100. Yield: 920 mg, quantitative. </div>
    <div id="p1669" num="1669" class="description-paragraph">Step 7. Preparation of conjugates 212a and 215a </div>
    <div id="p1670" num="1670" class="description-paragraph"> Conjugates 212a and 21a5 are prepared from compound 128 and 108a or 110a using an identical procedure to that used for compound 1. 

</div>
    <div id="p1671" num="1671" class="description-paragraph">Example 20. Synthesis of coniugates 218 and 221 Scheme 43. </div>
    <div id="p1672" num="1672" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/09/60/052e6852c173e2/imgf000243_0001.png"><img id="imgf000243_0001" he="98" wi="156" file="imgf000243_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="392" alt="Figure imgf000243_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f1/09/60/052e6852c173e2/imgf000243_0001.png"/></a></div>
    </div>
    <div id="p1673" num="1673" class="description-paragraph"> Scheme 44. </div>
    <div id="p1674" num="1674" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/c3/b5/06c9aa4120bea5/imgf000243_0002.png"><img id="imgf000243_0002" he="61" wi="150" file="imgf000243_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="244" alt="Figure imgf000243_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/c3/b5/06c9aa4120bea5/imgf000243_0002.png"/></a></div>
      
    </div>
    <div id="p1675" num="1675" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/3b/34/360cf106489647/imgf000244_0001.png"><img id="imgf000244_0001" he="10" wi="16" file="imgf000244_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="64" height="40" alt="Figure imgf000244_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/3b/34/360cf106489647/imgf000244_0001.png"/></a></div>
    </div>
    <div id="p1676" num="1676" class="description-paragraph">Step 1. Preparation of compound 111 </div>
    <div id="p1677" num="1677" class="description-paragraph"> Compound 111 was prepared from 4-(((tert-butoxycarbonyl)amino)methyl)phthalic acid (1 13g, 3.84mmol) and 88 (5g, 8.44mmol) using an identical procedure to that used for compound 89. Yield: 2.21g, 49%. </div>
    <div id="p1678" num="1678" class="description-paragraph">Step 2. Preparation of compound 112 </div>
    <div id="p1679" num="1679" class="description-paragraph"> A solution of 111 (2.21g, 1.87mmol) in CH<sub>2</sub>C1<sub>2</sub> (40mL) was slowly treated with TFA (5mL). After stirring (2h) the mixture was concentrated and subjected to chromatography to yield 112 (1.08g, 47%) as a colorless foam. Rf 0.1 (10% CH3OH-CH2CI2). </div>
    <div id="p1680" num="1680" class="description-paragraph">Step 3. Preparation of compound 113 </div>
    <div id="p1681" num="1681" class="description-paragraph"> Compound 113 was prepared from compound 112 (1.08g, 0.88mmol) and (2-oxo-2- phenyl-^<sup>2</sup>-ethyl)-D-glutamic acid (112mg, 0.39mmol) using an identical procedure to that used for compound 91. Yield: 600mg, 62%. </div>
    <div id="p1682" num="1682" class="description-paragraph">Step 4. Preparation of compound 114 </div>
    <div id="p1683" num="1683" class="description-paragraph"> Compound 114 was prepared from compound 113 using an identical procedure to that used for compound 92. </div>
    <div id="p1684" num="1684" class="description-paragraph">Step 5. Preparation of compound 115 </div>
    <div id="p1685" num="1685" class="description-paragraph"> Compound 115 was prepared from 4-(((tert-butoxycarbonyl)amino)methyl)phthalic acid (3.94g, 13.3mmol) and 9 (18.2g, 29.4mmol) using an identical procedure to that used for compound 93. Yield: 9.02g, 53%. 

 Step 6. Preparation of compound 116 </div>
    <div id="p1686" num="1686" class="description-paragraph"> Compound 116 was prepared from compound 115 (8g, 6.3mmol) using an identical procedure to that used for compound 112. Yield: 3.23g, 39%. Step 7. Preparation of compound 117 </div>
    <div id="p1687" num="1687" class="description-paragraph"> Compound 117 was prepared from compound 116 (3.23g, 2.45mmol) and (2-oxo-2- phenyl- <sup>2</sup>-ethyl)-D-glutamic acid (192mg, l . lmmol) using an identical procedure to that used for compound 95. Yield: 2.22g, 34%. Step 8. Preparation of compound 118 </div>
    <div id="p1688" num="1688" class="description-paragraph"> Compound 118 was prepared from compound 117 (2.22g, 0.84mmol) using an identical procedure to that used for compound 96. Yield: 2.02g, 91%. </div>
    <div id="p1689" num="1689" class="description-paragraph">Step 9. Preparation of conjugates 218 and 221 </div>
    <div id="p1690" num="1690" class="description-paragraph"> Conjugates 218 and 221 were prepared from compounds 128 and 114 or 118 using an identical procedure to that used for compound 1. </div>
    <div id="p1691" num="1691" class="description-paragraph">Example 20a. Synthesis of conjugates 218a and 221a Scheme 43a. </div>
    <div id="p1692" num="1692" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c9/07/07/77d0dea2ead9a3/imgf000245_0001.png"><img id="imgf000245_0001" he="95" wi="156" file="imgf000245_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="624" height="380" alt="Figure imgf000245_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c9/07/07/77d0dea2ead9a3/imgf000245_0001.png"/></a></div>
 Scheme 44a. 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/09/83/903262226fa659/imgf000246_0001.png"><img id="imgf000246_0001" he="58" wi="151" file="imgf000246_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="604" height="232" alt="Figure imgf000246_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/09/83/903262226fa659/imgf000246_0001.png"/></a></div>

<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/3a/60/511b6e4660ec5e/imgf000246_0002.png"><img id="imgf000246_0002" he="61" wi="151" file="imgf000246_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="604" height="244" alt="Figure imgf000246_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/3a/60/511b6e4660ec5e/imgf000246_0002.png"/></a></div>
 

</div>
    <div id="p1693" num="1693" class="description-paragraph">Step 1. Preparation of compound 111a </div>
    <div id="p1694" num="1694" class="description-paragraph"> Compound 111a is prepared from 4-(((tert-butoxycarbonyl)amino)methyl)phthalic acid (1.13g, 3.84mmol) and 88 (5g, 8.44mmol) using an identical procedure to that used for compound 89. Yield: 2.21g, 49%. </div>
    <div id="p1695" num="1695" class="description-paragraph">Step 2. Preparation of compound 112a </div>
    <div id="p1696" num="1696" class="description-paragraph"> A solution of 111a (2.2 lg, 1.87mmol) in CH<sub>2</sub>C1<sub>2</sub> (40mL) is slowly treated with TFA (5mL). After stirring (2h) the mixture is concentrated and subjected to chromatography to yield 112a (1.08g, 47%) as a colorless foam. Rf 0.1 (10% CH<sub>3</sub>0H-CH<sub>2</sub>C1<sub>2</sub>). </div>
    <div id="p1697" num="1697" class="description-paragraph">Step 3. Preparation of compound 113a </div>
    <div id="p1698" num="1698" class="description-paragraph"> Compound 113a is prepared from compound 112a (1.08g, 0.88mmol) and (2-oxo-2- phenyl- <sup>2</sup>-ethyl)-D-glutamic acid (112mg, 0.39mmol) using an identical procedure to that used for compound 91. Yield: 600mg, 62%. </div>
    <div id="p1699" num="1699" class="description-paragraph">Step 4. Preparation of compound 114a </div>
    <div id="p1700" num="1700" class="description-paragraph"> Compound 114a is prepared from compound 113a using an identical procedure to that used for compound 92. </div>
    <div id="p1701" num="1701" class="description-paragraph">Step 5. Preparation of compound 115a </div>
    <div id="p1702" num="1702" class="description-paragraph"> Compound 115a is prepared from 4-(((tert-butoxycarbonyl)amino)methyl)phthalic acid (3.94g, 13.3mmol) and 9 (18.2g, 29.4mmol) using an identical procedure to that used for compound 93. Yield: 9.02g, 53%. </div>
    <div id="p1703" num="1703" class="description-paragraph">Step 6. Preparation of compound 116a </div>
    <div id="p1704" num="1704" class="description-paragraph"> Compound 116a is prepared from compound 115a (8g, 6.3mmol) using an identical procedure to that used for compound 11a. Yield: 3.23g, 39%. </div>
    <div id="p1705" num="1705" class="description-paragraph">Step 7. Preparation of compound 117a </div>
    <div id="p1706" num="1706" class="description-paragraph"> Compound 117a is prepared from compound 116a (3.23g, 2.45mmol) and (2-oxo-2- phenyl- <sup>2</sup>-ethyl)glutamic acid (192mg, l . lmmol) using an identical procedure to that used for compound 95. Yield: 2.22g, 34%. 

 Step 8. Preparation of compound 118a </div>
    <div id="p1707" num="1707" class="description-paragraph"> Compound 118a is prepared from compound 117a (2.22g, 0.84mmol) using an identical procedure to that used for compound 96. Yield: 2.02g, 91%. </div>
    <div id="p1708" num="1708" class="description-paragraph">Step 9. Preparation of conjugates 21a8 and 221a </div>
    <div id="p1709" num="1709" class="description-paragraph"> Conjugates 218a and 22al are prepared from compounds 128 and 114a or 118a using an identical procedure to that used for compound 1. </div>
    <div id="p1710" num="1710" class="description-paragraph">Example 21. Synthesis of conjugate 224 </div>
    <div id="p1711" num="1711" class="description-paragraph">Scheme 45. </div>
    <div id="p1712" num="1712" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/bd/ee/9a069ba8ae2218/imgf000248_0001.png"><img id="imgf000248_0001" he="107" wi="166" file="imgf000248_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="664" height="428" alt="Figure imgf000248_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/bd/ee/9a069ba8ae2218/imgf000248_0001.png"/></a></div>
    </div>
    <div id="p1713" num="1713" class="description-paragraph">Step 1. Preparation of compounds 224 </div>
    <div id="p1714" num="1714" class="description-paragraph"> Conjugate 224 was prepared from compounds 96 and 130 using an identical procedure to that used for compound 1. 

 Example 21a. Synthesis of coniugate 224b Scheme 45a.</div>
    <div id="p1715" num="1715" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/a8/5d/7b42d4b5626921/imgf000249_0001.png"><img id="imgf000249_0001" he="70" wi="145" file="imgf000249_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="580" height="280" alt="Figure imgf000249_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/a8/5d/7b42d4b5626921/imgf000249_0001.png"/></a></div>
    </div>
    <div id="p1716" num="1716" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/f2/49/f800416e5d8d04/imgf000249_0002.png"><img id="imgf000249_0002" he="119" wi="155" file="imgf000249_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="620" height="476" alt="Figure imgf000249_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/f2/49/f800416e5d8d04/imgf000249_0002.png"/></a></div>
 Step 1. Preparation of compounds 224b </div>
    <div id="p1717" num="1717" class="description-paragraph"> Conjugate 224b is prepared from compounds 96b and 130 using an identical procedure to that used for compound 1. </div>
    <div id="p1718" num="1718" class="description-paragraph">Example 22 Synthesis of Coniugate 231 </div>
    <div id="p1719" num="1719" class="description-paragraph">Scheme 46 </div>
    <div id="p1720" num="1720" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/22/58/e76339c2fafce4/imgf000250_0001.png"><img id="imgf000250_0001" he="99" wi="158" file="imgf000250_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="396" alt="Figure imgf000250_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/22/58/e76339c2fafce4/imgf000250_0001.png"/></a></div>
    </div>
    <div id="p1721" num="1721" class="description-paragraph"> Scheme 47 </div>
    <div id="p1722" num="1722" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7d/58/e8/c1296bb109c7ee/imgf000250_0002.png"><img id="imgf000250_0002" he="62" wi="133" file="imgf000250_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="248" alt="Figure imgf000250_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7d/58/e8/c1296bb109c7ee/imgf000250_0002.png"/></a></div>
      
    </div>
    <div id="p1723" num="1723" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/03/f3/efdbd1f69f88d4/imgf000251_0001.png"><img id="imgf000251_0001" he="72" wi="154" file="imgf000251_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="616" height="288" alt="Figure imgf000251_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1f/03/f3/efdbd1f69f88d4/imgf000251_0001.png"/></a></div>
    </div>
    <div id="p1724" num="1724" class="description-paragraph"> Step 1 Preparation of compound 225 </div>
    <div id="p1725" num="1725" class="description-paragraph"> Compound 225 was prepared from 5-(2-aminoacetamido)isophthalic acid 106 (560mg, 1.5mmol) and 9 (2.24g, 3.6mmol) using an identical procedure to that used for 89. Yield 1.6g, 80%. </div>
    <div id="p1726" num="1726" class="description-paragraph">Step 2 Preparation of compound 226 </div>
    <div id="p1727" num="1727" class="description-paragraph"> Compound 226 was prepared in the same fashion as 14. Yield 1.22g, 78%. </div>
    <div id="p1728" num="1728" class="description-paragraph">Step 3 Preparation of compound 227 </div>
    <div id="p1729" num="1729" class="description-paragraph"> Compound 227 was prepared in the same fashion as 89, from Z-glutamic acid (108mg, 0.38mmol) and 226 (1.22g, 0.92mmol). Yield 471mg, 45%. </div>
    <div id="p1730" num="1730" class="description-paragraph">Step 4 Preparation of compound 228 </div>
    <div id="p1731" num="1731" class="description-paragraph"> Compound 228 was prepared in the same fashion as 14. Yield 460mg, Quant. </div>
    <div id="p1732" num="1732" class="description-paragraph">Step 5 Preparation of compound 229 </div>
    <div id="p1733" num="1733" class="description-paragraph"> Compound 229 was prepared from 228 (460mg, 0.17mmol) and 128 (125mg, 0 19mmol) in the same fashion as 89. Yield 365mg, 66%. </div>
    <div id="p1734" num="1734" class="description-paragraph">Step 6 Preparation of compound 231 </div>
    <div id="p1735" num="1735" class="description-paragraph"> Conjugate 231 was prepared using an identical procedure to that used for compound 1. 

 Example 22a Synthesis of Coniueate 231a </div>
    <div id="p1736" num="1736" class="description-paragraph">Scheme 46a </div>
    <div id="p1737" num="1737" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/d1/41/13a6872085da5a/imgf000252_0001.png"><img id="imgf000252_0001" he="99" wi="158" file="imgf000252_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="396" alt="Figure imgf000252_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/d1/41/13a6872085da5a/imgf000252_0001.png"/></a></div>
    </div>
    <div id="p1738" num="1738" class="description-paragraph"> Scheme 47a </div>
    <div id="p1739" num="1739" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/2e/45/d4a04db49c103a/imgf000252_0002.png"><img id="imgf000252_0002" he="62" wi="133" file="imgf000252_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="532" height="248" alt="Figure imgf000252_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/2e/45/d4a04db49c103a/imgf000252_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/f9/ea/802c9241f806c6/imgf000253_0001.png"><img id="imgf000253_0001" he="72" wi="155" file="imgf000253_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="620" height="288" alt="Figure imgf000253_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/f9/ea/802c9241f806c6/imgf000253_0001.png"/></a></div>
    </div>
    <div id="p1740" num="1740" class="description-paragraph"> Step 1 Preparation of compound 225a </div>
    <div id="p1741" num="1741" class="description-paragraph"> Compound 225a is prepared from 5-(2-aminoacetamido)isophthalic acid 106 (560mg, 1.5mmol) and 9 (2.24g, 3.6mmol) using an identical procedure to that used for 89. Yield 1.6g, 80%. </div>
    <div id="p1742" num="1742" class="description-paragraph">Step 2 Preparation of compound 226a </div>
    <div id="p1743" num="1743" class="description-paragraph"> Compound 226a is prepared in the same fashion as 14. Yield 1.22g, 78%. Step 3 Preparation of compound 227a </div>
    <div id="p1744" num="1744" class="description-paragraph"> Compound 227a is prepared in the same fashion as 89, from Z-glutamic acid (108mg, 0.38mmol) and 226a (1.22g, 0.92mmol). Yield 471mg, 45%. </div>
    <div id="p1745" num="1745" class="description-paragraph">Step 4 Preparation of compound 228a </div>
    <div id="p1746" num="1746" class="description-paragraph"> Compound 228a is prepared in the same fashion as 14. Yield 460mg, Quant. </div>
    <div id="p1747" num="1747" class="description-paragraph">Step 5 Preparation of compound 229a </div>
    <div id="p1748" num="1748" class="description-paragraph"> Compound 229a is prepared from 228a (460mg, 0.17mmol) and 128 (125mg, 0.19mmol) in the same fashion as 89. Yield 365mg, 66%. </div>
    <div id="p1749" num="1749" class="description-paragraph">Step 6 Preparation of compound 231a </div>
    <div id="p1750" num="1750" class="description-paragraph"> Conjugate 231a is prepared using an identical procedure to that used for compound 1. 

 Example 22b Synthesis of Coniugate 231b Scheme 46b </div>
    <div id="p1751" num="1751" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f6/7a/19/1911dac3b3f0b9/imgf000254_0001.png"><img id="imgf000254_0001" he="170" wi="158" file="imgf000254_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="680" alt="Figure imgf000254_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f6/7a/19/1911dac3b3f0b9/imgf000254_0001.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/05/c7/8a19fa51c128fa/imgf000255_0001.png"><img id="imgf000255_0001" he="72" wi="149" file="imgf000255_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="596" height="288" alt="Figure imgf000255_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/05/c7/8a19fa51c128fa/imgf000255_0001.png"/></a></div>
    </div>
    <div id="p1752" num="1752" class="description-paragraph">Step 1 Preparation of compound 225b </div>
    <div id="p1753" num="1753" class="description-paragraph"> Compound 225b is prepared from 5-(2-aminoacetamido)isophthalic acid 106 (560mg, 1.5mmol) and 9 (2.24g, 3.6mmol) using an identical procedure to that used for 89. Yield 1.6g, 80%. </div>
    <div id="p1754" num="1754" class="description-paragraph">Step 2 Preparation of compound 226b </div>
    <div id="p1755" num="1755" class="description-paragraph"> Compound 226b is prepared in the same fashion as 14. Yield 1.22g, 78%. </div>
    <div id="p1756" num="1756" class="description-paragraph">Step 3 Preparation of compound 227b </div>
    <div id="p1757" num="1757" class="description-paragraph"> Compound 227b is prepared in the same fashion as 89, from Z-glutamic acid (108mg, 0.38mmol) and 226b (1.22g, 0.92mmol). Yield 471mg, 45%. Step 4 Preparation of compound 228b </div>
    <div id="p1758" num="1758" class="description-paragraph"> Compound 228b is prepared in the same fashion as 14. Yield 460mg, Quant. </div>
    <div id="p1759" num="1759" class="description-paragraph">Step 5 Preparation of compound 229b </div>
    <div id="p1760" num="1760" class="description-paragraph"> Compound 229b is prepared from 228b (460mg, 0.17mmol) and 128 (125mg, 0.19mmol) in the same fashion as 89. Yield 365mg, 66%. </div>
    <div id="p1761" num="1761" class="description-paragraph">Step 6 Preparation of compound 231b </div>
    <div id="p1762" num="1762" class="description-paragraph"> Conjugate 231b is prepared using an identical procedure to that used for compound 1. 

 Example 23. Synthesis of coniugate 233 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/ab/d0/8dd525898f1cfe/imgf000256_0001.png"><img id="imgf000256_0001" he="24" wi="72" file="imgf000256_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="288" height="96" alt="Figure imgf000256_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/ab/d0/8dd525898f1cfe/imgf000256_0001.png"/></a></div>
</div>
    <div id="p1763" num="1763" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/64/b1/c6ab243fd5d344/imgf000256_0002.png"><img id="imgf000256_0002" he="145" wi="167" file="imgf000256_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="668" height="580" alt="Figure imgf000256_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/64/b1/c6ab243fd5d344/imgf000256_0002.png"/></a></div>
 Step 1. Preparation of compound 232 </div>
    <div id="p1764" num="1764" class="description-paragraph"> Compound 232 was prepared from compound 24 (650 mg, 0.33 mmol) and compound 69b (175 mg, 0.33 mmol) using an identical procedure to that used for compound 19. Yield: 380 mg, 47%. </div>
    <div id="p1765" num="1765" class="description-paragraph">Step 2. Preparation of compound 233 </div>
    <div id="p1766" num="1766" class="description-paragraph"> Compound 233 was prepared from compound 232 using identical procedures to that used for compound 1. Example 24. Synthesis of coniugate 235 </div>
    <div id="p1767" num="1767" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f5/33/a8/77e34754c5d77a/imgf000257_0001.png"><img id="imgf000257_0001" he="141" wi="153" file="imgf000257_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="612" height="564" alt="Figure imgf000257_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f5/33/a8/77e34754c5d77a/imgf000257_0001.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6e/bc/d6/475761048eea97/imgf000258_0001.png"><img id="imgf000258_0001" he="66" wi="154" file="imgf000258_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="264" alt="Figure imgf000258_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6e/bc/d6/475761048eea97/imgf000258_0001.png"/></a></div>
    </div>
    <div id="p1768" num="1768" class="description-paragraph"> Step 1. Preparation of compound 234 </div>
    <div id="p1769" num="1769" class="description-paragraph"> Compound 234 was prepared from compound 24 (1.1 g, 0.55 mmol) and compound 18 (175 mg, 0.33 mmol) using an identical procedure to that used for compound 19. Yield: 685 mg,</div>
    <div id="p1770" num="1770" class="description-paragraph">51%. </div>
    <div id="p1771" num="1771" class="description-paragraph">Step 2. Preparation of compound 235 </div>
    <div id="p1772" num="1772" class="description-paragraph"> Compound 235 was prepared from compound 234 using identical procedures for compound 1. </div>
    <div id="p1773" num="1773" class="description-paragraph">Example 25. Synthesis of conjugate 320 </div>
    <div id="p1774" num="1774" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/02/96/d5/eb8087ca1454ec/imgf000258_0002.png"><img id="imgf000258_0002" he="70" wi="164" file="imgf000258_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="656" height="280" alt="Figure imgf000258_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/02/96/d5/eb8087ca1454ec/imgf000258_0002.png"/></a></div>
 Step 1. Preparation of Racemic (cis) 5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4- c]pyrrole-l,3(3aH)-dione 301 </div>
    <div id="p1775" num="1775" class="description-paragraph"> To a cooled solution (0Â°C) of 3,4-dimethylfuran-2,5-dione (3 g, 24 mmol) and N-benzyl- l-methoxy-N-((trimethylsilyl)methyl)methanamine (7 g, 29.8 mmol) in dichloromethane (75 mL) was slowly added trifluoroacetic acid (75 Î¼Î¯). Stir overnight allowing the solution to slowly warm to room temperature as the ice bath melted. The reaction mixture was concentrated to dryness, dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate (2 x lOOmL), dried on magnesium sulfate, filtered and concentrated to dryness. Purification by column chromatography on silica gel (gradient: 20% ethyl acetate in hexanes to 100% ethyl acetate) afforded (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4-c]pyrrole- l,3(3aH)-dione as a yellow oil (3.5 g, 56%). </div>
    <div id="p1776" num="1776" class="description-paragraph">Step 2. Preparation of Racemic (cis) (l-Benzyl-3,4-dimethylpyrrolidine-3,4- diyl)dimethanol 302 </div>
    <div id="p1777" num="1777" class="description-paragraph"> To a cooled (0Â°C) solution of (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH- furo[3,4-c]pyrrole-l,3(3aH)-dione (3.5 g, 13.4 mmol) in anhydrous diethyl ether (50 mL) was added slowly lithium aluminum hydride pellets (1.5 g, 40 mmol) over three portions. The solution was stirred overnight warming to room temperature as the ice water bath melted. Upon completion, the reaction was cooled to 0Â°C and very slowly quenched with 1.5 mL of 5M NaOH followed by 1.5 mL of water. Stir for 30 minutes then add magnesium sulfate and filter. The filtrate was concentrated to afford ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4- diyl)dimethanol as a colorless oil (2.7 g). </div>
    <div id="p1778" num="1778" class="description-paragraph">Step 3. Preparation of Racemic (cis) (3,4-Dimethylpyrrolidine-3,4-diyl)dimethanol 303</div>
    <div id="p1779" num="1779" class="description-paragraph">To a solution of ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4-diyl)dimethanol (10 g, 40 mmol) in methanol (10 mL) was added 10% palladium on activated charcoal wet (1 g). The solution was stirred vigorously under a hydrogen atmosphere for 16 hours. Upon completion the solution was filtered through Celite, and concentrated to dryness to afford ((3R,4S)-3,4- Dimethylpyrrolidine-3,4-diyl)dimethanol as a colorless solid (5.5 g, 86%). </div>
    <div id="p1780" num="1780" class="description-paragraph">Step 4. Preparation of Racemic (cis) Methyl 10-(3,4-bis(hydroxymethyl)-3,4- dimethylpyrrolidin-l-yl)-10-oxodecanoate 304 </div>
    <div id="p1781" num="1781" class="description-paragraph"> A solution of 3 (1.3 g, 8.2 mmol) and monomethyl sebacate (1.8 g, 8.2 mmol) in CH2CI2 (lOOmL) was treated with HBTU (3.41g, 9.02mmol) and Hunig&#39;s base (5.71mL, 32.8mmol). 

 After stirring overnight the mixture was washed with NaHCCb (sat. aq.), water and brine, then dried (MgSC ), filtered and concentrated. The crude material was subjected to chromatography (gradient: 0% CH3OH-CH2CI2 to 20%) to yield 4 (1.8g, 61%). Step 5. Preparation of Racemic (cis) Methyl 10-(3-((bis(4-niethoxyphenyl)(phenyl)- methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10-oxodecanoate 305</div>
    <div id="p1782" num="1782" class="description-paragraph">A solution of 304 (1.8 g, 5.0 mmol) and 4,4&#39;-Dimethoxytrityl chloride (1.7 g, 5.0 mmol) in pyridine (180mL) was stirred overnight. The pyridine was then removed under reduced pressure and the crude material was subjected to chromatography (gradient: 0% CH3OH-CH2CI2 to 10%) to yield 5 (1.4 g, 42%) as a yellow oil. </div>
    <div id="p1783" num="1783" class="description-paragraph">Step 6. Preparation of Racemic (cis) Lithium 10-(3-((bis(4-methoxyphenyl)- (phenyl)methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10- oxodecanoate 306 </div>
    <div id="p1784" num="1784" class="description-paragraph"> To a solution of compound 305 (3.0 g, 4.6 mmol) in THF (50 mL) and water (50 mL) was added lithium hydroxide (121 mg, 5.0 mmol). The solution was stirred for 4 hours at room temperature then concentrated to remove the THF. The remaining aqueous solution was freeze dried overnight to afford a pale pink solid (2.9 g, quantitative). Compound 306 was prepared as a mixture of two cz<sup>&#39;</sup>s-diastereomers. </div>
    <div id="p1785" num="1785" class="description-paragraph">Scheme 51 Synthesis of peracetylated galactosamine 307 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/93/58/09f1ca9f9788ee/imgf000260_0001.png"><img id="imgf000260_0001" he="18" wi="26" file="imgf000260_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="104" height="72" alt="Figure imgf000260_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/93/58/09f1ca9f9788ee/imgf000260_0001.png"/></a></div>
 </div>
    <div id="p1786" num="1786" class="description-paragraph"> D-Galactosamine hydrochloride (250 g, 1 16 mol) in pyridine (1.5 L) was treated with acetic anhydride (1.25 L, 13.2 mol) over 45 minutes. After stirring overnight the reaction mixture was divided into three 1 L portions. Each 1 L portion was poured into 3 L of ice water and mixed for one hour After mixing the solids were filtered off, combined, frozen over liquid nitrogen and then lyophilized for five days to yield peracetylated galactosamine 7 (369.4 g, 82%) as a white solid. Rf (0.58, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). 

 Scheme 52 Synthesis of GalNAc monomer </div>
    <div id="p1787" num="1787" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/ba/2d/94cfc4fd13b941/imgf000261_0001.png"><img id="imgf000261_0001" he="43" wi="152" file="imgf000261_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="608" height="172" alt="Figure imgf000261_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/ba/2d/94cfc4fd13b941/imgf000261_0001.png"/></a></div>
    </div>
    <div id="p1788" num="1788" class="description-paragraph"> Step 1 Preparation of compound 309 </div>
    <div id="p1789" num="1789" class="description-paragraph"> A solution of 2-[2-(2-chloroethoxy)]ethanol 308 (100g, 593mmol) in water (1L) was treated with NaN3 (77g, 1.19mol) and heated (90Â°C). After stirring (72 hours) the solution was cooled (RT) and extracted (4x) with CH2CI2. The combined organics were washed with brine, dried (MgSC ), filtered, concentrated and used without further processing. Compound 9 (88.9g, 86%) was obtained as a pale yellow oil. </div>
    <div id="p1790" num="1790" class="description-paragraph">Step 2 Preparation of compound 310 </div>
    <div id="p1791" num="1791" class="description-paragraph"> A solution of 7 (2.76g, 7.1mmol) and 309 (1.37g, 7.8mmol) in 1,2-dichloroethane (40mL) was treated with Sc(OTf)<sub>3</sub> (174mg, 0.36mmol) and heated (85Â°C). After stirring (2 hours) the mixture was cooled (RT) and quenched by the addition of TEA (4mL) and concentrated. The crude material was subjected to chromatography to yield 310 (3.03g, 85%) as a pale yellow foam. </div>
    <div id="p1792" num="1792" class="description-paragraph">Step 3 Preparation of compound 311 </div>
    <div id="p1793" num="1793" class="description-paragraph"> A solution of 310 (3.02g, 5.99mmol) and Pd/C (300mg, 10% Pd loading - wet support) in EtOAc (30mL) was treated with TFA (576Î¼Î, 7.5mmol). The reaction mixture was purged with hydrogen gas (45min) then purged with nitrogen gas (lOmin), then filtered through celite. The filtrate was concentrated and then subjected to chromatography to yield 311 (2.67g, 75%) as a brown foam. 

 Scheme 53 Synthesis of aromatic core </div>
    <div id="p1794" num="1794" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4e/b1/21/daae918afbb5ac/imgf000262_0001.png"><img id="imgf000262_0001" he="30" wi="157" file="imgf000262_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="628" height="120" alt="Figure imgf000262_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4e/b1/21/daae918afbb5ac/imgf000262_0001.png"/></a></div>
    </div>
    <div id="p1795" num="1795" class="description-paragraph"> 312 313 </div>
    <div id="p1796" num="1796" class="description-paragraph">Step 1. Preparation of Dimethyl 5-(2-((2-oxo-2-phenyl-^<sup>2</sup>-ethyl)amino)acetamido)- isophthalate 312 </div>
    <div id="p1797" num="1797" class="description-paragraph"> A solution of dimethyl 5-aminoisophthalate (5 g, 24 mmol), Z-Gly-OH (5 g, 24 mmol), EDC (5 g, 26.3 mmol), HOBt (3.6 g, 26.3 mmol), NMM (2.9 mL, 26.3 mmol) in DMF (50 mL) was stirred overnight at room temperature. Upon completion, the reaction mixture was diluted with ethyl acetate (250 mL) and washed with each 1M HC1 (2 x 100 mL), saturated sodium bicarbonate (1 x 100 mL) and brine (2 x 100 mL). Dry on magnesium sulfate, filter and concentrate to dryness to afford Dimethyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)- acetamido)isophthalate as a colorless solid (7.2 g, 79%). </div>
    <div id="p1798" num="1798" class="description-paragraph">Step 2. Preparation of 5-(2-((2-oxo-2-phenyl-^<sup>2</sup>-ethyl)amino)acetamido)isophthalic acid 313 </div>
    <div id="p1799" num="1799" class="description-paragraph"> To a solution of methyl 5-(2-((2-oxo-2-phenyl- <sup>2</sup>-ethyl)amino)acetamido)isophthalate (7.2 g) in methanol (25 mL) and THF (25 mL) was added 1M NaOH (25 mL). The solution was stirred at room temperature for 2 hours then concentrated to remove THF and MeOH. The aqueous solution remaining was diluted with water (75 mL), cooled on an ice water bath and acidified to pH = 1 with 6M HC1. The solid was filtered and washed with water (3 x 100 mL). The solid was freeze dried to afford 5-(2-((2-oxo-2-phenyl- <sup>2</sup>-ethyl)amino)acetamido)- isophthalic acid (6.9 g, quantitative) . </div>
    <div id="p1800" num="1800" class="description-paragraph">Scheme 54: Preparation of tetramer </div>
    <div id="p1801" num="1801" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/e9/8e/5535872fea4b4a/imgf000262_0002.png"><img id="imgf000262_0002" he="36" wi="159" file="imgf000262_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="636" height="144" alt="Figure imgf000262_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9b/e9/8e/5535872fea4b4a/imgf000262_0002.png"/></a></div>
      
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/b8/e8/779faa85990a1f/imgf000263_0001.png"><img id="imgf000263_0001" he="58" wi="159" file="imgf000263_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="636" height="232" alt="Figure imgf000263_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/b8/e8/779faa85990a1f/imgf000263_0001.png"/></a></div>
    </div>
    <div id="p1802" num="1802" class="description-paragraph">Step 1 Preparation of compound 314 </div>
    <div id="p1803" num="1803" class="description-paragraph"> A solution of 313 (2.09g, 5.6mmol) and 311 (8.34g, 14.07mmol) in CH2CI2 (150mL) was treated with HBTU (6.4g, 16.9mmol) and Hunig&#39; s base (7.35mL, 42.2mmol). After stirring (overnight) the reaction mixture was poured into NaHCC (sat. aq.) then washed with water and brine, dried (MgSC ), filtered and concentrated. The crude material was subjected to chromatography (gradient 1 -12% CH3OH-CH2CI2) to yield 6 (3.97g, 55%) as a pale yellow foam. </div>
    <div id="p1804" num="1804" class="description-paragraph">Step 2 Preparation of compound 315 </div>
    <div id="p1805" num="1805" class="description-paragraph"> Compound 314 (3.92g, 3.07mmol), Pd/C (400mg, 10% loading - wet support) and trifluoroacetic acid (308Î¼Î¯, 4mmol) was purged with H2. After stirring under H2 (overnight), the mixture was purged with N2 (15-20 min) then filtered through celite and concentrated. The crude material was subjected to chromatography to yield 7 (3.36g, 86%) as a white to cream colored foam. </div>
    <div id="p1806" num="1806" class="description-paragraph">Step 3 Preparation of compound 316 </div>
    <div id="p1807" num="1807" class="description-paragraph"> Compound 316 was prepared in the same fashion as 314, from Z-glutamic acid (306mg, 1.09mmol) and 315 (3.3g, 2.6mmol). Yield 1.66g, 60%. </div>
    <div id="p1808" num="1808" class="description-paragraph">Step 4 Preparation of compound 317 </div>
    <div id="p1809" num="1809" class="description-paragraph"> Compound 317 was prepared in the same fashion as 315. Yield 1.65g, Quant. 

 Scheme 55 Preparation of complete conj </div>
    <div id="p1810" num="1810" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6c/ca/72/cbb23b069f736a/imgf000264_0001.png"><img id="imgf000264_0001" he="73" wi="158" file="imgf000264_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="292" alt="Figure imgf000264_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6c/ca/72/cbb23b069f736a/imgf000264_0001.png"/></a></div>
    </div>
    <div id="p1811" num="1811" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1c/77/fb/19e54846664c9e/imgf000264_0002.png"><img id="imgf000264_0002" he="72" wi="158" file="imgf000264_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="288" alt="Figure imgf000264_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1c/77/fb/19e54846664c9e/imgf000264_0002.png"/></a></div>
    </div>
    <div id="p1812" num="1812" class="description-paragraph">Step 1 Preparation of compound 318 </div>
    <div id="p1813" num="1813" class="description-paragraph"> A solution of 317 (1.91g, 0.75mmol) in CH<sub>2</sub>C1<sub>2</sub> (lOOmL) was treated first with Hunig&#39;s base (392Î¼Î<sub>^</sub>, 2.25mmol) then 6 (a mixture of two cw-diastereomers, 509mg, 0.79mmol) followed by HBTU (356mg, 0.94mmol). After stirring (overnight) the solution was poured into NaHCC (sat. aq.) then washed with water and brine, dried (MgSO t), filtered and concentrated. The crude material was subjected to chromatography to yield 318 (1.19g, 52%) as a white foam. 

 Step 2 Preparation of compound 319 </div>
    <div id="p1814" num="1814" class="description-paragraph"> A solution of 318 (1.19g, 0.39mmol) in 1,2 dichloroethane (lOOmL) was treated with TEA (542Î¼Î., 3.9mmol), DMAP (238mg, 1.95mmol) and succinic anhydride (195mg, </div>
    <div id="p1815" num="1815" class="description-paragraph">1.95mmol) and heated (85Â°C). After stirring (2.5 hours) the solution was removed from heat and treated with CH3OH (lOmL) and allowed to stir (1 hour). After stirring the mixture was poured into NaHCCb (sat. aq.) then washed with brine, dried (MgS04), filtered and </div>
    <div id="p1816" num="1816" class="description-paragraph">concentrated. The residue obtained was used without further processing. Yield = 1.4g, Quant. </div>
    <div id="p1817" num="1817" class="description-paragraph">Step 3 Preparation of conjugate 320 </div>
    <div id="p1818" num="1818" class="description-paragraph"> The succinate 319 was loaded onto IOOOA LCAA (long chain aminoalkyl) CPG (control pore glass) using standard amide coupling chemistry. A solution of diisopropylcarbodiimide (52.6 Î¼ÏÎ¹Î¿Î), N-hydroxy succinimide (0.3 mg, 2.6 Î¼Î¹ÏÎ¹Î¿Î) and pyridine (10 Î¼Î,) in anhydrous acetonitrile (0.3 mL) was added to 319 (20.6 mg, 8 Î¼ÏÎ¹Î¿Î) in anhydrous dichloromethane (0.2 mL). This mixture was added to LCAA CPG (183 mg). The suspension was gently mixed overnight at room temperature. Upon disappearance of 319 (HPLC), the reaction mixture was filtered and the CPG was washed with 1 mL of each dichloromethane, acetonitrile, a solution of 5% acetic anhydride / 5% N-methylimidazole / 5% pyridine in THF, then THF, acetonitrile and dichloromethane. The CPG was then dried overnight under high vacuum. Loading was determined by standard DMTr assay by UV/Vis (504 nm) to be 19 Î¼Î¹Î·Î¿Î/g. The resulting GalNAc loaded CPG solid support was employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) afforded the GalNAc-oligonucleotide conjugate 320 

</div>
    <div id="p1819" num="1819" class="description-paragraph">Example 26 Synthesis of conjugate 520 </div>
    <div id="p1820" num="1820" class="description-paragraph">Scheme 56 Preparation of activated linker </div>
    <div id="p1821" num="1821" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/02/52/bae3e176f25e2d/imgf000266_0001.png"><img id="imgf000266_0001" he="55" wi="150" file="imgf000266_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="220" alt="Figure imgf000266_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/02/52/bae3e176f25e2d/imgf000266_0001.png"/></a></div>
    </div>
    <div id="p1822" num="1822" class="description-paragraph"> 304 305 306 </div>
    <div id="p1823" num="1823" class="description-paragraph">Step 1. Preparation of Racemic (cis) 5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4- c]pyrrole-l,3(3aH)-dione 301 </div>
    <div id="p1824" num="1824" class="description-paragraph"> To a cooled solution (0Â°C) of 3,4-dimethylfuran-2,5-dione (3 g, 24 mmol) and N-benzyl- l-methoxy-N-((trimethylsilyl)methyl)methanamine (7 g, 29.8 mmol) in dichloromethane (75 mL) was slowly added trifluoroacetic acid (75 Î¼Î¯). Stir overnight allowing the solution to slowly warm to room temperature as the ice bath melted. The reaction mixture was concentrated to dryness, dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate (2 x lOOmL), dried on magnesium sulfate, filtered and concentrated to dryness. Purification by column chromatography on silica gel (gradient: 20% ethyl acetate in hexanes to 100% ethyl acetate) afforded (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH-furo[3,4-c]pyrrole- l,3(3aH)-dione as a yellow oil (3.5 g, 56%). </div>
    <div id="p1825" num="1825" class="description-paragraph">Step 2. Preparation of Racemic (cis) (l-Benzyl-3,4-dimethylpyrrolidine-3,4- diyl)dimethanol 302 </div>
    <div id="p1826" num="1826" class="description-paragraph"> To a cooled (0Â°C) solution of (3aR,6aS)-5-Benzyl-3a,6a-dimethyltetrahydro-lH- furo[3,4-c]pyrrole-l,3(3aH)-dione (3.5 g, 13.4 mmol) in anhydrous diethyl ether (50 mL) was added slowly lithium aluminum hydride pellets (1.5 g, 40 mmol) over three portions. The solution was stirred overnight warming to room temperature as the ice water bath melted. Upon completion, the reaction was cooled to 0Â°C and very slowly quenched with 1.5 mL of 5M NaOH followed by 1.5 mL of water. Stir for 30 minutes then add magnesium sulfate and filter. The filtrate was concentrated to afford ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4- diyl)dimethanol as a colorless oil (2.7 g). 

 Step 3. Preparation of Racemic (cis) (3,4-Dimethylpyrrolidine-3,4-diyl)dimethanol 303</div>
    <div id="p1827" num="1827" class="description-paragraph">To a solution of ((3R,4S)-l-Benzyl-3,4-dimethylpyrrolidine-3,4-diyl)dimethanol (10 g, 40 mmol) in methanol (10 mL) was added 10% palladium on activated charcoal wet (1 g). The solution was stirred vigorously under a hydrogen atmosphere for 16 hours. Upon completion the solution was filtered through Celite, and concentrated to dryness to afford ((3R,4S)-3,4- Dimethylpyrrolidine-3,4-diyl)dimethanol as a colorless solid (5.5 g, 86%). </div>
    <div id="p1828" num="1828" class="description-paragraph">Step 4. Preparation of Racemic (cis) Methyl 10-(3,4-bis(hydroxymethyl)-3,4- dimethylpyrrolidin-l-yl)-10-oxodecanoate 304 </div>
    <div id="p1829" num="1829" class="description-paragraph"> A solution of 3 (1.3 g, 8.2 mmol) and monomethyl sebacate (1.8 g, 8.2 mmol) in CH2CI2 (lOOmL) was treated with HBTU (3.41g, 9.02mmol) and Hunig&#39;s base (5.71mL, 32.8mmol). After stirring overnight the mixture was washed with NaHCCb (sat. aq.), water and brine, then dried (MgSC ), filtered and concentrated. The crude material was subjected to chromatography (gradient: 0% CH3OH-CH2CI2 to 20%) to yield 4 (1.8g, 61%). </div>
    <div id="p1830" num="1830" class="description-paragraph">Step 5. Preparation of Racemic (cis) Methyl 10-(3-((bis(4-methoxyphenyl)(phenyl)- methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10-oxodecanoate 305</div>
    <div id="p1831" num="1831" class="description-paragraph">A solution of 304 (1.8 g, 5.0 mmol) and 4,4&#39;-Dimethoxytrityl chloride (1.7 g, 5.0 mmol) in pyridine (180mL) was stirred overnight. The pyridine was then removed under reduced pressure and the crude material was subjected to chromatography (gradient: 0% CH3OH-CH2CI2 to 10%) to yield 5 (1.4 g, 42%) as a yellow oil. </div>
    <div id="p1832" num="1832" class="description-paragraph">Step 6. Preparation of Racemic (cis) Lithium 10-(3-((bis(4-methoxyphenyl)- (phenyl)methoxy)methyl)-4-(hydroxymethyl)-3,4-dimethylpyrrolidin-l-yl)-10- oxodecanoate 306 </div>
    <div id="p1833" num="1833" class="description-paragraph"> To a solution of compound 305 (3.0 g, 4.6 mmol) in THF (50 mL) and water (50 mL) was added lithium hydroxide (121 mg, 5.0 mmol). The solution was stirred for 4 hours at room temperature then concentrated to remove the THF. The remaining aqueous solution was freeze dried overnight to afford a pale pink solid (2.9 g, quantitative). Compound 306 was prepared as a mixture of two cz<sup>&#39;</sup>s-diastereomers. </div>
    <div id="p1834" num="1834" class="description-paragraph">Scheme 57 Synthesis of peracetylated galactosamine 507 

 AcO .OAc </div>
    <div id="p1835" num="1835" class="description-paragraph"> AcO- OAc </div>
    <div id="p1836" num="1836" class="description-paragraph">Galactosamine hydrochloride (250 g, 1.16 mol) in pyridine (1.5 L) is treated with acetic anhydride (1.25 L, 13.2 mol) over 45 minutes. After stirring overnight the reaction mixture is divided into three 1 L portions. Each 1 L portion is poured into 3 L of ice water and mixed for one hour. After mixing the solids are filtered off, combined, frozen over liquid nitrogen and then lyophilized for five days to yield peracetylated galactosamine 507 (369.4 g, 82%) as a white solid. Rf (0.58, 10% MeOH-CH<sub>2</sub>Cl<sub>2</sub>). </div>
    <div id="p1837" num="1837" class="description-paragraph">Scheme 58 Synthesis of GalNAc monomer </div>
    <div id="p1838" num="1838" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b9/9c/ec/2daf729c02461b/imgf000268_0001.png"><img id="imgf000268_0001" he="44" wi="154" file="imgf000268_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="176" alt="Figure imgf000268_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b9/9c/ec/2daf729c02461b/imgf000268_0001.png"/></a></div>
    </div>
    <div id="p1839" num="1839" class="description-paragraph">Step 1 Preparation of compound 509 </div>
    <div id="p1840" num="1840" class="description-paragraph"> A solution of 2-[2-(2-chloroethoxy)]ethanol 508 (100g, 593mmol) in water (1L) is treated with NaN3 (77g, 1.19mol) and heated (90Â°C). After stirring (72 hours) the solution is cooled (RT) and extracted (4x) with CH2CI2. The combined organics are washed with brine, dried (MgSC ), filtered, concentrated and used without further processing. Compound 509 (88.9g, 86%&gt;) is obtained as a pale yellow oil. </div>
    <div id="p1841" num="1841" class="description-paragraph">Step 2 Preparation of compound 510 </div>
    <div id="p1842" num="1842" class="description-paragraph"> A solution of 507 (2.76g, 7.1mmol) and 509 (1.37g, 7.8mmol) in 1,2-dichloroethane (40mL) is treated with Sc(OTf)<sub>3</sub> (174mg, 0.36mmol) and heated (85Â°C). After stirring (2 hours) the mixture is cooled (RT) and quenched by the addition of TEA (4mL) and concentrated. The crude material is subjected to chromatography to yield 510 (3.03g, 85%&gt;) as a pale yellow foam. </div>
    <div id="p1843" num="1843" class="description-paragraph">Step 3 Preparation of compound 511 </div>
    <div id="p1844" num="1844" class="description-paragraph"> A solution of 510 (3.02g, 5.99mmol) and Pd/C (300mg, 10% Pd loading - wet support) in EtOAc (30mL) is treated with TFA (576Î¼Î¯, 7.5mmol). The reaction mixture is purged with 

 hydrogen gas (45min) then purged with nitrogen gas (lOmin), then filtered through celite. The filtrate is concentrated and then subjected to chromatography to yield 511 (2.67g, 75%) as a brown foam. Scheme 59 Synthesis of aromatic core </div>
    <div id="p1845" num="1845" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ff/37/04/0a0ee2308b4a8b/imgf000269_0001.png"><img id="imgf000269_0001" he="34" wi="158" file="imgf000269_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="632" height="136" alt="Figure imgf000269_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ff/37/04/0a0ee2308b4a8b/imgf000269_0001.png"/></a></div>
    </div>
    <div id="p1846" num="1846" class="description-paragraph"> 312 313 </div>
    <div id="p1847" num="1847" class="description-paragraph">Step 1. Preparation of Dimethyl 5-(2-((2-oxo-2-phenyl-^<sup>2</sup>-ethyl)amino)acetamido)- isophthalate 312 </div>
    <div id="p1848" num="1848" class="description-paragraph"> A solution of dimethyl 5-aminoisophthalate (5 g, 24 mmol), Z-Gly-OH (5 g, 24 mmol),</div>
    <div id="p1849" num="1849" class="description-paragraph">EDC (5 g, 26.3 mmol), HOBt (3.6 g, 26.3 mmol), NMM (2.9 mL, 26.3 mmol) in DMF (50 mL) was stirred overnight at room temperature. Upon completion, the reaction mixture was diluted with ethyl acetate (250 mL) and washed with each 1M HC1 (2 x 100 mL), saturated sodium bicarbonate (1 x 100 mL) and brine (2 x 100 mL). Dry on magnesium sulfate, filter and concentrate to dryness to afford Dimethyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)- acetamido)isophthalate as a colorless solid (7.2 g, 79%). </div>
    <div id="p1850" num="1850" class="description-paragraph">Step 2. Preparation of 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)isophthalic acid 313 </div>
    <div id="p1851" num="1851" class="description-paragraph"> To a solution of methyl 5-(2-((2-oxo-2-phenyl-l <sup>2</sup>-ethyl)amino)acetamido)isophthalate</div>
    <div id="p1852" num="1852" class="description-paragraph">(7.2 g) in methanol (25 mL) and THF (25 mL) was added 1M NaOH (25 mL). The solution was stirred at room temperature for 2 hours then concentrated to remove THF and MeOH. The aqueous solution remaining was diluted with water (75 mL), cooled on an ice water bath and acidified to pH = 1 with 6M HC1. The solid was filtered and washed with water (3 x 100 mL). The solid was freeze dried to afford 5-(2-((2-oxo-2-phenyl- <sup>2</sup>-ethyl)amino)acetamido)- isophthalic acid (6.9 g, quantitative) . 

 Scheme 60: Preparation of tetramer </div>
    <div id="p1853" num="1853" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/83/32/2f/c89ff0ffd85a20/imgf000270_0001.png"><img id="imgf000270_0001" he="97" wi="151" file="imgf000270_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="604" height="388" alt="Figure imgf000270_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/83/32/2f/c89ff0ffd85a20/imgf000270_0001.png"/></a></div>
    </div>
    <div id="p1854" num="1854" class="description-paragraph">Step 1 Preparation of compound 514 </div>
    <div id="p1855" num="1855" class="description-paragraph"> A solution of 313 (2.09g, 5.6mmol) and 511 (8.34g, 14.07mmol) in CH2CI2 (150mL) is treated with HBTU (6.4g, 16.9mmol) and Hunig&#39; s base (7.35mL, 42.2mmol). After stirring (overnight) the reaction mixture is poured into NaHCCb (sat. aq.) then washed with water and brine, dried (MgSCu), filtered and concentrated. The crude material is subjected to </div>
    <div id="p1856" num="1856" class="description-paragraph">chromatography (gradient 1-12% CH3OH-CH2CI2) to yield 6 (3.97g, 55%) as a pale yellow foam. </div>
    <div id="p1857" num="1857" class="description-paragraph">Step 2 Preparation of compound 515 </div>
    <div id="p1858" num="1858" class="description-paragraph"> Compound 514 (3.92g, 3.07mmol), Pd/C (400mg, 10% loading - wet support) and trifluoroacetic acid (308Î¼Î¯, 4mmol) is purged with H2. After stirring under H2 (overnight), the mixture is purged with N2 (15-20 min) then filtered through celite and concentrated. The crude material is subjected to chromatography to yield 7 (3.36g, 86%) as a white to cream colored foam. </div>
    <div id="p1859" num="1859" class="description-paragraph">Step 3 Preparation of compound 516 </div>
    <div id="p1860" num="1860" class="description-paragraph"> Compound 516 is prepared in the same fashion as 514, from Z-glutamic acid (306mg, 1.09mmol) and 515 (3.3g, 2.6mmol). Yield 1.66g, 60%. 

 Step 4 Preparation of compound 517 </div>
    <div id="p1861" num="1861" class="description-paragraph"> Compound 517 is prepared in the same fashion as 515. Yield 1.65g, Quant. </div>
    <div id="p1862" num="1862" class="description-paragraph">Scheme 61 Preparation of complete conjugate </div>
    <div id="p1863" num="1863" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/7f/14/b8e4112cb65fa7/imgf000271_0001.png"><img id="imgf000271_0001" he="68" wi="147" file="imgf000271_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="588" height="272" alt="Figure imgf000271_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/7f/14/b8e4112cb65fa7/imgf000271_0001.png"/></a></div>
    </div>
    <div id="p1864" num="1864" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6e/a2/b1/3d065befc7aead/imgf000271_0002.png"><img id="imgf000271_0002" he="71" wi="154" file="imgf000271_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="616" height="284" alt="Figure imgf000271_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6e/a2/b1/3d065befc7aead/imgf000271_0002.png"/></a></div>
    </div>
    <div id="p1865" num="1865" class="description-paragraph">Step 1 Preparation of compound 518 </div>
    <div id="p1866" num="1866" class="description-paragraph"> A solution of 517 (1.91g, 0.75mmol) in CH2CI2 (lOOmL) is treated first with Hunig&#39; s base (392Î¼Î., 2.25mmol) then 306 (a mixture of two czs-diastereomers, 509mg, 0.79mmol) followed by HBTU (356mg, 0.94mmol). After stirring (overnight) the solution was poured into NaHCCb (sat. aq.) then washed with water and brine, dried (MgSO/t), filtered and concentrated. The crude material is subjected to chromatography to yield 518 (1.19g, 52%) as a white foam. 

 Step 2 Preparation of compound 519 </div>
    <div id="p1867" num="1867" class="description-paragraph"> A solution of 518 (1.19g, 0.39mmol) in 1,2 dichloroethane (lOOmL) is treated with TEA (542Î¼Î., 3.9mmol), DMAP (238mg, 1.95mmol) and succinic anhydride (195mg, 1.95mmol) and heated (85Â°C). After stirring (2.5 hours) the solution is removed from heat and treated with CH3OH (lOmL) and allowed to stir (1 hour). After stirring the mixture is poured into NaHCCb (sat. aq.) then washed with brine, dried (MgSC ), filtered and concentrated. The residue obtained is used without further processing. Yield = 1.4g, Quant. </div>
    <div id="p1868" num="1868" class="description-paragraph">Step 3 Preparation of conjugate 520 </div>
    <div id="p1869" num="1869" class="description-paragraph"> The succinate 519 is loaded onto IOOOA LCAA (long chain aminoalkyl) CPG (control pore glass) using standard amide coupling chemistry. A solution of diisopropylcarbodiimide (52.6 Î¼ÏÎ¹Î¿Î), N-hydroxy succinimide (0.3 mg, 2.6 Î¼Î¹Î·Î¿Î) and pyridine (10 Î¼Î in anhydrous acetonitrile (0.3 mL) is added to 519 (20.6 mg, 8 Î¼Î¹Î·Î¿Î) in anhydrous dichloromethane (0.2 mL). This mixture is added to LCAA CPG (183 mg). The suspension was gently mixed overnight at room temperature. Upon disappearance of 519 (HPLC), the reaction mixture is filtered and the CPG is washed with 1 mL of each dichloromethane, acetonitrile, a solution of 5% acetic anhydride / 5% N-methylimidazole / 5% pyridine in THF, then THF, acetonitrile and dichloromethane. The CPG is then dried overnight under high vacuum. Loading was determined by standard DMTr assay by UV/Vis (504 nm) to be 19 Î¼Î¹Î·Î¿Î/g. The resulting GalNAc loaded CPG solid support is employed in automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection followed by removal from the solid support (with concurrent galactosamine acetate deprotection) affords the GalNAc-oligonucleotide </div>
    <div id="p1870" num="1870" class="description-paragraph">conjugate 520. Example 27. Two Way Combinations of siRNA Molecules </div>
    <div id="p1871" num="1871" class="description-paragraph"> Certain embodiments of the present invention provide the use of combinations of two of the siRNA molecules described herein, e.g., as a combination in a composition or a nucleic acid-lipid particle, e.g. , a combination of two of siRNA molecules lm-80m or a combination of two of siRNA molecules 101 -137. </div>
    <div id="p1872" num="1872" class="description-paragraph">Example 28. Three Way Combinations of siRNA Molecules </div>
    <div id="p1873" num="1873" class="description-paragraph"> Certain embodiments of the present invention provide the use of combinations of three of the siRNA molecules described herein, e.g., as a combination in a composition or a nucleic acid-lipid particle, e.g. , a combination of three of siRNA molecules lm-80m or a combination of 

 three of siRNA molecules 101-137. While not intending to be limited to these combinations, certain combinations of three siRNA molecules include the following. </div>
    <div id="p1874" num="1874" class="description-paragraph"> By way of example, the three way siRNA combinations of siRNAs lm thru 15m are: lm-2m-3m; lm-2m-4m; lm-2m-5m; lm-2m-6m; lm-2m-7m; lm-2m-8m; lm-2m-9m; lm-2m- 10m;lm-2m-l lm;lm-2m-12m;lm-2m-13m;lm-2m-14m;lm-2m-15m;lm-3m-4m;lm-3m- 5m;lm-3m-6m;lm-3m-7m;lm-3m-8m;lm-3m-9m;lm-3m-10m;lm-3m-llm;lm-3m-12m;lm- 3m-13m;lm-3m-14m;lm-3m-15m;lm-4m-5m;lm-4m-6m;lm-4m-7m;lm-4m-8m;lm-4m- 9m;lm-4m-10m;lm-4m-llm;lm-4m-12m;lm-4m-13m;lm-4m-14m;lm-4m-15m;lm-5m- 6m;lm-5m-7m;lm-5m-8m;lm-5m-9m;lm-5m-10m;lm-5m-llm;lm-5m-12m;lm-5m-13m;lm- 5m-14m;lm-5m-15m;lm-6m-7m;lm-6m-8m;lm-6m-9m;lm-6m-10m;lm-6m-l lm;lm-6m- 12m; lm-6m-13m; lm-6m-14m; lm-6m-15m; lm-7m-8m; lm-7m-9m; lm-7m-10m; lm-7m- 1 lm; lm-7m-12m; lm-7m-13m; lm-7m-14m; lm-7m-l 5m; lm-8m-9m; lm-8m-10m; lm-8m- 1 lm;lm-8m-12m;lm-8m-13m;lm-8m-14m;lm-8m-15m;lm-9m-10m;lm-9m-llm;lm-9m- 12m;lm-9m-13m;lm-9m-14m;lm-9m-15m;lm-10m-llm;lm-10m-12m;lm-10m-13m;lm- 10m-14m;lm-10m-15m;lm-llm-12m;lm-llm-13m;lm-llm-14m;lm-llm-15m;lm-12m- 13m;lm-12m-14m;lm-12m-15m;lm-13m-14m;lm-13m-15m;lm-14m-15m;2m-3m-4m;2m- 3m-5m;2m-3m-6m;2m-3m-7m;2m-3m-8m;2m-3m-9m;2m-3m-10m;2m-3m-llm;2m-3m- 12m;2m-3m-13m;2m-3m-14m;2m-3m-15m;2m-4m-5m;2m-4m-6m;2m-4m-7m;2m-4m-8m;2m- 4m-9m;2m-4m-10m;2m-4m-llm;2m-4m-12m;2m-4m-13m;2m-4m-14m;2m-4m-15m;2m-5m- 6m;2m-5m-7m;2m-5m-8m;2m-5m-9m;2m-5m-10m;2m-5m-llm;2m-5m-12m;2m-5m-13m;2m- 5m-14m;2m-5m-15m;2m-6m-7m;2m-6m-8m;2m-6m-9m;2m-6m-10m;2m-6m-l lm;2m-6m- 12m;2m-6m-13m;2m-6m-14m;2m-6m-15m;2m-7m-8m;2m-7m-9m;2m-7m-10m;2m-7m- llm;2m-7m-12m;2m-7m-13m;2m-7m-14m;2m-7m-15m;2m-8m-9m;2m-8m-10m;2m-8m- llm;2m-8m-12m;2m-8m-13m;2m-8m-14m;2m-8m-15m;2m-9m-10m;2m-9m-llm;2m-9m- 12m;2m-9m-13m;2m-9m-14m;2m-9m-15m;2m-10m-llm;2m-10m-12m;2m-10m-13m;2m- 10m-14m;2m-10m-15m;2m-l lm-12m;2m-l lm-13m;2m-l lm-14m;2m-l lm-15m;2m-12m- 13m;2m-12m-14m;2m-12m-15m;2m-13m-14m;2m-13m-15m;2m-14m-15m;3m-4m-5m;3m- 4m-6m;3m-4m-7m;3m-4m-8m;3m-4m-9m;3m-4m-10m;3m-4m-llm;3m-4m-12m;3m-4m- 13m;3m-4m-14m;3m-4m-15m;3m-5m-6m;3m-5m-7m;3m-5m-8m;3m-5m-9m;3m-5m-10m;3m- 5m- 1 lm;3m-5m-12m;3m-5m-13m;3m-5m-14m;3m-5m-15m;3m-6m-7m;3m-6m-8m;3m-6m- 9m;3m-6m-10m;3m-6m-llm;3m-6m-12m;3m-6m-13m;3m-6m-14m;3m-6m-15m;3m-7m- 8m;3m-7m-9m;3m-7m-10m;3m-7m-llm;3m-7m-12m;3m-7m-13m;3m-7m-14m;3m-7m- 15m;3m-8m-9m;3m-8m-10m;3m-8m-llm;3m-8m-12m;3m-8m-13m;3m-8m-14m;3m-8m- 15m;3m-9m-10m;3m-9m-llm;3m-9m-12m;3m-9m-13m;3m-9m-14m;3m-9m-15m;3m-10m- 

1 lm;3m-10m-12m;3m-10m-13m;3m-10m-14m;3m-10m-15m;3m-l lm-12m;3m-l lm-13m;3m- 1 lm-14m;3m-l lm-15m;3m-12m-13m;3m-12m-14m;3m-12m-15m </div>
    <div id="p1875" num="1875" class="description-paragraph">15m;3m- 14m- 15m;4m-5m-6m;4m-5m-7m;4m-5m-8m;4m-5m-9m;4m-5m- 10m;4m-5m- 1 lm;4m-5m-12m;4m-5m-13m;4m-5m-14m;4m-5m-15m;4m </div>
    <div id="p1876" num="1876" class="description-paragraph">9m;4m-6m-10m;4m-6m-l lm;4m-6m-12m;4m-6m-13m;4m-6m-14m;4m-6m-15m </div>
    <div id="p1877" num="1877" class="description-paragraph">8m;4m-7m-9m;4m-7m-10m;4m-7m-l lm;4m-7m-12m;4m-7m-13m;4m-7m </div>
    <div id="p1878" num="1878" class="description-paragraph">15m;4m-8m-9m;4m-8m-10m;4m-8m-l lm;4m-8m-12m;4m-8m </div>
    <div id="p1879" num="1879" class="description-paragraph">15m;4m-9m-10m;4m-9m-l lm;4m-9m-12m;4m-9m-13m;4m-9m-14m </div>
    <div id="p1880" num="1880" class="description-paragraph">l lm;4m-10m-12m;4m-10m-13m;4m-10m-14m;4m-10m-15m;4m-l lm-12m;4m-l lm-l^ 1 lm-14m;4m-l lm-15m;4m-12m-13m;4m-12m-14m;4m-12m-15m;4m-13m-14m;4m-13m- 15m;4m- 14m- 15m;5m-6m-7m;5m-6m-8m;5m-6m-9m;5m-6m- 10m; 5m-6m- 11 m </div>
    <div id="p1881" num="1881" class="description-paragraph">12m;5m-6m-13m;5m-6m-14m;5m-6m-15m;5m-7m-8m;5m-7m-9m;5m-7m-10m;5m-7m- 1 lm;5m-7m-12m;5m-7m-13m;5m-7m-14m;5m-7m-15m;5m-8m-9m;5m-8m-10m;5m-8m- 1 lm;5m-8m-12m;5m-8m-13m;5m-8m-14m;5m-8m-15m;5m-9m-10m;5m-9m-l lm;5m-9m- 12m;5m-9m-13m;5m-9m-14m;5m-9m-15m;5m-10m-l lm;5m-10m-12m;5m-10m-13m;5m- 10m-14m;5m-10m-15m;5m-l lm-12m;5m-l lm-13m;5m-l lm-14m;5m-l lm-15m;5m-12m- 13m;5m-12m-14m;5m-12m-15m;5m-13m-14m;5m-13m-15m;5m-14m-15m;6m-7m-8m;6m- 7m-9m;6m-7m-10m;6m-7m-l lm;6m-7m-12m;6m-7m-13m;6m-7m-14m;6m-7m-15m;6m-8m- 9m;6m-8m-10m;6m-8m-l lm;6m-8m-12m;6m-8m-13m;6m-8m-14m;6m-8m-15m;6m-9m- 10m;6m-9m-l lm;6m-9m-12m;6m-9m-13m;6m-9m-14m;6m-9m-15m;6m-10m-l lm;6m-10m- 12m;6m-10m-13m;6m-10m-14m;6m-10m-15m;6m-l lm-12m;6m-l lm-13m;6m-l lm-14m;6m- 1 lm-15m;6m-12m-13m;6m-12m-14m;6m-12m-15m;6m-13m-14m;6m-13m-15m;6m-14m- 15m;7m-8m-9m;7m-8m-10m;7m-8m-l lm;7m-8m-12m;7m-8m-13m;7m-8m-14m;7m-8m- 15m;7m-9m-10m;7m-9m-l lm;7m-9m-12m;7m-9m-13m;7m-9m-14m;7m-9m-15m;7m-10m- l lm;7m-10m-12m;7m-10m-13m;7m-10m-14m;7m-10m-15m;7m-l lm-12m;7m-l lm-13m;7m- 1 lm-14m;7m-l lm-15m;7m-12m-13m;7m-12m-14m;7m-12m-15m;7m-13m-14m;7m-13m- 15m;7m-14m-15m;8m-9m-10m;8m-9m-l lm;8m-9m-12m;8m-9m-13m;8m-9m-14m;8m-9m- 15m;8m-10m-l lm;8m-10m-12m;8m-10m-13m;8m-10m-14m;8m-10m-15m;8m-l lm-12m;8m- l lm-13m;8m-l lm-14m;8m-l lm-15m;8m-12m-13m;8m-12m-14m;8m-12m-15m;8m-13m- 14m;8m-13m-15m;8m-14m-15m;9m-10m-l lm;9m-10m-12m;9m-10m-13m;9m-10m-14m;9m- 10m-15m;9m-l lm-12m;9m-l lm-13m;9m-l lm-14m;9m-l lm-15m;9m-12m-13m;9m-12m- 14m;9m-12m-15m;9m-13m-14m;9m-13m-15m;9m-14m-15m; 10m-l lm-12m; 10m-l lm- 13m; 10m-l lm-14m;10m-l lm-15m;10m-12m-13m;10m-12m-14m; 10m-12m-15m; 10m-13m- 14m; 10m-13m-15m;10m-14m-15m;l lm-12m-13m;l lm-12m-14m; l lm-12m-15m; l lm-13m- 

 14m; l lm-13m-15m; l lm-14m-15m; 12m-13m-14m; 12m-13m-15m; 12m-14m-15m; and 13m- 14m- 15m. </div>
    <div id="p1882" num="1882" class="description-paragraph"> Other combinations of three different siRNA include, for example, lm-10m-20m; lm- 10m-30m; lm-10m-40m; lm-10m-50m; lm-10m-60m; 10m-20m-30m; 10m-20m-40m; 10m- 20m-50m; 10m-20m-60m; 20m-30m-40m; 20m-30m-50m; 20m-30m-60m; 30m-40m-50m;</div>
    <div id="p1883" num="1883" class="description-paragraph">30m-40m-60m; 40m-50m-60m; lm-l lm-21m; lm-l lm-31m; lm-l lm-41m; lm-l lm-51m; lm- l lm-61m; l lm-21m-31m; l lm-21m-41m; l lm-21m-51m; l lm-21m-61m; 21m-31m-41m; 21m-31m-51m; 21m-31m-61m; 31m-41m-51m; 31m-41m-61m; 41m-51m-61m; 2m-12m-22m; 2m-12m-32m; 2m-12m-42m; 2m-12m-52m; 2m-12m-62m; 12m-22m-32m; 12m-22m-42m; 12m-22m-52m; 12m-22m-62m; 22m-32m-42m; 22m-32m-52m; 22m-32m-62m; 32m-42m- 52m; 32m-42m-62m; 42m-52m-62m. </div>
    <div id="p1884" num="1884" class="description-paragraph"> Other combinations of three different siRNA include, for example, 67m-68m-69m, 67m-68m-73m, 67m-69m-71m, 67m-70m-73m, 67m-71m-73m, 67m-71m-74m, 67m-72m-73m, 68m-69m-70m, 68m-69m-73m, 68m-70m-72m, 68m-71m-73m; 68m-72m-73m, 69m-70m-71m, 69m-70m-73m, 69m-71m-73m, 69m-72m-73m, 70m-71m-72m, 70m-71m-73m, 70m-72m-73m, 71m-72m-73m. </div>
    <div id="p1885" num="1885" class="description-paragraph">Example 29. IL-28B polymorphisms in Chronic Hepatitis B subjects </div>
    <div id="p1886" num="1886" class="description-paragraph">Study Goal </div>
    <div id="p1887" num="1887" class="description-paragraph"> Several host and viral factors have been found to be associated with differences in HBV clearance or persistence. However, an unexplained variability in treatment outcome still exists, suggesting that the genetic background of the host plays an important role. The literature surrounding the impact of certain SNPs on chronic HBV infection is currently somewhat controversial and not consistent. For example, some groups have found significant correlations between certain SNPs and different responses to PEGylated-interferon (peglFN) by chronic</div>
    <div id="p1888" num="1888" class="description-paragraph">HBV HBeAg-negative patients. Other groups have looked for, but failed to identify statistically significant correlations. </div>
    <div id="p1889" num="1889" class="description-paragraph"> siRNA-NP2, described below, is an HBV antigen inhibitor having a novel mechanism of action against HBV, which is distinct from that of IFN. With this novel mechanism of action, the correlation between certain SNPs and treatment response to siRNA-NP2 may be stronger or clearer than in the previous studies examining IFN. Thus, the goal of this study was to determinate whether IL-28B polymorphisms play a role in subjects with Chronic Hepatitis B (CHB) receiving an HBV antigen inhibitor (e.g., an INF free therapy), such as the siRNA-NP2 formulation described below. 

 While not intending to be limited by theory, it is hypothesized that individuals with these S Ps have better control of CHB, meaning that even if spontaneous clearance has not yet been achieved, such individuals are closer to reaching the &#39;tipping point&#39; needed to assert dominant control over the virus. Hepatitis B virus utilizes multiple mechanisms to enforce chronicity of infection, including maintaining high levels of antigen production that are thought to play roles in suppression of host immune responses, amongst other things. In patients with SNPs in, e.g., IL28B, the virus may be less able to upregulate gene expression to compensate for the gene silencing effect of siRNA-NP2, and so therefore, the gene silencing effect of siRNA-NP2 is more clearly detectable in this subset of patients. </div>
    <div id="p1890" num="1890" class="description-paragraph">Lipid Nanoparticle Formulation </div>
    <div id="p1891" num="1891" class="description-paragraph"> The following formulation is an RNA interference product that includes three synthetic double-stranded, small interfering RNAs directed against hepatitis B virus (HBV) messenger RNAs, targeting three distinct sites in the HBV genome. This combination of siRNAs is designed to inhibit viral replication, reduce all HBV transcripts, and lower all viral antigens. </div>
    <div id="p1892" num="1892" class="description-paragraph"> The lipid nanoparticle formulation comprises a mixture of three siRNAs targeting the HBV genome {see, siRNA listed below) Specifically, the following lipid nanoparticle (LNP) formulation was used to deliver the HBV siRNAs in the experiments reported herein. This formulation is referred to as siRNA-NP2 throughout this Example. </div>
    <div id="p1893" num="1893" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/54/e3/5c/b9c44e26492930/imgf000276_0001.png"><img id="imgf000276_0001" he="104" wi="118" file="imgf000276_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="472" height="416" alt="Figure imgf000276_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/54/e3/5c/b9c44e26492930/imgf000276_0001.png"/></a></div>
 Abbreviations: qs = quantum satus; USP-NF = United States Pharmacopoeia-National </div>
    <div id="p1894" num="1894" class="description-paragraph"> Formulary. </div>
    <div id="p1895" num="1895" class="description-paragraph"> A mixture of three siRNAs targeting the HBV genome were used in this experiment. The sequences of the three siRNAs are shown below. </div>
    <div id="p1896" num="1896" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/f9/78/171807e380c44e/imgf000277_0001.png"><img id="imgf000277_0001" he="49" wi="176" file="imgf000277_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="704" height="196" alt="Figure imgf000277_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/f9/78/171807e380c44e/imgf000277_0001.png"/></a></div>
    </div>
    <div id="p1897" num="1897" class="description-paragraph">Methods </div>
    <div id="p1898" num="1898" class="description-paragraph"> The study was a single-blind, placebo-controlled, multi-dose study in non-cirrhotic, virally suppressed subjects to evaluate safety and efficacy of siRNA-NP2 initially over 12 weeks in cohorts 1, 2 and 3. Cohort 4 was used to evaluated the safety, PK and anti -viral response of a more frequent dosing regimen (five bi-weekly doses of siRNA-NP2 with extended monthly dosing out to one year for patients who meet predefined response criteria). </div>
    <div id="p1899" num="1899" class="description-paragraph"> A total of 24 subjects on stable nucleoside therapy were enrolled in the initial 3 cohorts, randomized 3 : 1 (active vs placebo): Cohort 1, HBeAg(-) at 0.2 mg/kg; Cohort 2, HBeAg(-) at 0.4 mg/kg; Cohort 3, HBeAg(+) at 0.4 mg kg. Subjects received siRNA-NP2 as 3 monthly IV doses. </div>
    <div id="p1900" num="1900" class="description-paragraph"> Cohort 4 was an open label multi-dose study in non-cirrhotic HBeAg (-) virally suppressed subjects. A total of 12 subjects on stable nucleoside therapy were enrolled to receive siRNA-NP2 0.4 mg/kg bi-weekly for a total of five doses over 8 weeks. Subjects with HBsAg &lt;1000 RJ/mL AND &gt;1.0 logio decrease from baseline at Day 71 continued with up to 10 additional monthly doses for a total treatment duration of 48 weeks. Subjects were monitored for safety, PK and HBV markers, and HBV genotype was assessed by line probe assay (ÎÎÎÎ- LiPA; Innogenetics N.V., Ghent, Belgium). </div>
    <div id="p1901" num="1901" class="description-paragraph"> The IL-28B associated single nucleotide polymorphism (SNP), rsl2979860 (chr. </div>
    <div id="p1902" num="1902" class="description-paragraph"> 19ql3), was analyzed using a real-time PCR assay. The assay utilized the 5-prime nuclease activity of a thermostable polymerase and unique primers and fluorescent probes to detect the SNP (rsl2979860 C/T) in whole blood samples for subjects enrolled on cohort 4. 

 Results and Conclusion </div>
    <div id="p1903" num="1903" class="description-paragraph"> Of 12 subjects, 9 (75%) were male, having a mean age of 48.3 years. Eight of the subjects had the 8 IL28B genotype CC (66%), 8 had HBV genotype C (66%) and the mean baseline HBsAg was 3.43 (logio IU/mL) (Tablel). Eleven subjects completed 5 doses of siR A- NP2 0.4 mg/kg. All subjects experienced a reduction in HBsAg from baseline. Seven of 11 (64%) subjects were considered responders prior to or at Day 71; 5/7 (71%) subjects met the criteria by Day 22 (2 doses). Mean HBsAg decline for responders was -1.6 loglO IU/mL at treatment Day 64 with a maximum individual HBsAg decline -2.7 loglO IU/mL; in addition, 5/7 (71%)) responders reached HBsAg&lt; 50 IU/mL. Based on this data, it is suggested that the CC genotype for SNP rs 12979860 is indicative of a patients demonstrating a higher likelihood of showing a significant response to siRNA-NP2. </div>
    <div id="p1904" num="1904" class="description-paragraph">Table 1. HBsAG assessment -Cohort 4 </div>
    <div id="p1905" num="1905" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/92/f2/5e07952c804a1a/imgf000278_0001.png"><img id="imgf000278_0001" he="87" wi="158" file="imgf000278_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no" width="632" height="348" alt="Figure imgf000278_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/92/f2/5e07952c804a1a/imgf000278_0001.png"/></a></div>
      
    </div>
    <div id="p1906" num="1906" class="description-paragraph">Table 2. Summary of Demographic and Baseline Characteristics - Cohort 4 Safety </div>
    <div id="p1907" num="1907" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/12/97/ea264b65ddf00f/imgf000279_0001.png"><img id="imgf000279_0001" he="228" wi="160" file="imgf000279_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="640" height="912" alt="Figure imgf000279_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/12/97/ea264b65ddf00f/imgf000279_0001.png"/></a></div>
      
    </div>
    <div id="p1908" num="1908" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ce/17/36/4c602d4c8406a0/imgf000280_0001.png"><img id="imgf000280_0001" he="115" wi="159" file="imgf000280_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="636" height="460" alt="Figure imgf000280_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ce/17/36/4c602d4c8406a0/imgf000280_0001.png"/></a></div>
    </div>
    <div id="p1909" num="1909" class="description-paragraph"> *Stronger responders: subjects with HBsAg results &lt;1000 IU/ml and &gt;1 loglO decline </div>
    <div id="p1910" num="1910" class="description-paragraph">baseline during the biweekly dosing. Weaker responders: subjects with HBsAg results &gt;1000 IU/ml and &lt;1 loglO decline in HBsAG from baseline during the biweekly dosing. 
</div>
  </div>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM180615394" lang="EN" load-source="WIPO-OCR" class="claims ocr">
    <claim-statement>CLAIMS WHAT IS CLAIMED IS: </claim-statement>
    <claim id="clm-0001" num="1">
      <div class="claim-text">1. A method comprising detecting a hepatitis B virus (HBV) infected patient&#39;s genotype at rsl2079860, wherein a C/C genotype at rsl2079860 is indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0002" num="2">
      <div class="claim-text">2. A method comprising: </div>
      <div class="claim-text"> a) analyzing a biological sample obtained from a hepatitis B virus (HBV) infected patient to detect the patient&#39; s genotype at rs 12079860; and </div>
      <div class="claim-text"> b) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0003" num="3">
      <div class="claim-text">3. A method comprising: </div>
      <div class="claim-text"> a) obtaining a biological sample from a hepatitis B virus (HBV) infected patient; and b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; and </div>
      <div class="claim-text"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0004" num="4">
      <div class="claim-text">4. The method of any one of claims 1-3, further comprising administering an effective amount of an HBV antigen inhibitor to the HBV infected patient having a C/C genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0005" num="5">
      <div class="claim-text">5. A method comprising: </div>
      <div class="claim-text"> a) obtaining a biological sample from a hepatitis B virus (HBV) infected patient; </div>
      <div class="claim-text"> b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; and </div>
      <div class="claim-text"> c) administering an effective amount of an HBV antigen inhibitor to a patient having a C/C genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0006" num="6">
      <div class="claim-text">6. A method comprising: 

 a) obtaining a biological sample from a hepatitis B virus (HBV) infected patient; </div>
      <div class="claim-text"> b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; </div>
      <div class="claim-text"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
      <div class="claim-text"> d) administering an effective amount of an HBV antigen inhibitor to the patient. </div>
    </claim>
    <claim id="clm-0007" num="7">
      <div class="claim-text">7. A method of treating a hepatitis B virus (HBV) infected patient, comprising </div>
      <div class="claim-text">administering to the patient an effective amount of an HBV antigen inhibitor, wherein the patient had been determined to have a C/C genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0008" num="8">
      <div class="claim-text">8. The method of any one of claims 4-7, wherein the HBV antigen inhibitor is a core antigen inhibitor. </div>
    </claim>
    <claim id="clm-0009" num="9">
      <div class="claim-text">9. The method of any one of claims 4-7, wherein the HBV antigen inhibitor is a surface antigen inhibitor. </div>
    </claim>
    <claim id="clm-0010" num="10">
      <div class="claim-text">10. The method of any one of claims 4-9, wherein the HBV antigen inhibitor is selected from an oligonucleotide, a small molecule or a polypeptide. </div>
    </claim>
    <claim id="clm-0011" num="11">
      <div class="claim-text">1 1. The method of claim 10, wherein the HBV antigen inhibitor is a small molecule. </div>
    </claim>
    <claim id="clm-0012" num="12">
      <div class="claim-text">12. The method of claim 10, wherein the HBV antigen inhibitor is an oligonucleotide. </div>
    </claim>
    <claim id="clm-0013" num="13">
      <div class="claim-text">13. The method of claim 12, wherein the oligonucleotide is a siRNA molecule. </div>
    </claim>
    <claim id="clm-0014" num="14">
      <div class="claim-text">14. The method of claim 13, wherein the HBV antigen inhibitor is an siRNA molecule selected from the siRNA molecules described in Tables A and B. </div>
    </claim>
    <claim id="clm-0015" num="15">
      <div class="claim-text">15. The method of claim 13, wherein the HBV antigen inhibitor is a composition comprising a combination of two or more siRNA molecules selected from the siRNA molecules described in Tables A and B. 

</div>
    </claim>
    <claim id="clm-0016" num="16">
      <div class="claim-text">16. The method of claim 13, wherein the HBV antigen inhibitor is a composition comprising a combination of three or more siRNA molecules selected from the siRNA molecules described in Tables A and B. </div>
    </claim>
    <claim id="clm-0017" num="17">
      <div class="claim-text">17. The method of claim 16, wherein the HBV antigen inhibitor is a composition comprising siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    </claim>
    <claim id="clm-0018" num="18">
      <div class="claim-text">18. A method comprising: </div>
      <div class="claim-text"> a) obtaining a biological sample from a hepatitis B virus (HBV) infected patient; </div>
      <div class="claim-text"> b) analyzing the sample to detect the patient&#39;s genotype at rs 12079860; </div>
      <div class="claim-text"> c) identifying the HBV infected patient as having a higher likelihood of responding to an HBV antigen inhibitor when a C/C genotype at rsl2079860 is detected, as compared to a patient having a different genotype at rsl2079860; and </div>
      <div class="claim-text"> d) administering an effective amount of an HBV antigen inhibitor to the patient, wherein the HBV antigen inhibitor is a composition comprising siRNA 67m (SEQ ID NO: 142 and 143), siRNA 71m (SEQ ID NO: 144 and 145) and siRNA 74m (SEQ ID NO: 10 and 24). </div>
    </claim>
    <claim id="clm-0019" num="19">
      <div class="claim-text">19. The method of any one of claims 12-18, wherein the oligonucleotide (e.g., siRNA) is comprised in a lipid nanoparticle formulation, wherein the lipid nanoparticle formulation comprises a cationic lipid and a non-cationic lipid. </div>
    </claim>
    <claim id="clm-0020" num="20">
      <div class="claim-text">20. The method of claim 19, wherein the cationic lipid is selected from the group consisting of l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N- dimethylaminopropane (DLenDMA), l,2-di-y-linolenyloxy-N,N-dimethylaminopropane (Î³- DLenDMA; Compound (515)) , 3-((6Z,9Z,28Z,3 lZ)-heptatriaconta-6,9,28,3 l-tetraen-19- yloxy)-N,N-dimethylpropan-l -amine (DLin-MP-DMA; Compound (508)), (6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) (Compound (507)), </div>
      <div class="claim-text">(6Z, 16Z)-12-((Z)-dec-4-enyl)docosa-6, 16-dien-l 1-yl 5-(dimethylamino)pentanoate (Compound (513)), a salt thereof, and a mixture thereof. </div>
    </claim>
    <claim id="clm-0021" num="21">
      <div class="claim-text">21. The meth f claim 20, wherein the cationic lipid is: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/ea/17/4f10d280b5aef8/imgf000283_0001.png"><img id="imgf000283_0001" he="15" wi="97" file="imgf000283_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="388" height="60" alt="Figure imgf000283_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/ea/17/4f10d280b5aef8/imgf000283_0001.png"/></a></div>
 

3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylpropan-l-amine (508). </div>
    </claim>
    <claim id="clm-0022" num="22">
      <div class="claim-text">22. The method of any one of claims 19-21, wherein the non-cationic lipid is cholesterol or a derivative thereof. </div>
    </claim>
    <claim id="clm-0023" num="23">
      <div class="claim-text">23. The method of any one of claims 19-21, wherein the non-cationic lipid is a phospholipid. </div>
    </claim>
    <claim id="clm-0024" num="24">
      <div class="claim-text">24. The method of any one of claims 19-21, wherein the non-cationic lipid is a mixture of a phospholipid and cholesterol or a derivative thereof. </div>
    </claim>
    <claim id="clm-0025" num="25">
      <div class="claim-text">25. The method of claim 23 or 24, wherein the phospholipid is selected from the group consisting of dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), and a mixture thereof. </div>
    </claim>
    <claim id="clm-0026" num="26">
      <div class="claim-text">26. The method of claim 25, wherein the phospholipid is DSPC. </div>
    </claim>
    <claim id="clm-0027" num="27">
      <div class="claim-text">27. The method of any one of claims 19-26, wherein the lipid formulation further comprises a conjugated lipid that inhibits aggregation of particles. </div>
    </claim>
    <claim id="clm-0028" num="28">
      <div class="claim-text">28. The method of claim 27, wherein the conjugated lipid that inhibits aggregation of particles is a polyethyleneglycol (PEG)-lipid conjugate. </div>
    </claim>
    <claim id="clm-0029" num="29">
      <div class="claim-text">29. The method of claim 28, wherein the PEG-lipid conjugate is selected from the group consisting of a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG- DAA) conjugate, a PEG-phospholipid conjugate, a PEG-ceramide (PEG-Cer) conjugate, a PEG- dimyristyloxypropyl (PEG-DMA) conjugate and a mixture thereof. </div>
    </claim>
    <claim id="clm-0030" num="30">
      <div class="claim-text">30. The method of claim 29, wherein the PEG-lipid conjugate is a PEG-C-DMA conjugate. </div>
    </claim>
    <claim id="clm-0031" num="31">
      <div class="claim-text">31. The method of any one of claims 19-30, wherein the cationic lipid comprises from about 48 mol % to about 62 mol % of the total lipid present in each particle within the formulation. 

</div>
    </claim>
    <claim id="clm-0032" num="32">
      <div class="claim-text">32. The method of any one of claims 24-31, comprising a phospholipid and cholesterol or cholesterol derivative, wherein the phospholipid comprises from about 7 mol % to about 17 mol % of the total lipid present in each particle within the formulation and the cholesterol or derivative thereof comprises from about 25 mol % to about 40 mol % of the total lipid present in each particle within the formulation. </div>
    </claim>
    <claim id="clm-0033" num="33">
      <div class="claim-text">33. The method of any one of claims 27-32, wherein the conjugated lipid that inhibits aggregation of particles comprises from about 0.5 mol % to about 3 mol % of the total lipid present in each particle within the formulation. </div>
    </claim>
    <claim id="clm-0034" num="34">
      <div class="claim-text">34. The method of any one of claims 12-14, wherein the oligonucleotide (e.g., siRNA) is conjugated to a targeting moiety. </div>
    </claim>
    <claim id="clm-0035" num="35">
      <div class="claim-text">35. The method of claim 34, wherein the oligonucleotide (e.g., siRNA) is comprised within a compound of formula (I): 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/d4/89/a9b6f3667869d9/imgf000285_0001.png"><img id="imgf000285_0001" he="18" wi="43" file="imgf000285_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="172" height="72" alt="Figure imgf000285_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f1/d4/89/a9b6f3667869d9/imgf000285_0001.png"/></a></div>
 </div>
      <div class="claim-text"> (I) </div>
      <div class="claim-text">wherein: </div>
      <div class="claim-text"> R<sup>1</sup> a is targeting ligand; </div>
      <div class="claim-text"> L<sup>1</sup> is absent or a linking group; </div>
      <div class="claim-text"> L<sup>2</sup> is absent or a linking group; </div>
      <div class="claim-text"> R<sup>2</sup> is the oligonucleotide (e.g., siRNA); </div>
      <div class="claim-text"> the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl; </div>
      <div class="claim-text"> each R<sup>A</sup> is independently selected from the group consisting of hydrogen, hydroxy, CN, F, CI, Br, I, -Ci-2 alkyl-OR<sup>B</sup>, Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl; wherein the Ci-io alkyl C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C1-3 alkoxy; </div>
      <div class="claim-text"> R<sup>B</sup> is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group that is bound to a solid support; and </div>
      <div class="claim-text"> n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 

 or a salt thereof. </div>
    </claim>
    <claim id="clm-0036" num="36">
      <div class="claim-text">36. The method of any one of claims 4-35, wherein an effective amount of an HBV antigen inhibitor for a patient having a C/C genotype at rsl2079860 is less than an effective amount of an HBV antigen inhibitor for a patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0037" num="37">
      <div class="claim-text">37. The method of any one of claims 4-35, wherein an HBV infected patient having a C/C genotype at rsl2079860 is administered a different HBV antigen inhibitor treatment regimen than an HBV infected patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0038" num="38">
      <div class="claim-text">38. The method of claim 37, wherein the HBV infected patient having a C/C genotype at rsl2079860 is administered a lower dosage of the HBV antigen inhibitor and/or is administered the HBV antigen inhibitor for a shorter period of time as compared to an HBV infected patient having a different genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0039" num="39">
      <div class="claim-text">39. The method of any one of claims 4-38, further comprising administering at least one additional therapeutic agent. </div>
    </claim>
    <claim id="clm-0040" num="40">
      <div class="claim-text">40. The method of claim 39, wherein the at least one additional therapeutic agent selected from the group consisting of: </div>
      <div class="claim-text"> (A) an agent that controls viral replication; </div>
      <div class="claim-text"> (B) an agent that reduces viral Ags; </div>
      <div class="claim-text"> (C) an immune enhancer; and </div>
      <div class="claim-text"> (D) an immune stimulant. </div>
    </claim>
    <claim id="clm-0041" num="41">
      <div class="claim-text">41. The method of any one of claims 1 -40, wherein the HBV infected patient is further infected with hepatitis D virus (HDV). </div>
    </claim>
    <claim id="clm-0042" num="42">
      <div class="claim-text">42. An HBV antigen inhibitor for the prophylactic or therapeutic treatment of a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860. </div>
    </claim>
    <claim id="clm-0043" num="43">
      <div class="claim-text">43. The use of an HBV antigen inhibitor to prepare a medicament for treating a hepatitis B virus infection in a patient determined to have a C/C genotype at rsl2079860. 

</div>
    </claim>
    <claim id="clm-0044" num="44">
      <div class="claim-text">44. A kit comprising: </div>
      <div class="claim-text"> a) an HBV antigen inhibitor; </div>
      <div class="claim-text"> b) instructions for administering the inhibitor to a hepatitis B virus (HBV) infected patient determined to have a C/C genotype at rsl2079860. 
</div>
    </claim>
  </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">PCT/US2018/049998</span>
      <span itemprop="priorityDate">2017-09-11</span>
      <span itemprop="filingDate">2018-09-07</span>
      <span itemprop="title">Methods for treating hepatitis b infections 
       </span>
      <span itemprop="ifiStatus">Ceased</span>
      
      <a href="/patent/WO2019051257A2/en">
        <span itemprop="representativePublication">WO2019051257A2</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    

    <h2>Applications Claiming Priority (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201762556870P</span>
            
          </td>
          <td itemprop="priorityDate">2017-09-11</td>
          <td itemprop="filingDate">2017-09-11</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US62/556,870</span>
            
          </td>
          <td itemprop="priorityDate"></td>
          <td itemprop="filingDate">2017-09-11</td>
          <td itemprop="title"></td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Publications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">WO2019051257A2</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/WO2019051257A2/en">
              WO2019051257A2
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-03-14</td>
        </tr>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">WO2019051257A3</span>
            
            <a href="/patent/WO2019051257A3/en">
              WO2019051257A3
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-03-26</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=65635203</h2>

    <h2>Family Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2018/049998</span>
            <span itemprop="ifiStatus">Ceased</span>
            
            <a href="/patent/WO2019051257A2/en">
              <span itemprop="representativePublication">WO2019051257A2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2017-09-11</td>
          <td itemprop="filingDate">2018-09-07</td>
          <td itemprop="title">Methods for treating hepatitis b infections 
       </td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Country Status (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">TW</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/TW201920687A/en">
              <span itemprop="representativePublication">TW201920687A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/WO2019051257A2/en">
              <span itemprop="representativePublication">WO2019051257A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (12)</h2>
    <table>
      <caption>* Cited by examiner, â  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2020097520A1/en">
              <span itemprop="publicationNumber">WO2020097520A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2020-05-14</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">Cationic lipids containing silicon 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2020255062A1/en">
              <span itemprop="publicationNumber">WO2020255062A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-06-20</td>
          <td itemprop="publicationDate">2020-12-24</td>
          <td><span itemprop="assigneeOriginal">Janssen Sciences Ireland Unlimited Company</span></td>
          <td itemprop="title">Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021113820A1/en">
              <span itemprop="publicationNumber">WO2021113820A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-12-06</td>
          <td itemprop="publicationDate">2021-06-10</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Conjugates and methods for treating liver fibrosis 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023280227A3/en">
              <span itemprop="publicationNumber">WO2023280227A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-06</td>
          <td itemprop="publicationDate">2023-02-16</td>
          <td><span itemprop="assigneeOriginal">Profoundbio Us Co.</span></td>
          <td itemprop="title">Linkers, drug linkers and conjugates thereof and methods of using the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023034719A1/en">
              <span itemprop="publicationNumber">WO2023034719A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-30</td>
          <td itemprop="publicationDate">2023-03-09</td>
          <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
          <td itemprop="title">Functionalized n-acetylgalactosamine analogs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/JP2023510109A/en">
              <span itemprop="publicationNumber">JP2023510109A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-12-20</td>
          <td itemprop="publicationDate">2023-03-13</td>
          <td><span itemprop="assigneeOriginal">ã¢ã«ãã¼ã¿ã¹ã»ãã¤ãªãã¡ã¼ãã¼ã»ã³ã¼ãã¬ã¤ã·ã§ã³</span></td>
          <td itemprop="title">
        Synthetic process and intermediates
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11649260B2/en">
              <span itemprop="publicationNumber">US11649260B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-06-18</td>
          <td itemprop="publicationDate">2023-05-16</td>
          <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
          <td itemprop="title">Functionalized N-acetylgalactosamine nucleosides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11725194B2/en">
              <span itemprop="publicationNumber">US11725194B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-12-19</td>
          <td itemprop="publicationDate">2023-08-15</td>
          <td><span itemprop="assigneeOriginal">Janssen Sciences Ireland Unlimited Company</span></td>
          <td itemprop="title">Hepatitis B virus (HBV) vaccines and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11993626B2/en">
              <span itemprop="publicationNumber">US11993626B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-15</td>
          <td itemprop="publicationDate">2024-05-28</td>
          <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
          <td itemprop="title">Functionalized N-acetylgalactosamine analogs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/EP4114417A4/en">
              <span itemprop="publicationNumber">EP4114417A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-03-06</td>
          <td itemprop="publicationDate">2024-08-14</td>
          <td><span itemprop="assigneeOriginal">OD Therapeutics Limited</span></td>
          <td itemprop="title">
        THERAPEUTIC AGENTS AND CONJUGATES THEREOF
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12116382B2/en">
              <span itemprop="publicationNumber">US12116382B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-28</td>
          <td itemprop="publicationDate">2024-10-15</td>
          <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
          <td itemprop="title">Functionalized N-acetylgalactosamine analogs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN118993970A/en">
              <span itemprop="publicationNumber">CN118993970A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-05-17</td>
          <td itemprop="publicationDate">2024-11-22</td>
          <td><span itemprop="assigneeOriginal">èå·å¯å£«è±å»è¯è¡ä»½æéå¬å¸</span></td>
          <td itemprop="title">Preparation method of L96 side chain compound 
       </td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Family Cites Families (1)</h2>
    <table>
      <caption>* Cited by examiner, â  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10415037B2/en">
              <span itemprop="publicationNumber">US10415037B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2014-10-02</td>
          <td itemprop="publicationDate">2019-09-17</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">Compositions and methods for silencing hepatitis B virus gene expression 
       </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2018</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-09-07</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/US2018/049998</span>
            <a href="/patent/WO2019051257A2/en"><span itemprop="documentId">patent/WO2019051257A2/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-09-11</span>
            <span itemprop="countryCode">TW</span>
            <span itemprop="applicationNumber">TW107131908A</span>
            <a href="/patent/TW201920687A/en"><span itemprop="documentId">patent/TW201920687A/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  

  

  <h2>Cited By (17)</h2>
  <table>
    <caption>* Cited by examiner, â  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11725194B2/en">
            <span itemprop="publicationNumber">US11725194B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2017-12-19</td>
        <td itemprop="publicationDate">2023-08-15</td>
        <td><span itemprop="assigneeOriginal">Janssen Sciences Ireland Unlimited Company</span></td>
        <td itemprop="title">Hepatitis B virus (HBV) vaccines and uses thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12350383B2/en">
            <span itemprop="publicationNumber">US12350383B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-11-09</td>
        <td itemprop="publicationDate">2025-07-08</td>
        <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
        <td itemprop="title">Cationic lipids containing silicon 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2020097520A1/en">
            <span itemprop="publicationNumber">WO2020097520A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2018-11-09</td>
        <td itemprop="publicationDate">2020-05-14</td>
        <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
        <td itemprop="title">Cationic lipids containing silicon 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2020255062A1/en">
            <span itemprop="publicationNumber">WO2020255062A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2019-06-20</td>
        <td itemprop="publicationDate">2020-12-24</td>
        <td><span itemprop="assigneeOriginal">Janssen Sciences Ireland Unlimited Company</span></td>
        <td itemprop="title">Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021113820A1/en">
            <span itemprop="publicationNumber">WO2021113820A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2019-12-06</td>
        <td itemprop="publicationDate">2021-06-10</td>
        <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
        <td itemprop="title">Conjugates and methods for treating liver fibrosis 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/JP2023510109A/en">
            <span itemprop="publicationNumber">JP2023510109A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2019-12-20</td>
        <td itemprop="publicationDate">2023-03-13</td>
        <td><span itemprop="assigneeOriginal">ã¢ã«ãã¼ã¿ã¹ã»ãã¤ãªãã¡ã¼ãã¼ã»ã³ã¼ãã¬ã¤ã·ã§ã³</span></td>
        <td itemprop="title">
        Synthetic process and intermediates
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20230113948A1/en">
            <span itemprop="publicationNumber">US20230113948A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2019-12-20</td>
        <td itemprop="publicationDate">2023-04-13</td>
        <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
        <td itemprop="title">Synthetic processes and intermediates 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/EP4114417A4/en">
            <span itemprop="publicationNumber">EP4114417A4</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2020-03-06</td>
        <td itemprop="publicationDate">2024-08-14</td>
        <td><span itemprop="assigneeOriginal">OD Therapeutics Limited</span></td>
        <td itemprop="title">
        THERAPEUTIC AGENTS AND CONJUGATES THEREOF
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11649260B2/en">
            <span itemprop="publicationNumber">US11649260B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-06-18</td>
        <td itemprop="publicationDate">2023-05-16</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized N-acetylgalactosamine nucleosides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023280227A3/en">
            <span itemprop="publicationNumber">WO2023280227A3</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-07-06</td>
        <td itemprop="publicationDate">2023-02-16</td>
        <td><span itemprop="assigneeOriginal">Profoundbio Us Co.</span></td>
        <td itemprop="title">Linkers, drug linkers and conjugates thereof and methods of using the same 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11692001B2/en">
            <span itemprop="publicationNumber">US11692001B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-30</td>
        <td itemprop="publicationDate">2023-07-04</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized n-acetylgalactosamine analogs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN118434751A/en">
            <span itemprop="publicationNumber">CN118434751A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-08-30</td>
        <td itemprop="publicationDate">2024-08-02</td>
        <td><span itemprop="assigneeOriginal">åç»´çç©ç§æå¬å¸</span></td>
        <td itemprop="title">
        Functionalized N-acetylgalactosamine analogs
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11884691B2/en">
            <span itemprop="publicationNumber">US11884691B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-30</td>
        <td itemprop="publicationDate">2024-01-30</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized n-acetylgalactosamine analogs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023034719A1/en">
            <span itemprop="publicationNumber">WO2023034719A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-08-30</td>
        <td itemprop="publicationDate">2023-03-09</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized n-acetylgalactosamine analogs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11993626B2/en">
            <span itemprop="publicationNumber">US11993626B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-12-15</td>
        <td itemprop="publicationDate">2024-05-28</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized N-acetylgalactosamine analogs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12116382B2/en">
            <span itemprop="publicationNumber">US12116382B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-11-28</td>
        <td itemprop="publicationDate">2024-10-15</td>
        <td><span itemprop="assigneeOriginal">Hongene Biotech Corporation</span></td>
        <td itemprop="title">Functionalized N-acetylgalactosamine analogs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN118993970A/en">
            <span itemprop="publicationNumber">CN118993970A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2023-05-17</td>
        <td itemprop="publicationDate">2024-11-22</td>
        <td><span itemprop="assigneeOriginal">èå·å¯å£«è±å»è¯è¡ä»½æéå¬å¸</span></td>
        <td itemprop="title">Preparation method of L96 side chain compound 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019051257A3/en">
              <span itemprop="publicationNumber">WO2019051257A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-03-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201920687A/en">
              <span itemprop="publicationNumber">TW201920687A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-06-01</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20230165973A1/en">
                <span itemprop="publicationNumber">US20230165973A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-06-01">2023-06-01</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2019051257A2/en">
                <span itemprop="publicationNumber">WO2019051257A2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2019-03-14">2019-03-14</time>
            
            
          </td>
          <td itemprop="title">Methods for treating hepatitis b infections 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US10626393B2/en">
                <span itemprop="publicationNumber">US10626393B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-04-21">2020-04-21</time>
            
            
          </td>
          <td itemprop="title">Delivering CRISPR therapeutics with lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP3201338B1/en">
                <span itemprop="publicationNumber">EP3201338B1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-11-03">2021-11-03</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20180245074A1/en">
                <span itemprop="publicationNumber">US20180245074A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-08-30">2018-08-30</time>
            
            
          </td>
          <td itemprop="title">Treating hepatitis b virus infection using crispr 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US12290567B2/en">
                <span itemprop="publicationNumber">US12290567B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-05-06">2025-05-06</time>
            
            
          </td>
          <td itemprop="title">Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2016071857A1/en">
                <span itemprop="publicationNumber">WO2016071857A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2016-05-12">2016-05-12</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing ebola virus expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP3329003A2/en">
                <span itemprop="publicationNumber">EP3329003A2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-06-06">2018-06-06</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2018222910A1/en">
                <span itemprop="publicationNumber">WO2018222910A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-12-06">2018-12-06</time>
            
            
          </td>
          <td itemprop="title">Therapeutic compositions and methods for treating hepatitis b 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20240050463A1/en">
                <span itemprop="publicationNumber">US20240050463A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-02-15">2024-02-15</time>
            
            
          </td>
          <td itemprop="title">Therapeutic compositions and methods for treating hepatitis b 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2018232330A1/en">
                <span itemprop="publicationNumber">WO2018232330A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-12-20">2018-12-20</time>
            
            
          </td>
          <td itemprop="title">Therapeutic compositions and methods for treating hepatitis b 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK1234102B/en">
                <span itemprop="publicationNumber">HK1234102B</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2022-02-25">2022-02-25</time>
            
            
          </td>
          <td itemprop="title">Compositions and methods for silencing hepatitis b virus gene expression 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-04-24">2019-04-24</time></td>
          <td itemprop="code">121</td>
          <td itemprop="title">Ep: the epo has been informed by wipo that ep was designated in this application</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">18854293</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">EP</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A2</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2020-03-12">2020-03-12</time></td>
          <td itemprop="code">NENP</td>
          <td itemprop="title">Non-entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref country code</strong>:
              <span itemprop="value">DE</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2020-11-11">2020-11-11</time></td>
          <td itemprop="code">32PN</td>
          <td itemprop="title">Ep: public notification in the ep bulletin as address of the adressee cannot be established</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20/08/2020)</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-04-07">2021-04-07</time></td>
          <td itemprop="code">122</td>
          <td itemprop="title">Ep: pct application non-entry in european phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">18854293</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">EP</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A2</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
